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Summary 
Ageing of the population, as a result of the increase of life expectancy, is followed by 
the growth of age-related neurodegenerative diseases and dementia. Amongst all 
neurodegenerative diseases, Alzheimer’s disease (AD) is the most prevalent, affecting 
5 to 7% of people over the age of sixty and comprising about 60% to 70% of all the 
dementia cases. Dementia in general, and AD in particular, are considered public 
global health priorities regarding their high prevalence, their high dependence, their 
economic cost and their impact on caregivers. The clinical interest in establishing an 
early diagnosis has led to a concept of a transitional state between normal and 
dementia known as Mild Cognitive Impairment (MCI). This stage was operationalized 
as a higher cognitive impairment, particularly in memory, than the one expected for 
the age and education levels, but not sufficient to establish dementia. MCI subjects, 
particularly the amnestic subtype (aMCI), present a heightened risk of conversion to 
dementia, particularly AD. Combining both the interest in capturing the earliest stages 
of AD and the new available biomarkers of the illness, the International Working Group 
on AD developed and published new diagnostic criteria for AD. The core diagnostic 
criterion includes the evidence of a significant and progressive episodic memory 
impairment confirmed by objective testing, thus suggesting the use of cued recall 
measures based on encoding specificity such as the Free and Cued Selective Reminding 
Test (FCSRT). The FCSRT is a memory test that controls attention and cognitive 
processing, requiring subjects to search, in the learning process, for items in response 
to their semantic category cues; moreover, these same category cues are later used to 
elicit recall of the items not retrieved on free recall, coordinating acquisition and 
retrieval. 
Considering both the interest in the standard implementation of the IWG criteria and 
the usefulness of the suggested diagnostic tools, the main purpose of the first chapter 
of the current thesis aims at adapting the FCSRT and validating its usefulness, on a 
memory clinic basis, to the Portuguese population. Our specific purposes were to show 
that: 1) AD patients do not improve with cueing or, at the very least, improve 
significantly less than patients with other dementing and non-dementing conditions; 2) 
aMCI patients display an intermediate pattern of severity between healthy ageing and 
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AD; 3) this paradigm is more accurate at identifying people affected by AD than other 
declarative memory tests with no support for encoding or cue for retrieval; 4) a great 
predictive value for conversion to AD is detectable among MCI patients that exhibit a 
similar profile of impairment to AD.  
After the FCSRT transcultural adaptation process, we started a validation set of studies 
that tried to cover both psychometric and clinical validity in AD spectrum disorders 
(MCI and mild AD). A longitudinal study, i.e., prediction of conversion to AD, revealed 
that an impaired FCSRT has a great predictive value of conversion. We showed also 
that this test enables the isolation of an amnestic syndrome of the hippocampal type 
as representative of typical-AD, through the inclusion of a group of behavioural variant 
of frontotemporal dementia patients that showed to benefit from this paradigm when 
compared to AD. All these studies corroborate the arguments of the IWG in favour of 
the use of the FCSRT in the objective assessment of memory in AD spectrum disorders. 
By adapting and validating the FCSRT, we also contributed to the increase of 
Portuguese-adapted neuropsychological instruments’ availability and to present a 
different paradigm of verbal memory evaluation. 
Apart from the objective episodic memory deficit, additional brain systems may be 
altered in the AD spectrum surpassing the medial temporal lobes and involving the 
medial and lateral parietal cortices, thus leading to impairment in other cognitive 
domains. Sensory and motor impairments, which focus on age-related and 
neuropathological changes, have been reported as preceding the well-known AD 
cognitive alterations. 
AD neuropathological findings have been reported in the visual cortex, thus 
contributing to distinct forms of visual impairment in AD. These deficits range from 
contrast sensitivity and colour perception deficits to impairments in higher-order visual 
functions, including motion, object and face perception and visual attention, as well as 
visual memory and learning. 
The main focus of the second chapter of this thesis is the investigation of the 
visuospatial processing in MCI and AD patients. In particular, we considered the 
performance of these pathological groups in psychophysical tasks, hence assessing 
both the dorsal and the ventral pathways. 
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Our results corroborated the existence of AD visual deficits among the two visual 
pathways and showed specific impairments on motion perception and integration as 
early as in the MCI stage. The important and specific role of the ventral pathway for 
face stimuli was confirmed by structure-function correlation analysis, suggesting that 
the ventral pathway provides the substrate for information re-routing and 
reorganization in the presence of dorsal stream vulnerability in MCI. 
In sum, the work presented in this thesis allowed us to confirm the FCSRT as a valid 
and accurate memory test, as well as a useful tool, in the objective characterization of 
the amnestic syndrome associated with AD. Moreover, we suggest the assessment of 
visual functions as an additional diagnostic tool for improving the knowledge of AD 
spectrum disorders, and consider that future interventions can be designed to 
compensate for visual problems in these pathologies, such as using higher contrast or 
larger stimuli.  
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Sumário 
O envelhecimento da população, como consequência do aumento da esperança média 
de vida, tem sido acompanhado de um incremento na prevalência das doenças 
neurodegenerativas. A doença de Alzheimer (DA) é a forma mais prevalente, 
afectando 5 a 7% das pessoas com mais de 60 anos e sendo responsável por 60 a 70% 
de todos os casos de demência. A demência em geral, e a DA em particular, são 
consideradas áreas de intervenção prioritária em saúde pública tendo em conta o 
número de doentes, a elevada dependência, os custos directos e indirectos, e o 
impacto nos cuidadores. A evolução no sentido de um diagnóstico precoce permitiu 
identificar um estádio de transição entre o envelhecimento normal e a demência 
conhecido como Defeito Cognitivo Ligeiro (DCL). Foi operacionalizado como um 
compromisso cognitivo, particularmente da memória, desadequado à 
idade/escolaridade, mas insuficiente para constituir demência. Os sujeitos, 
especialmente do subtipo amnésico (DCLa), apresentam um risco elevado de 
conversão para demência, em particular para DA. Aliando o interesse em caracterizar 
as fases precoces da DA à valorização de novos biomarcadores da doença, o 
“International Working Group on Alzheimer´s Disease” (IWG) desenvolveu e publicou 
novos critérios de diagnóstico para a DA. Como critério major de diagnóstico propõe-
se a evidência de um défice de memória significativo e progressivo confirmado 
objectivamente em testes de memória, sugerindo para esse efeito a utilização de 
medidas de evocação guiada baseadas em codificação específica, tal como o Teste de 
Recordação Selectiva Livre e Guiada (TRSLG). O TRSLG é um teste de memória que 
controla a atenção e o processamento cognitivo, durante o processo de aprendizagem, 
ao impor aos sujeitos a codificação dos itens em resposta à sua categorização 
semântica; além disso, os itens não reproduzidos livremente são facilitados através da 
utilização das mesmas pistas, coordenando assim a aprendizagem e a evocação. 
Considerando o interesse na implementação estandardizada dos novos critérios de 
diagnóstico IWG, e utilizando as ferramentas propostas, o principal objectivo do 
primeiro capítulo desta tese prende-se com a adaptação e validação do TRSLG para o 
diagnóstico precoce da DA, num contexto de clínica de memória, para a população 
portuguesa. Pretendíamos comprovar que: 1) os doentes com DA não beneficiam da 
XVII 
 
utilização de pistas semânticas, comparativamente ao que acontece noutros tipos de 
demência; 2) os sujeitos com DCLa revelam um padrão de desempenho de severidade 
intermédia entre o envelhecimento normal e a DA; 3) este paradigma é mais preciso 
na identificação de sujeitos com DA do que outro tipo de testes de memória; 4) os 
sujeitos com DCL que apresentam um perfil de alteração da memória equivalente aos 
DA estão em maior risco de conversão para esta.  
Após o processo de adaptação transcultural do TRSLG para a população portuguesa, 
desenvolveu-se um conjunto de estudos de validação que confirmaram as qualidades 
psicométricas, bem como a utilidade clínica do TRSLG, nas perturbações do espectro 
da DA (DCL e DA ligeira). Um estudo longitudinal, de predição da conversão de DCL 
para DA, mostrou que uma alteração no TRSLG revela um elevado valor preditivo de 
conversão. Confirmámos ainda que o teste permite isolar o síndrome amnésico de 
disfunção do hipocampo característico da DA típica, através da inclusão de um grupo 
de demência frontotemporal (variante comportamental) que mostrou beneficiar deste 
paradigma comparativamente ao da DA. No seu conjunto, estes estudos corroboram a 
proposta do IWG em favor da utilização do TRSLG na avaliação objectiva da memória 
nas patologias no espectro da DA. Com a adaptação e validação do TRSLG 
contribuímos ainda para aumentar o leque de instrumentos neuropsicológicos 
adaptados para a população portuguesa, nomeadamente com a introdução de um 
paradigma alternativo na avaliação da memória verbal. 
Além do declínio da memória episódica relacionado com as estruturas mesiais do lobo 
temporal, outros sistemas cerebrais podem sofrer alterações na DA, tais como o córtex 
parietal medial e lateral, produzindo alterações noutros domínios cognitivos. Estudos 
de envelhecimento normal e patológico descrevem alterações sensoriais e motoras 
precedendo as alterações da memória e os achados neuropatológicos no córtex visual, 
que podem ser precoces nalguns doentes, corroborando a importância do 
compromisso visual na DA. Nestes défices incluem-se a redução de sensibilidade ao 
contraste e percepção da cor, alterações em funções de processamento visual superior 
como a percepção do movimento e atenção visual, bem como o declínio da memória e 
aprendizagem visuais. 
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O enfoque principal do segundo capítulo desta tese é a investigação do processamento 
visuoespacial no DCL e na DA utilizando tarefas psicofísicas integrativas, vocacionadas 
para avaliar tanto a via dorsal como a via ventral. 
Os resultados corroboraram a presença de défices visuais nas duas vias visuais, na DA, 
salientando-se as alterações específicas na percepção e integração do movimento no 
estádio precoce de DCL. Foi ainda possível, através de análises de correlação estrutura-
função, confirmar um papel importante e específico da via ventral no processamento 
de estímulos faciais, levando-nos a sugerir que a via ventral fornece o substrato para 
reencaminhar e reorganizar a informação na presença da vulnerabilidade da via dorsal 
no DCL. 
Em suma, o trabalho desenvolvido fundamenta a utilização do TRSLG como um teste 
de memória válido e útil na caracterização objectiva da síndrome amnésica associada à 
DA em contexto de consultas de memória. Além disso, contribui para alargar o 
conhecimento das perturbações cognitivas noutros domínios, confirmando que as 
funções visuais estão afectadas precocemente, levando-nos a propor intervenções que 
compensem as alterações visuais destas patologias recorrendo, por exemplo, à 
utilização de maior contraste ou de estímulos maiores.  
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In this general introduction, we describe the historical evolution and the clinical and 
neurocognitive characteristics of the pathologies of the Alzheimer’s disease (AD) 
spectrum. We depict the evolutionary criteria for the diagnosis of these conditions, as 
well as its biological footprints – the biomarkers. Our main focus of attention is the 
impairment of episodic memory as the cognitive hallmark of AD. In addition, we 
deepen our research arena into the visuospatial processing of AD spectrum disorders 
in trying to look for new biomarkers. The general outline of this thesis is presented at 
the bottom of this introduction. 
 
Background  
Ageing of the population, as a result of the increase average of life expectancy, is 
followed by the growth of age-related neurodegenerative diseases. Among ageing 
disorders, dementia is one of the most significant. Its prevalence increases 
exponentially with age, beginning at about 1% at age 60 years, and doubles every 5 
years after the age of 65 (Alzheimer’s Disease International, 2009). Amongst all types 
of dementia, AD is the most common, comprising about 60% to 70% of all the 
dementia cases (World Health Organization & Alzheimer’s Disease International, 
2012). It is already a huge health problem of the elderly, comparable in incidence to 
the risk of myocardial and/or cerebral infarction, and it has become one of the leading 
causes of death in modern societies. Dementia in general and AD in particular, is 
considered a public global health priority considering its high prevalence, economic 
impact, and associated stigma and social exclusion (World Health Organization & 
Alzheimer’s Disease International, 2012). In Portugal, a very recent study suggests that 
about 5.9% of the population aged ≥60 years suffers from dementia, and probably 
more than 80.000 persons have AD (Santana, Farinha, Freitas, Rodrigues, & Carvalho, 
2015).  
 
Alzheimer’s disease 
AD is an age-related neurodegenerative brain disorder that is the main cause of 
memory impairment and global cognitive decline in the elderly. It was first described 
with this denomination in 1906 by the German psychiatrist Alois Alzheimer after 
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examining the brain of August D., a fifty-year-old woman that “had been suffering for a 
long time from weakness of memory, psychopathological manifestations, and that was 
no longer capable to do any physical or mental work” (Weiner, 2009). This 
constellation of symptoms, typical of the well-known “senile dementia”, affecting a 
young woman, raised many questions concerning nosological classification. It took 
several years to assume both the early and late forms as the same histological entity. 
The disease is characterized by neuronal death, loss of synapses, and the abnormal 
accumulation of neuritic plaques and neurofibrillary tangles, first in strategic areas and 
later in more widespread regions of the cortex (Braak & Braak, 1997; Terry, Katzman, 
& Bick, 1994). The identification of these histological alterations is still mandatory for a 
definitive diagnosis, according to the most recent diagnostic criteria. Clinical-AD 
diagnosis is generally based in the history and in the neurological examination, 
complemented by neuropsychological evidence of cognitive dysfunction (Blennow, de 
Leon, & Zetterberg, 2006), mainly in memory domain. The evidence of an early 
memory deficit in this condition is supported both by neuropathological and imaging 
findings due to a pronounced damage in the hippocampus and related structures (such 
as the entorhinal cortex). Other brain regions (frontal, temporal, and parietal 
association cortices) become increasingly involved as the disease progresses (Braak & 
Braak, 1997). In general, primary motor and sensory cortices and most subcortical 
structures are spared (Salmon, 2000). Apart from the prominent amnesia, additional 
deficits occur in language and semantic knowledge (i.e. aphasia), abstract reasoning 
and other executive functions, attention, constructional and visuospatial abilities 
(Salmon, 2000). 
Despite the fact that a definitive diagnosis can only be achieved on the basis of brain 
biopsy or autopsy, the clinical diagnosis of AD is usually classified as “possible” or 
“probable” (Mckhann et al., 1984) according to the two most widely used and 
accepted sets of criteria: the National Institute of Neurological Disorders and Stroke–
Alzheimer Disease and Related Disorders (NINCDS–ADRDA; Mckhann et al., 1984), and 
the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR; 
American Psychiatric Association, 2000). As such, the clinical approach to accomplish a 
differential diagnosis relies on information from a variety of sources, fulfilled in a two-
step diagnostic process where a dementia syndrome is initially identified and then 
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criteria apply based on the clinical features of the AD phenotype (Dubois et al., 2007). 
Impairment on activities of daily living (ADL) has come to define the threshold for the 
diagnosis of dementia beyond the identification of a cognitive abnormality (Dubois et 
al., 2007) on the two criteria sets; and both underline that the cognitive deficits are not 
due to, and not better accounted for, any other systemic or brain condition. The DSM-
IV-TR criteria require the presence of memory impairment and disturbances in at least 
one additional cognitive domain, both of which cause significant impairment in social 
function or ADL; the course of the disease is characterized by gradual onset and 
continuing cognitive decline (American Psychiatric Association, 2000). The NINCDS–
ADRDA clinical criteria do not require evidence of cognitive interference with social or 
occupational functioning on its criteria, but refers impaired ADL as a support for the 
diagnosis of probable AD; it includes deficits in two or more areas of cognition, a 
progressive worsening of memory and other cognitive functions, and includes the 
specification that the onset of AD is insidious (Mckhann et al., 1984).  
The great amount of research within AD is justified not only by its clinical and 
pathological complexity, but also by the imperative need to establish an early and 
accurate diagnosis that is crucial for intervention, namely to develop effective 
treatment strategies and also to plan assistance and economical resources.  
This clinical interest in establishing an early diagnosis associated with the fact that the 
progression to AD is gradual, has led to the suggestion of a transitional state between 
normal ageing and dementia (Petersen, 2003; Petersen et al., 1999; Santana, 2003). 
The concern about the characterization of this intermediate state between healthy 
ageing and dementia has been attempted by diverse designations and definitions. 
 
Towards an early diagnosis – concept development 
The first definition of a memory deficit, in normal adults, is endorsed to Kral (1962) 
who used the designation of “benign senescent forgetfulness” (BSF) to categorize age-
associated changes in memory. Nevertheless, he did not operationalize the concept. 
Importantly, BSF was characterized as an age-related problem that did not cross a 
pathological onset, even though Kral ensured that it was likely a mild form of the same 
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process which gave rise to the “malignant senescent forgetfulness” (Davis & 
Rockwood, 2004). 
Further definitions were influenced by changing viewpoints on cognitive disorders, and 
an important conceptual advance was to recognize dementing disorders as disease 
processes that are distinct from healthy ageing (Blessed, Tomlinson, & Roth, 1968; 
Wells, 1971). Thus the term “senility” was eventually rejected in favour of “dementia” 
as the former implied only an ageing process, whereas the latter was meant to signify 
a syndrome or state of illness-health, caused by a number of diseases, mainly AD 
(Davis & Rockwood, 2004).  
After Kral’s BSF, in an attempt to characterize the phenomenon more precisely, a 
workgroup of the National Institute of Mental Health suggested the term "age-
associated memory impairment" (AAMI; Crook et al., 1986). Its criteria included: the 
presence of complaints of gradual memory loss in everyday problems in persons over 
the age of 50 years, objective evidence of impairment on a standardized memory test 
as compared to young adults (1 standard deviation – SD – below the mean test value 
norms), evidence of adequate intellectual function, and absence of dementia or any 
medical condition that could produce cognitive deterioration (Crook, Bahar, & 
Sudilovsky, 1987-1988). 
These first two definitions carried out the same conceptual and methodological errors, 
i.e., they adopted patterns of normality that did not account for age (Santana, 2003) 
and did not specify individualized memory tests what, depending on the instrument 
used, could classify almost all elderly subjects on the AAMI category (Petersen, 2003). 
Likewise, the criteria do not necessarily represent decline, which is a point central to 
the assumptions both of age-relatedness and of illness (Davis & Rockwood, 2004). 
Moreover, the clinical course of AAMI was not known, and it had been debated 
whether it could be viewed as an intermediary state in a continuum from normal 
ageing to dementia (especially AD), or just a representation of an increased variability 
of cognitive performance in the elderly population (Hänninen, 1996). Consequently, 
milder stages of dementia performed similarly to AAMI when assessed with memory 
tests or with cognitive and behavioural scales (Brayne, 1994).  
Blackford and La Rue (1989) altered Crooks criteria by adding an upper age limit of 79 
years, requiring standardized self-report memory questionnaires, and using results on 
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a battery of four or more tests of memory to define categories of impairment based on 
both young adult and age-matched norms: AAMI, age-consistent memory impairment 
(ACMI), or late-life forgetfulness (LLF). They also required preserved general 
intelligence and revised the exclusion criteria (Davis & Rockwood, 2004). 
Levy (1994) reviewed the AAMI concept and suggested the definition of "ageing-
associated cognitive decline" (AACD) with specific diagnostic criteria. The novelty of 
this concept was the adoption, on its classification, of age and education specific cut-
off points on neuropsychological tests, the requirement of a broader assessment of 
cognitive domains (memory and learning, attention and concentration, thinking, 
language, and visuospatial functioning), and the notion of progression over time 
(Santana, 2003).  
These attempts in trying to enable a clearer distinction between healthy and 
pathological ageing expanded to clinical setting instruments and, in 1982, two clinical 
staging scales, were published: the clinical dementia rating (CDR; Hughes, Berg, 
Danziger, Coben, & Martin, 1982; Morris, 1993) and the global deterioration scale 
(GDS; Reisberg, Ferris, de Leon, & Crook, 1982). The CDR allows to distinguish a stage 
of “questionable dementia” (CDR 0.5), from people termed healthy (CDR 0) and those 
with dementia (CDR 1 = mild, CDR 2 = moderate, CDR 3 = severe). Individuals at CDR 
0.5 have mild consistent forgetfulness and doubtful or mild impairment on functioning 
of instrumental ADL (IADL) (Morris, 1993). Similarly, stages 2 and 3 of the GDS account 
for mild cognitive decline: very mild in the former (subjective memory complaints, but 
no objective evidence of memory deficit on clinical interview), and mild in the latter 
(earliest clear-cut deficits with manifestations in more than one area, objective 
evidence of memory deficit on interview, decreased performance in demanding 
employment and social settings) (Reisberg et al., 1982). 
The DSM-IV (American Psychiatric Association, 1994) comprised the notion of an “age-
related cognitive decline” (ARCD) on the section “additional conditions that may be 
focus of clinical attention”, apart from dementia classification. This category refers to 
objective identified decline in cognitive functioning (memory or other cognitive 
functions impairment) consequent to the ageing process that is within normal limits 
given the person's age, that is not attributable to a specific mental disorder or 
neurological condition (American Psychiatric Association, 1994). Nevertheless, criticism 
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to this concept is related to its imprecision and to the fact that it does not address 
notions of healthy ageing and incipient disease (Petersen, 2003). When the cognitive 
impairment is better accounted for by the direct effects of a general medical condition 
than by a mental disorder, DSM-IV refers this entity as “mild neurocognitive disorder” 
(MND). It is assured, however, that individuals with ARCD may have similar levels of 
cognitive impairment to MND, but the decline is considered to be part of the 
normative aging process rather than attributable to a general medical condition 
(American Psychiatric Association, 1994). Nevertheless, the recent DSM-5 (American 
Psychiatric Association, 2013) included a subsection entitled neurocognitive disorders 
(ND) that distinguishes between “major” and “mild” ND. While the former replaces the 
previous DSM-IV’s term “dementia or other debilitating conditions”, the latter is 
defined by a noticeable decrement in cognitive functioning that goes beyond the 
normal changes of normal ageing and that may (or may not) progress to dementia. 
The International Classification of Diseases, 10th revision (ICD-10; World Health 
Organization, 1993), suggested the concept of “mild cognitive disorder” (MCD), whose 
criteria include the report of a mild cognitive dysfunction (memory, learning and 
concentration) quantified by formal neuropsychological testing, that was not believed 
to be due to dementia or other nervous system conditions but, rather, as secondary to 
systemic illness or impairment. MCD is applicable to people of all ages, and early 
attempts to apply its criteria to population studies of elderly people have been 
unsuccessful (Ritchie & Touchon, 2000). As a result, the validity and usefulness of MCD 
as a separate nosological entity was questioned (Christensen et al., 1995). 
Finally, the Canadian Study of Health and Aging developed the concept of “cognitive 
impairment, no dementia” (CIND), including both early disease and age-related 
problems (Graham et al., 1997). This category was meant to encompass a variety of 
conditions which, while giving rise to cognitive impairment, did not meet the criteria 
for dementia (Davis & Rockwood, 2004). The concept divides conditions towards the 
likelihood of progression to dementia: disorders such as AAMI, depression, alcoholism, 
vascular, and delirium, are likely to be “pre-dementia” syndromes; while in others 
(tumours, schizophrenia and mental retardation) a diagnosis of dementia is effectively 
excluded (Davis & Rockwood, 2004; Gauthier et al., 2006; Petersen, 2003). In general, 
subjects diagnosed with CIND have a higher rate of progression to dementia than 
General Introduction 
 
27 
 
those without cognitive impairment (Tuokko et al., 2003). Nonetheless, CIND subjects 
revealed a high rate of dependence in one or more ADL in the Italian Longitudinal 
Study on Aging (Di Carlo et al., 2000). As a consequence, the impact of functional 
impairment needs to be taken into account thereafter in all classifications of cognitive 
states in older adults (Davis & Rockwood, 2004). 
Findings of longitudinal population studies, evaluating the outcomes of a variety of 
definitions of cognitive impairment, have shown a prevalence in the general elderly 
population between 3% and 19%, with an incidence of 8–58 per 1000 per year, and a 
risk of developing dementia of 11–33% over 2 years (Ritchie, 2004), and about 8–10% 
per year over 5 years (Fisk, Merry, & Rockwood, 2003). Fisk et al. (2003) showed that 
changes on the definition altered the prevalence of cognitive impairment; however, 
these changes did not modify the proportion of progression to dementia. Still, the 
several definitions were unstable, and each included a group who had improved after 
5 years (Davis & Rockwood, 2004). Findings of population-based studies have shown 
that up to 44% of patients with cognitive impairment, at their first visit, were 
estimated to return to normal a year later (Ganguli, Dodge, Shen, & DeKosky, 2004; 
Ritchie, 2004). These epidemiological studies underline the fact that there are many 
factors affecting cognition performance in elderly populations apart from 
neurodegeneration, such as: “education, vascular risk factors, psychiatric status, 
genetic background, hormonal changes, and use of anticholinergic drugs; and that 
these factors can account for the reversibility of many cognitive impairment cases” 
(Gauthier et al., 2006). 
 
Mild cognitive impairment 
The term mild cognitive impairment (MCI) was first used in association with the stage 3 
of the GDS (Reisberg et al., 1982). Subjects at GDS stage 3 have objective evidence of 
mild deficits in cognition that may manifest in more than one area, which affect 
complex occupational and social activities. 
The currently most widespread use of MCI is the notion proposed by Petersen (1995) 
and aims to identify the stage where a cognitive impairment is greater than expected, 
considering subjects’ age and education level, but not sufficiently debilitated to reach 
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dementia (Petersen et al., 1999). MCI has shown to be clinically useful as it carries a 
heightened risk of conversion to dementia, particularly AD. It is thought to represent a 
transitional stage within a cognitive continuum that spans from normal ageing to early 
dementia (Petersen et al., 1999). Its criteria were defined as: complaint of defective 
memory (preferably corroborated by an informant), objective memory impairment for 
age and education (1.5 SD below the mean of their peer group on memory tests), 
normal general cognitive functioning, preserved ADL, and absence of dementia 
(Petersen et al., 1999). Many studies have shown increased rates of progression to AD 
in MCI individuals compared to individuals with no cognitive impairment (Bowen et al., 
1997; Geslani, Tierney, Herrmann, & Szalai, 2005; Morris et al., 2001; Tierney et al., 
1996). 
Some investigators have equated GDS 3 or CDR 0.5 to Petersen’s notion of MCI, but 
Petersen believes that this assumption might not always be correct, stating that “as 
severity scales, these stages may correspond to MCI or may describe individuals with 
very mild dementia” (Petersen et al., 1999). As such, Petersen et al. (1999) believe that 
GDS and CDR are severity rating scales and not diagnostic instruments; consequentially 
they do not represent MCI’s syndrome as described by him.  
Although the earlier criteria for MCI were specific to memory deficits, developments 
have extended so that its definition could include non-memory deficits and 
impairment in several cognitive domains, and clinical subtypes with multiple 
aetiologies and many potential causes (Petersen, 2004; Winblad et al., 2004). A 
consensus conference concluded that while MCI represents a high-risk stage for the 
development of AD, its heterogeneity requires sub-classifications, such as: “amnestic 
MCI” (aMCI) which focuses on memory loss and may progress to AD; “multiple 
domains slightly impaired MCI” that may represent normal aging or may progress to 
AD or vascular dementia; and “single non-memory domain MCI” that may have a wide 
variety of outcomes (Petersen et al., 2001). More recently, multi-domain MCI was 
redefined and divided into amnestic and non-amnestic subtypes (Winblad et al., 2004). 
The classification of MCI can be operationalized in a stepwise manner, taking into 
account each criterion, as following: first, persons should be judged as not normal in 
spite of not fulfilling diagnostic criteria for dementia; secondly, functional ADL are 
mainly preserved, or at least with minimal impairment; furthermore, there should be 
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evidence of cognitive decline, measured either by self and/or informant report in 
conjunction with deficits on objective cognitive tasks, and/or evidence of decline over 
time on objective neuropsychological assessment (Winblad et al., 2004). 
In order to determine the specific subtype of MCI, comprehensive cognitive 
assessment through neuropsychological testing is essential. Nevertheless, no generally 
accepted instruments were recommended and specific domains of episodic memory 
might be assessed with different paradigms (word list learning procedure or paragraph 
recall) (Winblad et al., 2004). If the subject’s memory is significantly lower than would 
be expected for their age and educational level, the clinician must determine whether 
other cognitive domains are also impaired (e.g. language, executive function or 
visuospatial skills) and when non-memory domains are intact, classifying the person as 
having aMCI; if there are mild deficits in a number of different domains, multi-domain 
MCI (with or without a memory component) applies (Petersen et al., 2001; Winblad et 
al., 2004). Alternatively, when there is cognitive impairment in a single non-memory 
domain – like an isolated deficit in language or visuospatial skill – single non-memory 
domain MCI would be the appropriate classification (Petersen et al., 2001; Winblad et 
al., 2004). 
Besides the increased risk of progressing (or “converting”) to dementia (AD) among 
aMCI persons (Petersen, 2000), findings on community-based samples have shown 
that 11.1 to 21.2% of those with aMCI remained stable MCI, and 33.3 to 55.6% 
converted to non-MCI, half of them reverting to normal two-years later (Ganguli et al., 
2004). These epidemiological studies highlight that many factors affecting cognitive 
performance in elderly populations can account for the reversibility of many MCI cases 
(Gauthier et al., 2006). 
Although accepting that the rate of progression to AD is increased in MCI, researchers 
have drawn conflicting hypothesis on why not all individuals identified with MCI 
appear to progress to AD (Davis & Rockwood, 2004). It has been suggested that MCI 
may represent an incipient form of AD which would be revealed with a sufficiently long 
period of follow-up – “early-stage AD” (Morris et al., 2001) or “prodromal AD” (Dubois 
& Albert, 2004; Dubois, 2000). Alternatively, MCI may represent a heterogeneous 
group of individuals, among which some are at an increased risk to develop a 
neurodegenerative dementia, while others have a more non-progressive form of 
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cognitive impairment (Davis & Rockwood, 2004); supporting the latter view is the 
previously referred finding of reversibility of many MCI cases (Davis & Rockwood, 
2004; Ganguli et al., 2004). 
 
Revising the established criteria 
Combining both the interest in capturing the earliest stages of AD and the new 
available biomarkers of the illness, the International Working Group on AD (IWG-1; 
Dubois et al., 2007) developed and published new diagnostic criteria for AD. These 
revised criteria were established in order to overcome the limitations of both the DSM-
IV-TR and the NINCDS-ADRDA (1984 version). The IWG-1 core diagnostic criterion 
includes the evidence of a significant and progressive episodic memory impairment 
confirmed by objective testing; supportive features include at least one biological 
footprint of the disease: presence of medial temporal lobe atrophy, abnormal 
cerebrospinal fluid biomarker, specific pattern on functional neuroimaging with FDG-
PET or an autosomal dominant mutation within the immediate family (Dubois et al., 
2007). The IWG-1 criteria were the first to introduce biomarkers into the core 
diagnostic framework in the presence of two requisite features (Dubois et al., 2010). 
The IWG-1 suggests that AD could be recognised in vivo and independently of 
dementia, therefore moving AD from a clinicopathological to a clinicobiological entity 
(Dubois et al., 2010). The great advance in the AD-biomarkers field is also due to the 
intense research interest in characterising the earliest stages of AD that precede 
dementia’s threshold, defined by functional disability (Dubois et al., 2007). By relying 
on AD- specific clinical and biological features, the newly proposed criteria enable its 
diagnosis with a high level of accuracy, even at the stage of earliest clinical 
manifestations – prodromal stage (Dubois et al., 2007, 2010). The IWG-1 suggested 
and operationalised the term prodromal AD to define the symptomatic pre-dementia 
phase of AD that is characterised by symptoms not severe enough to meet diagnostic 
criteria for AD. This concept refers to clinically affected patients who do not yet have 
dementia and who are diagnosed to have AD on the basis of their clinical presentation 
and supportive evidence of Alzheimer’s pathology from biomarkers (Dubois et al., 
2010). 
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Prodromal AD must be distinguished from the wide and heterogeneous state of 
cognitive functioning that falls outside normal ageing (Dubois & Albert, 2004). This 
state corresponds to the previously reported nosological terms of AAMI, AACD, ARCD, 
MCD, CIND and MCI. The IWG-1 recognises the subtyping of Petersen’s MCI in order to 
address its assumed clinical and pathological heterogeneity. However, it is known that 
not all aMCI patients that clinically progress to dementia met neuropathological 
criteria for AD. Accordingly, the IWG-1 believes that applying clinically AD criteria to 
aMCI, without objective evidence such as neuroimaging or cerebrospinal fluid (CSF) 
analyses, will lack specificity for predicting the future development of AD, due to the 
high presence of non-AD pathology (Dubois et al., 2007). As such, the IWG-1 proposal 
for a multidimensional identification of AD would advance the heterogeneous state of 
MCI to the next level of identifying prodromal AD (Dubois et al., 2007). 
Despite the IWG-1 great interest in capturing the early stages of AD, this framework 
aimed also to amend the low specificity of DSM-IV-TR and NINCDS-ADRA criteria 
against other dementias, by improving both the recognition of non-AD dementias and 
the identification of AD phenotype (Dubois et al., 2007).  
Although the IWG-1 framework raised an innovative way to classify AD, it did not 
initially address the nosology of AD-related states as “dual clinicobiological entities” 
that require both a clinical typical phenotype and AD specific neuropathological 
changes (Dubois et al., 2010). Additionally, it focused only on typical AD with amnestic 
presentations, and some conditions that were not considered within the new research 
criteria framework include: clinically asymptomatic individuals who are positive for 
biomarkers of Alzheimer’s pathology; clinically symptomatic individuals without 
evidence of biomarker findings; and those with atypical features (atypical AD) (Dubois 
et al., 2010). Atypical presentations of AD include non-amnestic focal cortical 
syndromes, such as progressive non-fluent aphasia, logopenic aphasia, and posterior 
cortical atrophy (PCA), which are neuropathologically confirmed as being AD (Dubois et 
al., 2010, 2014). Therefore, in 2010, the IWG provided a broader diagnostic coverage 
of the AD clinical spectrum and proposed a common new lexicon to account for the 
different entities and concepts related to AD. The basis of this lexicon is to consider AD 
solely as a clinical and symptomatic entity that encompasses both the pre-dementia 
and the dementia phases (Dubois et al., 2010). Prodromal AD is also called “pre-
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dementia stage of AD”, in the new lexicon, and is now included in the new definition of 
AD; AD is distinguished based on its clinical phenotype as “typical” (most common 
clinical phenotype) and “atypical” (less common and well characterised clinical 
phenotypes that occur with Alzheimer’s pathology); “mixed AD” (diagnostic criteria for 
typical AD and additional evidence of other comorbid disorders); “preclinical states of 
AD” (including both “asymptomatic at-risk state for AD” and “pre-symptomatic AD”). 
MCI remains as a term of exclusion for individuals who are suspected to have but do 
not meet the proposed new research criteria for AD (meaning that they do not present 
the clinicobiological phenotype of prodromal AD either because memory symptoms 
are not characteristic of AD or because they are biomarker negative) (Dubois et al., 
2010). The new lexicon specifies that prodromal AD should not be confused with 
preclinical AD: while the former describes a symptomatic disease phase, no matter 
how early, the latter refers to the preceding asymptomatic state (Dubois et al., 2010). 
Importantly, it proposed the conceptual shift between prodromal AD and MCI: 
subjects previously diagnosed as having MCI should no longer be considered at risk for 
developing AD dementia, but should instead be recognised as already having AD at a 
prodromal stage with an inevitable progression to AD dementia over time (Dubois et 
al., 2010). According to the IWG-1 new criteria, a clinical phenotype combined with 
biomarker evidence will now no longer be predictive of AD but diagnostic; therefore 
the diagnosis of prodromal AD is preferred over MCI, considering that an early 
identification of the disease responsible for the syndrome is more valuable for the 
patient in terms of prognosis and treatment (Dubois et al., 2010).  
The National Institute on Aging–Alzheimer’s Association (NIA–AA; Jack et al., 2011) 
criteria were updated to encompass also the biological footprints that were developed 
and established ever since. These revised diagnostic guidelines, similarly to IWG, 
advanced the NINCDS–ADRDA framework to cover the full staging of the disease: the 
dementia phase (due to AD; McKhann et al., 2011); the symptomatic, pre-dementia 
phase (MCI due to AD; Albert et al., 2011); and the asymptomatic, preclinical phase of 
AD (Sperling et al., 2011). Accordingly, the revised NIA-AA framework distinguishes the 
syndromic labels (that denote different qualitative and quantitative clinical expressions 
of disease) from the pathophysiological process (that underlies the syndrome) across 
the three phases. Although the reference to biomarkers is used in the revised 
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definitions in all three AD-disease phases, the role of biomarkers differs somewhat 
amongst them. In the preclinical phase, “biomarkers are used to establish the presence 
of AD pathophysiological processes in research subjects with no or very subtle overt 
symptoms” (Jack et al., 2011). In both the MCI and AD dementia phases, clinical criteria 
are dominant and biomarkers are complimentary, i.e., the core clinical diagnostic 
criteria are completely operational in a setting, regardless of biomarkers’ access. 
Considering this general rule, in the symptomatic pre-dementia phase (MCI due to AD), 
biomarkers are used to establish the underlying aetiology and its severity indicates the 
likelihood of imminent progression to AD dementia (Albert et al., 2011; Jack et al., 
2011). In the dementia phase (due to AD), biomarkers are used to adjust the level of 
certainty that the pathophysiological processes causes the dementia in an individual 
(Jack et al., 2011; McKhann et al., 2011). The two major classes of biomarkers (amyloid 
accumulation and neuronal degeneration or injury) are treated as equivalently in both 
the MCI and dementia criteria. In contrast, in the preclinical criteria, they are ranked in 
a temporal hierarchy in which amyloid biomarkers become abnormal first and 
neuronal injury biomarkers become abnormal later (Jack et al., 2011; Sperling et al., 
2011). While this temporal ordering concept for biomarkers is central to the staging 
proposed in the preclinical research criteria, its use is much more conservative in 
symptomatic subjects, as “it was felt to be a judicious approach pending more 
definitive outcomes research in this area” (Jack et al., 2011). Another fundamental 
difference is that the core clinical criteria of the recommendations regarding AD 
dementia and MCI due to AD are intended to guide diagnosis in clinical settings, while 
the preclinical AD is intended for research purposes (Jack et al., 2011). Concerning the 
diagnosis of MCI due to AD, whose definition is very similar to the one previously 
described by Petersen et al. (1999, 2001), its core clinical criteria include: a concern 
regarding a change in cognition, an impairment in one or more cognitive domains, 
preservation of independence in functional abilities, and absence of dementia (Albert 
et al., 2011). The applicability of criteria for MCI due to AD, as it is proposed by the 
NIA-AA framework in both the community and clinical trials settings, has already been 
confirmed (Petersen et al., 2013). These criteria represent an improvement in the 
previous efforts to define MCI and define an entity of MCI owing to AD 
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pathophysiological processes, based on the conjunction of the clinical diagnosis and 
the presence of biomarkers (Jack et al., 2011).  
In what respects the criteria for dementia because of AD, and specially the revised 
criteria for probable AD dementia, it has expanded the scope of the 1984 NINCDS–
ADRDA framework and included biomarker enhancements to the diagnosis of AD 
dementia (Jack et al., 2011). The diagnosis of dementia due to AD is divided into 
probable AD dementia, possible AD dementia (atypical course and mixed 
presentation), and probable or possible AD dementia with evidence of the AD 
pathophysiological process (including biomarker evidence). A two-step diagnostic 
process of an initial criterion for dementia followed by clinical criteria for probable AD 
is sustained in this revised version, and it includes the amnestic and non-amnestic 
(language, visuospatial, and executive dysfunction) presentations, according to the 
initial and most prominent cognitive deficits (McKhann et al., 2011).  
Finally, the preclinical stages of AD aim at reviewing biomarker, epidemiological, and 
neuropsychological AD-evidence, and to develop recommendations to determine the 
factors which best predict the risk of progression from “normal” cognition to MCI and 
AD dementia; these recommendations are solely intended for research purposes and 
do not have any clinical implications (Sperling et al., 2011). 
The NIA-AA framework shared many features with the IWG-1 criteria, including the 
integration of AD biomarkers in the diagnostic process, and the recognition of an 
asymptomatic biomarker-positive stage (Dubois et al., 2007, 2014; Jack et al., 2011). 
However, the NIA–AA criteria differ conceptually from the IWG criteria in several 
points (Dubois et al., 2014): i) The NIA–AA suggested three different sets of diagnostic 
criteria, one for each disease stage: dementia phase (due to AD), pre-dementia phase 
(MCI due to AD), and preclinical phase of AD (Jack et al., 2011), while the IWG criteria 
characterises a disease (AD) and not a syndrome (MCI or dementia) (Dubois et al., 
2014); ii) although both frameworks recognise that the disease starts before the 
occurrence of clinical symptoms, the NIA–AA criteria support the diagnosis of AD in 
asymptomatic individuals with biomarker evidence of amyloid accumulation (Sperling 
et al., 2011), whereas the IWG-1 considers it to be only an at risk of disease state 
(Dubois et al., 2007); iii) the NIA–AA criteria provides, both for the MCI and dementia 
stages, different levels of probabilistic likelihood (high, intermediate, or unlikely) that 
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the syndrome is due to AD based on biomarker information (Albert et al., 2011; Dubois 
et al., 2014; McKhann et al., 2011); iv) the NIA–AA diagnostic framework has the 
advantage of being applicable when no supportive biomarkers are available, although 
at the expense of diagnostic specificity (Dubois et al., 2014). Yet, “the IWG criteria are 
less complex in their semiology, have the advantage of consistency, and are more 
readily applicable in clinical trials and in clinical diagnosis when biomarkers are 
available” (Dubois et al., 2014). 
In 2014, advances to improve the diagnostic framework were proposed by the IWG-2 
(Dubois et al., 2014). The diagnosis of AD was simplified, requiring the presence of an 
appropriate clinical AD phenotype (typical or atypical) and a pathophysiological 
biomarker consistent with the presence of Alzheimer’s pathology; and further 
elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, 
and for the preclinical states of AD (Dubois et al., 2014). The proposed diagnostic 
change for typical AD is to include either pathophysiological markers of Alzheimer’s 
amyloid pathology in CSF (Aβ and tau) or evidence of amyloid deposition in [Pittsburgh 
compound B (PiB-PET)]. The rationale is that they exhibited the highest specificity 
when correlated to the underlying AD pathology in post-mortem studies, and are the 
“most specific biomarkers to determine that an individual is within the AD continuum 
even several years before the clinical onset of disease” (Dubois et al., 2014). This 
change in the diagnostic algorithm enabled AD diagnosis to be extended into the 
prodromal stage, where the disease can be identified with supportive biomarkers as 
markers of Alzheimer’s pathology. Thus, the designation of prodromal AD disappears, 
and the designation of AD encompassing both the pre-dementia and dementia stages 
uses the same criteria irrespective of the severity of cognitive and functional deficits 
(Dubois et al., 2014). 
Vos et al. (2015) compared the two sets of framework from the IWG (1 and 2) and the 
NIA-AA criteria on prevalence and outcome of Alzheimer’s disease at the MCI stage in 
a 3-year longitudinal study, based on a large multicentre consortium. Their results 
support the use of all the framework research criteria to identify AD at the MCI stage. 
The NIA-AA criteria revealed the most accurate prognosis in clinical settings, whereas 
for clinical trials, selection of subjects either in the NIA-AA (high AD likelihood) or the 
IWG-2 (prodromal AD) could be considered (Vos et al., 2015). 
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Memory impairment  
Due to the early and pronounced damage in the hippocampus and its related 
structures, memory is the leading cognitive impairment in (typical) AD. These brain 
medial temporal regions are one of the major structures of the Papez circuit involved 
in the declarative memory and specially in episodic memory, which is critical for the 
acquisition and retention of new information (Squire & Kandel, 1999; Squire, Stark, & 
Clark, 2004). The initial symptom of a decline in episodic memory – “forgetfulness” – is 
often expressed in ADL as an inability to remember recent events, conversations or 
appointments and forgetting the names of new acquaintances (Salmon, 2000). 
Because memory problems are also the most frequent complaint in the elderly 
(Goeman & De Deyn, 2003) and may be the result of normal ageing or of various 
clinical conditions (such as depression), they should be carefully taken into account as 
they are also associated to a high risk of AD. Impairment in declarative episodic 
memory (the fact-oriented memory system that allows the storage and recall of 
specific information and experiences) is the most prevalent and prominent feature of 
AD spectrum disorders, and its objective evidence on neuropsychological tests is 
transversal to all the clinical diagnostic criteria (Albert et al., 2011; American 
Psychiatric Association, 1994, 2000; Dubois et al., 2007, 2010, 2014; Jack et al., 2011; 
Mckhann et al., 1984, 2011; Morris et al., 2001; Petersen, 2004; Petersen et al., 1999; 
World Health Organization, 1993); likewise it is often considered an essential (but not 
sufficient) feature for a clinical diagnosis. Neuropsychological evaluation of AD patients 
reveal significant impairments in their ability to learn and retain new verbal or non-
verbal information (i.e., anterograde amnesia), as well as deficits in the ability to 
recollect previously well-known information from the past (i.e., retrograde amnesia) 
(Salmon, 2000); while the former gets worse with the disease progression, the latter is 
more present in the more advanced stages of AD. Memory for concepts, the meaning 
of words, and factual information may also be impaired in patients with AD, even in its 
early stages; furthermore these memory deficits encompass all aspects of cognition 
and contribute to impairments in non-memory cognitive domains such as language, 
conceptualization, and visuospatial functioning (Salmon, 2000).  
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According to cognitive psychology, memory processing is based in a three-stage 
information system: encoding (learning), storage and retrieval (Baddeley, 2004). 
Moreover, three kinds of memory are distinguishable, providing a suitable framework 
for conceptualizing and understanding dysfunctional memory: sensory memory (or 
registration), short term (immediate memory), and long term memory (Lezak, 1995). 
Clinically, measures of the ability to learn and retain new information are quite useful 
in differentiating between healthy ageing elders and AD patients, and delayed recall 
trials revealed to be more effective than measures of learning across trials (Salmon, 
2000). Nevertheless, “impaired delayed recall is not itself evidence of an AD-related 
memory disorder”, and deficits in encoding and storage processes that are 
characteristic for AD must be distinguished from non-AD deficits that can also affect 
delayed recall, such as attentional difficulties or inefficient retrieval strategies that may 
be present in normal ageing or in other clinical conditions (Dubois et al., 2007). 
The nature of the memory defect of AD has been studied through a variety of methods 
and paradigms, mostly looking at aspects of verbal memory. On tests of free recall, AD 
patients perform very poorly either on tests with meaningful material (sentences, 
stories) or on rote learning tasks, displaying the most severe losses in the earliest 
stimuli presented in a series (primacy effect) (Lezak, 1995). Moreover, AD patients’ 
responses on memory tests tend to include as many or more intrusions or other kinds 
of errors as correct answers, and they do not benefit either from repetition or cueing 
(Lezak, 1995). Forgetting further compromises the defective learning process, leading 
to retrieval and recognition problems where the latter is represented by a deficit in 
discriminating between target items and distractors or false positive responses, thus 
comprising a large proportion of the total number of responses (Lezak, 1995). 
The contribution of cognitive studies in searching for an early AD-diagnosis revealed 
that the changes associated to AD can be detected before its effective diagnosis, and 
people experiencing these impairments can be distinguished from healthy elders 
through the administration of conventional neuropsychological tests; moreover, the 
literature supports that it is possible to identify and quantify the cognitive deficits 
associated with the preclinical stages of AD and MCI using neuropsychological 
measures (Collie & Maruff, 2000).  
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Buschke, Sliwinski, Kuslansky, and Lipton (1997) proved that an accurate diagnosis of 
the episodic memory deficit of AD can be improved through the use of tests that 
provide encoding specificity. This principle states that memory retrieval is best in 
conditions that match encoding conditions the closest, enabling superior memory 
effectiveness when information available at encoding is also present at retrieval 
(Tulving & Thomson, 1973). Within the encoding specificity paradigm, test materials 
are encoded along specific cues that are used to control for an effective encoding and 
are subsequently presented to maximise retrieval (Tulving & Thomson, 1973).  
Cognitive decline on tasks that involve episodic learning and recall are consistently 
reported as being able to discriminate preclinical AD patients both from normal elderly 
controls and probable AD subjects (Collie & Maruff, 2000). Furthermore, aMCI patients 
present a memory deficit with normal short-term memory abilities and poor episodic 
long-term memory when comparable to mild AD patients, thus supporting the 
hypothesis that “a pure amnesic syndrome characterizes the preclinical phase of AD” 
(Perri, Carlesimo, Serra, & Caltagirone, 2005). This amnestic profile of AD-related 
disorders is typically characterized by poor learning and rapid memory decay over 
relatively short periods, often concurrent with damage to the medial temporal 
structures (Squire, Stark, & Clark, 2004), and should be confirmed for an accurate 
diagnosis of (typical) AD spectrum disorders through the use of cued recall measures 
based on encoding specificity (Dubois et al., 2007, 2014). 
Despite the episodic memory deficit, other cognitive changes could be associated to 
AD, such as impairment in orientation, executive functioning, language, praxis, 
visuospatial abilities and gnosis (Dubois et al., 2007; Geldmacher, 2009). As previously 
referred, the presence of a dysfunction in at least another cognitive domain, along 
with memory, is mandatory on NIA-AA (McKhann et al., 2011) and DSM-IV-TR criteria 
(American Psychiatric Association, 2000). 
Therefore, the neuropsychological evaluation is considered fundamental on the 
investigation of AD. Together with a comprehensive neuropsychological assessment 
covering different cognitive functions, the evaluation of functional performance on 
ADL is of great importance on the diagnosis. 
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Biomarkers 
According to Jack et al. (2011) “biomarkers are parameters (physiological, biochemical, 
anatomic) that can be measured in vivo and that reflect specific features of disease-
related pathophysiological processes”. The increasing availability of data on 
biomarkers’ performance and operationalization reinforces their robustness and 
scientific progress on AD research (Dubois et al., 2014). In the most recent 
frameworks, researchers divided biomarkers’ categories according to their relation to 
AD pathology. The NIA-AA group considered two major categories: biomarkers of Aβ 
accumulation, and biomarkers of neuronal degeneration or injury (Jack et al., 2011); 
and the IWG-2 categorised them as pathophysiological or topographical if they 
identified downstream brain changes indicative of the regional distribution of AD 
pathology (Dubois et al., 2014). 
Cerebrospinal fluid (CSF) 
Although AD may be seen as a multifactorial disorder, with “different primary 
mechanisms resulting in similar patterns of neuronal failure and pathological 
expression in different individuals” (Geldmacher, 2009), its hallmark pathological 
features remain, besides neuronal death and synaptic dysfunction, the neuritic plaques 
(NP) and the neurofibrillary tangles (NFT) (Braak & Braak, 1997) only accessed through 
brain biopsy/autopsy. NP are extracellular structures with a central core of amyloid 
beta (Aβ) and cellular elements, namely dystrophic neuritis; NFT consist of intracellular 
collections of tau protein hyperphosphorylated and deposited as abnormal filaments 
with a distinctive paired helical structure (Geldmacher, 2009). Along with Aβ 
aggregation, the tau protein represents hallmarks of AD, and although there are 
several mechanistic links between both proteins, controversy remains about which 
one is primary involved in the cascade of events that leads to neuronal death in AD. 
The hypothesis of the amyloid cascade (Hardy & Higgins, 1992) as well as the 
identification of mutation in the Aβ precursor protein (APP), as a cause of early genetic 
cases of AD, place Aβ as a primary pathophysiological target in the majority of disease-
models. Despite these evidences, mechanisms leading to Aβ deposition and plaque 
formation in late-onset cases are much more controversial (Geldmacher, 2009): 
“either an increased proportion of Aβ is produced, or there is reduced clearance of Aβ, 
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or there is some combination of the two factors”. Moreover there are other factors 
playing as intermediary mechanisms of cellular death and eventually as triggering 
factors in the amyloid cascade, namely oxidative stress or bioenergetic failure 
(Swerdlow & Khan, 2004). Those proteins can be accessed in CSF and their 
concentrations are expected to reflect brain events, namely sequestration of Aβ42 in 
NP, conditioning low CSF levels as well as increased levels of tau and of its 
phosphorylated form (P-tau) as consequence of neuronal death. Back in the old 
NINCDS–ADRDA guidelines, CSF examination was recommended as an exclusion 
procedure for non-AD dementia (Mckhann et al., 1984); since that time, the CSF AD-
profile, with low Aβ levels and high tau (total or phosphorylated) when compared to 
healthy controls (Motter et al., 1995; Vandermeeren et al., 1993), was recognized and 
valued as an important biomarker for AD and was further included in the most recent 
diagnostic framework criteria (Dubois et al., 2007, 2010, 2014; McKhann et al., 2011). 
Moreover, since the high diagnostic value of CSF biomarkers in MCI stage has been 
proved over memory impairment in the diagnostic scheme, its inclusion as a diagnostic 
criterion provides an incremental value in identifying prodromal AD (Dubois et al., 
2007). As referred before, the high specificity of CSF biomarkers, when correlated to 
the underlying AD pathology in post-mortem studies, enabled the IWG-2 criteria to 
keep it as a pathophysiological benchmark criterion for typical AD (Dubois et al., 2014). 
Nevertheless, because CSF proteins are also altered in other neurological disorders, 
and Aβ elevations in AD are more specific than tau alterations, the NIA-AA divided 
these proteins into the major categories: low Aβ42 as a biomarker of Aβ accumulation, 
and elevated tau as a marker of neuronal degeneration or injury (Jack et al., 2011). 
Neuroimaging 
Neuronal death and widespread cortical synaptic loss occur in AD and are the major 
determinants of cognitive disability, with the deep layers of the temporal cortex and 
the hippocampus suffering the greatest degree of synaptic loss (Geldmacher, 2009) 
and leading to significant cortical atrophy. This atrophy of the medial temporal lobe 
(MTL) structures, assessed through cerebral structural Magnetic Resonance Imaging 
(MRI), showed to be common in AD, frequent in MCI, but less frequent in healthy 
ageing (De Leon et al., 1997; Visser, Scheltens, Pelgrim, & Verhey, 2005). As expected, 
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a strong correlation between MTL volumes and memory performance has been 
showed in patients with AD (Deweer et al., 1995). Nonetheless, in MCI studies, and 
despite the fact that qualitative MTL atrophy ratings could identify prodromal AD, its 
low accuracy limits its usefulness as an early-identification biomarker (Dubois et al., 
2007). Because MRI had proved to be important in differential diagnosis, by 
distinguishing patients with AD from those with non-AD dementia (Wahlund, 2000), 
the inclusion of MTL atrophy as a supportive diagnostic criterion for AD is justified in 
order to exclude other causes of MTL structural abnormality (Dubois et al., 2007). Its 
assumption as a biomarker in the framework of the different diagnostic criteria is more 
contentious: while the NIA-AA criteria placed structural MRI achievements as a 
biomarker of neuronal degeneration or injury, within a pattern involving medial, basal, 
and lateral temporal lobes and medial and lateral parietal cortices atrophy (Jack et al., 
2011); the IWG-2 framework positioned it as downstream topographical marker 
playing the role of an additional investigation to exclude other causes of cognitive 
disorders or dementia (Dubois et al., 2014). 
Molecular neuroimaging methods are gradually more integrated into the clinical 
routine evaluation of dementia. Those include single-photon emission computed 
tomography (SPECT), positron emission tomography (PET) as in vivo nuclear 
radioisotopic scans that can measure blood flow (HMPAO SPECT), glucose metabolism 
[fluorodeoxyglucose (FDG-PET)], and, more recently, protein aggregates of amyloid 
(PiB-PET) and tau (tau radiotracers). Within AD diagnosis, both techniques have been 
successful in distinguishing different forms of dementia and also in discriminating 
patients from normal subjects (Coleman, 2005; Dougall, Bruggink, & Ebmeier, 2004). 
The most consistent pattern described in AD is a reduction of glucose metabolism or 
hypoperfusion in posterior bilateral temporal parietal regions and in the posterior 
cingulate gyrus (Coleman, 2005). Using this regional pattern, FDG-PET reached 
sensitivity and specificity of 86% in the discrimination between AD patients from 
healthy controls (Patwardhan, McCrory, Matchar, Samsa, & Rutschmann, 2004), while 
SPECT pooled weighted sensitivity and specificity values of 77% and 89%, respectively 
(Dougall et al., 2004). The relevance of these molecular neuroimaging techniques in 
the prognosis of clinical deterioration in MCI patients is controversial due to the small 
samples size and limited follow-ups. The usefulness of FDG-PET reached an overall 
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diagnostic accuracy of 84% for predicted conversion to AD (Mosconi et al., 2004), 
whereas SPECT images identified pre-clinical AD with an accuracy of 78% when 
combined with baseline memory deficits; the hypoperfusion pattern involved the 
parietal and temporal lobes, precuneus, and posterior cingulate cortex (Borroni et al., 
2006). Because the low diagnostic accuracy of SPECT falls below the requisite of 80% 
accuracy levels, it was not included in any of the criteria (Dubois et al., 2007; Jack et al., 
2011). On the other hand, the decreased glucose metabolism on FDG-PET has been 
included as a supportive feature in the IWG-1 criteria (Dubois et al., 2007), and as a 
biomarker of neuronal degeneration or injury in the NIA-AA framework (Jack et al., 
2011); but the IWG-2 framework positioned it also as a downstream topographical 
marker, which may “better serve in the measurement and monitoring of the course of 
disease” (Dubois et al., 2014). More recently, the powerful PET techniques that 
provide in-vivo visualisation of amyloid and potentially NFT are gaining ground – 
amyloid PET (or PiB-PET) (Klunk et al., 2004). Both quantitative and qualitative 
measures of amyloid pathology with PET ligands have strongly correlated with post-
mortem senile NP pathology (Wolk et al., 2011) and have shown good predictability for 
progression to AD dementia in MCI groups (Visser & Knopman, 2009). Therefore, 
amyloid PET is considered as a valid pathophysiological marker of brain fibrillar 
amyloid pathology (Dubois et al., 2014). Accordingly, it is included in the more recent 
framework criteria both as a pathophysiological biomarker (Dubois et al., 2014) and as 
a biomarker of Aβ accumulation (Jack et al., 2011). 
Genetics 
AD is a genetically complex and heterogeneous disorder, as it follows an age-related 
dichotomy in which rare autosomal dominant mutations cause early-onset familial AD, 
while risk for late-onset AD is probably modulated by genetic variants with relatively 
low penetrance but high prevalence (Tanzi, 1999). Early-onset (<60 years) AD is caused 
by defects in any of three different genes: presenilin 1 (PSEN1) on chromosome 14, 
presenilin 2 (PSEN2) on chromosome 1, and the amyloid β protein precursor (APP) on 
chromosome 21; yet, late-onset AD is associated with genetic polymorphisms that 
appear to operate as risk factors and/or genetic modifiers (Tanzi, 1999). The ε4 allele 
of the apolipoprotein E (ApoE) is the only firmly established genetic susceptibility 
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factor associated with anticipation and increased risk for sporadic late-onset AD (Tanzi, 
1999). However, the contribution of the ApoE to AD pathogenesis is still controversial: 
whereas some admit its involvement in Aβ circulation serving as an amyloid catalyst or 
“pathological chaperone” (Wisniewski & Frangione, 1992), others indicate it as an 
inflammatory and/or acute phase protein that plays an essential role in accelerating 
the disease progress (Nilsson, Rogers, & Potter, 1998). While ApoE-ε4 has been 
confirmed as a strong risk factor for AD, it is clearly not necessary for the development 
of AD: first, it is present in 20-30% of the general population, so its presence in an AD 
subject does not necessarily mean that it is responsible for the disease; second, even 
though carriers of the ε4 allele in homozygosity have a great risk (80%), it is not 
sufficient to cause the disease; finally, the ApoE-ε4 appears to act primarily as a 
modifier of age at onset of AD (Tanzi, 1999). For these reasons, none of the diagnostic 
frameworks considers the carriage of the ε4 allele as a positive AD biomarker (Dubois 
et al., 2007, 2014; McKhann et al., 2011). On the other hand, the autosomal dominant 
mutations (PSEN1, PSEN2, or APP) are fully penetrant which means that a proband 
with genetic-testing evidence of one of those mutations can be considered as “strongly 
supportive for the diagnosis of AD for affected individuals within the immediate family 
who did not themselves have a genetic test for this mutation” (Dubois et al., 2007). For 
the IWG-1 and IWG-2 diagnostic frameworks, the presence of an autosomal dominant 
genetic mutation is a diagnostic marker of the disease that, together with an amnestic 
deficit, meets criteria for AD (Dubois et al., 2007, 2014). The NIA-AA criteria considers 
the evidence of a causative genetic mutation, in one of the referred genes, as 
increasing the certainty of an AD pathology condition (McKhann et al., 2011). 
 
Looking for new biomarkers  
As previously reported, apart from the objective episodic memory deficit, additional 
brain systems may be altered in the AD spectrum leading to impairment in other 
cognitive changes such as orientation, executive functioning, language, praxis, 
visuospatial abilities and gnosis (Dubois et al., 2007; Geldmacher, 2009). Besides, 
structural imaging in AD reveals a pattern of atrophy that surpasses the medial 
temporal lobes and involves the medial and lateral parietal cortices (Jack et al., 2011). 
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This pattern is corroborated by molecular neuroimaging that demonstrates both 
hypometabolism and hypoperfusion in bilateral temporal parietal regions and in the 
posterior cingulate gyrus (Coleman, 2005). Moreover, recent evidence indicates that 
sensory and motor changes may precede these well-known AD cognitive alterations, 
focusing on age-related and neuropathological changes in the olfactory, visual, 
auditory, and motor systems (Albers et al., 2015). 
Vision is a well-studied cortical function that encompasses not only occipital but also 
temporal and parietal brain areas. Accordingly, the visuospatial processing is 
supported by two main pathways: the ventral stream – consisting of occipitotemporal 
regions that enable the recognition of object shape properties (Milner & Goodale, 
2008) - and the dorsal pathway that is involved in spatial vision and motion perception, 
including structure-from-motion (SFM) integration, which comprises extracting three-
dimensional shapes from depth and motion cues (Farivar, 2009; Konen & Kastner, 
2008). For this reason, visual function studies associated with these two pathways 
allow to infer about the performance of the temporal and parietal lobes. In the specific 
case of AD, studies focusing on vision are important because ventral and dorsal regions 
may be important for predicting AD and understanding its pathophysiology (Jacobs et 
al., 2015; Rizzo, Anderson, & Nawrot, 2000; Villain et al., 2010). Moreover, AD 
neuropathological findings (NFT and NP) are also present in the visual cortical areas, 
especially in the visual association areas (Valenti, 2004), leading to impaired visual 
function in this condition. 
Visual impairments have been extensively reported in AD, ranging from contrast 
sensitivity and colour perception deficits to impairments in higher-order visual 
functions, including: SFM perception, object and face perception and visual attention, 
visual memory and learning (Duffy, Tetewsky, & O’Brien, 2000; Rizzo et al., 2000). 
These visual perceptual impairments, apart from deficits in topographical memory, 
may explain why AD patients get lost in familiar surroundings, providing evidence for 
the clinically important symptom of visuospatial disorientation present in this 
condition (Tetewsky & Duffy, 1999). Furthermore, posterior cortical atrophy (PCA) or 
AD’s visuospatial presentation (McKhann et al., 2011) is now accepted amongst the 
atypical forms of AD (Dubois et al., 2010, 2014). This condition is characterized by an 
insidiously progressive cognitive disorder where patients present early visual 
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complaints due to deficits in complex visual processing (Mendez, 2004), and is 
associated with atrophy of the occipital and occipitoparietal regions of the cerebral 
cortex.  
There is a lack of visual function studies in MCI, especially when compared to the 
amount of research in AD. Nevertheless, some studies report deficits in high-level 
visual functions, showing visual search and attentional impairment in MCI (Mapstone, 
Steffenella, & Duffy, 2003; Tales, Snowden, Haworth, & Wilcock, 2005). It seems that 
MCI subjects are impaired in some functions early on, but other functions seem to be 
preserved, at least in the initial stages. It would be interesting to investigate 
comprehensible visual function through the spectrum of AD, using MCI as a target and 
compare it to AD and healthy ageing subjects. Another important assessment-goal is 
the potential value of the visual function status as a predictor of MCI-conversion to 
dementia, either through the use of psychophysical techniques (like the majority of 
behavioural studies) or through the support of both structural and functional 
neuroimaging techniques. This topic will be addressed in the second chapter of this 
thesis through the investigation of the visuospatial processing in MCI and AD patients. 
 
General outline of the thesis 
The present thesis is divided in two chapters. In Chapter I we focus on the impairment 
of episodic memory and revise the interest of the cued recall measures, based on 
encoding specificity, for the assessment of AD spectrum disorders. In Chapter II we 
investigate the visuospatial processing of these conditions as a potential new 
biomarker. 
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CHAPTER I 
 
 
 
 
 
 
 
 
 
 
“Hay que haber empezado a perder la memoria, aunque sea solo a retazos, para darse cuenta 
de que esta memoria es lo que constituye toda nuestra vida. (…) Nuestra memoria es nuestra 
coherencia, nuestra razón, nuestra acción, nuestro sentimiento. Sin ella, no somos nada.”  
In Mi último suspiro, LUIS BUÑUEL
 
Introduction 
 
53 
 
In this chapter, we focus on the impairment of episodic memory of AD spectrum 
disorders and specifically address the use of cued recall measures based on encoding 
specificity, such as the Free and Cued Selective Reminding Test (FCSRT), as suggested 
by the IWG-1 (Dubois et al., 2007) and the IWG-2 (Dubois et al., 2014) criteria.  
 
Background  
Memory impairment is essential for the diagnosis of both aMCI (Petersen et al., 1999, 
2001) and AD (American Psychiatric Association, 2000; Dubois et al., 2007, 2014; 
McKhann et al., 2011), and also a strong predictor of dementia’s development (Dubois 
et al., 2007, 2014; Geerlings, Jonker, Bouter, Adèr, & Schmand, 1999). A compromise 
of the long-term episodic memory is the characteristic profile of mild AD (Perri, Serra, 
Carlesimo, Caltagirone, & Early Diagnosis Group of the Italian Interdisciplinary Network 
on Alzheimer’s Disease, 2007), as it reflects the early involvement of the hippocampus 
and its related structures. Moreover, these brain structures are critical in memory 
consolidation and tasks of delayed recall are particularly sensitive to hippocampal 
dysfunction. Standard criteria for the diagnosis of both aMCI and AD require an 
objective validation of a significant impairment in episodic memory on 
neuropsychological testing (Albert et al., 2011; Dubois et al., 2007, 2014; McKhann et 
al., 2011; Petersen et al., 1999, 2001). Therefore, the test used to identify this memory 
impairment should be highly accurate (Petersen, Smith, Ivnik, Kokmen, & Tangalos, 
1994), and individual deviations must be concretely specified along with its cut-off 
values (Petersen, 2004). In AD clinical practice, verbal memory impairment is assessed 
using different neuropsychological test paradigms (Burrell & Piguet, 2015; Lezak, 
Howieson, Bigler, & Tranel, 2012; Salmon, 2000). In addition to story passages (e.g., 
Wechsler Memory Scale – Logical Memory; WMS LM), common tasks include pairs 
(e.g., WMS Paired-Associate Learning), arrays (the Rey Auditory Verbal Learning Test - 
RAVLT, the Buschke Selective Reminding Test - SRT), or lists of words with variable 
semantic relations (the California Verbal Learning Test – CVLT, the Free and Cued 
Selective Reminding Test – FCSRT). Most of these tasks include immediate and delayed 
(i.e., after 20 – 30 min) recalls (free and/or cued) components, as well as recognition 
(Burrell & Piguet, 2015).  
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Considering the framework criteria for both AD and aMCI, there is no particular 
suggestion of a memory test for the diagnosis of aMCI (Petersen et al., 1999, 2001) or 
NIA-AA (Albert et al., 2011; McKhann et al., 2011). On the other hand, the IWG-1 
(Dubois et al., 2007) and the IWG-2 (Dubois et al., 2014) proposals suggested the use of 
cued recall measures for the early diagnosis of AD, based on encoding specificity to 
assess the memory impairment of AD spectrum disorders, such as the FCSRT (Buschke, 
1984; Grober & Buschke, 1987). 
 
The memory impairment in AD spectrum disorders 
Episodic memory deficits can be achieved either by tests that control for encoding at 
the time of study and provide retrieval cues at the time of testing or by traditional 
free-recall procedures in which encoding is typically not controlled and cues are not 
provided at retrieval (Carlesimo, Perri, & Caltagirone, 2011). Nevertheless, in the 
specific case of AD, the former type of declarative memory test is expected to be more 
effective than the latter in differentiating AD patients (preclinical or clinical phase) 
either from healthy controls or from patients with memory deficits caused by other 
pathological conditions (Carlesimo et al., 2011). In fact, an impairment on tasks of 
delayed recall as sensitive measures to hippocampal dysfunction is not itself evidence 
of an AD-related memory disorder, and the effectiveness of delayed recall trials 
(Salmon, 2000) in differentiating between patients with AD and healthy ageing 
subjects or other conditions is dependent on the paradigm for encoding the 
information. Accordingly, performance in delayed recall and consolidation reflect the 
quality of learning, and because of that, paradigms that control and superimpose 
reinforcement to the encoding process may increase test acuity (Belleville, Sylvain-Roy, 
de Boysson, & Ménard, 2008; Buschke, Sliwinski, Kuslansky, & Lipton, 1997; Moulin, 
James, Freeman, & Jones, 2004; Wang & Zhou, 2002). Therefore, deficits in encoding 
and storage processes that are characteristic of AD must be distinguished from non-AD 
deficits that can also affect delayed recall, such as attentional difficulties or inefficient 
retrieval strategies that may be present in normal ageing or in other clinical conditions 
(Dubois et al., 2007). Thus, if the experimental conditions ensure support for 
elaborative encoding and provide valuable cues at the time of retrieval, healthy 
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subjects and non-AD patients may have normal or quasi-normal retrieval accuracy 
(Carlesimo et al., 2011). It is predicted that the memory deficit in AD can be 
differentiated from deficits in the other conditions due to the presence of the 
qualitative features of mesio-temporal amnesia in the former and, conversely, the 
presence of memory impairment with qualitative features similar to frontal lobe 
amnesia in the latter (Carlesimo et al., 2011). 
The involvement of the hippocampal formation and entorhinal region in the AD 
spectrum is reflected as early as in aMCI, whose main cognitive characteristic is a 
deficit of declarative memory (Petersen et al., 2001). Therefore, the memory tests 
used in the assessment should be able to identifiy aMCI deficits that are more likely 
due to a severe failure of learning than to long-term processes of defective storage 
mechanisms (Carlesimo et al., 2011) and to define a pattern of memory dysfunction 
between MCI and AD. Highly accurate tests should indicate a similar profile of 
impairment among MCI patients with a higher risk of conversion to AD, therefore 
confirming its great predicitive value for conversion to AD. 
In this context, a memory test is undoubtly valid for the early detection of AD if its 
paradigm is correlated with supportive AD features, such as neuroimaging measures, 
showing the characteristic involvement of medial temporal lobe structures, and 
neurochemical (CSF) biomarkers. 
All these reasons reinforce the recommendation of the FCSRT (Buschke, 1984; Grober 
& Buschke, 1987) to assess the memory impairment of AD spectrum disorders by the 
IWG-1 (Dubois et al., 2007) and the IWG-2 (Dubois et al., 2014) criteria. 
 
The Free and Cued Selective Reminding Test (FCSRT) 
The FCSRT was designed to improve the original Buschke SRT (Buschke, 1973) for a 
more complete and accurate assessment of verbal learning and memory, and for the 
detection of its impairment (Buschke, 1984). The FCSRT method relies on cued recall, 
which allows the “control of processing by manipulation of encoding as well as 
retrieval through specified concurrent processing of cues and to-be-remembered 
target items during learning” (Buschke, 1984). 
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The paradigm that underlies the FCSRT is based on encoding specificity. This principle 
states that “specific encoding operations performed on what is perceived determine 
what is stored, and what is stored determines what retrieval cues are effective in 
providing access to what is stored”, i.e., memory retrieval is best in situations that 
match encoding conditions the closest, enabling superior memory effectiveness when 
the information available at encoding is also present at retrieval (Figure I) (Tulving & 
Thomson, 1973). This procedure has shown to promote deeper engagement with 
attention and semantic processing in the encoding phase of memory, and it also 
controls the conditions of retrieval through the use of the same cues to direct learning 
and produce effective cued recall (Tulving & Thomson, 1973). Tulving and Thomson 
(1973) argued that cueing aids recall if the cue information has been encoded with the 
target word at presentation and thus forms part of the same encoded unit. Moreover, 
in terms of cueing, a semantically orienting task leads to a higher retention than 
structural tasks in which the non-semantic aspects of the words are attended to (Craik 
& Tulving, 1975). Additionally, attention to the word's meaning is a necessary 
prerequisite of good retention (Craik & Tulving, 1975). Moreover, it is suggested that 
at encoding “the stimulus is interpreted in terms of the system's structured record of 
past learning, that is, knowledge of the world or semantic memory”, whereas at 
retrieval the information provided as a cue utilizes the same structure of semantic 
memory in order to reconstruct the initial encoding (Craik & Tulving, 1975).  
 
 
 
 
 
 
 
Concerning the type of stimulus, there is the suggestion that pictures allow a better 
retention due to a concomitant verbal and image code stimulation, whereas written 
words are confined to verbal coding (Paivio, 1995). Yet, turning individuals’ attention 
to semantic aspects of the to-be recalled pictures and words during encoding was 
found to eliminate the picture superiority effects (Paivio, 1975).  
Figure I - The Encoding Specificity Principle (based on Tulving & Thomson, 1973) 
Storage/ 
Retention 
Retrieval 
Encoding/ 
Learning 
 Semantic Cues 
Introduction 
 
57 
 
The FCSRT (Buschke, 1984; Grober & Buschke, 1987) is a memory test that controls 
attention and cognitive processing, requiring subjects to search for items in response 
to their category cues in the learning process. This multi-trial test uses a “selective 
reminding” paradigm by presenting only the words not recalled, instead of all the to-
be-remembered words. This paradigm is intended to facilitate learning by directing the 
subject's attention to the words not recalled in the previous trial. Furthermore, the 
category cues are given later to participants in order to elicit the recall of the items not 
retrieved on the free recall trial, thus controlling acquisition and retrieval. Performance 
on the cued recall trial provides an estimate of the items that the subject has stored, 
and it has been shown that this estimate is minimally affected by guessing (Grober, 
Gitlin, Bang, & Buschke, 1992). 
There are two versions of the FCSRT: the Busckhe’s FCSRT (Buschke, 1984; Buschke’s 
FCSRT. Copyright, 2002), that includes words to be identified and remembered, and 
the Grober-Busckhe modified version (Grober & Buschke, 1987), that includes pictures 
and comprises an immediate cued recall during the learning phase after the 
identification of a group of four items. The picture and word versions of the FCSRT 
showed to be moderately associated (free recall – 0.56; total recall – 0.46) in a sample 
of cognitively normal older adults, but should not be considered equivalent; still, 
formulas of conversion between the two versions are provided for nondemented older 
adults (Zimmerman et al., 2015). Nevertheless, the FCSRT (words’ version) present 
“printed words to avoid perceptual errors, ensure that all subjects use the same verbal 
encoding to learn the same items, and avoid dual perceptual and verbal encoding” 
(Buschke’s FCSRT. Copyright, 2002). 
This paradigm has been used in several normative studies in the aging population, 
providing normative data to be available for different language/cultural populations 
(Dion et al., 2015; Frasson et al., 2011; Girtler et al., 2015; Ivnik et al., 1997; Hind 
Mokri, Avila-Funes, Meillon, Gutiérrez Robledo, & Amieva, 2013; O’Connell & Tuokko, 
2002; Palomo et al., 2013; Peña-Casanova et al., 2009) and proving its interest as a 
valid neuropsychological instrument for the assessment of episodic memory. This test 
was also used in healthy ageing (Castro-Lionard et al., 2011; Vercambre et al., 2010) 
and confirmed that cognitive complaints of the elderly can either reflect objective 
memory impairment independently of affective disorders (Rouch et al., 2015), or be 
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associated with depressive symptoms rather than objective cognitive performance 
(Minett, Da Silva, Ortiz, & Bertolucci, 2008); furthermore, a poor performance on the 
FCSRT was associated with smaller hippocampal volumes and lower levels of 
hippocampal N-acetyl aspartate/creatine ratio metabolites among nondemented older 
adults (Zimmerman et al., 2008). 
This test was also used to assess memory deficits in other conditions, such as diabetes 
(Grober, Hall, Hahn, & Lipton, 2011), endogenous hormones (Zimmerman et al., 2011), 
blood pressure levels (Beauchet et al., 2010; Sacktor et al., 1999), chronic obstructive 
pulmonary disease (Crews et al., 2001), alcoholism (Chanraud et al., 2009), sleep 
behaviour disorders (Uguccioni et al., 2013; Uguccioni, Pallanca, Golmard, Leu-
Semenescu, & Arnulf, 2015), neurodegenerative Langerhans cell histiocytosis (Le 
Guennec et al., 2014), CADASIL (Epelbaum et al., 2011). 
Information concerning the psychometric properties of the FCSRT is scarce in the 
literature and limited to the modified Grober-Buschke procedure (Grober, Ocepek-
Welikson, & Teresi, 2009). When comparing the three available English test equivalent 
forms, the factor analysis indicate a single construct or dimension which the authors 
presumed to be memory ability. The three forms show good concurrent criterion 
validity, good internal consistencies and similar values of accuracy in the diagnosis of 
mild dementia (Grober et al., 2009). Moreover, the study of Zimmerman et al. (2015) 
reported good values of test-retest reliability for the Busckhe’s FCSRT word version 
(free recall – 0.80; total recall – 0.83), and modest association (r=0.36) between the 
FCSRT free recall and the WMS LM I subtest among healthy elders. 
The version of the test used throughout the present work is the Busckhe’s FCSRT. This 
version starts by asking subjects to identify words in response to a unique category 
cue. The 16 items to be learned are presented four at a time on a card, distributed by 
one word per quadrant. The subject is asked to search each card and point to and 
name aloud each item after its semantic cue was aurally presented. During this 
procedure, the subject is instructed to learn the 16 words. After this, there are three 
recall trials, each preceded by 20 seconds of counting backward to prevent recall from 
short-term memory. Each recall trial consists of two parts. First, each subject has up to 
two minutes to freely recall as many items as possible. Next, aurally presented 
category cues are provided for items not retrieved by free immediate recall (IR) - cued 
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IR. If subjects fail to retrieve the item within the category cue, they are reminded by 
presenting the cue and the item together. The sum of free and cued recalls gives a 
measure of total IR - TR. After a 30-minute interval, while subjects are required to 
perform non-verbal tasks, the same procedure of recalling (freely and cued) is done 
(delayed recall – DR) allowing the measure of free DR, cued DR, and total DR. 
 
The FCSRT in AD-related memory assessment  
The rationale underneath the use of the FCSRT in clinical neuropsychology is that its 
controlled search procedure during learning results in apparently normal cued recall by 
some amnesic patients with impaired free recall learning, suggesting that their ability 
to encode and retrieve may be relatively intact when they are induced to carry out 
effective processing during learning (Buschke, 1984). Consequently, the cued recall 
should be useful for the evaluation of residual learning and memory capacity. 
In the case of AD spectrum disorders, testing memory by controlling the learning 
conditions proved to be more sensitive to AD early signs (Buschke et al., 1997), and 
was able to distinguish its genuine deficits in encoding and storage from the memory 
deficits associated with normal ageing (Grober & Buschke, 1987). The memory 
impairment associated with healthy ageing was likely to be secondary to impaired 
attention, inefficient information processing, or ineffective retrieval operations 
(Grober & Buschke, 1987; Petersen, Smith, Kokmen, Ivnik, & Tangalos, 1992). Retrieval 
deficits that occur in healthy elders showed to improve with controlled learning 
procedures (Buschke, Sliwinski, Kuslansky, & Lipton, 1995; Grober, Merling, Heimlich, 
& Lipton, 1997). On the contrary, in patients with dementia of the AD-type these 
procedures have very limited benefits, and these patients are often not helped by 
semantic cueing (Buschke et al., 1997). As a consequence, controlled learning 
measures should expand the differences produced by normal ageing and dementia, 
thus improving discriminative validity (Grober, Sanders, Hall, & Lipton, 2010; Oltra-
Cucarella, Pérez-Elvira, & Duque, 2014), and allow the identification of the earliest 
stages of AD (Dubois et al., 2007, 2014). The utility of this cued selective reminding 
paradigm has been widely reported in the memory dysfunction characterization of AD 
(review studies, as following: (Carlesimo et al., 2011; de Souza, Sarazin, Goetz, & 
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Dubois, 2009; Lin, O’Connor, Rossom, Perdue, & Eckstrom, 2013; Lin, O’Connor, 
Rossom, Perdue, Burda, et al., 2013; Peña-Casanova, Sánchez-Benavides, de Sola, 
Manero-Borrás, & Casals-Coll, 2012). 
The first reported studies incorporated samples of AD, vascular dementia (VaD), and 
mixed dementia in their analysis. The total recall score was found to enable a higher 
sensitivity in identifying individuals with dementia compared to the free recall 
procedure (Grober, Buschke, Crystal, Bang, & Dresner, 1988; Grober & Buschke, 1987). 
Regarding specificity in identifying healthy matches, higher results were also achieved 
for total recall score rather than for free recall (Grober et al., 1988; Grober & Buschke, 
1987). In the same context, Buschke et al. (1997) proved that encoding specificity tests 
had substantially higher sensitivity (93%) and specificity (99%) for the diagnosis of early 
dementia than paradigms with category cues only used for retrieval (53%, 94%), the 
WMS Paired Associates (68%, 91%), and the WMS Logical Memory (48%, 92%). The 
FCSRT free recall showed a good sensitivity (86%) and a medium specificity (73%), at 
optimal cut-off values, for identifying dementia in primary care settings (Grober, Hall, 
Mcginn, et al., 2008). High values of sensitivity (100%) and specificity (87.2%) were also 
reported for the diagnosis of dementia in a Spanish elderly population sample (del Ser, 
Sánchez-Sánchez, García de Yébenes, Otero, & Munoz, 2006). In study specific 
populations, such as Spanish speaking Latino patients, the FCSRT proved also to be an 
effective tool for dementia screening, since its impairment were 10 times more likely 
to predict dementia than an intact recall, whereas an impaired Mini-Mental State 
Examination (MMSE) were 4.5 times more likely to predict dementia than intact scores 
in educationally diverse primary care populations (Grober, Ehrlich, Troche, Hahn, & 
Lipton, 2014); Mokri et al. (2012) suggested that participants with reading abilities 
exhibit more efficient learning processes with potentially better spontaneous encoding 
strategies, in the FCSRT, but not necessarily better memory capacity. Aging subjects 
with higher cognitive reserve revealed a greater protective effect of executive function 
(digit symbol substitution test) and episodic memory (FCSRT) against gait speed decline 
(Holtzer, Wang, Lipton, & Verghese, 2012). This paradigm was also used to assess the 
effect of drugs with anticholinergic properties on verbal episodic memory function, but 
while some proved no direct impairment on explicit memory (Grober et al., 1992), 
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others revealed a significant unfavourable effect of these drugs on episodic verbal 
memory (Fortin et al., 2011). 
Other studies using the FCSRT and analyzing the relationship between biological risk 
factors for dementia reported: a higher adherence to a Mediterranean-type diet was 
not associated with risk for incident dementia (Féart et al., 2009); the cholesteryl ester 
transfer protein was associated with slower memory decline, lower incident dementia, 
and AD risk (Sanders et al., 2010); stable memory scores after one year of deep brain 
stimulation in mild AD patients (Fontaine et al., 2013). 
The importance of studying AD as an independent diagnostic entity led subsequent 
studies to specifically include AD patients on their pathological samples. Consequently, 
the validity of the cued selective reminding paradigm for AD was found to effectively 
discriminate between mildly AD and controls (sensitivity of 88% with specificity set at 
95%), but little more effective in detecting very mild AD (sensitivity of 62% with 
specificity of 95%) than the WMS Logical Memory subtest (sensitivity of 58% with 95% 
of specificity) (Brown & Storandt, 2000). The authors attribute this discrimination 
difficulty to the presence of outliers in the very mildly demented group that did not fall 
below the level of memory performance of people at the low end of “normal” ability 
represented by the control group (Brown & Storandt, 2000). Vogel, Mortensen, Gade, 
& Waldemar (2007) found also equivalent discriminative validities (sensitivity >88%, 
and specificity >89%) for very mild AD, between a category cued recall paradigm and 
the 10-word memory list from the ADAS-cog (as a measure of free recall). Carcaillon, 
Amieva, Auriacombe, Helmer, and Dartigues (2009) found that the MMSE subscores 
for orientation to time and the 3-word recall task were well correlated with FCSRT 
scores; additionally, the summation of these two MMSE subscores was more strongly 
associated with dementia and AD than the FCSRT scores and the total MMSE score. 
Drolet et al. (2014) compared the performance of healthy elders and AD’s on the 
FCSRT and the RAVLT and found that: the RAVLT demonstrated a slightly better 
sensitivity (100%) and specificity (100%) than the FCSRT (90% and 100%, respectively) 
in classifying subjects; the FCSRT showed ceiling effects and a decline in performance 
on free recall throughout trials in AD patients, but was less sensitive to recency effects 
than the RAVLT, possibly providing a more realistic view of the long-term memory 
performance of these patients; the semantic cues provided in the FCSRT appeared to 
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increase intrusions in AD whereas the interference list in the RAVLT was the first 
source of false recognitions in both healthy elderly and AD. The FCSRT was included as 
memory test in neuropsychological batteries for AD assessment (Millet et al., 2008; 
Mormont, Jamart, & Robaye, 2012). 
Furthermore, the FCSRT was able to differentiate AD patients from other forms of 
dementia in general (Grober, Hall, Mcginn, et al., 2008), since the latter benefited 
more from controlled learning procedures, and specifically from VaD (Grober, Hall, 
Sanders, & Lipton, 2008; Grober et al., 2010; Traykov et al., 2005) and FTD (Basely, 
Ceccaldi, Boyer, Mundler, & Guedj, 2013; Bertoux et al., 2014; Pasquier, Grymonprez, 
Lebert, & Van der Linden, 2001), supporting the presence of an amnestic syndrome of 
the hippocampal type as representative of typical-AD spectrum disorders. 
A poor performance on the FCSRT has also shown a high correlation with the medial 
temporal lobe, by means of atrophy (Diamond et al., 2007; Sánchez-Benavides et al., 
2010, 2014; Sarazin et al., 2010; Wenger, Negash, Petsersen, & Petersen, 2011), 
hypoperfusion (Habert et al., 2011) and hypometabolism (Van Der Gucht et al., 2014), 
and was also significantly associated with CSF profile of AD (Rami et al., 2011; Wagner 
et al., 2012; Xie et al., 2014); thus, when combined with an AD-biomarker, the FCSRT 
improves the diagnostic accuracy in the early detection of AD. Functional imaging 
showed correlations between the FCSRT and the inferior parietal lobule, the 
precuneus, the hippocampus and the parahippocampal gyrus in mild AD dementia 
over 6 months (McLaren et al., 2012), and evidenced the involvement of the posterior 
cingulate cortex as a potential risk for AD in the elderly (Bernard et al., 2015).  
Genetic susceptibility factor, through the presence of the ApoE-ε4 allele, presented 
conversely results: while some found it to be correlated with an impaired FCSRT 
(Caselli et al., 2004; Hall, Lipton, Katz, & Wang, 2015; Petersen, 1995), others found no 
relation (Amariglio et al., 2015). 
In early stages of decline, such as MCI or prodromal AD, the observed deficits are 
usually only psychometrically defined, i.e., the subject performs the cognitive task with 
a lower performance than what is expected for their reference population (Peña-
Casanova et al., 2012). As such, transitional states of amnestic impairment between 
normal ageing and dementia are expected to have a detectable episodic memory 
Introduction 
 
63 
 
deficit on cognitive tests, but with an intermediate pattern of severity between healthy 
ageing and AD. The FCSRT has evidenced this gradual pattern of impairment among 
normal ageing, MCI, and AD (Boeve et al., 2003; Petersen, 2004; Petersen et al., 1999). 
This result was also supported by Saka, Mihci, Topcuoglu, and Balkan (2006) that found 
enhanced cued recall paradigms to highly and moderately discriminate AD and MCI 
from controls, respectively. The FCSRT, as a measure of low verbal memory 
performance, was also included in neuropsychological batteries for MCI assessment 
(Barbeau et al., 2004; Onen, Henry-Feugeas, Roy, Baron, & Ravaud, 2008; Poissonnet 
et al., 2012; Traykov et al., 2007). FCSRT results enabled to show a higher degree of 
memory impairment in MCI patients with apathy (Robert et al., 2006). 
Costa et al. (2014) documented that, in subjects with aMCI associated to Parkinson’s 
disease, episodic memory impairment is related to retrieval rather than to 
consolidation failure, as these patients had an impaired free recall but normal cued 
recall and a better performance than regular aMCI; moreover, memory deficits might 
be due to altered frontal-related executive functioning in this population. 
Due to the increased risk of progression to dementia among people with memory 
complaints – mainly MCI subjects – an intra-subject longitudinal comparison would be 
of more interest to predict the progression of cognitive decline, rather than 
comparisons to general population norms (Peña-Casanova et al., 2012). Cued recall 
paradigms were also analysed for the purpose of predicting AD. Ivanoiu et al. (2005) 
showed that this memory test correctly classified 88% of the MCI and subjective 
memory complaints participants, being the best predictor of the status of MCI and 
mild AD as well as of the outcome of the MCI patients, when compared to other verbal 
(Ten Word-List Recall from CERAD) and visual ("Doors" and the "Shapes" tests from 
"The Doors and People Test Battery") memory tests. Dickerson, Sperling, Hyman, 
Albert, and Blacker (2007) revealed that the presence of both higher CDR-sum of boxes 
(OR=1.65) and lower verbal memory and executive function at baseline predicted 
greater likelihood of probable AD in patients with MCI, with similar odds (OR) between 
the FCSRT (OR=0.78) and the CVLT (OR=1.2). Mura et al. (2014) investigated the 
sensitivity of a large set of neuropsychological tests to detect cognitive changes due to 
prodromal AD, and the results showed that the most sensitive tests in detecting 
cognitive changes due to prodromal AD were the FCSRT (free, total, and delayed free 
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recalls), followed by the semantic verbal fluency and the Deno100 (both language 
tets). Moreover, while the two free recalls of the FCSRT were better at detecting 
cognitive changes at high levels of cognition, the total recall score was better for low 
levels of cognition. The total recall of ther FCSRT was also the most sensitive (>79%) 
and specific (>89%) test for conversion diagnosis of prodromal AD, among other 
neuropsychological tests (the Benton Visual Retention Test for visual memory; the 
Deno 100 and verbal fluency for language; a serial digit learning test and the double 
task of Baddeley for working memory; WAIS similarities for conceptual elaboration; 
and the Stroop test, the TMT, and the WAIS digit symbol test for executive functions) 
(Sarazin et al., 2007). Rabin et al. (2012) also showed that the free recall of the FCSRT 
was the neuropsychological measure most strongly associated with incident AD when 
compared to WMS LM, Trail Making Test, Digit Symbol and Digit Span, Letter Fluency 
Test, and the short form of the Boston Naming Test; nevertheless, the risk of 
developing AD was associated both with the FCSRT, the WMS LM and the informant 
reports, showing the incremental effect of informant reports in addition to the 
neuropsychological test scores. In an imaging study, Koric et al. (2013) enhanced that 
cued recall deficits are associated with a progression of atrophy that closely parallels 
the spatiotemporal distribution of neurofibrillary degeneration in early AD, which is 
indicative of possible AD pathological changes. 
While the previous paragraph has shown the usefulness of the FCSRT in the 
assessment of aMCI patients (prodromal AD), we will now focus on studies of 
prediction of AD among healthy ageing – preclinical AD. These studies aim at defining 
the nature and timing of cognitive changes in order to understand AD’s natural history 
and therefore define prediction models and preventive interventions. Grober and 
Kawas (1997) found that learning that controls cognitive processing, and not retention, 
was superior in the detection of preclinical and very early AD. Grober, Hall, Lipton, et 
al. (2008) showed that while a decline in episodic memory (FCSRT) accelerated 7 years 
before diagnosis in subjects with incident AD that were followed for up to 15 years, 
deficits in executive function accelerated 2–3 years before diagnosis, and in verbal 
intelligence close to diagnosis. This profile supports pathologic data suggesting that 
structures which mediate memory are affected earlier than frontal structures during 
the preclinical onset of AD, and that VIQ does not decline during the preclinical onset 
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of AD. Grober, Lipton, Hall, and Crystal (2000) proved that poor performance on free 
recall from FCSRT predicts future dementia, supporting the existence of a preclinical 
phase present for at least 5 years before diagnosis. Nevertheless, Auriacombe et al. 
(2010) stated that the FCSRT had reasonable sensitivity (>60%) and specificity (>77%), 
and excellent negative predictive values (>98%), but low positive predictive values 
(<16%) for AD, i.e., many subjects with low scores on the FCSRT remained free of 
dementia at 5 years. These results indicate that low FCSRT scores must be interpreted 
with caution, as subjects who often do not have memory complaints may have 
unrecognized poor memory status. The FCSRT was also included in neuropsychological 
batteries for the early detection of patients in the pre-demented stage of AD, proving 
its utility as a measure of low verbal memory performance (Amariglio et al., 2015; 
Mahieux et al., 2009). Derby et al. (2013) reported that the free recall of the FCSRT had 
better operating characteristics than the immediate recall of the WMS LM for 
identifying those with memory complaints who will develop incident AD dementia over 
2-4 years, with the former presenting sensitivities >81%, and specificities >70%, and 
the latter sensitivities of >67%, and specificities of >68%. Papp et al. (2015) showed 
that the sensitivity of free versus cued memory paradigms may be dependent on the 
biomarker-defined stage of preclinical AD among clinically normal older adults, as 
following: a reduced free recall seems to be associated with amyloidosis alone, while a 
decline in cued recall may represent a progression to amyloidosis and 
neurodegeneration. Holtzer, Verghese, Wang, Hall, and Lipton (2008) claimed to be 
the first proving that within-person across-neuropsychological test variability was 
associated with development of incident dementia independent of neuropsychological 
test performance (FCSRT was included). 
 
General outline and aims of Chapter I 
The main purpose of the first chapter aimed at adapting the FCSRT for the portuguese 
population and validating its usefulness, on a memory clinic basis, to the AD spectrum 
early diagnosis, hence contributing to the IWG-1 and IWG-2 criteria by means of 
finding that: 1) AD patients do not improve with cueing or, at the very least, improve 
significantly less than patients with other dementing and non-dementing conditions; 2) 
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aMCI patients display an intermediate pattern of severity between healthy ageing and 
AD; 3) this paradigm is more accurate at identifying people affected by AD than other 
declarative memory tests with no support for encoding or cue for retrieval – free recall 
procedures; 4) a great predicitive value for conversion to AD is detectable among MCI 
patients that exhibit a similar profile of impairment to AD.  
Study 1, Adaptation of the Free and Cued Selective Reminding Test to the Portuguese 
population, describes the transcultural adaptation of the FCSRT to Portuguese, taking 
into account linguistic and cultural adequacy criteria. Materials and instruction of the 
FCSRT were provided to our team by the original author (Buschke’s FCSRT. Copyright, 
2002. Albert Einstein College of Medicine of Yeshiva University, New York). The 
selection of the 16 stimulus words followed the same principles of the English version 
– intermediate frequency words were selected within a semantic category 
(frequencies in Portuguese from the CORLEX database) (Nascimento et al., 2003). 
Results from the validation of the FCSRT for MCI and AD through the analysis of the 
diagnostic accuracy and the suggestion of cut-off scores are provided in Study 2, 
Validation of the Free and Cued Selective Reminding Test for Mild Cognitive 
Impairment and Alzheimer's disease. Moreover, the results from this study enabled to 
illustrate the heterogeneity of MCI at baseline.  
In Study 3, Construct and diagnostic validities of the Free and Cued Selective Reminding 
Test in the Alzheimer’s disease spectrum, we assessed the construct related and 
diagnostic validities of the FCSRT in AD spectrum disorders. The factorial structure of 
two models, and respective construct and diagnostic validities were analysed. The 
appropriated convergent validity and the lack of discriminant validity support the two-
factors as measuring the same construct, i.e. memory ability. High classification 
accuracy and diagnostic validity were present for both aMCI and AD groups.  
Study 4, The Free and Cued Selective Reminding Test for predicting progression to 
Alzheimer's disease in patients with Mild Cognitive Impairment, aims to investigate 
whether the performance on the FCSRT would enhance the ability to predict 
conversion to AD in an aMCI group. A longitudinal study was conducted and 
neuropsychological tests were analysed on the relative risk of conversion to AD. The 
FCSRT demonstrated utility for detecting AD at its prodromal stage, thus supporting its 
use as a valid clinical marker.  
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Chapters 5 and 6 compared the performance of MCI and AD patients on the FCSRT and 
on other memory tests. 
In Study 5, Selective Reminding and Free and Cued Selective Reminding in Mild 
Cognitive Impairment and Alzheimer´s disease, we compared the psychometric 
properties and accuracies of the SRT and the FCSRT in discriminating aMCI from AD. 
Like FCSRT, SRT also comprises a “selective reminding” paradigm that presents only 
the missing words from the previous recall trial. But, while in the FCSRT semantic cues 
are provided to elicit recall, in the SRT subjects are merely reminded of the missing 
items by repeating them. Both tests are widely used in dementia neuropsychological 
assessments. Our results revealed a benefit of category cueing (FCSRT) on both groups, 
and a higher accuracy in discriminating aMCI from AD patients on the FCSRT. 
In Study 6, The Free and Cued Selective Reminding Test and the Wechsler Memory 
Scale in discriminating Mild Cognitive Impairment from Alzheimer’s disease, we 
compared the Wechsler Memory Scale [Logical Memory (LM) and Verbal Paired 
Associative Learning subtests] and the FCSRT in terms of psychometric properties of 
accuracy in classifying aMCI and AD. All instruments revealed good results, whilst the 
FCSRT was able to classify more patients as having memory impairment in the aMCI 
group rather than the WMS subtests. The FCSRT proved to be good in discriminating 
the two groups in both lower and higher educational levels, whereas the LM was more 
useful in higher educated patients. 
In order to confirm the ability of the FCSRT in assessing the genuine deficits in 
encoding and storage processes characteristic of typical-AD spectrum disorders, as a 
result of an amnestic syndrome of the hippocampal type, we examined in Study 7 – 
The Free and Cued Selective Reminding Test distinguishes Alzheimer’s disease from 
Frontotemporal Dementia, the usefulness of the FCSRT in the distinction between 
behavioural frontotemporal dementia (FTD) and AD. Results proved that while AD 
patients exhibited an overall impairment in FCSRT, FTD subjects showed to benefit 
more from the controlled learning through category cues. AD patients were 
significantly more likely to have an impaired FCSRT. The FCSRT has shown its utility in 
the distinction between FTD and AD, therefore increasing the diagnostic accuracy. 
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To conclude this chapter, we present a discussion covering all the results achieved 
throughout this work plan, reflecting on the main limitations of our studies, and 
emphasizing the main conclusions and implications for the neuropsychological 
contribution to the clinical practice and the scientific research on AD spectrum 
disorders. 
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Abstract 
The Free and Cued Selective Reminding Test (FCSRT) involves a new paradigm of 
memory assessment, using selective reminding with semantic cueing. This allows for 
an assessment of memory that is independent of normal age-related changes in 
cognition. Therefore, the FCSRT has shown to be useful for memory characterization in 
Alzheimer’s disease (AD). 
The International Working Group on Alzheimer’s disease (2007) has suggested new 
diagnostic criteria for AD. The main criterion is evidence for a significant and 
progressive episodic memory impairment confirmed by objective testing. The authors 
suggest the FCSRT to assess memory, since it showed high sensitivity and specificity in 
the differentiation of AD patients from healthy controls and from other dementias. 
The goal of this paper is to describe the adaptation of the FCSRT for the Portuguese 
population, taking into account linguistic and cultural adequacy criteria. 
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Introduction 
A memória no envelhecimento normal e patológico 
O estudo da memória constitui uma etapa fundamental da avaliação neuropsicológica 
de populações geriátricas, não só porque “o esquecimento” é uma das queixas mais 
comuns dos doentes idosos (Goeman & De Deyn, 2003), sendo motivo frequente de 
encaminhamento para consultas da especialidade (Lezak, Howieson, & Loring, 2004), 
mas também porque a memória é a capacidade cognitiva mais afectada no contexto 
das doenças neurológicas e psiquiátricas do envelhecimento (Delis & Kramer, 2000).  
As queixas de memória mais frequentes referem-se à dificuldade em aprender e/ou 
recordar informação, objectos e/ou eventos (Lezak et al., 2004). Este tipo de memória 
é habitualmente designado por “memória declarativa” (memória de longo-prazo), e 
representa a “informação que pode ser convertida em recordações conscientes sob a 
forma de proposição verbal ou de imagem visual” (Squire & Kandel, 2002, p.23). A 
memória declarativa pode ainda dividir-se em dois subtipos: memória episódica – 
recordação de acontecimentos específicos (“episódios”), delimitados no tempo e no 
espaço e com um carácter contextual, e a memória semântica – recordação de 
acontecimentos gerais, inerentes a uma determinada cultura e aprendidos como 
“conhecimento” (por exemplo, o alfabeto) (Lezak et al., 2004). A memória episódica, 
também designada comummente por “memória recente”, é a mais sensível ao dano 
neurológico e ao envelhecimento pelo que constituirá o principal alvo do nosso 
interesse.  
A memória é uma função cognitiva central e complexa a partir da qual a informação 
nova é codificada, guardada e recuperada no cérebro e estes processos desenvolvem-
se em determinadas estruturas cerebrais, com localização no lobo frontal e no lobo 
temporal. Do lobo temporal destacam-se as estruturas mesiais (hipocampo e 
amígdala) e neocorticais (córtices perirrinal, entorrinal e parahipocampal) (Squire & 
Kandel, 2002b). O processamento mnésico inicia-se na fase de “codificação” ou 
aprendizagem, i.e., a capacidade de o indivíduo processar e adquirir uma nova 
informação. A aprendizagem implica consolidação (o que é aprendido é consolidado) e 
a “consolidação refere-se ao processo hipotético de reorganização dentro das 
representações da informação armazenada, que se mantém durante o esquecimento 
da informação” (Squire, 1986, citado por Lezak et al., 2004). O processo de 
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consolidação resulta na fase de “armazenamento” ou retenção – que representa a 
conservação das informações adquiridas. Por fim, a “recuperação” da informação 
engloba o conjunto de mecanismos que permite aceder à informação adquirida.  
Uma vez que a memória representa um processo dividido em diversas fases, as 
alterações mnésicas podem assumir perfis distintos resultantes do envolvimento 
diferenciado dos processos já citados. O mesmo se passa com o designado 
“envelhecimento fisiológico”. No decorrer do envelhecimento normal verifica-se, 
genericamente, um decréscimo na capacidade mnésica, embora nem todos os tipos de 
memória evidenciem declínio (Goeman & De Deyn, 2003). Vários estudos têm sugerido 
que a memória a curto prazo e, também, a memória semântica são relativamente 
resistentes ao envelhecimento, enquanto outras funções, tais como a memória 
episódica a longo prazo, apresentam alterações relevantes (Goeman & De Deyn, 2003). 
Num estudo em que se pretendeu avaliar o funcionamento mnésico em sujeitos idosos 
cognitivamente normais utilizando diversas provas de memória, Petersen, Smith, 
Kokmen, Ivnik, e Tangalos (1992) evidenciaram que a aprendizagem ou aquisição 
declinava significativamente com o aumento de idade. Por outro lado, a evocação 
diferida ou o esquecimento mantinham-se relativamente estáveis ao longo da idade, 
quando ajustados em função da quantidade de material inicialmente aprendido. Os 
resultados descritos são importantes na caracterização do funcionamento mnésico 
normal mas têm implicações ainda mais relevantes no diagnóstico das alterações 
patológicas do envelhecimento e, em particular, na investigação de alterações 
precoces da memória na demência. De acordo com a investigação de Petersen et al. 
(1992), deverá suspeitar-se de uma alteração patológica do processamento mnésico 
quando se verifica um declínio mais acentuado do que o esperado para a idade na fase 
da aprendizagem; um prejuízo na aquisição que não melhora com técnicas de 
ajuda/pistas; ou uma alteração significativa na evocação diferida.  
A avaliação neuropsicológica da memória pressupõe a utilização de diferentes tipos de 
tarefas com o objectivo de “identificar os componentes mnésicos (registo, retenção, 
recuperação) que se encontram comprometidos ou preservados” (Simões, Lopes, & 
Pinho, 2003, p.247). A memória episódica é habitualmente avaliada com recurso a 
tarefas de memorização de listas de palavras, com uma posterior restituição das 
mesmas usando a recordação livre ou o índice de reconhecimento (Amieva et al., 
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2007). Uma crítica habitualmente apontada a este tipo de provas remete para o facto 
de não permitirem controlar as estratégias efectivamente utilizadas pelo sujeito, 
sobretudo nas fases de codificação e de recuperação (Amieva et al., 2007), o que 
poderá comprometer o rigor da avaliação da memória. 
A doença de Alzheimer 
O envelhecimento da população em países desenvolvidos, resultante do incremento 
da esperança média de vida, é acompanhado de uma elevação da prevalência das 
doenças degenerativas associadas à idade. De entre as patologias típicas do 
envelhecimento, a demência é a mais significativa, ao afectar cerca de 5% dos 
indivíduos com mais de 60 anos e ao registar uma incidência e prevalência que 
duplicam a cada 5 anos de idade (Jorm, 1990). A doença de Alzheimer (DA) é a forma 
de demência mais comum, compreendendo cerca de 50 a 80% entre todos os tipos de 
demência (Lobo et al., 2000). Em Portugal, a Alzheimer Europe (2009, Projecto 
European Collaboration on Dementia – Eurocode – conduzido pela Alzheimer Europe e 
financiado pela Comissão Europeia, www.alzheimerportugal.org) prevê que existam 
cerca de 153.000 pessoas com demência e 90.000 com DA. 
A identificação precoce da DA é crucial para uma intervenção e tratamento eficazes, 
assim como para o estabelecimento de um plano assistencial para estes doentes. 
Como é típico das doenças degenerativas, o défice cognitivo manifesta-se 
gradualmente, o que implica, pelo menos conceptualmente, que exista um estado 
intermediário ou transitório entre o envelhecimento saudável e a demência do tipo 
Alzheimer (Petersen, 2000; Petersen, 2004; Petersen et al., 2001; Santana, 2003). O 
conceito de Défice Cognitivo Ligeiro - DCL (Mild Cognitive Impairment- MCI, na 
terminologia anglo-saxónica) sugerido por Petersen et al. (1999), corresponde a este 
estadio transicional e aplica-se aos sujeitos que apresentam um declínio cognitivo 
superior ao esperado para a idade, mas que mantêm a sua autonomia funcional. Não 
são normais, mas também não poderão ser classificados de dementes de acordo com 
os critérios internacionais vigentes (DSM-IV-TR: American Psychiatric Association, 
2000; NINCDS-ADRDA: Mckhann et al., 1984). Este vazio classificativo é aliás uma das 
limitações mais sérias apontadas aos sistemas de classificação e de diagnóstico 
referidos. Outras opiniões críticas salientam uma deficiente operacionalização dos 
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critérios clínicos, a não utilização de instrumentos de avaliação neuropsicológica 
recomendados e a sua desactualização no que respeita aos biomarcadores entretanto 
identificados (Blennow, de Leon, & Zetterberg, 2006).  
O International Working Group on Alzheimer’s Disease (IWG; Dubois et al., 2007) 
desenvolveu e publicou uma proposta de novos critérios de diagnóstico para DA, 
tentando colmatar as limitações dos ainda vigentes de forma a englobar todo o 
espectro da doença (incluindo as fases mais precoces de declínio cognitivo - DCL) e 
valorizar os biomarcadores laboratoriais e de imagem. Nesta nova proposta, o critério 
de diagnóstico principal considera a evidência objectiva de uma alteração significativa 
e progressiva da memória episódica, desde que associada a, pelo menos, um marcador 
biológico da doença (Dubois et al., 2007). Os autores sugerem que o défice mnésico 
seja comprovado com a utilização de metodologias que controlem a aprendizagem do 
material a reter, para que seja possível obter uma medida de memória não confundível 
com o declínio cognitivo associado ao envelhecimento normal. Nesta linha, propõem 
que a avaliação deva desenvolver-se com base num paradigma de codificação 
específica, visto este ter revelado sensibilidade e especificidade elevadas na 
diferenciação entre doentes com Alzheimer e controlos saudáveis ou outras formas de 
demência (Buschke, Sliwinski, Kuslansky, & Lipton, 1997) e sugerem, explicitamente, o 
Teste de Recordação Selectiva Livre e Guiada (Free and Cued Selective Reminding Test, 
Buschke, 1984). Desde a publicação de Dubois et al. (2007), tem havido a preocupação 
de avaliar a validade destes critérios, ou seja testar a sua sensibilidade e 
especificidade. A questão da especificidade é obviamente a mais complexa porque 
implica a confirmação de que os doentes que apresentam um defeito progressivo de 
memória (demonstrado pelo paradigma TRSLG) evoluem efectivamente para DA. Estes 
resultados começaram a emergir muito recentemente na literatura científica 
(Bouwman et al., 2010; Ewers et al., 2012).  
O Teste de Recordação Selectiva Livre e Guiada (TRSLG) 
O paradigma de recordação selectiva foi originalmente proposto por Buschke (Buschke 
& Fuld, 1974; Buschke, 1973) na prova Selective Reminding Test (SRT). Este paradigma 
baseia-se numa medida de aprendizagem forçada, uma vez que o indivíduo é 
selectivamente recordado das palavras não evocadas. Mais tarde, Buschke (1984) 
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adicionou uma componente de evocação com ajuda a este teste. Esta versão é 
conhecida como Teste de Recordação Selectiva Livre e Guiada (TRSLG).  
O TRSLG (Buschke, 1984) é uma prova de aprendizagem e memória verbal que permite 
controlar as condições de codificação e de recuperação através da utilização de pistas 
semânticas no controlo da aprendizagem e na evocação. A aprendizagem é controlada 
ao impor aos sujeitos a codificação dos itens em resposta à sua categorização 
semântica; estas mesmas pistas são posteriormente utilizadas para facilitar a evocação 
dos itens não reproduzidos na evocação livre. Este paradigma fomenta a especificidade 
da codificação, revelando-se mais eficaz ao permitir uma recordação através de pistas 
e ao garantir uma atenção selectiva e de enquadramento semântico de todos os itens 
(Buschke, 1984). Desta forma, asseguram-se os pressupostos defendidos pelo Princípio 
de Codificação Específica (Tulving & Thomson, 1973) que defende que o modo como a 
informação é codificada determina o modo como é retida e armazenada, bem como o 
tipo de indicadores/pistas que facilitam o acesso à informação retida. Por outro lado, é 
de salientar que no TRSLG são utilizadas as mesmas pistas semânticas na fase de 
aprendizagem e na fase de evocação, seguindo os princípios definidos de que uma 
pista só é eficaz na recuperação de informação se tiver sido utilizada na codificação 
dos itens (Tulving & Thomson, 1973) e que a presença de pistas na fase de codificação 
e na fase de evocação facilita a recordação dos itens (Tulving & Osler, 1968). 
O TRSLG (Buschke, 1984) é composto por 16 itens/palavras categorizados 
semanticamente e não relacionados entre si. As 16 palavras são apresentadas, 4 de 
cada vez, em 4 cartões separados, cada um dos quais divididos em 4 quadrantes. Os 
cartões são apresentados na mesma ordem a todos os indivíduos. O examinador pede 
aos indivíduos para apontar e ler em voz alta cada palavra do cartão (por exemplo, 
“figo”) em resposta à sua categoria semântica (“fruto”) – Aprendizagem Controlada. 
Após uma tarefa distractora de contagem decrescente, durante 20 segundos – para 
evitar repetição – a memória é avaliada através da Evocação Livre. Para os itens não 
recordados espontaneamente na Evocação Livre, são fornecidas as mesmas pistas 
semânticas usadas na codificação, na tentativa de que eles sejam evocados (Evocação 
com Ajuda). Se esta ajuda falhar, o sujeito é, então, recordado do item-alvo 
(recordação selectiva). O teste é constituído por 3 ensaios de Evocação Livre e de 
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Evocação com Ajuda e cada ensaio é precedido de uma tarefa de interferência de 20 
segundos. Um ensaio de Evocação Diferida é efectuado 30 minutos depois. 
A memória e a aprendizagem em cada ensaio são medidas através da Evocação Livre e 
da Evocação Total (somatório da Evocação Livre e com Ajuda). A Evocação com Ajuda é 
uma medida de recuperação “auto-organizada”, enquanto a Evocação Total representa 
a medida da recuperação máxima, fornecendo uma estimativa da codificação e da 
retenção. 
Em 1987, Grober e Buschke apresentaram uma versão alternativa deste instrumento - 
o Teste de Recordação Selectiva Livre e Guiada - Evocação Imediata (TRSLG-EI). Esta 
versão obedece aos mesmos princípios conceptuais do TRSLG: utiliza uma medida de 
aprendizagem controlada de 16 itens não relacionados, a mesma codificação por 
pistas, e a recordação selectiva com a utilização das mesmas pistas. Como aspecto 
diferenciador, no TRSLG-EI substituíram-se as palavras por desenhos de objectos 
impressos em cartões, facilmente reconhecíveis e codificados a partir de categorias 
semânticas (uma para cada figura). Para além disto, no TRSLG-EI é realizada uma tarefa 
de evocação imediatamente após a identificação dos itens. Este procedimento é feito 
para cada cartão, num total de quatro e denomina-se fase de estudo (study phase). 
Segue-se uma fase de teste (test phase) constituída por três ensaios de evocação, 
análogos ao do TRSLG. Nesta versão, não existe uma tarefa de evocação diferida. 
Comparando as duas versões, Buschke (2002) indica a sua preferência pela utilização 
de palavras escritas (em detrimento do recurso a desenhos) no sentido de evitar erros 
perceptuais, assegurar que todos os sujeitos utilizam a mesma codificação verbal na 
aprendizagem dos itens, e impedir uma codificação dupla – perceptual e verbal. 
Buschke (2002) explica também que foi propositado não incluir no TRSLG a Evocação 
Imediata com Ajuda (recordação do item-alvo), quando a evocação imediata falha 
durante a fase de aprendizagem. Neste contexto, são vários os elementos de 
enquadramento referidos por Tounsi et al. (1999, citado por Buschke, 2002). Em 
primeiro lugar, a aprendizagem adicional, quando a evocação imediata falha, deteriora 
a medida de aprendizagem através da evocação. O TRSLG mede a aprendizagem 
através do número de itens evocados quando a mesma apresentação (estandardizada) 
de cada item prevê uma oportunidade idêntica de aprender cada item – Aprendizagem 
Controlada. O número de itens aprendidos pode ser medido através do número de 
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itens evocados apenas quando todos os itens foram apresentados com igual 
frequência para aprender. A evocação de diferentes sujeitos pode apenas comparar-se 
quando foi dada a cada um a mesma oportunidade de aprender os itens; se dois 
sujeitos evocam o mesmo número de itens, mas um recebeu aprendizagem adicional 
para alguns itens e o outro não, os seus níveis de evocação não indicam a mesma 
“quantidade” de aprendizagem. Em segundo lugar, quando a evocação imediata falha, 
a aprendizagem adicional possibilita maior facilidade na aprendizagem em sujeitos 
com alterações de memória, uma vez que estes têm mais falhas na evocação imediata 
e porque o número de omissões na evocação imediata aumenta ao longo do 
desenvolvimento da patologia (Tounsi et al., 1999, citado por Buschke, 2002). Em 
casos patológicos, a aprendizagem adicional pode favorecer a evocação e tornar mais 
difícil a detecção da alteração na aprendizagem e/ou na memória. Quando a memória 
é avaliada longitudinalmente em sujeitos com deterioração progressiva observa-se que 
a aprendizagem adicional dificulta a detecção e quantificação do aumento do défice. 
Por outro lado, a evocação imediata durante a aprendizagem, com aprendizagem 
adicional quando a evocação imediata falha, ainda não demonstrou mais rigor quer na 
avaliação da memória, quer na discriminação do défice mnésico. Finalmente, a 
evocação imediata durante a aprendizagem, com aprendizagem adicional quando a 
evocação imediata falha, demora mais tempo e prolonga a sessão de avaliação. 
Não são conhecidos estudos acerca das propriedades psicométricas do TRSLG. Grober, 
Ocepek-Welikson, e Teresi (2009) descreveram algumas das propriedades 
psicométricas das três formas (A, B e C) do TRSLG-EI, aplicadas a uma população 
geriátrica. A análise factorial sugere a presença de um modelo unidimensional que os 
autores consideram tratar-se da capacidade de memória. As três formas revelaram 
uma boa validade concorrente, bons indicadores de consistência interna ( = 0,85; 
0,86 e 0,88, respectivamente) e valores semelhantes de sensibilidade (≥75%) e 
especificidade (≥82%) na detecção de demência ligeira, traduzindo uma acuidade 
adequada de classificação.  
Grober, Merling, Heimlich, e Lipton (1997) compararam a performance entre a versão 
original (SRT) e o TRSLG-EI num grupo de sujeitos idosos sem patologia, comparando o 
número de palavras evocadas nas duas versões. Verificaram que o paradigma de ajuda 
semântica do TRSLG-EI permitiu a evocação do dobro de palavras, comparativamente 
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ao SRT. Os autores concluíram que o procedimento e o método de recordação 
subjacente ao TRSLG-EI facilitam a evocação livre. 
Estudos Internacionais  
A versão original (inglês) do TRSLG (Free and Cued Selective Reminding Test) foi 
desenvolvida por Buschke (1984). Os dados normativos para esta prova fazem parte do 
projecto MOANS (Mayo’s Older Americans Normative Studies, Ivnik et al., 1997). A 
amostra é constituída por 734 sujeitos, com idades compreendidas entre os 56 e os 98 
anos. Os resultados são apresentados por intervalos de idade, uma vez que a 
escolaridade e o género evidenciaram uma influência mínima.  
A versão espanhola do TRSLG (Test de Recuerdo Libre y Selectivamente Facilitado) foi 
criada como parte dos Estudos Normativos Multicentros Espanhóis (Projecto 
NEURONORMA) (Peña-Casanova, Gramunt-Fombuena, et al., 2009). A amostra 
normativa é constituída por 340 participantes, de idades entre os 50 e os 94 anos. Os 
resultados brutos foram transformados em resultados ajustados à idade e, 
posteriormente, convertidos em resultados ajustados à escolaridade. O estudo 
confirma uma influência da idade e da escolaridade no desempenho no TRSLG, 
enquanto o género teve um efeito sem significado. Constatou-se um declínio em todas 
as medidas da prova com o aumento da idade e um efeito discreto da escolaridade 
(cerca de 11% na evocação total) (Peña-Casanova, Blesa, et al., 2009). 
A versão TRSLG-EI (Test de rappel libré/rappel indicé à 16 items) foi adaptada para o 
Francês por Amieva et al. (2007). Este estudo normativo, conhecido como “L’étude des 
3 Cités” envolve uma amostra de 1458 sujeitos, com idade igual ou superior a 65 anos. 
Os dados normativos foram calculados de acordo com a idade (65 – 70 anos, 70 – 74 
anos, 74 – 78 anos, 78 – 90 anos), nível de escolaridade (ensino primário ou curso 
técnico versus ensino secundário e superior) e género. A avaliação longitudinal 
(intervalos de 2 e 5 anos) dos participantes do estudo de normalização (Amieva et al., 
2007) permitiu analisar a validade do TRSLG-EI na predição de demência (Auriacombe 
et al., 2010). Os índices de Evocação Livre e Evocação Total (livre e com ajuda) 
mostraram uma boa sensibilidade e razoável especificidade na predição de DA, ainda 
que o valor preditivo positivo tenha sido baixo. Por outro lado, o valor preditivo 
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negativo mostrou resultados excelentes, indicando que os indivíduos com pontuações 
acima do valor médio têm um risco mínimo de desenvolver DA em 5 anos. 
O paradigma subjacente ao TRSLG e ao TRSLG-EI tem sido utilizado em faixas etárias 
mais avançadas, quer no plano do estudo do envelhecimento normal, quer na 
investigação clínica de doenças associadas ao envelhecimento.  
Assim, esta prova tem sido utilizada como medida de avaliação da memória verbal em 
estudos recentes de populações de idosos saudáveis (de Souza, Sarazin, Goetz, & 
Dubois, 2009; Vercambre et al., 2010), ou em estudos prospectivos associados ao risco 
de desenvolver demência (Féart et al., 2009; Grober, Lipton, Katz, & Sliwinski, 1998; 
Grober, Lipton, Hall, & Crystal, 2000; Holtzer, Verghese, Wang, Hall, & Lipton, 2008). 
Comparativamente a outras provas, os resultados no TRSLG mostraram correlações 
significativas com os subtestes de orientação temporal e a tarefa de evocação no Mini-
Mental State Examination (MMSE; Carcaillon, Amieva, Auriacombe, Helmer, & 
Dartigues, 2009; Folstein, Folstein, & McHugh, 1975; Guerreiro, 1998). Por sua vez, 
Rouch et al. (2008) comprovaram que a alteração mnésica, no envelhecimento normal, 
está relacionada com queixas cognitivas mas não com perturbações afectivas. Já 
Minett, Da Silva, Ortiz, e Bertolucci (2008) demonstraram que queixas subjectivas de 
memória estão mais associadas a sintomatologia depressiva do que a uma alteração 
cognitiva objectiva. Adicionalmente, Zimmerman et al. (2008) verificaram que uma 
baixa performance no TRSLG, no envelhecimento normal, estava relacionada com 
alterações neuroquímicas e volumétricas (atrofia) do hipocampo. 
A maior parte dos estudos realizados em contexto clínico (demência) tem-se 
debruçado especificamente sobre a DA: na confirmação do envolvimento precoce da 
memória na DA pré-clínica (Grober et al., 1997; Grober et al., 2008; Mahieux et al., 
2009) e na DA (Grober, Hall, Lipton, et al., 2008). Millet et al. (2008) utilizaram uma 
adaptação desta prova para mostrar que a memória implícita (priming) em doentes 
com DA está preservada. Outros estudos procuraram relacionar estruturas anatómicas 
cerebrais associadas à memória na DA e desempenhos no teste. Neste contexto, 
Sarazin et al. (2010) observaram uma relação entre baixa performance no TRSLG e 
atrofia do hipocampo esquerdo ao nível da região CA1, e Diamond et al. (2007) 
apontaram para a existência de uma relação entre o desempenho nesta prova e uma 
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activação nos córtices temporal esquerdo superior e pré-frontal esquerdo, numa 
experiência de Ressonância Magnética Funcional. 
Alguns estudos têm comprovado a utilidade desta prova na avaliação do défice 
mnésico no DCL: isolado (Traykov et al., 2007; Wenger, Negash, Petersen, & Petersen, 
2010), ou em associação a outras alterações, especificamente, memória visual 
(Barbeau et al., 2004) e apatia (Robert et al., 2006). 
O perfil de alteração mnésica semelhante entre o DCL e a DA tem sido descrito em 
estudos de comparação nos dois grupos clínicos (Onen, Henry-Feugeas, Roy, Baron, & 
Ravaud, 2008; Petersen et al., 1999) ou de progressão do primeiro para o segundo 
(Petersen, 1995; Sarazin et al., 2007). Comparativamente a outros meios de 
diagnóstico, esta prova de memória tem mostrado uma elevada especificidade, na 
detecção da DA precoce, quando associada a medidas de Tomografia 
Computadorizada por Emissão de Fotão Único (SPECT) (Habert et al., 2011) e de 
Ressonância Magnética (Sánchez-Benavides et al., 2010). 
Ainda em contexto clínico, este teste foi utilizado na caracterização do perfil mnésico 
em diferentes condições: demência vascular subcortical (Epelbaum et al., 2011; 
Traykov et al., 2005), na presença de factores de risco vascular (Beauchet et al., 2010; 
Sacktor et al., 1999; Sanders et al., 2010), dependência alcoólica (Chanraud et al., 
2009), no impacto do consumo de escopolamina (fármaco anticolinérgico) na 
memória, no envelhecimento normal e na demência (Grober, Gitlin, Bang, & Buschke, 
1992). 
A utilização deste paradigma de avaliação da memória (e do TRSLG) tem comprovado a 
sua sensibilidade aos diversos contextos clínicos e facilitado a caracterização do défice 
mnésico no envelhecimento normal.  
O presente trabalho tem por objectivo central descrever o processo de adaptação 
transcultural do TRSLG para a população portuguesa. Desta forma, torna-se possível a 
avaliação da validade deste instrumento no contexto dos novos critérios para DA 
propostos pelo IWG (Dubois et al., 2007). 
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Methods 
Fase 1: Autorização 
A autorização para a realização de estudos de adaptação e validação do TRSLG para a 
população portuguesa foi solicitada e concedida em 2010 (Buschke, 2002; Buschke’s 
FCSRT, Copyright, 1996-2000. Albert Einstein College of Medicine of Yeshiva University, 
New York; devido à necessidade de salvaguardar direitos de autor, os itens não são 
aqui apresentados). A adaptação da prova e a tradução para português do respectivo 
manual de instruções de administração e de cotação foram realizadas nesse mesmo 
ano. 
Fase 2:  
 Criação da lista de palavras 
A adaptação para o português da prova original em inglês foi realizada por uma 
especialista em Linguística, fluente na língua inglesa e com experiência em tarefas de 
adaptação de provas de avaliação cognitiva (co-autora C.M.).  
Deu-se preferência a itens mais facilmente passíveis de representação pictórica, uma 
vez que a versão original do TRSLG contempla a utilização de imagens em alternativa 
às palavras (Buschke, 2002). Deste modo, a possibilidade de uma opção por esta 
metodologia de apresentação dos estímulos fica ressalvada. Decorrente deste cuidado, 
foram seleccionados apenas nomes. 
A lista final de palavras é constituída por 16 itens que respeitam os critérios 
considerados pelos autores na selecção das palavras da língua inglesa:  
a) De acordo com o manual do FCSRT, os itens devem apresentar frequência moderada 
(Buschke, 2002). Assim sendo, procedeu-se à verificação da frequência dos itens que 
constam da prova adaptada para português na base de frequências lexicais CORLEX 
(Nascimento et al., 2003). Todos apresentam frequência média na língua portuguesa, 
com um valor, na CORLEX, que se situa no intervalo de 28-161;  
b) Cada item representa uma categoria semântica distinta. Seleccionaram-se 16 
categorias semânticas entre as 48 distribuídas pelas três formas originais (A, B e C). 
Outras categorias possíveis e constantes das listas originais foram preteridas por: i) 
dificuldades em encontrar nomes correspondentes com frequência média na CORLEX; 
ii) não corresponderem a nomes, mas a adjectivos; iii) corresponderem a nomes 
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próprios, cuja frequência não é apresentada na CORLEX; iv) apresentarem designações 
que, em português, serão pouco transparentes. 
Para além de salvaguardar os pressupostos da versão original, outros critérios foram 
tidos em conta, nomeadamente: a) exclusão de nomes polissémicos, homógrafos, 
homófonos e estrangeirismos; b) salvaguarda, no conjunto dos itens, da existência de 
alguma diversidade quanto à letra e som (sempre consonânticos) iniciais, sobretudo 
nos itens pertencentes a categorias semânticas mais próximas; c) selecção de nomes 
bi-, tri- e tetrassilábicos. 
Para a ordenação final dos itens, foram colocados itens/categorias semânticas com 
maior grau de afinidade em diferentes cartões de apresentação. 
 Tradução do manual 
O manual do TRSLG contempla as instruções para a administração da prova e os 
critérios para a cotação dos diferentes índices. O manual foi traduzido da versão 
original (Buschke, 2002). 
 
Results and Discussion 
A escassez de instrumentos rigorosos e sensíveis, na detecção de défices nas áreas 
cognitivas mais vulneráveis ao processo de envelhecimento e doença, constitui uma 
limitação na área da avaliação psicológica, com consequências limitativas em 
diferentes domínios/circunstâncias: no diagnóstico e detecção precoce do défice 
cognitivo, na reavaliação do défice num contexto de acompanhamento clínico e na 
elaboração de planos de intervenção. Por este motivo, em países onde faltam 
instrumentos de avaliação sólidos, é fundamental a criação de novos testes ou a 
adaptação e validação de testes cujos resultados já demonstraram sensibilidade e 
especificidade noutros países e/ou contextos (Guerreiro, 2005).  
Frequentemente recorre-se à adaptação de instrumentos já disponíveis noutras 
línguas e experimentados em populações clínicas. Esta metodologia apresenta a 
vantagem de serem já conhecidos os resultados da sua aplicabilidade clínica 
permitindo, assim, antever a sua validade e utilidade no estudo de determinada 
função cognitiva. A adaptação é uma forma de maximizar a conformidade cultural dum 
instrumento e, dessa forma, minimizar o enviesamento resultante da simples tradução 
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da versão original. Como referem Malda, van de Vijver, Srinivasan, Transler, Sukumar, 
& Rao (2008) mais do que traduzir um instrumento, a sua adaptação respeita 
idiossincrasias linguísticas e culturais. 
No que se refere especificamente à tradução e adaptação de testes, a Comissão 
Internacional de Testes (2010) contempla a possibilidade de tradução das provas a 
partir da sua versão original. No entanto, a mera tradução dos itens linguísticos 
originais não será, para todos os casos, a solução mais recomendável. 
Frequentemente, é preferível o recurso ao processo de adaptação das provas, através 
do qual se melhor se controla o grau de adequação dos itens às características da 
língua materna da população-alvo. No processo de adaptação de um instrumento para 
outra língua, o essencial é que sejam utilizados procedimentos metodológicos 
rigorosos e que se respeitem os pressupostos da versão original da prova 
(International Test Commission, 2010). A utilização de um instrumento, numa 
determinada população, sem uma adaptação prévia criteriosa compromete a validade, 
a precisão e a posterior interpretação dos resultados. 
O processo de adaptação do TRSLG para a população Portuguesa foi norteado pelas 
linhas orientadoras propostas na literatura (Giusti & Befi-Lopes, 2008; Hambleton, 
2005; International Test Commission, 2010). Assim, procurou-se alcançar o grau 
máximo possível de paridade relativamente à versão original, de forma a evitar 
distorções ao nível da equivalência de construto (Giusti & Befi-Lopes, 2008; 
Hambleton, 2005; International Test Commission, 2010; Malda et al., 2008). Herdman, 
Fox-Rushby, & Badia (1998) alertam para o facto da tradução ipsis verbis de um item 
poder adulterar o seu verdadeiro significado. Desta forma, sugerem uma abordagem 
universalista de adaptação transcultural de instrumentos, que considere uma avaliação 
da equivalência entre a versão original e a nova versão. Estes autores defendem que a 
equivalência entre as duas versões deve ser avaliada a seis níveis: conceptual, de item, 
semântica, operacional, de mensuração e funcional.  
A versão portuguesa do TRSLG procurou respeitar, sempre que aplicável, a 
equivalência com a sua versão original, de acordo com o modelo de Herdman et al. 
(1998). Neste processo de adaptação não se verifica uma “tradução” dos itens, mas 
sim uma selecção de palavras de frequência média para determinadas categorias 
semânticas, tal como sugerido no original (Buschke, 1984, 2002). As categorias 
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semânticas foram seleccionadas de um total de 48 disponíveis na versão original. Os 
restantes critérios utilizados na escolha dos itens levaram em consideração 
particularidades linguísticas da Língua Portuguesa.  
 
Conclusion 
A versão Portuguesa do TRSLG resulta de um processo de adaptação que procurou 
respeitar as orientações existentes na literatura sobre esta problemática. Neste 
processo, foram tidos em conta os pressupostos da versão original, bem como a 
adequação à realidade portuguesa (linguística e cultural). 
O enfoque deste trabalho foi dado aos procedimentos a priori do processo de 
adaptação de testes. No entanto, este estudo deve ser complementado com 
investigações a posteriori (através da recolha e análise de dados) de forma a validar a 
adaptação.  
Pretendemos, com este trabalho de adaptação, aumentar o leque de alternativas nos 
testes de avaliação da memória episódica verbal. O TRSLG constitui uma mais-valia, 
não só por apresentar um paradigma de avaliação diferente dos testes mais usuais, 
como por ser o teste recentemente proposto pelo IWG (Dubois et al., 2007) para a 
avaliação objectiva das alterações de memória em doentes com DA. 
O TRSLG é objecto de estudo de um programa de trabalhos que permitirá completar o 
processo de adaptação aqui descrito. Deste programa de trabalhos destacamos: i) a 
avaliação das qualidades psicométricas do TRSLG, nomeadamente validade 
concorrente, e ii) estudos de validação clínica e exploração da capacidade diagnóstica 
no DCL, na DA e na Demência Frontotemporal. 
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Abstract  
The International Working Group on Alzheimer’s disease (AD) suggested the Free and 
Cued Selective Reminding Test (FCSRT) to assess memory, since it showed high 
sensitivity and specificity in the differentiation of AD from healthy controls and other 
dementias. The FCSRT involves the use of selective reminding with semantic cueing in 
memory assessment. This study aims to validate the FCSRT for Mild Cognitive 
Impairment (MCI) and AD through the analysis of the diagnostic accuracy and the 
suggestion of cut-off scores. Patients were classified in two groups according to 
standard criteria: MCI (n=100) and AD (n=70). A matched control group (n=101) of 
cognitively healthy subjects was included.  
The reliability and the validity of the FCSRT were analysed on the Immediate (IR) and 
Delayed (DR) recalls. The Cronbach’s alpha was 0.915 for the IR and 0.879 for the DR. 
The total recall measures revealed good Areas Under the Curve for MCI (IR: .818; DR: 
.828) and excellent for AD (IR: .987; DR: .991). Furthermore, the MCI group was 
subdivided with respect to a non-similar/similar AD pattern of impairment, with almost 
half of the subjects showing an AD-like decline. This analysis represents a novel 
contribution regarding the properties of the FCSRT in illustrating the heterogeneity of 
MCI at baseline. The FCSRT has proved to be a very useful tool in the characterization 
of the memory impairment of the AD spectrum. 
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Introduction 
The International Working Group proposal for early diagnosis of Alzheimer’s disease 
(AD) (Dubois et al., 2007) considers the evidence of significant and progressive episodic 
memory deficit as the core diagnostic criterion. This impairment should be confirmed 
by objective testing and corroborated by the presence of at least one supportive 
neuroradiological, neurometabolic, or neurochemical abnormal biomarker of AD. This 
memory-criterion applies to cases of amnestic Mild Cognitive Impairment (aMCI), a 
clinical entity characterized by an isolated deficit of declarative memory in the absence 
of dementia (Petersen et al., 2001; Petersen et al., 1999). By providing a diagnostic set 
of tools that is able to capture the earliest stages of the disease (AD), the new criteria 
aim to consider MCI as a preclinical phase of AD or prodromal AD (Albert et al., 2011; 
Dubois et al., 2007, 2010). The authors recommend the use of the Free and Cued 
Selective Reminding Test (FCSRT; Buschke, 1984) to assess memory, since it showed 
high sensitivity and specificity in differentiating AD patients from healthy controls 
(Grober, Sanders, Hall, & Lipton, 2010) and from other types of dementia (Buschke, 
Sliwinski, Kuslansky, & Lipton, 1997). In fact, the performance in FCSRT has been 
associated with preclinical and early dementia in several longitudinal epidemiological 
studies (Ivnik et al., 1997; Peña-Casanova et al., 2009; Sarazin et al., 2007). This test 
provides a measure of memory under conditions that control attention and cognitive 
processing in order to obtain an assessment of memory without the effect of the 
normal age-related changes in cognition (Dubois et al., 2007, 2010).  
The FCSRT was designed to coordinate acquisition and retrieval by using the same 
semantic cues to control learning and elicit effective cued recall, enabling encoding 
specificity (Buschke et al., 1997). Encoding specificity is a technique that produces 
efficient learning and memory in normal ageing, (Ivnik et al., 1997). However, in 
conditions such as AD, brain regions that are essential for these cognitive processes 
(i.e., medial temporal structures) are usually impaired. Thus, tasks that maximize 
encoding specificity, such as the FCSRT, might be particularly sensitive to early AD 
(Petersen, Smith, Ivnik, Kokmen, & Tangalos, 1994).  
The relevance of this selective reminding paradigm has been widely reported in the 
memory dysfunction characterization of AD (Brown & Storandt, 2000; Buschke et al., 
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1997; Grober, Buschke, Crystal, Bang, & Dresner, 1988; Grober & Buschke, 1987; 
Grober & Kawas, 1997; Grober et al., 2008; Ivanoiu et al., 2005; Mahieux et al., 2009; 
Saka, Mihci, Topcuoglu, & Balkan, 2006; Sánchez-Benavides et al., 2010; Vogel, 
Mortensen, Gade, & Waldemar, 2007) and of MCI (Ivanoiu et al., 2005; Saka et al., 
2006). The comparable profiles of memory dysfunction of MCI and of AD have also 
been described (Petersen et al., 1999). Further, this similar profile has been described 
for MCI patients with a higher risk of conversion to AD (Sarazin et al., 2007). 
Nevertheless, results pointing to the superiority of this paradigm for differentiating AD 
or MCI patients from healthy elderly are controversial (Carlesimo, Perri, & Caltagirone, 
2011). A poor performance on the FCSRT has also shown a high correlation with 
atrophy in the medial temporal lobe (Sánchez-Benavides et al., 2010; Sarazin et al., 
2010) and was significantly associated with cerebrospinal fluid (CSF) AD-biomarkers 
(Wagner et al., 2012), increasing the validity of this paradigm in the early detection of 
AD. Despite the amount of literature describing the utility of the FCSRT in the 
characterization of the memory deficit of AD and MCI patients, to our knowledge no 
study has yet explored the heterogeneity of MCI patients, at baseline, with respect to a 
non-similar/similar AD pattern of impairment on the FCSRT. 
The FCSRT allows several scores which can be investigated as measures of diagnostic 
accuracy in AD and also in the characterization of the memory impairment that is 
typical of this pathology. Studies on the validity of the properties of the FCSRT 
paradigm (for a review see Carlesimo et al., 2011) have been reported using the 
modified Grober-Buschke (Grober & Buschke, 1987) procedure. The Grober-Busckhe 
modified version differs from the Busckhe FCSRT as it includes an immediate cued 
recall during the learning phase after the identification of a group of four items. The 
immediate total recall, i.e., the sum of the free and the cued recall, revealed better 
sensitivity and specificity in identifying individuals with AD (Grober et al., 1988; Grober 
& Buschke, 1987) and MCI (Saka et al., 2006) than the free recall alone. Information 
concerning the psychometric properties of the FCSRT paradigm is scarce in the 
literature and limited to the modified Grober-Buschke procedure (Grober, Ocepek-
Welikson, & Teresi, 2009). When comparing the three available test forms, the factor 
analyses indicate a single construct or dimension which the authors presume to be 
memory ability. The three forms show good concurrent criterion validity, good internal 
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consistencies and similar values of accuracy in the diagnosis of mild dementia (Grober 
et al., 2009).  
The main objective of the present study is to validate the FCSRT in the assessment and 
characterization of the memory dysfunction of MCI and AD patients. This was carried 
out through the analyses of the FCSRT diagnostic accuracy and with the proposal of the 
optimal cut-off scores for MCI and AD detection. Additionally, we compared the 
performance of MCI and AD patients in order to divide the MCI group with respect to a 
non-similar/similar AD pattern of impairment. We believe that this approach 
represents a novel contribution in terms of analysing the heterogeneity of MCI 
patients, regarding the FCSRT, at baseline. 
 
Methods 
Participants 
The clinical study sample included 100 MCI patients and 70 AD patients, recruited at 
the Neurology Department of Coimbra University Hospital where they have periodic 
medical examination and are enrolled in controlled prospective evaluation. Diagnostic 
investigation included a standard clinical evaluation, an extensive cognitive and staging 
assessment, laboratory tests, imaging studies and Apolipoprotein E allele genotyping. 
Standard laboratory tests essential to exclude a reversible form of dementia (including 
chemistry profile, CBC count, thyroid function tests, vitamin B12 and folic acid level, 
syphilis and Lyme serology), imaging studies (CT or MRI) and SPECT were always 
performed; while Positron Emission Tomography and Cerebrospinal Fluid analysis, and 
genetic studies were more restricted, although considered in younger patients. A 
comprehensive evaluation battery was administered, including: 1) Cognitive 
instruments as the Mini-Mental State Examination (MMSE; Folstein, Folstein, & 
McHugh, 1975; Guerreiro, 1998), the Alzheimer Disease Assessment Scale-Cognitive 
(ADAS-Cog; Guerreiro, Fonseca, Barreto, & Garcia, 2008; Mohs, Rosen, & Davis, 1983) 
and a comprehensive neuropsychological battery with normative data for the 
Portuguese population (Battery of Lisbon for the Assessment of Dementia - BLAD; 
Guerreiro, 1998) exploring memory and other cognitive domains (attention, language, 
verbal and non-verbal reasoning, visuospatial ability, calculation, right-left orientation, 
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and praxis) – data not shown; 2) The Clinical Dementia Rating (CDR; Garrett et al., 
2008; Morris, 1993) was used for global staging. 
Altogether, these auxiliary exams supported the diagnosis which was established by a 
multidisciplinary team headed by a board certified neurologist based on international 
consensus diagnostic criteria. The MCI group included patients classified as “amnestic” 
(single or multi-domain) (Petersen, 2007) and was selected according to Petersen’s 
criteria (Albert et al., 2011; Petersen, 2004, 2007) operationalized as this: 1) A 
subjective complaint of memory decline (reported by the subject or an informant); 2) 
An objective memory impairment (considered when scores on standard memory tests 
were >1.5 SDs below age/education adjusted norms) with or without deficits in other 
cognitive domains; 3) Normal general cognition suggested by normal scores in the 
MMSE and ADAS-Cog; 4) Largely normal daily life activities; 5) Absence of dementia, 
indicated by a CDR rating of 0.5. The standard criteria for the diagnosis of AD were the 
Diagnostic and Statistical Manual of Mental Disorders – fourth edition (DSM-IV-TR; 
American Psychiatric Association, 2000); and the National Institute of Neurological and 
Communicative Disorders and Stroke- Alzheimer’s Disease and Related Disorders 
(NINCDS-ADRDA; McKhann et al., 1984). The AD group only included patients with mild 
severity (CDR = 1). Moreover, to be eligible for this particular study, we considered 
that patients had to be in a stable condition, without acute significant events or 
recent/undergoing changes in medication, and we defined as exclusion criteria 
neurological or psychiatric conditions other than MCI or AD; CT or MRI demonstration 
of significant vascular burden (Román et al., 1993) (large cortico-subcortical infarct; 
extension superior to 25% of subcortical white matter lesions; uni- or bilateral thalamic 
lacune; lacune in head of caudate nucleus; more than 2 lacunes). 
The control group is composed by 101 cognitively healthy adults belonging to the local 
community (recruited among the patients’ spouses, hospital or university staff, or their 
relatives), that were age and education matched to the patients. They had no history 
of neurological or psychiatric relevant condition, including abuse of alcohol or drugs or 
head trauma; neither significant motor, visual or auditory deficits which could 
influence the neuropsychological performance. All control subjects were assessed 
using the following instruments for a global assessment: a complete socio-
demographic questionnaire; an inventory of current clinical health status, and past 
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habits and medical history; the MMSE; the CDR; and the Geriatric Depression Scale 
(GDS-30; (Barreto, Leuschner, Santos, & Sobral, 2008; Yesavage et al., 1982). All 
subjects had normal MMSE scores (mean 28.95), were fully autonomous in daily life 
activities (CDR) with information supplemented with information obtained through a 
general practitioner, and/or an informant. The depressive complaints were measured 
through clinical interview and GDS-30, excluding subjects with a score of 20 or more 
points in this instrument. 
All subjects from the 3 groups were submitted to the same experimental research 
protocol. Informed consent was obtained from all participants, and the study was 
conducted in accordance with the tenets of the Declaration of Helsinki, with the 
approval of our local ethics committee. 
Demographic and clinical characteristics of the population are shown in Table 2.1. 
Procedure 
Subjects were assessed using the Portuguese version of the FCSRT (Lemos, Martins, 
Simões, & Santana, 2012). Materials and instruction of the FCSRT were provided by the 
original author (Buschke’s FCSRT. Copyright, 2002. Albert Einstein College of Medicine 
of Yeshiva University, New York). The FCSRT (Buschke, 1984; Grober & Buschke, 1987) 
is a multi-trial memory test that use a “selective reminding” paradigm by presenting 
only the words not recalled, instead of all the to-be-remembered words. This paradigm 
is intended to facilitate learning by directing the subject's attention to the words not 
recalled on the previous trial.  
The test starts by asking subjects to identify words in response to a unique category 
cue. The 16 items to be learned are presented four at a time on a card, distributed by 
one word per quadrant. The subject is asked to search each card and point to and 
name aloud each item after its semantic cue was aurally presented. During this 
procedure, the subject is informed to learn the 16 words. There are three recall trials, 
each preceded by 20 seconds of counting backward to prevent recall from short-term 
memory. Each recall trial consisted of two parts. First, each subject had up to two 
minutes to freely recall as many items as possible. Next, aurally presented category 
cues were provided for items not retrieved by free immediate recall (free IR). If 
subjects failed to retrieve the item with the category cue, they were reminded by 
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presenting the cue and the item together - cued immediate recall (cued IR). The sum of 
free and cued recalls gives a measure of total immediate recall (total IR). The same 
procedure of recalling (freely and cued) is done after a 30 minute interval (Delayed 
Recall – DR), while subjects are required to perform non-verbal tasks, allowing the 
measure of the free DR, cued DR, total DR. 
Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 19.0) (IBM SPSS, Inc., Chicago, IL). When data significantly deviated from 
normal distributions (verified using the Kolmogorov-Smirnov normality check and 
Levene homogeneity tests), we did therefore choose to apply non-parametric 
statistical methods. Results with p<.05 were considered statistically significant. 
Descriptive statistics were used for sample’s characterization, comparisons between 
variables were performed with the use of the general linear model [one-way analysis 
of variance (ANOVA)] with post-hoc Tukey for multiple comparisons where 
appropriate; or the Kruskal-Wallis one-way ANOVA for k samples with pairwise 
comparisons with adjusted p value; the χ2 test was used for comparisons between 
categorical variables. Cronbach’s alpha reliability coefficient was considered as an 
index of internal consistency, and analysed separately for the immediate and delayed 
recalls. 
A series of binary logistic regressions, using the Backward (conditional) method, were 
performed to assess the effect of the demographic characteristics (age, education and 
gender) and the measure of the FCSRT (cued and total IR; cued and total DR) on the 
likelihood of having MCI or AD. The variance inflation factor (VIF) was used to check for 
the problem of multicollinearity among the predictor variables, considering a VIF < 5 as 
no evidence of multicollinearity; a 5 ≤ VIF ≤ 10 as moderate multicollinearity; and a VIF 
> 10 as serious multicollinearity problem with the variables. The fit of the logistic 
regression model was assessed through the receiver operating characteristics (ROC) 
curve analysis. In this analysis, the areas under the curve (AUC) can vary between 0.5 
and 1, with larger AUC indicating better diagnostic accuracy. The optimal cut-off points 
for each measure of the FCSRT that generated the highest Youden index were 
selected, with higher Younden index indicating maximization of the sensitivity and 
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specificity. For the analysis of the predictive value of the measures of the FCSRT we 
calculated, for each cut-off point, the sensitivity (the probability for subjects with 
cognitive impairment to have a positive test), specificity (the probability for subjects 
without cognitive impairment to have a negative test), the positive predictive value 
(PPV, the probability of disease in subjects who have a positive test), the negative 
predictive value (NPV, the probability of the classification “lack of disease” in subjects 
who have a negative test), and the classification accuracy (the probability of correct 
classification of subjects with or without cognitive impairment).  
The classification of the MCI group with respect to a similar/non-similar AD pattern of 
impairment was done using a hierarchical cluster analysis for a range of two to three 
solutions using the furthest neighbour method with squared Euclidian distance 
measure, complemented with a dispersion diagram.  
 
Results 
Sample characterization 
Demographical and clinical characteristics of the population are shown in Table 2.1. No 
statistically differences were found on age [F(2,268)=1.868, p =.157], educational level 
(χ2KW(2)=.611, p =.737), or gender [χ
2
(2)=4.554, p=.103] between the three groups.  
As expected, a significant effect was found for MMSE performance (χ2KW(2)=146.860, 
p<.001) among the three groups. Therefore, multiple comparisons revealed that both 
MCI (p<.001) and AD (p<.001) performed poorly on the MMSE, when compared to 
control subjects; and AD patients had a worse performance, when compared to MCI 
subjects (p<.001).  
Significant differences were found between ApoE-ε4 carriers and non-carriers among 
the clinical groups [χ2(1)=4.390, p=.036]. 
Psychometric properties – internal consistency reliability 
Internal consistency reliability of the FCSRT was estimated using Cronbach’s alpha. 
Within this analysis the Cronbach’s alpha of the FCSRT as an index of internal 
consistency was 0.915 for the immediate recall and 0.879 for the delayed recall on the 
total study sample, confirming an overall good reliability of the test when used to 
examine Portuguese participants. 
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Table 2.1 Population demographical characteristics and performance on the FCSRT  
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination. 
Note:  
Comparisons between Controls-MCI, Controls-AD and MCI-AD patients were carried out by a one-way ANOVA with post-hoc Tukey 
tests, Kruskal-Wallis 1-way ANOVA for k samples with pairwise comparisons, or χ2 test, where: 
* Controls vs. MCI: p <.001; Controls vs. AD: p <.001 
† MCI vs. AD: p <.001. 
¥ MCI vs. AD: p <.05. 
 
Group differences  
When analysing the performance on all the FCSRT selected measures, both the MCI 
and the AD groups were impaired relative to controls (p<.001), and there was also a 
significant difference between the AD and MCI patients (p<.001) (Table 2.2). The 
overall profile on the FCSRT was Controls>MCI>AD.  
Table 2.2 Performance on the FCSRT 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; IR – 
Immediate Recall; DR – Delayed Recall. 
Note: Data are expressed as median [IQR].  
Comparisons between Controls-MCI, Controls-AD and MCI-AD patients were carried out by the Kruskal-Wallis 1-way ANOVA for k 
samples with pairwise comparisons, where: 
* Controls vs. MCI: p <.001; Controls vs. AD: p <.001; MCI vs. AD: p <.001. 
 
 
 
 Control subjects 
(n=101) 
MCI 
(n=100) 
AD 
(n=70) 
Gender (m:f) 48:53 39:61 22:48 
Age (years), mean (SEM) 70.22 (0.76) 71.08 (0.83) 72.63 (0.98) 
Education Level (years), median [IQR] 4 [4, 11] 4 [4, 9] 4 [4, 11] 
MMSE (score), median [IQR] 29 [28, 30] 28 [25, 29]* 21 [19, 25]*/† 
ApoE ε4 carrier, n (%) ---- 44 (44) 42 (61)¥ 
 Control 
subjects  
(n=101) 
MCI 
(n=100) 
AD 
(n=70) 
χ2KW 
Between-
group 
comparisons 
FCSRT Free IR 22 [18.5, 27] 11.5 [6, 20.75] 3 [1, 7] 148.949 p < .001* 
FCSRT Cued IR 18 [14, 20] 14 [11, 18] 9 [4, 12.25] 79.120 p < .001* 
FCSRT Total IR 40 [37, 44] 28 [19.25, 36.75] 11 [6, 19] 152.164 p < .001* 
FCSRT Free DR 9 [7, 10.5] 4 [0, 7] 0 [0, 0] 144.851 p < .001* 
FCSRT Cued DR 5 [4, 7] 4 [3, 6] 2 [1, 3.25] 64.423 p < .001* 
FCSRT Total DR 15 [13, 15] 9 [5, 12] 3 [1, 4] 155.897 p < .001* 
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Cut-off points and accuracy of the FCSRT 
In order to assess the measure of the FCSRT (free, cued and total IR; free, cued and 
total DR) on the likelihood of having MCI or AD, a series of binary logistic regressions, 
using the Backward (conditional) method, were performed.  
Table 2.3 presents the significant logistic regression models for predicting MCI and AD 
using FCSRT measures. In this analysis age, education and gender were included as 
covariates. The two free recall measures (IR and DR) were automatically excluded from 
the collinearity statistics, and therefore not included on the logistic regression 
computation. The VIFs showed that there was no evidence of a problem among all the 
predictor variables (all VIFs < 5, and on average: 1< VIF <2). 
For the MCI group, significant effects were found for both total recall measures (IR and 
DR) (p<.001) on the logit modelling the probability of being MCI. The FCSRT cued recall 
did not reach significance on both IR and DR. Neither age, nor education, nor gender 
reached significance on the likelihood of having MCI. 
For the AD patients, similar results were found. The analysis showed that the two total 
measures (IR and DR) were significantly associated with the dementia status (p<.001). 
However, the FCSRT cued IR (p=.007) and age (p=.036), on the DR analysis, showed 
also significant effects. The other demographic characteristics were not statistically 
significant (Table 2.3). 
Table 2.3 Significant logistic regression models for predicting MCI and AD using the FCSRT (IR 
and DR)  
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; IR – 
Immediate Recall; DR – Delayed Recall. 
 
 B S.E. 𝑋𝑤𝑎𝑙𝑑
2
 df p-value Exp(B) 95% C.I. for EXP(B) 
MCI        
Total IR -.165 .025 44.397 1 .000 .848 ]0.808; 0.890[ 
Total DR -.463 .071 42.976 1 .000 .629 ]0.548; 0.723[ 
AD        
Cued IR .459 .170 7.252 1 .007 1.582 ]1.113; 2.208[ 
Total IR -.704 .182 14.899 1 .000 .495 ]0.346; 0.707[ 
Age -.166 .079 4.395 1 .036 .847 ]0.725; 0.989[ 
Total DR -1.163 .269 18.669 1 .000 .312 ]0.184; 0.530[ 
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In order to evaluate the fit of the logistic regression models in the diagnostic accuracy 
of the FCSRT measures (total IR and total DR) in discriminating MCI and AD patients 
from cognitively healthy controls, the receiver operating characteristic (ROC) curve and 
the corresponding predictive values were implemented (Figure 2.1). 
 
Figure 2.1 ROC curve analyses of the FCSRT total recall measures (IR –light grey; DR – dark 
grey) to detect MCI (left) and AD (right). 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; IR – 
Immediate Recall; DR – Delayed Recall. 
 
The ROC curves revealed that the total recall measures had good AUC’s for MCI [IR: 
.818 (95% IC = .759 - .878); DR: .828 (95% IC = .769 - .887)] and excellent AUC’s for AD 
[IR: .987 (95% IC = .971 - 1.000); DR: .991 (95% IC = .979 - 1.000)]. 
The optimal cut-off scores for maximum accuracy (Youden index), of each total recall 
measure, and its respective values of sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and classification accuracy are described in 
Table 2.4.  
For MCI patients, the cut-off scores were set at ≤35 (out of 48) for total IR and ≤12 (out 
of 16) for total DR, since they produced the greatest Youden index. For AD subjects, 
the cut-off scores were set at ≤27 (out of 48) for total IR and ≤8 (out of 16) for total DR 
as it fixed excellent values of diagnosis accuracy. 
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Table 2.4 Diagnostic classification accuracy of the FCSRT 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; IR – 
Immediate Recall (maximum score =48); DR – Delayed Recall (maximum score =16); AUC – area under the operating characteristics 
curve; PPV - positive predictive value; NPV - negative predictive value. 
Note1: Sensitivity, Specificity, PPV, NPV and Classification Accuracy values are expressed in percentage. 
Note2: Cut-off values indicate the minimum score required for absence of signal. 
 
Distinguishing MCI from AD 
In order to better discriminate MCI patients from the dementia stage of AD we 
performed a similar array of statistical analysis within the FCSRT performance between 
the two clinical samples. The demographical variables were again included as 
covariates. 
A new binary logistic regression was performed within the total IR and total DR recalls, 
in order to know which of these two measures was better in discriminating MCI from 
AD. A significant effect was found for the immediate total recall (𝐵𝑡𝑜𝑡𝑎𝑙 𝐼𝑅 =
−.074;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 4.017;  𝑝 = .045; 𝑂𝑅 =  .928) on the logit modelling the probability 
of being AD, when compared to MCI. Once more, the ROC curve analyses was 
implemented in order to evaluate the fit of the logistic regression models in the 
diagnostic accuracy of the FCSRT total IR in discriminating between MCI from AD 
patients. The ROC curves revealed that the total IR had a good AUC of .844 (95% IC = 
.786 - .902) (Figure 2.2). Respective values of sensitivity, specificity, PPV, NPV, and 
classification accuracy are described in Table 2.4.  
 Cut-off AUC Sensitivity Specificity PPV NPV Classification accuracy 
MCI        
Total IR ≤35 .818 72 83 81 75 78 
Total DR ≤12 .828 76 81 80 77 79 
AD        
Total IR ≤27 .987 94 99 99 95 97 
Total DR ≤8 .991 96 97 97 96 96 
MCI vs AD        
Total IR ≤21 .844 84 71 74 82 78 
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Figure 2.2 ROC curve analyses of the FCSRT total IR measure to discriminate MCI from AD. 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; IR – 
Immediate Recall. 
 
Distinguishing MCI sub-groups 
The new AD criteria aim to consider some cases of aMCI as a pre-dementia 
symptomatic stage of AD, the so-called prodromal AD (Albert et al., 2011; Dubois et al., 
2007; 2010). The pattern of cognitive performance in prodromal AD is characterized by 
the AD specific episodic memory deficit suggested by the new AD criteria (Dubois et 
al., 2007; 2010). 
With the purpose of analysing the accuracy of the distinction between MCI and AD 
patients, and taking into consideration the assumption that some cases of aMCI may 
be considered as a pre-dementia symptomatic stage of AD (prodromal AD), we decided 
to divide the MCI group with respect to a similar/non-similar AD pattern of 
impairment. For that, we used the cut-off score of ≤27 for AD (out of 48) of the FCSRT 
total IR (see Table 2.4), as it revealed to be the best measure in discriminating MCI 
from AD. We have considered that all the subjects with a FCSRT total IR ≤27 would be 
MCI-AD, and the subjects with a performance above this cut-off score would be MCI-
MCI. After this new subdivision, 54 MCI patients out of 100 revealed a MCI-MCI 
pattern, whereas 46 subjects had a similar pattern of impairment as AD and were 
considered MCI-AD. Therefore, we compared the performance of the three groups on 
the MMSE and on the FCSRT total DR (in order to be a different measure of the FCSRT 
from the one used to divide the MCI group). Demographical characteristics and 
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performance of the pathological subgroups, on the MMSE and on the FCSRT total DR, 
are shown in Table 2.5.  
Table 2.5 Demographical characteristics and performance of the pathological subgroups on 
the FCSRT 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination; FCSRT – Free 
and Cued Selective Reminding Test; DR – Delayed Recall. 
Note:  
Comparisons between MCI-MCI, MCI-AD and AD patients were carried out by a one-way ANOVA with post-hoc Tukey tests, 
Kruskal-Wallis 1-way ANOVA for k samples with pairwise comparisons, or χ2 test, where: 
* MCI-MCI vs. MCI-AD: p <.05; MCI-MCI vs. AD: p <.05;  
** MCI-MCI vs. MCI-AD: p <.001; MCI-MCI vs. AD: p <.001; 
† MCI-AD vs. AD: p <.001. 
 
In terms of demographical characteristics, a significant effect for age was found 
between the three groups [F(2,167)=4.484, p=.013], where post-hoc analysis revealed 
significant differences between MCI-MCI and MCI-AD (p=.019); MCI-MCI and AD: (p= 
.041); but with no differences when comparing MCI-AD and AD (p=.845). No 
statistically differences were found on educational level (χ2KW(2)=1.510, p=.470), 
between the three groups. 
A significant effect was found for MMSE performance (χ2KW(2)=94.244, p<.001) among 
the three groups, with multiple comparisons revealing significant differences among 
the three groups (p<.001). A significant effect was also found for the FCSRT total DR 
(χ2KW(2)=100.121, p<.001) with an overall profile of MCI-MCI>MCI-AD=AD. 
Significant differences were found between ApoE-ε4 carriers and non-carriers among 
the three groups [χ2(2)=24.120, p<.001], with differences between MCI-MCI and MCI-
AD subgroups [χ2(1)=19.965, p<.001]; MCI-MCI and AD patients [χ
2
(1)=16.591, p<.001]; 
but not between MCI-AD and ADs [χ2(1)=.761, p=.383). 
A dispersion diagram (Figure 2.3), complemented by a hierarchical cluster analysis, was 
performed to classify the neuropsychological profiles on the MMSE and FCSRT Total DR 
according to their similarity based on the three groups (MCI-MCI, MCI-AD and AD). 
 MCI-MCI 
(n=54/100) 
MCI-AD 
(n=46/100) 
AD 
(n=70) 
Age (years), mean (SEM) 69.04 (1.17) 73.48 (1.08)* 72.63 (0.98)* 
Education Level (years), median [IQR] 4 [4, 9] 4 [4, 9.5] 4 [4, 11] 
MMSE (score), median [IQR] 29 [27, 30] 26 [24, 28]** 21 [19, 25]**/† 
FCSRT Total DR, median [IQR] 12 [11, 15] 4.5 [2, 7]** 3 [1, 4]** 
ApoE ε4 carrier, n (%) 13 (24) 31 (69)** 42 (61)** 
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Misclassifications were used to identify the optimal number of clusters, resulting in a 
two cluster solution (Table 2.6).  
 
Figure 2.3 Recall FCSRT Total DR dispersion against performance on the MMSE for MCI-MCI, 
MCI-AD and AD.  
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination; FCSRT –Free 
and Cued Selective Reminding Test; DR – Immediate Recall.  
Spearman correlation (r2 = .712, p< .001) was performed between the two measures. 
 
Table 2.6 Crosstabulation of cluster membership on the groups’ subdivision, for the two 
cluster solution 
 
Complete Linkage 
Total 
1 2 
MCI subgroups 
and AD 
MCI-MCI Count (%) 49 (90.7) 5 (9.3) 54 (100.0) 
MCI-AD Count (%) 7 (15.2) 39 (84.8) 46 (100.0) 
AD Count (%) 4 (5.7) 66 (94.3) 70 (100.0) 
Total Count (%) 60 (35.3) 110 (64.7) 170 (100.0) 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease 
Discussion  
The main purpose of this study is to validate the FCSRT for MCI and AD because it is 
the memory test suggested by the International Working Group on AD (Dubois et al., 
2007). According to these criteria (Dubois et al., 2007), objective testing using the 
FCSRT must confirm the presence of significant and progressive episodic memory 
impairment. Thus, a low free recall and total recall performance on FCSRT constitutes 
the core neuropsychological marker of prodromal AD as recommended in the newly 
proposed diagnostic criteria (Dubois et al., 2007). 
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Overall, in our analyses, none of the demographic characteristics showed a significant 
effect on the results, namely the education level. As most of the screening and 
cognitive tests are sensitive to education (Jefferson et al., 2011; Muniz-Terrera, 
Matthews, Dening, Huppert, & Brayne, 2009), they require different cut-offs 
depending on the educational level. However, the absence of any significant effect by 
education on the FCSRT for predicting MCI and AD suggests that the FCSRT measures 
can be used to classify subjects in different pathological groups without the need of 
adjustment for different educational levels. This is a very important issue since socio-
demographic diversity is common, especially in countries where levels of education are 
generally low such as Portugal. 
The FCSRT revealed an overall good reliability (internal consistency) when used to 
examine Portuguese subjects. 
A great advantage of the FCSRT’s paradigm is that it allows the distinction between the 
three different components of episodic memory: registration (by ensuring that all 
items have been truly registered), storage (by providing the semantic cues for 
facilitating the access to stored information), and retrieval (by the spontaneous recall 
of items after delay) (Sarazin et al., 2010). Like in other studies (Grober et al., 2010; 
Sarazin et al., 2010), the total recall item (the sum of the spontaneous and the cued 
recalls) revealed to be the most important measure in the distinction between patients 
and controls. This result is interesting as the total recall reflects the amount of 
information that is stored by the subject and it is the most important marker of long 
term episodic memory (Sarazin et al., 2010). 
The analysis of group differences indicated that the FCSRT was able not only to 
distinguish the clinical groups from the control group, but also to separate the degree 
of impairment between MCI and AD. The two pathological groups showed impairment 
on the three measures of the test: free, cued and total. This proves that MCI and AD 
have a similar pattern of impairment. In neither case did the patients seem to show to 
benefit from category cues, as the impairment occurred also on the cued recall. 
Nevertheless, the AD group was significantly worse on all these measures.  
When analysing the impact of the FCSRT two recalls, on the likelihood of having MCI or 
AD, significant effects were found for the two total recall measures. Total recall, which 
is the sum of the free and the cued recalls, is an interesting parameter to consider as it 
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reflects the amount of information that is stored spontaneously and facilitated by the 
subject. Accordingly, we analysed the diagnostic accuracy and the corresponding cut-
off scores for the FCSRT on MCI and AD patients. The ROC curves revealed that the 
total recall measures had good AUCs for MCI (IR: .818; DR: .828) and excellent AUCs for 
AD (IR: .987; DR: .991). For MCI patients, the cut-off scores were set at ≤35 for total IR 
and ≤12 for total DR with good values of accuracy. For AD subjects, the cut-off scores 
were set at ≤27 for total IR and ≤8 for total DR with fixed excellent values of diagnosis 
accuracy.  
Studies on the validity of the properties of the FCSRT paradigm were reported using 
the modified Grober-Buschke (Grober & Buschke, 1987) procedure (Grober et al., 
2009). The immediate total recall, i.e., the sum of the free and the cued recall, 
revealed better sensitivity and specificity in identifying individuals with AD (Grober et 
al., 1988; Grober & Buschke, 1987) and MCI (Saka et al., 2006) than the free recall. 
Nevertheless, Saka et al. (2006) proved the superiority of the immediate total recall in 
terms of sensitivity, but showed that it is less specific when compared to the free recall 
in discriminating AD patients from healthy elders. Vogel et al. (2007) analysed the 
delayed recall and revealed that it increased the sensitivity of the total recall in AD 
identification when compared to the immediate recall. Another study assessed the 
validity of this test for predicting dementia two and five years after the initial 
evaluation and reported good sensitivity, fair specificity and high negative predictive 
values for the diagnosis of dementia on the subtests of free and total immediate recall. 
However, positive predictive values were low as many subjects with low scores for free 
and total recall remained free of dementia after 5 years (Auriacombe et al., 2010). 
Nevertheless, in our study both the immediate and the delay recalls showed a 
significant impairment in the two clinical groups. This result is in line with the 
hypothesis of a memory deficit, mainly in encoding, in AD patients (Grober & Kawas, 
1997). Moreover, the delayed recall measure showed to be more sensitive, although 
the immediate recall presented a higher value of specificity. This proves the 
importance of having a delayed recall to account for the milder forms of cognitive 
decline (Ivanoiu et al., 2005) such as MCI, and avoid the inclusion of false negatives 
that can occur when the immediate recall is the only memory measure tested. 
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As the new criteria (Dubois et al., 2007) aim to capture the earliest stages of the 
disease (AD) and some cases of aMCI that may be considered as a preclinical phase of 
AD or prodromal AD (Albert et al., 2011; Dubois et al., 2007, 2010), we decided to 
analyse and compare the performance of the two pathological groups. The immediate 
total recall revealed to be the best measure of the FCSRT in discriminating MCI 
patients from AD, with a good AUC of .844. This result is interesting, considering the 
great impairment of AD patients in encoding and storing new information (Tounsi et 
al., 1999). To better understand an AD-like profile of impairment among MCI patients, 
we subdivided the MCI group into MCI-MCI and MCI-AD sub-groups. This split was 
done according to a FCSRT total IR ≤27, since it proved to be the best measure to 
discriminate the two clinical groups. The MCI patients with a performance above this 
cut-off point were allocated to the MCI-MCI sub-group, and the remaining patients, 
with a performance on FCSRT total IR below 27, were allocated to the MCI-AD sub-
group. After this new subdivision, almost half of the subjects (46%) showed an AD-like 
pattern of impairment. Among the three pathological groups, a pattern of impairment 
was observed for the FCSRT with an overall profile of MCI-MCI>MCI-AD=AD. 
Furthermore, the MCI-AD group showed an increased distribution of the ApoE-ε4 
allele, which is a major risk factor for sporadic AD (Fleisher et al., 2007). The frequency 
of ε4 allele carriers in the MCI-AD group was similar to that observed in the AD group, 
while the MCI-MCI group had a significantly lower percentage of ε4 allele carriers. 
Therefore, we performed a cluster analysis based on the cognitive performance, which 
produced a two cluster solution. The first cluster was made up predominantly of MCI-
MCI subjects, and the second cluster was essentially a combination of the MCI-AD and 
AD patients. With this approach we believe that the heterogeneity of the MCI group 
may be subdivided according to an AD-similar pattern of performance with respect to 
the FCSRT profile. The diagnostic properties of the FCSRT were reported in the 
literature. However, we believe that our study brings a novel contribution to the 
attempt to differentiate MCI patients in terms of an AD-like pattern of impairment at 
baseline. This approach facilitates the aim of capturing the earliest stages of AD 
(Dubois et al., 2007) by exploring the performance on the FCSRT in a hierarchical 
manner (subdividing the MCI group with respect to a non-similar/similar AD pattern of 
impairment). Although the most important objective is to capture the earliest stages of 
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AD, we have examined the pattern of performance in a memory test, which alone 
should not be enough to characterize the patients as prodromal AD. Therefore, these 
results should be corroborated in the future with studies relating to AD biomarkers. 
In sum, our study demonstrated that the FCSRT is a useful tool in the memory 
dysfunction characterization of the AD spectrum. The FCSRT proved to be helpful in 
the differentiation of ADs and MCIs from controls. It also showed that MCI is a 
heterogeneous group that certainly includes cases of patients at a higher risk of being 
prodromal ADs (Albert et al., 2011; Dubois et al., 2007, 2010). The importance of the 
underlying paradigm of this test in discriminating the possible prodromal ADs, should 
be confirmed by research that correlates the performance on the FCSRT with AD 
biomarkers. Thus, studies comparing memory tests that use different paradigms, and 
longitudinal studies with follow-ups of MCI subjects should be carried out in order to 
achieve accuracy for predicting dementia. 
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Abstract  
The Free and Cued Selective Reminding Test (FCSRT) is a memory test that controls 
attention and acquisition, by providing category cues in the learning process. Because 
it enables an assessment of memory unconfounded by normal age-related changes in 
cognition and a high accuracy on Alzheimer’s disease (AD) evaluation, it has been 
suggested by the International Working Group on AD. Our aim was to assess the 
construct related validity of the FCSRT in the AD spectrum disorders.  
Patients were classified in two groups according to standard criteria: amnestic Mild 
Cognitive Impairment (n=100) and AD (n=70). A matched control group (n=101) of 
cognitively healthy subjects was included. The factorial structure of two models, and 
respective construct and diagnostic validities were analyzed.  
Both models revealed adequate fit values. The appropriated convergent validity and 
the lack of discriminant validity support the two-factors as measuring the same 
construct (memory ability). The unidimensionality of the FCSRT enabled us to add a 
global score for the FCSRT. All recalls of the FCSRT enabled high classification accuracy 
and diagnostic validity for both pathological groups.  
This study represents a novel contribution regarding the adequacy of the FCSRT in 
terms of construct and diagnostic validities, and shows the interest of including both 
immediate (learning) and delayed (retention) recalls. It gives also new possibilities 
regarding the use of the FCSRT in the memory assessment of AD spectrum disorders. 
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Introduction 
The Free and Cued Selective Reminding Test (FCSRT; Buschke, 1984) provides a 
measure of memory under conditions that control attention and cognitive processing, 
in order to obtain an assessment of memory unconfounded by normal age-related 
changes in cognition. Testing memory by controlling learning conditions was suggested 
to distinguish the genuine AD deficits in encoding and storage, from the memory 
deficits associated with normal aging that are likely to be secondary to impaired 
attention, inefficient information processing, or ineffective retrieval operations 
(Grober & Buschke, 1987). Retrieval deficits that occur in healthy elderly subjects 
showed to improve with controlled learning procedures (Buschke, Sliwinski, Kuslansky, 
& Lipton, 1995; Grober, Merling, Heimlich, & Lipton, 1997). On the contrary, in 
patients of the AD clinical spectrum these procedures have very limited benefits 
(Boeve et al., 2003; Buschke, 1984; Saka, Mihci, Topcuoglu, & Balkan, 2006). As a 
consequence, controlled learning procedures should expand the differences produced 
by normal aging and dementia and thus improving discriminative validity (Grober, 
Sanders, Hall, & Lipton, 2010). As such, the International Working Group (IWG-1; 
Dubois et al., 2007, 2010) proposal for the early diagnosis of Alzheimer’s disease (AD) 
suggested the use of the FCSRT to assess memory. By providing a diagnostic set of 
tools that is able to capture the earliest stages of the disease (AD), the new criteria 
aims to consider some cases of amnestic Mild Cognitive Impairment (aMCI) as 
symptomatic prodromal AD (Albert et al., 2011; Dubois et al., 2007, 2010). According 
to the IWG-1 criteria, subjects were classified in the prodromal AD group if they had 
memory impairment and at least one abnormal AD biomarker: presence of medial 
temporal lobe atrophy, abnormal CSF biomarkers, specific pattern on functional 
neuroimaging with FDG-PET or an autosomal dominant mutation within the immediate 
family (Dubois et al., 2007). More recently, the IWG-2 criteria reinforced the choice of 
the FCSRT, along with abnormal CSF biomarkers, as valid clinical markers for typical 
prodromal AD (aMCI and abnormal biomarkers) (Dubois et al., 2014). 
It is expected that different levels of impairment discriminate between normal aging 
and early dementia, as AD patients would have limited benefit from controlled 
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learning; thus, it may allow identifying the earliest stages of AD (Albert et al., 2011; 
Dubois et al., 2007, 2010; 2014). 
The utility of this cued selective reminding paradigm has been widely reported in the 
memory dysfunction characterization of AD (Brown & Storandt, 2000; Carlesimo, Perri, 
& Caltagirone, 2011; Grober & Kawas, 1997; Grober et al., 2008b; Mahieux et al., 2009; 
Sarazin et al., 2010; Vogel, Mortensen, Gade, & Waldemar, 2007) and aMCI (Ivanoiu et 
al., 2005; Saka et al., 2006; Wagner et al., 2012). The comparable profiles of memory 
dysfunction of MCI and of AD have also been described (Petersen, 2004a; Petersen et 
al., 1999; Sánchez-Benavides et al., 2014). Further, this similar profile has been 
described for MCI patients with a higher risk of conversion to AD (Petersen, 2007; 
Sarazin et al., 2010). The FCSRT also showed its capability to differentiate a group of 
aMCI patients according to their similarity with AD impaired performance (Lemos, 
Simões, Santiago, & Santana, 2015). Normative studies of the FCSRT provided 
reference data for a reliable use of the test (Ivnik et al., 1997; Peña-Casanova et al., 
2009).  
Studies on the psychometric properties of the FCSRT paradigm’s validity (for a review 
on the Buschke’s different controlled learning procedures see Carlesimo et al., 2011) 
have been reported using the modified Grober-Buschke procedure (FCSRT-IR; Grober 
& Buschke, 1987). The FCSRT-IR version differs from the FCSRT as it includes an 
immediate cued recall during the learning phase after the identification of a group of 
four items. The total recall, i.e., the sum of free and cued recalls, delivered better 
sensitivity and specificity in identifying individuals with AD (Grober & Buschke, 1987; 
Lemos et al., 2015) and with aMCI (Lemos et al., 2015; Saka et al., 2006) than the free 
recall alone. Information on the psychometric properties of the FCSRT paradigm is 
scarce in the literature and limited to the FCSRT-IR procedure (Grober, Ocepek-
Welikson, & Teresi, 2009). In that study, when comparing the three available test 
forms, the factor analyses indicated a single construct or dimension which the authors 
presume to be memory ability. The three forms showed good concurrent criterion 
validity, good internal consistencies and similar values of accuracy in the diagnosis of 
mild dementia (Grober et al., 2009).  
In the FCSRT category cues are provided for items not retrieved by free recall. If 
subjects fail to retrieve the item with the category cue, they are reminded by 
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presenting the cue and the item together. The sum of free and cued recall gives a 
measure of total recall (Immediate Total Recall - ITR). The same procedure of recalling 
(freely and cued) is done after a 30 minute interval (Delayed Total Recall - DTR). 
Standard criteria for the diagnosis of both aMCI and AD require an objective 
confirmation of the memory dysfunction (American Psychiatric Association, 2000; 
Dubois et al., 2007; McKhann et al., 2011; Petersen, Doody, et al., 2001). Therefore, 
the test used to identify the memory impairment should be highly accurate (Petersen, 
Smith, Ivnik, Kokmen, & Tangalos, 1994) and individual deviations must be concretely 
specified along with its cut-off values (Petersen, 2004a). 
Valid and accurate neuropsychological tests must have good diagnostic classification 
properties. In terms of memory, a significant impairment in neuropsychological testing 
is essential to the diagnosis of both aMCI and AD (Dubois et al., 2007; 2014; Portet et 
al., 2006).  
Apart from the study on the FCSRT-IR (Grober et al., 2009), and as far as we are aware 
of, there are no available studies on the factorial structure of the Buschke’s FCSRT in 
clinical (AD spectrum) populations nor in community samples, representing an 
important gap in the construct related validity of this test.  
Construct validity is an important concept that relates to the importance of validating a 
psychometric test for use in a particular clinical population (American Educational 
Research Association, American Psychological Association, & National Council on 
Measurement in Education, 1999). Basically, the goal is to guarantee that the 
psychological instrument is accurately evaluating the underlying dimension(s), rather 
than something different, in the clinical population in which it is being used (Maroof, 
2012). 
The main objectives of the present study are to analyze the FCSRT factorial structure 
and to establish its respective construct and diagnostic validities in the AD spectrum 
disorders.  
 
Methods  
Participants and Procedures 
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The total sample was composed of 271 participants distributed between two main 
sub-groups (Lemos et al., 2015). 
The healthy group is composed by 101 cognitively healthy adults belonging to the local 
community (recruited among the patients’ spouses, hospital or university staff, or their 
relatives) that were age and education matched to the patients. They had no history of 
neurological or psychiatric relevant condition, including abuse of alcohol or drugs or 
head trauma; neither significant motor, visual or auditory deficits which could 
influence the neuropsychological performance. All control subjects were assessed 
using the following instruments for a global assessment: a complete sociodemographic 
questionnaire; an inventory of current clinical health status, and past habits and 
medical history; the Mini-Mental State Examination (MMSE; Folstein, Folstein, & 
McHugh, 1975; Guerreiro, 1998); the Clinical Dementia Rating (CDR; Garrett et al., 
2008; Morris et al., 2001); and the Geriatric Depression Scale (GDS-30; Barreto, 
Leuschner, Santos, & Sobral, 2008; Yesavage et al., 1983). All subjects had normal 
MMSE scores (mean 28.95), were fully autonomous in daily life activities (CDR=0) and 
their information was provided by a general practitioner and/or an informant. The 
depressive complaints were measured through clinical interview and GDS-30, 
excluding subjects with a score of 20 or more points in this instrument. 
The clinical study sample included 100 aMCI patients and 70 AD patients, recruited at 
the Neurology Department of Coimbra University Hospital where they have periodic 
medical examination and are enrolled in controlled prospective evaluation. Diagnostic 
investigation included a standard clinical evaluation, an extensive cognitive and staging 
assessment, laboratory tests, imaging studies and Apolipoprotein E allele genotyping. 
Standard laboratory tests essential to exclude a reversible form of dementia (including 
chemistry profile, CBC count, thyroid function tests, vitamin B12 and folic acid level, 
syphilis and Lyme serology), imaging studies (CT or MRI) and SPECT were always 
performed; Positron Emission Tomography and Cerebrospinal Fluid analysis and 
genetic studies were more restricted although applied to younger patients. A 
comprehensive evaluation battery was administered, including: 1) Cognitive 
instruments such as the MMSE, the Alzheimer Disease Assessment Scale-Cognitive 
(ADAS-Cog; Guerreiro, Fonseca, Barreto, & Garcia, 2008; Mohs, Rosen, & Davis, 1983) 
and a comprehensive neuropsychological battery with normative data for the 
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Portuguese population (Battery of Lisbon for the Assessment of Dementia; Guerreiro, 
1998) exploring memory (Logical memory and Verbal Paired-Associate Learning from 
the Wechsler Memory Scale) and other cognitive domains (attention, language, verbal 
and non-verbal reasoning, visuospatial ability, calculation, right-left orientation, and 
praxis) – data not shown; 2) the CDR which was used for global staging. Altogether, 
these auxiliary exams supported the diagnosis which was established by a 
multidisciplinary team headed by a board certified neurologist, based on international 
consensus diagnostic criteria. The aMCI group included single or multi-domain 
amnestic patients (Petersen, 2007) and was selected according to Petersen’s criteria 
(Albert et al., 2011; Petersen, 2007; Petersen, 2004b) operationalized in the following 
terms: 1) A subjective complaint of memory decline (reported by the subject or an 
informant); 2) An objective memory impairment (considered when scores on standard 
memory tests were >1.5 SDs below age/education adjusted norms) or without deficits 
in other cognitive domains; 3) Normal general cognition suggested by normal scores in 
the MMSE (Guerreiro, 1998) and ADAS-Cog (Guerreiro et al., 2008); 4) Largely normal 
daily life activities; 5) Absence of dementia, indicated by a CDR rating of 0.5. The 
standard criteria for the diagnosis of AD were the Diagnostic and Statistical Manual of 
Mental Disorders – fourth edition (DSM-IV-TR; American Psychiatric Association, 2000) 
and the National Institute of Neurological and Communicative Disorders and Stroke - 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et 
al., 2011; McKhann et al., 1984). The AD group only included patients with mild 
severity (CDR = 1). Moreover, to be eligible to this particular study, we considered that 
patients had to be in a stable condition, without acute significant events or 
recent/undergoing changes in medication, and we defined as exclusion criteria 
neurological or psychiatric conditions other than aMCI or AD; CT or MRI demonstration 
of significant vascular burden (Román et al., 1993) (large cortico-subcortical infarct; 
extensive subcortical white matter lesions superior to 25%; uni- or bilateral thalamic 
lacune; lacune in head of the caudate nucleus; more than 2 lacunes). 
In the present study, the FCSRT was not used in the diagnostic process. 
All participants were submitted to the same experimental research protocol. Informed 
consent was obtained from all participants, and the study was conducted in 
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accordance with the tenets of the Declaration of Helsinki, with the approval of our 
local ethics committee.  
Measure: Free and Cued Selective Reminding Test (FCSRT) 
Subjects were assessed using the Portuguese version of the Buschke’s FCSRT (Lemos, 
Martins, Simões, & Santana, 2012). Materials and instruction of the FCSRT were 
provided by the original author (Buschke’s FCSRT. Copyright, 2002. Albert Einstein 
College of Medicine of Yeshiva University, New York). The selection of the 16 stimulus 
words followed the same principles as the English version – intermediate frequency 
words were selected within a semantic category (frequencies in Portuguese in the 
CORLEX database (Nascimento et al., 2003). The FCSRT (Buschke, 1984) is a multi-trial 
memory test that use a “selective reminding” paradigm by presenting only the words 
not recalled, instead of all the to-be-remembered words. This paradigm is intended to 
facilitate learning by directing the subject's attention to the words not recalled in the 
previous trial. It controls attention and cognitive processing, requiring subjects to 
search for items in response to their category cues, in the learning process; moreover, 
these same category cues are later used to elicit recall of the items not retrieved on 
free recall, coordinating acquisition and retrieval. 
The test starts by asking subjects to identify words in response to a unique category 
cue. The 16 items to be learned are presented four at a time on a card, distributed by 
one word per quadrant. The subject is asked to search each card and point to and 
name aloud each item after its semantic cue was aurally presented. During this 
procedure, the subject is informed to learn the 16 words. There are three recall trials, 
each preceded by 20 seconds of counting backward to prevent rehearsal and obtain 
retrieval from long-term memory. Each recall trial consisted of two parts. First, each 
subject had up to two minutes to freely recall as many items as possible. Next, aurally 
presented category cues were provided for items not retrieved by free recall. If 
subjects failed to retrieve the item with the category cue, they were reminded by 
presenting the cue and the item together. The sum of free and cued recalls gives a 
measure of total recall (ITR). The same procedure of recalling (freely and cued) is done 
after a 30 minute interval (Delayed Total Recall – DTR), while subjects are required to 
perform non-verbal tasks. 
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The FCSRT version used in this study differs from the modified FCSRT-IR version 
included in the study of Grober et al. (2009), as it includes words rather than pictures 
and does not include immediate cued recall in the learning phase. 
Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 19.0) (IBM SPSS, Inc., Chicago, IL). When data significantly deviated from 
normal distributions (verified using the Kolmogorov-Smirnov normality check and 
Levene homogeneity tests), we did therefore choose to apply non-parametric 
statistical methods. Results with p<.05 were considered statistically significant. 
Descriptive statistics were used for sample’s characterization, comparisons between 
variables were performed with the use of the general linear model [one-way analysis 
of variance (ANOVA)] with Tukey's post-hoc test for multiple comparisons where 
appropriate; or the Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc comparisons 
with adjusted p value; the χ2 test was used for comparisons between categorical 
variables.  
Confirmatory Factor Analysis (CFA) was conducted to provide further evidence to 
FCSRT’s construct validity. Two separate models were tested in this analysis. The 
model estimation was done with polychoric correlations and the weighted least 
squares mean and variance adjusted estimation procedure implemented in Mplus6 
(Muthén & Muthén, Los Angeles, CA). To evaluate the goodness of fit of the tested 
factorial structures we considered the indices CFI (Comparative Fit Index), TLI (Tucker-
Lewis Index), and RMSEA (Root Mean Square Error of Approximation), according to the 
suggestion of Schermelleh-Engel, Moosbrugger, and Müller (2003). The cut-off criteria 
proposed by Schermelleh-Engel et al. (2003) were considered as indicative of goodness 
of fit, as following: CFI and TLI good fit ~.97, acceptable fit >.0.95; RMSEA: good fit 
≤.05, adequate fit ].05, .08[. Convergent and discriminant validities were also 
examined as outcomes of the CFA.  
A Linear Discriminant Analysis (LDA) classificatory model, with an enter method, was 
performed to determine whether the FCSRT would distinguish the three experimental 
groups. Equal a priori classification probabilities were used for LDA to avoid biases 
from the data sets. 
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Receiver operating characteristic (ROC) curves were plotted for the FCSRT recall 
measures to assess their diagnostic validity for aMCI and AD patients. This analysis was 
implemented in MedCalc (version 12.7; MedCalc Software, Ostend, Belgium). The 
areas under the curve (AUC) can vary between 0 and 1, with larger AUC indicating 
better accuracy. The optimal cutoff points were calculated for each group according to 
the highest Youden index, which indicates the cutting score that maximizes of the 
sensitivity and specificity of the classification process.  
 
Results  
Sample characterization 
Demographical and clinical characteristics of the population are shown in Table 3.1. No 
statistically differences were found on age [F(2,268)=1.868, p=.157], educational level 
(χ2KW(2)=.611, p=.737), or gender [χ
2
(2)=4.554, p=.103] between the three groups.  
As expected, a significant effect was found for MMSE performance (χ2KW(2)=146.860, 
p<.001) among the three groups. Therefore, multiple Dunn’s post-hoc comparisons 
revealed that both aMCI (p<.001) and AD (p<.001) performed poorly on the MMSE, 
when compared to control subjects; and AD patients had a worst performance, when 
compared to aMCI subjects (p<.001). 
When analyzing the performance on all the FCSRT measures, both the aMCI (p=.001) 
and the AD groups were impaired relative to controls, and there was also a significant 
difference between the AD and aMCI patients (p<.001) (Table 3.1). The overall profile 
on the FCSRT was Controls>aMCI>AD.  
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Table 3.1 Population demographical characteristics and performance on the FCSRT 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination; 
FCSRT – Free and Cued Selective Reminding Test (Buschke’s word version); ITR – immediate total tecall; DTR – delayed total recall; 
TR – total recall (ITR+DTR). 
Note: Results are expressed as median [IQR] for all variables except for age: mean (SEM) and gender. 
Comparisons between Controls-aMCI, Controls-AD and aMCI-AD patients were carried out by a one-way ANOVA with post-hoc 
Tukey tests, Kruskal-Wallis 1-way ANOVA for k samples with pairwise comparisons, or χ2 Pearson Chi-Square test, where: 
* Controls vs. aMCI: p<.001; Controls vs. AD: p<.001 
† aMCI vs. AD: p<.001. 
Construct Validity  
 Confirmatory Factor Analysis 
The CFA was performed to provide further evidence of the FCSRT’s construct validity. 
Two models were contemplated: the first model was based on the model proposed by 
Grober et al. (2009), accounting for the unidimensionality that underlies the FCSRT, 
which is memory ability. Accordingly, Grober et al. (2009) studied the immediate free 
recall during the 3 trials on their analysis, while we included both the ITR and the DTR 
in our first model. Nevertheless, we also fitted a two-factor model in our sample in 
order to evaluate both learning (ITR) and retention (DTR).  
Both models have similar acceptable goodness of fit to the data matrix (Table 3.2). 
Table 3.2 Fit indices of the Confirmatory Factor Analysis models 
Models  χ2 df p χ2/df CFI TLI RMSEA 
One-factor model 1311.526 464 <.001 2.83 .964 .962 .082 
Two-factor model 1250.043 463 <.001 2.69 .967 .964 .079 
Abbreviations: χ2 – Chi-square test statistic; df – degrees of freedom; χ2/df – relative Chi-square; CFI – comparative fit index; TLI –
Tucker-Lewis index; RMSEA – root mean square error of approximation. 
 
The unidimensionality of the FCSRT enabled us to add a global score for the two recalls 
of the FCSRT on the subsequent analysis. 
 Total 
(N=271) 
Control subjects 
(n=101) 
aMCI 
(n=100) 
AD 
(n=70) 
Gender (male), n (%) 162 (59.8) 53 (52.5) 61 (61.0) 48 (68.6) 
Age (years) 71.16 (0.49) 70.22 (0.76) 71.08 (0.83) 72.63 (0.98) 
Education Level (years) 4 [4, 11] 4 [4, 11] 4 [4, 9] 4 [4, 11] 
MMSE (score) 29 [24, 29] 29 [28, 30] 28 [25, 29]* 21 [19, 25]*/† 
FCSRT ITR (score) 32 [17, 40] 40 [37, 44] 28 [19.25, 36.75]* 11 [6, 19]*/† 
FCSRT DTR (score) 11 [4, 15] 15 [13, 15] 9 [5, 12]* 3 [1, 4]*/† 
FCSRT TR (score) 43 [21, 54] 54 [50, 59] 36.5 [24, 50]* 13 [8, 24]*/† 
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Given the fit results for the two-factor model, we also examined the convergent 
validity estimated from the averaged variance extracted (AVE; Fornell & Larcker, 1981) 
which denotes the proportion of variance in the items explained by the underlying 
factors, therefore measuring how the items converge in a given factor. The respective 
results were AVEITR=.64 and AVEDTR=.717, which is suggestive of appropriated 
convergent validity, according the criterion AVE >.5 (Fornell & Larcker, 1981). 
Discriminant validity of the two factors was not observed since the squared 
correlations between the factors (r2=1) was larger than the AVE for each of the two 
factors (Fornell & Larcker, 1981). Thus, this result corroborates the unidimensionality 
underlining the FCSRT - assumed to be memory ability. 
Diagnostic Validity 
 Discriminant analysis 
The FCSRT recalls were analyzed independently, as predictor variables, to highlight 
their relative contribution in the discriminating the three groups, through a Linear 
Discriminant Analysis (LDA). All Wilks’ lambdas were significant at p<.05. The FCSRT ITR 
(λ Wilks =.411; χ2(2) = 238.324; p<.001; RCanonical =.767) had an accuracy of 67.9% in 
classifying the subjects; while the FCSRT DTR (λ Wilks =.395; χ2(2) = 248.859; p<.001; 
RCanonical =.778) revealed an accuracy of 65.7% in the classification among the three 
groups. The summation of the two recalls FCSRT TR (λ Wilks =.393; χ2(2) = 250.389; 
p<.001; RCanonical =.779) was the predictor with higher accuracy (68.3%) in the 
subjects classification (Table 3.3). 
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Table 3.3 Classification results of the FCSRT 
 
Predicted Group 
Membership 
Control 
(n=101) 
aMCI 
(n=100) 
AD 
(n=70) 
FC
SR
T 
IT
R
 
Count (%) 
Control 88 (87.1) 13 (12.9) 0 (0) 
aMCI 33 (33) 45 (45) 22 (22) 
AD 2 (2.9) 17 (24.3) 51 (72.9) 
FC
SR
T 
D
TR
 
Count (%) 
Control 89 (88.1) 12 (11.9) 0 (0) 
aMCI 36 (36) 31 (31) 33 (33) 
AD 2 (2.9) 10 (14.3) 58 (82.9) 
FC
SR
T 
TR
  Control 90 (89.1) 11 (10.9) 0 (0) 
Count (%) aMCI 33 (33) 43 (43) 24 (24) 
 AD 2 (2.9) 16 (22.9) 52 (74.3) 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding 
Test (Buschke’s word version); ITR – immediate total recall; DTR – delayed total recall; TR – total recall (ITR+DTR). 
 
Comparison of ROC curves between the FCSRT scores  
The ROC curve analysis was conducted to evaluate the diagnostic accuracy of the 
FCSRT to discriminate aMCI and AD patients from cognitively healthy adults. The ROC 
curves revealed that the two recall measures had good AUC’s for aMCI both 
independently [ITR: .818 (95% CI = .757 - .869); DTR: .824 (95% CI = .764 - .874)] and 
summed (TR: .828 (95% CI = .769 - .878) and excellent AUC’s for AD [ITR: .986 (95% CI = 
.956 -.998); DTR: .990 (95% CI = .962 -.999); TR: .990 (95% CI = .960 - .999)].  
Similar analyses were done in order to know which measure was better in 
discriminating aMCI from AD. The ROC curves revealed that all FCSRT recall measures 
had good AUC’s ITR: .846 (95% CI = .783 - .897); DTR: .838 (95% CI = .774 - .890); TR: 
.852 (95% CI = .789 - .901). 
The optimal cut-off scores for maximum accuracy (Youden index), of each measure, 
and its respective values of sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and classification accuracy are described in Table 3.4. 
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Table 3.4 Diagnostic classification accuracy of the FCSRT 
Abbreviations: MCI – Mild Cognitive Impairment; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective Reminding Test; ITR – 
immediate total recall (maximum score =48); DTR – delayed total recall (maximum score =16); TR – total recall (ITR+DTR, 
maximum score =64); AUC – area under the operating characteristics curve; PPV - positive predictive value; NPV - negative 
predictive value. 
Note1: Sensitivity, Specificity, PPV, NPV and Classification Accuracy values are expressed in percentage. 
Note2: Cut-off values indicate the minimum score required for absence of signal. 
 
Discussion 
This study aimed to evaluate the factorial structure of the Buschke’s FCSRT (Buschke’s 
FCSRT. Copyright, 2002) and analyze its validity in cognitively healthy subjects, as well 
as in aMCI and AD patients.  
The three groups were matched for all the demographic variables, despite the low 
educational level among them.  
The analysis of group differences indicated that the FCSRT was able to distinguish the 
clinical groups from the control group, but also to separate the degree of impairment 
between aMCI and AD. In fact, the usefulness of the FCSRT in assessing memory in 
aMCI and AD patients has been extensively reported (Brown & Storandt, 2000; 
Carlesimo et al., 2011; Grober & Kawas, 1997; Grober et al., 2008; Ivanoiu et al., 2005; 
Lemos et al., 2015; Mahieux et al., 2009; Saka et al., 2006; Sarazin et al., 2010; Vogel et 
al., 2007; Wagner et al., 2012).  
To provide further evidence to FCSRT’s construct related validity, two models were 
tested using CFA: a one-factor structure adapted from the model proposed by Grober 
et al. (2009) that accounts for the unidimensionality of memory ability; and a two-
  
Cut-off AUC Sensitivity Specificity PPV NPV 
Classification 
accuracy 
M
C
I 
Total ITR ≤35 .818 72 83 81 75 78 
Total DTR ≤12 .824 76 80 80 77 78 
Total TR ≤45 .828 67 89 78 73 75 
A
D
 
Total ITR ≤27 .986 94 99 99 95 97 
Total DTR ≤8 .990 96 97 97 96 96 
Total TR ≤36 .990 97 98 98 97 98 
M
C
I v
s.
 A
D
 Total ITR ≤21 .846 86 72 75 84 79 
Total DTR ≤4 .838 77 76 76 77 77 
Total TR ≤28 .852 87 70 74 84 79 
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factor model, considering the two factors as learning (total recall) and retention 
(delayed recall). In the study of Grober et al. (2009) the factor analysis indicated a 
single construct, but it comprised the FCSRT-IR (Grober & Buschke, 1987) procedure 
that only includes free recall from the test (learning) phase and uses pictures rather 
than words. Furthermore, Grober et al. (2009) included data from patients at a 
geriatric primary care center with cases of mild dementia with no specified type. In our 
study, we included both recalls in our first model, and the ITR (learning) and DTR 
(retention) independently in the two-factor model. Moreover, the presence of 
appropriated convergent validity and the lack of discriminant validity can be explained 
by the fact that both factors are evaluating memory ability, and therefore measuring 
the same construct. The unidimensionality of the FCSRT enabled us to add a global 
score for the FCSRT, which was further analyzed in terms of accuracy for the AD 
spectrum disorders. 
Another major finding of the present study was the high classification accuracy of the 
FCSRT recalls. Overall, the FCSRT showed a good accuracy in classifying the subjects 
among the groups (67.9% on the ITR, 65.7% on the DTR, and 68.3% on the TR). All 
measures enabled good accuracies in classifying either the control (normal aging) or 
the AD (memory impairment) groups. Results for the aMCI group are less clear, with 
different classifications among the three recalls. The aMCI is a very heterogeneous 
condition that comprises different levels of memory impairment. For a subject to be 
classified as an aMCI patient, it is necessary to have a subjective memory complaint 
corroborated by an objective impairment, in the absence of dementia (Petersen et al., 
1999, 2001). For this reason, aMCI is recognized as a very heterogeneous condition 
with an unclear distinction from early AD. Another important argument is that aMCI 
patients are at a higher risk of conversion to AD (Petersen et al., 1999, 2001). 
Consequently, the new AD criteria aim to consider some cases of aMCI patients as 
symptomatic prodromal AD, in the presence of impaired FCSRT in addition to AD-
biomarker evidence (Albert et al., 2011; Dubois et al., 2007, 2010; 2014). In fact, 
(Lemos et al., 2015) confirmed the usefulness of the FCSRT in the characterization of 
the memory impairment of the AD spectrum, and showed that half of the aMCI 
patients included had an AD-alike pattern of impairment.  
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The ROC analysis supported the classification results by comparing the accuracy of the 
FCSRT measures in the discrimination among the three groups. The results revealed 
that, all the recalls enabled better accuracies in discriminating AD patients, than MCI 
subjects. When comparing the two pathological groups, the three recalls revealed 
similar results. Nonetheless the similar results in accuracy among the recalls, we 
believe that the outcomes from the two-factor model construct validity of the FCSRT 
allow to additionally support the importance of including both total (learning) and 
delayed (retention) recalls. The immediate recall provides qualitative and quantitative 
information regarding learning, while the delayed recall report memory 
consolidation/retention that is particularly sensitive to the hippocampal dysfunction 
present in AD spectrum disorders. In fact, both learning and retention correspond to 
the process of memory functioning. This shows the significance of a delayed recall to 
comprise the milder forms of cognitive decline (Albert et al., 2011; Grober & Kawas, 
1997; Ivanoiu et al., 2005; Sánchez-Benavides et al., 2014) such as aMCI, and avoid the 
inclusion of false negatives that can happen when learning is the only memory 
measure tested. Furthermore, Saka et al. (2006) proved the superiority of the total 
recall in terms of sensitivity, but showed that it is less specific when compared to the 
free recall in discriminating AD patients from healthy elders. Vogel et al. (2007) 
analyzed the delayed recall and revealed that it increased the sensitivity of the total 
recall in AD identification. According to Salmon (2000), clinically, measures of the 
ability to learn and retain new information are quite useful in differentiating between 
healthy aging elders and AD patients, and delayed recall trials revealed to be more 
effective than measures of learning across trials. Nevertheless, the IWG-1 criteria for 
AD stated that “impaired delayed recall is not itself evidence of an AD-related memory 
disorder”, and deficits in encoding and storage processes that are characteristic for AD 
must be distinguished from non-AD deficits that can also affect delayed recall, such as 
attentional difficulties or inefficient retrieval strategies that may be present in normal 
aging or in other clinical conditions (Dubois et al., 2007). With this approach, we 
believe that we have given a new possibility in terms of using the FCSRT in AD 
spectrum disorders; psychometrically the FCSRT showed that its factor structure can 
be regarded either unidimensionally (memory), or as a two-factor model (learning and 
retention). Thus, it is our understanding that the motivation for deciding which recall 
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to use should be driven either by differences in study setting, research purposes or 
clinician preference. According to our results, the FCSRT recalls may be used and 
reported: i) independently (for a qualitative approach of the retained material), ii) as a 
composed result/global value (for a more simple way of reporting the result), or iii) as 
a single unit (in order to reduce patients’ fatigue, or on follow-up evaluations). The 
motivation for the latter version of a single unit is based on the finding that the 
learning trials of the FCSRT provided similar information as the delayed recall; thus it 
may have the advantage of reducing patient fatigue and could be used mainly AD 
(both at baseline or follow-up evaluations). In fact, regarding the FCSRT-IR version, the 
majority of studies do not apply a delayed recall condition (Zimmerman et al., 2015). 
The paradigm that underlies the FCSRT is based on the encoding specificity. This 
procedure has shown to promote deeper engagement with attentional and semantic 
processing in the encoding phase of memory, and it also controls the conditions of 
retrieval through the use of the same cues to direct learning and produce effective 
cued recall (Tulving & Thomson, 1973). Concerning the type of stimulus used, despite 
the suggestion that pictures might enable a better retention due to a concomitant 
verbal and image code stimulation, whereas written words are confined to verbal 
coding (Paivio, 1995); turning individuals’ attention to semantic aspects of the to-be 
recalled pictures and words during encoding was found to eliminate the picture 
superiority effects (Paivio, 1975). Accordingly, the FCSRT (words version) present 
“printed words to avoid perceptual errors, ensure that all subjects use the same verbal 
encoding to learn the same items, and avoid dual perceptual and verbal encoding” 
(Buschke’s FCSRT. Copyright, 2002). 
Concerning dementia studies, memory tests that require the ability to control 
acquisition and retrieval are known to optimize encoding specificity and thus may be 
more sensitive to the early signs of AD (Buschke, 1987) than tests that use different 
paradigms. 
We believe that our work brings an original contribution by studying the construct and 
diagnostic validities of the FCSRT, the memory test specifically recommended to 
objectively assess the memory impairment of AD spectrum disorders by the IWG-1 and 
IWG-2 (Dubois et al., 2007, 2014). By comprising both the immediate and the delayed 
recall of the test, we were able to measure learning and retention on the process of 
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memory ability, which are very important cognitive constructs and give vital 
information on memory processing. Additionally, our version includes words and not 
pictures. To date, and as far as we know, there have been no studies on the factorial 
structure of this version of the FCSRT in general, nor in AD spectrum disorders in 
particular. Thus, this study contributes to overcome a significant gap in the evaluation 
of the construct related validity of the FCSRT.  
In sum, in this study we confirmed the usefulness of the FCSRT in analyzing aMCI and 
AD patients’ memory impairments and proved its effectiveness in their classification. 
Moreover, the factorial structure of the FCSRT revealed robust results.  
The possibility of a complete analysis, in terms of the properties of an instrument, is a 
valuable advantage that results in an important contribution to outline a more 
systematic and comprehensive neuropsychological evaluation. 
The present results may be limited by the relatively small sample size. The factor 
analyses resulted in acceptable properties, although larger samples would be more 
appropriate. Another limitation of the present study is the low educational level of our 
samples, even though the three groups were matched for this variable. A low 
education level, along with a high socio-demographic diversity, is representative of the 
geriatric population in Portugal. For these reasons, some future considerations should 
be taken into account when analyzing the present results, namely the need for more 
studies conducted in different cultural contexts other than the Portuguese. Moreover, 
as we aimed to study the construct and diagnostic validities of the FCSRT in AD 
spectrum disorders, we have exclusively included MCI subjects of the amnestic type 
and AD patients. Consequently one must be advised against generalizing the obtained 
results to other clinical populations. We also believe that longitudinal studies with 
follow-ups of aMCI subjects should be carried on to confirm the utility of the FCSRT at 
baseline.  
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Abstract 
Amnestic mild cognitive impairment (aMCI) patients carry a greater risk of conversion 
to Alzheimer’s disease (AD). Therefore, the International Working Group (IWG) on AD 
aims to consider some cases of aMCI as symptomatic prodromal AD. The core 
diagnostic marker of AD is a significant and progressive memory deficit, and the Free 
and Cued Selective Reminding Test (FCSRT) was recommended by the IWG to test 
memory in cases of possible prodromal AD. This study aims to investigate whether the 
performance on the FCSRT would enhance the ability to predict conversion to AD in an 
aMCI group. A longitudinal study was conducted on 88 aMCI patients, and 
neuropsychological tests were analyzed on the relative risk of conversion to AD. During 
follow-up (23.82 months), 33% of the aMCI population converted to AD. An impaired 
FCSRT TR was significantly associated with the risk of conversion to dementia, with a 
mean time to conversion of 25 months. The FCSRT demonstrates utility for detecting 
AD at its prodromal stage, thus supporting its use as a valid clinical marker. 
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Introduction 
Among all types of dementia, Alzheimer’s disease (AD) is the most common, 
comprising about 50% to 80% of all the dementia cases. It is an area of significant 
health concern in the elderly, and has become one of the leading causes of death in 
modern society (Corey-Bloom, 2004; Ferri et al., 2005). AD diagnosis is generally 
supported by clinical history, neurological examination, and neuropsychological 
evidence of cognitive dysfunction, especially in the memory domain (American 
Psychiatric Association, 2000; McKhann et al., 1984; 2011). 
The clinical interest in establishing an early diagnosis has led to the concept of a 
transitional state between normal aging and dementia (i.e., prodromal AD). This stage 
is widely known as amnestic Mild Cognitive Impairment (aMCI; Petersen et al., 1999), 
and aims to identify individuals with memory impairment greater than what is 
expected for their age and education level, but who are not sufficiently debilitated in 
their activities of daily living to be considered as demented (Petersen et al., 1999). 
Thus, the confirmation of a deficit in memory through a reliable instrument is essential 
for the diagnosis of aMCI (Petersen et al., 1999, 2001). aMCI diagnosis has proven to 
be clinically useful, as these patients carry a greater risk of conversion to dementia/AD 
(approximately 12% per year) (Albert et al., 2011; Petersen et al., 1999, 2001), while 
others may stay in a stable form of selective memory impairment (Dawe, Procter, & 
Philpot, 1992). In the early stages of AD, neuropathologic changes are already present 
in medial temporal regions (hippocampal formations, parahippocampal gyrus, and 
entorhinal cortex), areas which are critical for long-term episodic memory (Blennow, 
de Leon, & Zetterberg, 2006; Morris et al., 2001; Sarazin et al., 2010). Consequently, 
this early involvement of medial temporal structures leads to a deficit in episodic 
memory, rendering it a reliable neuropsychological marker of AD (Heister et al., 2011; 
Richard, Schmand, Eikelenboom, & Van Gool, 2013). Along with the baseline diagnostic 
criteria, severity of the memory deficit is also a dominant predictor of progression to 
dementia (Dubois et al., 2007; Fleisher et al., 2007; Geerlings, Jonker, Bouter, Adèr, & 
Schmand, 1999; Morris et al., 2001). Early identification of patients with increased risk 
is crucial, as disease-modifying treatments may have the greatest potential in the 
earliest disease stages (DeKosky & Marek, 2003). Moreover, the lack of reliable tools to 
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detect and follow preclinical AD has been pointed out as one of the main obstacles for 
the development of new treatments (Lansbury, 2004).  
The International Working Group (IWG-1) developed and published revised diagnostic 
criteria for AD (Dubois et al., 2007, 2010), in an attempt to address the limitations of 
the Diagnostic and Statistical Manual of Mental Disorders – fourth edition (DSM-IV-TR; 
American Psychiatric Association, 2000) and the National Institute of Neurological and 
Communicative Disorders and Stroke- Alzheimer’s Disease and Related Disorders 
(NINCDS-ADRDA; McKhann et al., 1984). The IWG-1 criteria apply to both the early 
stages and the full spectrum of the illness, and include biomarkers of AD pathology to 
increase the confidence that subjects with aMCI have AD as the underlying cause 
(Dubois et al., 2007, 2010). The core clinical criterion is the evidence of a significant 
and progressive episodic memory impairment confirmed by objective testing (Dubois 
et al., 2007, 2010). Dubois et al. (2007, 2010) recommend a cued recall test to define 
memory impairment, such as the Free and Cued Selective Reminding Test (FCSRT; 
Buschke, 1984; Grober & Buschke, 1987), as it demonstrated high sensitivity and 
specificity in differentiating AD patients from both healthy controls (Grober, Sanders, 
Hall, & Lipton, 2010) and those with other forms of dementia (Grober, Hall, Sanders, & 
Lipton, 2008; Lemos, Duro, Simões, & Santana, 2014; Pasquier, Grymonprez, Lebert, & 
Linden, 2001). More recently, the IWG-2 criteria reinforced the choice of the FCSRT as 
a valid clinical marker for typical prodromal AD (aMCI) (Dubois et al., 2014). 
In patients with AD, the amnestic profile is typically characterized by poor learning and 
rapid memory decay over relatively short periods, often concurrent with damage to 
the mesial temporal structures, such as the hippocampus (Squire, Stark, & Clark, 2004). 
It is of clinical importance that deficits in encoding and storage processes that are 
characteristic of AD can be distinguished from non-AD memory deficits that may have 
a different etiology. Therefore, the accurate diagnosis of an episodic memory deficit, 
so often observed in AD patients, may be improved upon by the use of test paradigms 
that provide information on encoding specificity (Buschke, Sliwinski, Kuslansky, & 
Lipton, 1997). Memory tests that require the ability to control acquisition and retrieval 
may optimize encoding specificity and thus may be more sensitive to the early signs of 
dementia (Buschke, 1984) than tests that use different paradigms.  
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The FCSRT is based on a selective reminding paradigm where acquisition and retrieval 
are reinforced by using the same cues to control learning and elicit effective cued 
recall. The utility of this paradigm has been widely reported in the memory dysfunction 
characterization of AD (Brown & Storandt, 2000; Carlesimo, Perri, & Caltagirone, 2011; 
Grober & Kawas, 1997; Grober, Hall, Lipton, et al., 2008; Mahieux et al., 2009; Sarazin 
et al., 2010; Vogel, Mortensen, Gade, & Waldemar, 2007) and aMCI (Ivanoiu et al., 
2005; Saka, Mihci, Topcuoglu, & Balkan, 2006; Wagner et al., 2012). The comparable 
profiles of memory dysfunction of MCI and AD have also been described (Petersen, 
2004b; Petersen et al., 1999). Further, this similar profile has been described for aMCI 
patients with a higher risk of conversion to AD (Auriacombe et al., 2010; Grober, 
Lipton, Hall, & Crystal, 2000; Petersen, 2007; Sarazin et al., 2010). In a recent study, the 
FCSRT showed its capability to differentiate aMCI patients based on a non-
similar/similar AD pattern of impairment, and to infer that those AD-alike patients 
could possibly have prodromal AD (Lemos, Simões, Santiago, & Santana, 2015). Thus, it 
is imperative to examine how the memory tests suggested in diagnostic criteria show 
predictive value of the MCI diagnosis for conversion to dementia. In fact, Sarazin et al. 
(2007) have demonstrated that the FCSRT is able to distinguish patients at an early 
stage of AD from MCI non-converters, using the modified Grober-Buschke procedure 
(Grober & Buschke, 1987).  
The current study aimed to investigate whether performance on the FCSRT would 
enhance the ability to predict incident AD in a group of aMCI patients. Positive findings 
would support its interest as a valid clinical marker for typical AD. 
 
Methods 
Participants 
The clinical study sample included 100 aMCI patients recruited at the Neurology 
Department of our local hospital between 2010 and 2012 (Lemos et al., 2015).  
The patients enrolled had clinical semiannual evaluations and were followed until they 
developed dementia or until they had been cognitively stable for at least two years 
(follow-up M= 23.82 months). Eighty-eight out of the 100 aMCI patients met the 
follow-up criteria and comprise the longitudinal study group. From the 12 patients lost 
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to the clinical follow-up, 4 died and 8 declined to participate in the follow-up 
observation (considered as dropouts). 
MCI patients were of the amnestic type (single or multi-domain) (Petersen, 2007) at 
baseline, and were selected according to Petersen’s criteria (Albert et al., 2011; 
Petersen, 2004a). A neurologist completed a medical history with the patient and 
caregiver at baseline, and also conducted a general physical, neurological, and 
psychiatric examination of the patient. Standard tests included apolipoprotein E (ApoE) 
allele genotyping, laboratory, and imaging studies. A comprehensive battery was 
administered by experienced neuropsychologists. This included the Mini-Mental State 
Examination (MMSE; Folstein, Folstein, & McHugh, 1975; Guerreiro, 1998), the 
Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog; Guerreiro, Fonseca, 
Barreto, & Garcia, 2008; Mohs, Rosen, & Davis, 1983), and a comprehensive 
neuropsychological battery with normative data for the Portuguese population 
(Battery of Lisbon for the Assessment of Dementia; Guerreiro, 1998).Tests of interest 
for the present study within the neuropsychological battery included Logical Memory 
(LM; Immediate and Delayed Recall; Wechsler Memory Scale (WMS; Wechsler, 1987), 
and Verbal Paired-Associate Learning (VPAL; Immediate Recall). The Clinical Dementia 
Rating (CDR; Garrett et al., 2008; Morris, 1993) for global staging, and the Geriatric 
depression Scale (GDS-30; Barreto, Leuschner, Santos, & Sobral, 2008; Yesavage et al., 
1983) to exclude severe depression (i.e., GDS-30 ≥ 20) were also administered. 
All the available information (baseline cognitive testing, staging scales, clinical 
laboratory and imaging studies) was used to reach a consensus research diagnosis, 
headed by a board certified neurologist. A similar approach was used for semiannual 
follow-up evaluations. The baseline inclusion criteria for aMCI (single or multi-domain) 
were those proposed by Petersen (2007) and were operationalized as follows: 1) A 
subjective complaint of memory decline (reported by the subject or an informant); 2) 
An objective memory impairment (i.e., scores on standard memory tests > 1.5 SD 
below age/education adjusted norms) with or without deficits in other cognitive 
domains; 3) Normal general cognition suggested by normal scores on the MMSE and 
the ADAS-Cog; 4) Largely normal activities of daily living; 5) Absence of dementia, 
indicated by a CDR rating of 0.5. Exclusion criteria were a significant underlying 
medical or neurological illness revealed by lab tests or imaging; a relevant psychiatric 
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disease, including severe depression; CT or MRI demonstration of significant vascular 
burden (large cortico-subcortical infarct; extensive subcortical white matter lesions 
greater than 25%; uni- or bilateral thalamic lacunes; lacunes in the head of the caudate 
nucleus; > 2 lacunes) (Román et al., 1993). 
Every six months, clinical, cognitive, and functional status was reassessed. Dementia 
was diagnosed according to the DSM-IV-TR (American Psychiatric Association, 2000) 
and AD was diagnosed according to the NINCDS-ADRDA criteria (McKhann et al., 1984). 
Conversion to AD required meeting clinical diagnostic criteria for probable AD, and was 
confirmed by the coordinator of the clinical study based on multiple types of 
assessments, and with an emphasis on clinician expertise and documentation of a 
functional decline (CDR). Patients in this study were classified has having undergone 
conversion based on: 1) Objective evidence on cognitive testing of deterioration to 
dementia using the MMSE and the ADAS-Cog scores and qualitative evaluation (i.e., 
impairment of memory plus other domains); 2) Changes in global CDR rating from 0.5 
to 1 or more, confirming the cognitive profile of dementia and loss of autonomy. The 
onset of AD was defined as the date when the diagnosis was made. 
All subjects were submitted to the same experimental research protocol. Informed 
consent was obtained from all participants, and the study was conducted in 
accordance with the tenets of the Declaration of Helsinki, with the approval of our 
local ethics committee. 
Demographic and clinical characteristics of the population are shown in Table 4.1. 
Procedure 
At baseline, subjects were assessed using the Portuguese version of the Buschke’s 
FCSRT (Buschke, 1984) adapted by Lemos, Martins, Simões, and Santana (2012). 
Materials and instructions for the FCSRT were provided by the original author 
(Buschke’s FCSRT. Copyright, 2002. Albert Einstein College of Medicine of Yeshiva 
University, New York). The selection of the 16 stimulus words followed the same 
principles as the English version – intermediate frequency words were selected within 
a semantic category (frequencies in Portuguese in the CORLEX database) (Nascimento 
et al., 2003). In the present study, the FCSRT was not used in the diagnostic process. 
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The test starts by asking subjects to identify words in response to a unique category 
cue. The 16 items to be learned are presented four at a time on a card, distributed one 
word per quadrant. The subject is asked to search each card and point to and name 
aloud each item after its semantic cue is verbally presented. During this procedure, the 
subject is informed to learn the 16 words. The FCSRT version used in this study differs 
from the modified Grober-Buschke version used by Sarazin et al. (2007), as it does not 
include immediate cued recall in the learning phase. There are 3 recall trials, each 
preceded by 20 seconds of counting backward to prevent recall from short-term 
memory. Each recall trial consists of two parts. First, each subject has up to two 
minutes to freely recall as many items as possible. Next, verbally presented category 
cues are provided for items not retrieved by free recall. If subjects fail to retrieve the 
item with the category cue, they are reminded by presenting the cue and the item 
together. The sum of free and cued recall gives a measure of total recall (TR). The same 
procedure of recalling (free and cued) is done after a 30-minute interval, during which 
subjects are required to perform non-verbal tasks (Delayed Total Recall – DTR).  
In this study, we used the total recall measures (immediate and delayed) in the 
analysis.  
Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social Sciences 
(SPSS, version 19.0) (IBM SPSS, Inc., Chicago, IL). As data significantly deviated from 
normal distributions and homogeneous variances (verified using the Kolmogorov-
Smirnov normality check and Levene homogeneity tests, respectively), a non-
parametric statistical methods for group comparison was applied. Results with p<.05 
were considered statistically significant. Demographic, clinical, and neuropsychological 
data were analyzed using the Mann-Whitney test for numerical data, and the Pearson 
χ2 test for nominal data, allowing comparisons between the two groups of patients 
(aMCI-aMCI and aMCI-AD). 
Survival curves methods were chosen for the analysis, as conversion to dementia 
occurred at different times and the observations were censored. Kaplan-Meier curves 
were used to illustrate the differences in progression to AD between the two groups. 
Survival time was calculated as the interval from the initial baseline evaluation to the 
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diagnosis of dementia. For patients who remained non-demented, survival time was 
censored at the date of the last clinical assessment. Variables were considered binary, 
as following: ApoE-ε4 allele carriers and non-carriers; memory tests with presence or 
absence of impairment according to the previously established cut-offs [LM and VPAL 
as 2 SDs below adjusted z-scores; Guerreiro, 1998; Silva et al., 2012]; FCSRT below 
standardized cut-offs for AD [TR≤27; DR≤8; Lemos et al., 2015]. Multivariate Cox 
proportional hazards regression models with forward selection procedure were used 
to estimate the effects of these variables on the relative risk of conversion from aMCI 
to AD. Hazard ratios (HR) with 95% confidence intervals (CI) were reported. The 
variance inflation factor (VIF) was used to check for the problem of multicollinearity 
among the predictor variables, considering a VIF < 5 as no evidence of 
multicollinearity; a 5 ≤ VIF ≤ 10 as moderate multicollinearity; and a VIF > 10 as 
significant multicollinearity amongst the variables.  
Results 
Baseline and follow-up characteristics 
At baseline, 100 non-demented patients reporting subjective cognitive complaints with 
objective memory impairment were included. During the follow-up time (M = 23.82 
months), 29 patients (33%) converted to dementia, and 59 (67%) did not. All the cases 
that progressed to dementia were diagnosed as AD (Figure 4.1). 
 
Figure 4.1 Study flow diagram 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease. 
Baseline aMCI patients 
(n=100) 
Not followed (n= 12) 
4 deaths 
8 dropouts 
 Follow-up (n=88) 
(mean time=23.82 months) 
Converters (aMCI-AD) 
(n=29; 33%) 
Non-converters (aMCI-aMCI) 
(n=59; 67%) 
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Demographical and clinical characteristics of the population are shown in Table 4.1. No 
statistically significant differences were found in age [U =763.5, p =.413], educational 
level (U = 809.5, p =.666), or gender [χ2 (1) = 1.054, p = .305] between the two groups. 
Significant differences were found between ApoE-ε4 carriers and non-carriers among 
the groups [χ2 (1) = 7.877, p = .005]. The follow-up time was not significantly different 
between the two samples [U =733.0, p =.277]. 
Table 4.1 Baseline demographical and clinical characteristics of the population 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease.  
Note: Data are expressed as mean (SEM), except for gender and ApoE. 
Comparisons between Non-converters-Converters were carried out by independent two-sample Mann-Whitney test or Pearson χ2 
test for nominal variables, where: 
* aMCI-aMCI vs. aMCI-AD: p <.05. 
 
A significant effect was found for the neuropsychological performance, at baseline, on 
almost all measures (MMSE: U =401.0, p <.001, ADAS-Cog: U =383.5, p =.001; LM IR: U 
=413.5, p <.05; LM DR: U =350, p <.05; FCSRT TR: U =333.5, p <.001; FCSRT DR: U =365, 
p <.001), except for VPAL (p =.190). As expected, on follow-up, the two global cognitive 
measures demonstrated significant differences (MMSE: U =212.5, p <.001, ADAS-Cog: 
U =194.5, p <.001) among the groups. When global scale comparisons were performed 
within groups between baseline and follow-up assessments, no differences were found 
for the aMCI-aMCI group (MMSE: Z=-1.871; p=.061; ADAS-Cog: Z=-1.056; p=0.291), but 
significant differences were found in the aMCI-AD sample (MMSE: Z=-3.141; p=.002; 
ADAS-Cog: Z=-3.478; p=.001) (Table 4.2). 
 
 
 
 
 
 Non-converters (aMCI-aMCI) 
(n=59) 
Converters (aMCI-AD) 
(n=29) 
Gender (m:f) 25:34 9:20 
Age (years), mean (SEM) 69.63 (1.05) 67.00 (3.76) 
Education Level, years 6.29 (0.54) 7.03 (0.83) 
ApoE (ε4: non ε4 carrier) 20:39 19:10* 
Follow-up time, months 24.62 (.93) 22.20 (1.39) 
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Table 4.2 Neuropsychological performance of the population 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination; 
ADAS-Cog – Alzheimer’s Disease Assessment Scale–Cognitive; FCSRT TR – Free and Cued Selective Reminding Test Total Recall.  
Note: Data are expressed as mean (SEM).  
Comparisons between Non-converters-Converters were carried out by independent two-sample Mann-Whitney test, where: 
* At baseline, aMCI-aMCI vs. aMCI-AD: p <.05 
** At baseline, aMCI-aMCI vs. aMCI-AD: p <.001 
# At follow-up, aMCI-aMCI vs. aMCI-AD: p <.001 
NS – Non significant. 
Within groups, differences between baseline and follow-up were assessed by the Wilcoxon rank-sum test, where: 
‡ Baseline vs. Follow-up: p <.05  
In ADAS-Cog a higher score represents a higher level of impairment. 
 
Relation between baseline neuropsychological performance and risk of developing AD 
Figures 2.4 show the Kaplan-Meier estimates of the probability of conversion to AD in 
patients with aMCI for ApoE-ε4 allele and the neuropsychological tests (LM and 
FCSRT).  
For ApoE, 49% of the ε4 allele carriers converted to AD, compared to 20% of ε4 non-
carriers. The mean time of conversion was slightly reduced for ε4 allele carriers (29 vs. 
31 months; χ2 (1) = 3.978, p=.046) (Figure 4.2). 
 Non-converters (aMCI-aMCI) 
(n=59) 
Converters (aMCI-AD) 
(n=29) 
Baseline Follow-up Baseline Follow-up 
MMSE, score 27.90 (.27) 27.37 (.38) 25.48 (.48)** 22.63 (.76)#/‡ 
ADAS-Cog, score 8.21 (.50) 8.91 (.66) 11.63 (.85)* 16.31 (.84)#/‡ 
LM IR, score 6.28 (.41) 5.00 (.60)* 
LM DR, score 4.29 (.34) 2.55 (.48)* 
VPAL IR, score 11.86 (.61) 11.07 (.73)NS 
FCSRT TR, score 31.59 (1.30) 19.97 (1.78)** 
FCSRT DR, score 10.39 (.60) 5.62 (.68)** 
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Figure 4.2 Kaplan-Meier survival curves for the conversion to Alzheimer’s disease (AD) in 
patients with amnestic Mild Cognitive Impairment (aMCI) with regard to presence of ApoE-ε4 
allele. 
 
On WMS LM IR, 50% under the z-score threshold converted to AD, compared to 21% 
who were above the cutoff. The mean time to conversion was significantly reduced for 
those below the cutoff (24 vs. 34 months; χ2 (1) = 8.738, p=.003). On WMS LM DR, 44% 
under the z-score threshold converted to AD, compared to 14% who were above the 
cutoff. The mean time to conversion was significantly reduced for those with 
impairment (27 vs. 36 months; χ2 (1) = 9.748, p=.002) (Figure 4.3). 
 
Figure 4.3 Kaplan-Meier survival curves for the conversion to Alzheimer’s disease (AD) in 
patients with amnestic Mild Cognitive Impairment (aMCI) on WMS Logical Memory. 
Abbreviations: IR – Immediate Recall; DR – Delayed Recall. 
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For subjects with FCSRT TR below cutoff, the conversion to AD occurred in 57% of the 
subjects, whereas a normal FCSRT resulted in 11% conversion events. Mean time to 
conversion was significantly reduced in patients with a pathological FCSRT profile 
compared to those with a normal FCSRT profile (25 vs 37; χ2 (1) = 23.602, p<.001). For 
FCSRT DR, 54% of the subjects under the threshold converted to AD at follow-up, 
compared to 15% of those who were above the cutoff. The mean time to conversion 
was significantly different reduced in the aMCI group with an impaired performance 
(26 vs 36; χ2 (1) = 16.176, p<.001) (Figure 4.4). 
 
Figure 4.4 Kaplan-Meier survival curves for the conversion to Alzheimer’s disease (AD) in 
patients with amnestic Mild Cognitive Impairment (aMCI), regarding the performance on the 
FCSRT. 
Abbreviations: FCSRT – Free and Cued Selective Reminding Test; TR – Total Recall; DR – Delayed Recall. 
 
Collinearity statistics showed that there was no evidence of significant collinearity 
among the predictor variables (all VIFs < 5, and on average: 1< VIF <3). 
The FCSRT TR was the only variable that significantly predicted elevated risk of 
conversion to AD (HR = 6.945, 95% CI = 2.524-19.107, p<.001), with worse 
performance associated with elevated risk.  
 
Discussion   
The main objective of the present study was to investigate whether performance on 
the FCSRT would enhance the ability to predict incident AD in a group of aMCI 
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patients. Patients whose clinical presentation met criteria for aMCI (Petersen, 2007; 
Petersen, 2004b; Petersen et al., 1999, 2001) were specifically included in order to 
cover the full aMCI spectrum seen in the memory clinic – both patients who may have 
prodromal AD and patients that remain with a stable aMCI condition (Albert et al., 
2011; Dubois et al., 2007, 2010). The outcome measure was progression to AD-type 
dementia according to the DSM-IV-TR (American Psychiatric Association, 2000) and the 
NINCDS-ADRDA (McKhann et al., 1984) criteria. The aMCI group included in the 
baseline was subdivided by conversion to AD (aMCI-AD) or stable aMCI (aMCI-aMCI) 
during the follow-up period. The two groups were matched for demographical 
variables, though significant differences were found concerning the distribution of the 
ApoE-ε4 allele and the neuropsychological performance (MMSE, ADAS-Cog, WMS LM 
IR and DR, and FCSRT IR and DR). Similar results have already been indicated as clinical 
predictors of progression to AD in aMCI patients (Baldeiras et al., 2010; Fleisher et al., 
2007; Rabin et al., 2012). We observed a high rate of conversion during the follow-up 
time (23.82 months), where 33% of the aMCI population converted to AD. This high 
rate of conversion might indicate that prodromal AD was already present among aMCI 
patients at baseline. Comparisons within groups revealed no differences in the MMSE 
and ADAS-Cog between the two evaluation moments in the aMCI-aMCI group, but 
significant differences in the aMCI-AD sample. A survival analysis enhanced the 
contributions of the presence of ApoE-ε4 allele and the neuropsychological tests (LM 
and FCSRT) for the prediction of incident AD. Thus, the only variable that remained 
significantly associated with the risk of conversion to dementia during the follow-up 
was the FCSRT TR. Moreover, the mean time of conversion for aMCI patients with an 
impaired FCSRT TR was 25 months, whereas for subjects with a normal FCSRT, mean 
time to conversion was 37 months. The FCSRT has previously revealed its superiority 
among other neuropsychological tools, for detecting AD at its prodromal stage 
(Auriacombe et al., 2010; Lemos, Cunha, Afonso, Simões, & Santana, 2014; Mura et al., 
2013; Rabin et al., 2012; Sarazin et al., 2007), and therefore is considered an ideal 
diagnostic tool for prodromal AD, according to the IWG-1 criteria (Dubois et al., 2007, 
2010; Sarazin et al., 2007). 
The FCSRT has shown to have better predictive validity than the commonly used WMS 
LM IR test both on the development of incident AD in a community based cohort with 
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memory complaints (Derby et al., 2013), and in MCI patients with a CSF profile for AD 
pathology (Wagner et al., 2012). Nevertheless, the recently IWG-2 criteria indicated 
that other memory tests, mainly those based on list-learning and delayed recall, also 
can be effective in the identification of the amnestic syndrome of AD. Thus, the IWG-2 
concluded that list-learning memory tests such as the FCSRT (or other episodic 
memory tests with established high specificity for AD across the disease span) are 
preferred (Dubois et al., 2014). 
A significant impairment in memory testing is essential to the diagnosis of both aMCI 
and AD (Albert et al., 2011; Dubois et al., 2007, 2010; Petersen, 2007; Petersen et al., 
1999). A deficit in the delayed recall of episodic long-term memory would be 
particularly characteristic of initial AD (Perri, Serra, Carlesimo, Caltagirone, & Early 
Diagnosis Group of the Italian Interdisciplinary Network on Alzheimer’s Disease, 2007), 
as it reflects the early involvement of medial temporal lobe structures. Genuine 
deficits in encoding and storage processes that are characteristic of AD must be 
distinguished from non-AD deficits that can also affect recall as a result of difficulties in 
attention, which are present in other geriatric conditions (Dubois et al., 2007). Low 
performance may reflect impaired encoding of the information, thus decreasing the 
consolidation of new verbal material (Belleville, Sylvain-Roy, de Boysson, & Ménard, 
2008; Moulin, James, Freeman, & Jones, 2004). Therefore, the design of the test is very 
important, as an accurate assessment of memory depends on the quality of learning, 
which is later reflected in effective retrieval (Buschke et al., 1997). By controlling both 
encoding and retrieval with the same semantic cues, the FCSRT can isolate storage 
deficits due to hippocampal damage, and thereby identify the amnestic syndrome of 
AD, even in the early stages of the disease (Sarazin et al., 2007). This allows for 
differentiation of memory impairment due to attentional problems that may be 
present in other dementias not of the Alzheimer’s type (Grober, Hall, Sanders, et al., 
2008; Lemos, Duro, et al., 2014; Pasquier et al., 2001). The studies that determined the 
predictive value of the FCSRT for future conversion to dementia showed no evidence 
of accuracy superiority for delayed recall measures compared to immediate recall, 
supporting the hypothesis of a failure at the initial learning process (despite providing 
semantic cues), rather than forgetting due to inadequate storage of the information 
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(Carlesimo et al., 2011). Moreover, according to Carlesimo et al. (2011), the FCSRT is 
able to discriminate between memory deficits due to impaired storage processes, and 
deficits originated from a failure of encoding and/or retrieval. While a deficit in storage 
processes would be characteristic of AD, presumably due to its early hippocampal 
involvement, impairment in executive functions would be characterized by a deficit of 
elaborative encoding and strategic retrieval processes (present in other dementia 
syndromes and other geriatric conditions). Previous studies have shown that 
impairment in list-learning tests might predict accurately the conversion to AD 
(Chapman et al., 2011; Maruff et al., 2004; Rabin et al., 2009; Silva et al., 2012). 
Nevertheless, the IWG-1 and the IWG-2 criteria recommend a cued recall instrument 
to define memory impairment, such as the FCSRT (Dubois et al., 2007, 2010, 2014). 
A previous cluster analysis study (Lemos et al., 2015) demonstrated an AD-alike 
pattern of impairment among the aMCI group with regard to performance on the 
FCSRT. aMCI patients with impaired FCSRT scores were similar to AD patients in terms 
of performance, and different from patients with normal FCSRT scores. The authors 
concluded that the heterogeneity of the aMCI group may be subdivided according to 
an AD-similar pattern of performance in the FCSRT profile. 
Significant correlations between a poor performance on the FCSRT and AD biomarkers 
have also been shown with regard to medial temporal lobe (Sánchez-Benavides et al., 
2014; Sarazin et al., 2010) and cerebrospinal fluid biomarkers (Wagner et al., 2012). 
Accordingly, a low performance in the FCSRT, along with evidence of abnormal CSF 
biomarkers, represent a combination of valid clinical markers for typical prodromal AD, 
as suggested by the IWG-2 diagnostic criteria (Dubois et al., 2014).  
In sum, the FCSRT has been shown to differentiate aMCI from AD patients (Grober & 
Buschke, 1987; Ivanoiu et al., 2005; Lemos et al., 2015) at baseline, allowed for the 
division of the aMCI group according to an AD-alike pattern of impairment at baseline 
(Lemos et al., 2015), and was associated with the risk of conversion to AD in follow-up 
studies (Auriacombe et al., 2010; Petersen, 2007; Sarazin et al., 2010). This study 
corroborates the new AD criteria in conceptualizing the prodromal period preceding 
the onset of AD by using the FCSRT to evaluate the memory deficit. An early and 
accurate identification of individuals at a higher risk for AD is crucial, given that 
understanding the biological and cognitive processes occurring at the prodromal stage 
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may lead to novel therapeutic goals for disease prevention and/or treatment 
(Khachaturian et al., 2008), in addition to planning for caregiver assistance and 
economic burden.  
The main limitation of this study is the strict focus on neuropsychological test data. 
Studies with the inclusion of other AD-biomarkers should be considered in the future. 
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Abstract 
The Selective Reminding Test (SRT) and the Free and Cued Selective Reminding Test 
(FCSRT) are multi-trial memory tests that use a common “selective reminding” 
paradigm that aims to facilitate learning by presenting only the missing words from the 
previous recall trial. While in the FCSRT semantic cues are provided to elicit recall, in 
the SRT subjects are merely reminded of the missing items by repeating them. These 
tests have been used to assess age-related memory changes and to predict dementia. 
The performance of healthy elders on these tests has been compared before, showing 
that twice as many words were retrieved from long-term memory in the FCSRT 
compared to the SRT. In this study we compared their properties and their accuracy in 
discriminating amnestic Mild Cognitive Impairment (aMCI, n=20) from Alzheimer’s 
disease (AD, n=18). AD patients performed significantly worse than aMCI subjects on 
both tests. The percentage of items recalled during the learning trials was significantly 
higher for the FCSRT on both groups, and a higher number of items were later 
retrieved, showing the benefit of category cueing. Our key finding was that the FCSRT 
showed higher accuracy in discriminating aMCI from AD patients. 
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Introduction 
The Selective Reminding Test (SRT; Buschke, 1973) and the Free and Cued Selective 
Test Reminding (FCSRT; Buschke, 1984; Grober & Buschke, 1987) are multi-trial 
memory tests that use a “selective reminding” paradigm, presenting only the words 
not recalled, instead of the entire list of the to-be-remembered words. This procedure, 
present in both the SRT and the FCSRT, is intended to facilitate learning by directing 
the subject's attention to the words not recalled on the previous trial.  
The FCSRT differs from the SRT in that it includes a procedure that promotes attention 
and cognitive processing in the learning process. Subjects are told to search for items 
(e.g., hammer) in response to category cues (e.g., tool), instead of just the item itself. 
Another difference between the two tests is in the method used to remind subjects of 
the missed items during recall. In the SRT, subjects are simply reminded of the items 
that were not recalled on the previous trial; the items are merely represented. In the 
FCSRT, the category cue is presented for the missed item, to help the subject recall it 
by category. Cued recall has been shown to provide an estimate of all the items that 
the subject has stored, rather than just those that are freely recalled, and to be 
minimally affected by guessing (Grober, Gitlin, Bang, & Buschke, 1992). Using the same 
category cues during the learning and recall phases is thought to coordinate 
acquisition and recall, to ensure attention, and to promote deep semantic processing 
in the encoding phase, increasing its specificity to the memory process itself (Tulving & 
Osler, 1968; Tulving & Thomson, 1973). 
These tests have been extensively investigated in the assessment of age-related 
memory changes as well as in the diagnosis and prediction of dementia. The SRT has 
been widely used to characterize the memory impairment in dementia in general 
(Sherwin, Chertkow, Schipper, & Nasreddine, 2011; Strauss, Sherman, & Spreen, 2006), 
as well as the memory profile of Alzheimer’s disease (AD) in particular (Campo, 
Morales, & Martínez-Castillo, 2003; Degenszajn, Caramelli, Caixeta, & Nitrini, 2001; 
Hall et al., 2007; Starkstein, Boller, & Garau, 2005). 
The FCSRT, with its cued selective reminding paradigm, has been used to characterize 
the memory dysfunction typical of both AD (Brown & Storandt, 2000; Buschke, 
Sliwinski, Kuslansky, & Lipton, 1997; Grober & Kawas, 1997; Grober, Hall, Lipton, et al., 
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2008; Mahieux et al., 2009; Vogel, Mortensen, Gade, & Waldemar, 2007) and of 
amnestic Mild Cognitive Impairment (aMCI; Ivanoiu et al., 2005; Saka, Mihci, 
Topcuoglu, & Balkan, 2006; Wenger, Negash, Petersen, & Petersen, 2010). It has 
shown both differences and similarities in the profile of memory dysfunction in the 
two disorders. For instance, the FCSRT indicated a similar profile of memory 
dysfunction in some individuals with aMCI and AD (Onen, Henry-Feugeas, Roy, Baron, 
& Ravaud, 2008; Petersen et al., 1999; Sánchez-Benavides et al., 2010). The similarity 
was especially clear in aMCI-patients who had a higher risk of conversion to AD 
(Petersen et al., 1995; Sarazin et al., 2007). 
The FCSRT was recently recommended by the International Working Group on 
Alzheimer’s disease (Dubois et al., 2007) due to its high sensitivity and specificity in the 
differentiation of AD patients from healthy controls (Grober, Sanders, Hall, & Lipton, 
2010) as well as from individuals with other dementia types (Buschke et al., 1997). 
Grober, Merling, Heimlich, and Lipton (1997) compared the performance of healthy 
elders on both the SRT and the FCSRT to determine which test produces better recall in 
normal aging, as well as to identify the factors that account for superior recall. They 
studied 33 very elderly (average age = 88.6) subjects and a group of 23 less-elderly 
subjects (average age = 76.4). Twice as many words were retrieved from long-term 
memory in FCSRT compared to the SRT. This improvement in free recall may be 
attributed to the cued method of reminding of the FCSRT. 
In the current study, these same two tests were compared to determine which is more 
sensitive in discriminating aMCI from AD, and to determine whether, as previously 
found, the FCSRT is more sensitive in discriminating aMCI from AD. We hypothesized, 
as did (Grober et al., 1997), that a higher percentage of words would be recalled in 
FCSRT than SRT in both groups because of the paradigm that underlies the FCSRT, 
which promotes attention and semantic processing. As that procedure is thought to 
minimize the effects of mild cognitive decline, the FCSRT should enhance the accuracy 
in detecting AD patients, where attention and semantic processing are more impaired. 
The AD patients are less able to use the assistance provided by the FCSRT, in contrast 
to the aMCI group, where attention and semantic processing have not yet significantly 
deteriorated. 
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Materials and Methods 
Participants 
The clinical study sample included 21 aMCI patients (14 women and 6 men) and 18 AD 
patients (11 women and 7 men), recruited at the Dementia Clinic of the Neurology 
Department of our local University Hospital. The diagnostic investigation involves a 
standard clinical evaluation, extensive psychological and cognitive assessment, 
laboratory tests, and imaging studies. Certain laboratory tests (including chemistry 
profile, CBC count, thyroid function tests, vitamin B12 and folic acid level, syphilis and 
Lyme serology), imaging studies (CT, MRI, or SPECT), and Apolipoprotein E allele 
genotyping were always performed. Positron Emission Tomography, Cerebrospinal 
Fluid analysis, and genetic studies were more selectively done, largely in younger 
patients. The psychological battery administered included: 1) Cognitive tests: the Mini-
Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975; Guerreiro et al., 
2008), the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog; Guerreiro, 
Fonseca, Barreto, & Garcia, 2008; Mohs, Rosen, & Davis, 1983), and a comprehensive 
neuropsychological battery with normative data for the Portuguese population (BLAD; 
Guerreiro, 1998) exploring memory as well as other cognitive domains. 2) The Clinical 
Dementia Rating (CDR; Garrett et al., 2008; Morris, 1993) was used for global staging. 
3) The Geriatric Depression Scale (GDS-30; Barreto, Leuschner, Santos, & Sobral, 2008; 
Yesavage et al., 1982) was used to exclude severe depression. 
These auxiliary exams were used to support diagnoses of a multidisciplinary team 
headed by a board certified neurologist, based on international consensus diagnostic 
criteria. The MCI group included patients classified as “amnestic” (single or multi-
domain) (Petersen, 2007) and was selected according to Petersen’s criteria (Albert et 
al., 2011; Petersen, 2004): 1) A subjective complaint of memory decline (reported by 
the subject or an informant); 2) Objective memory impairment (defined as scores on 
standard memory tests >1.5 SD below age/education adjusted norms) with or without 
deficits in other cognitive domains; 3) Normal general cognition indicated by normal 
scores on the MMSE and ADAS-Cog; 4) Largely normal daily life activities; 5) Absence of 
dementia (CDR = 0.5). The mean age of aMCI subjects was 69.8 years (SD = 7.88; range 
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= 52 – 80); their mean educational level was 6.6 years (SD = 4.55; range = 2 – 17). 
MMSE scores ranged between 22 and 30, with a mean of 26.95 (SD = 2.39). 
The criteria for the diagnosis of AD were those in the Diagnostic and Statistical Manual 
of Mental Disorders – fourth edition (DSM-IV-TR; American Psychiatric Association, 
2000) and the National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders (NINCDS-ADRDA; McKhann et al., 
1984, 2011). The AD group only included patients with mild severity (CDR = 1 and 
MMSE ≥ 17 points). Moreover, to be eligible for this particular study, patients had to 
be stable, without acute significant events or recent or in-progress changes in 
medication. Other exclusion criteria were: Neurological/psychiatric conditions other 
than aMCI or AD; CT or MRI demonstration of significant vascular disorder (large 
cortico-subcortical infarct; extensive subcortical white matter lesions (> 25%); uni- or 
bilateral thalamic lacunes; lacunes in head of caudate nucleus; more than 2 lacunes 
(Román et al., 1993). The mean age for AD subjects was 73.89 years (SD = 6.97; range = 
57 – 83); their mean educational level was 8 years (SD = 4.52; range = 3 – 17). MMSE 
scores ranged between 17 and 26, with a mean of 21.56 (SD = 2.89).  
The two groups did not differ on demographical variables: age [t (36) = -1.686, p= 
.101], educational level (U = 140.50, p = .251), and gender [χ2 (1) = 3.789, p = .052]. 
Performance on the MMSE, as expected, was worse for AD patients compared to aMCI 
subjects (U = 25.50; p <.001). 
The same experimental research protocol was used for all subjects. Informed consent 
was obtained from all participants, and the study was conducted in accordance with 
the tenets of the Declaration of Helsinki, with the approval of our local ethics 
committee. 
Procedure 
 Selective Reminding Test (SRT)  
In a first session, subjects performed the Portuguese adapted version of the SRT 
Afonso, 2010; Buschke, 1973). For Trial 1, subjects read a list of 12 unrelated words 
presented one at a time on index cards at 5 second intervals. Mispronunciations are 
corrected by the examiner. Immediately after reading all the words, subjects are given 
120” to recall as many words as possible, in any order. Subsequent learning trials (total 
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of 12) involve the selective presentation of only those items not recalled on the 
immediately preceding trial. The subject is asked to verbally repeat them. A cued-recall 
trial is presented after the last selective reminding trial, which is defined as the 3rd 
consecutive trial on which all 12 words are recalled (up to 12 trials). For cueing in the 
SRT, the first two or three letters of each word are presented on an index card, and the 
subject is asked to recall the corresponding word from the list. Following the cued-
recall trial, a multiple-choice recognition trial is presented. The subjects are not 
forewarned of a delayed recall trial, given 30 minutes after the multiple-choice 
recognition trial.  
Of the possible variables that can be computed, we selected: 1) the total of 
immediately recalled words across trials (SRT Total IR), 2) the total of words recalled 
after the 30 minute interval (SRT Total DR – delayed recall), 3) long-term storage (LTS – 
words recalled twice in a row, assumed to be in long-term/permanent storage from 
that point on), and 4) short-term storage (STS – the remaining words not in LTS). 
 Free and Cued Selective Reminding Test (FCSRT) 
Subjects were then given, in a second moment, the Portuguese version of the FCSRT 
(Buschke, 1984; Grober & Buschke, 1987; Lemos, Martins, Simões, & Santana, 2012). 
Materials and instruction of the FCSRT were provided to our group by the original 
author (Buschke’s FCSRT. Copyright, 2002. Albert Einstein College of Medicine of 
Yeshiva University, New York). Sixteen items are to be learned. The 16 items to be 
learned are presented four at a time on a card, distributed in four quadrants, one item 
per quadrant. The test starts by asking subjects to identify words in response to a 
unique category cue, each one. The subject is asked to search each card and point to 
and name aloud each item after its semantic cue was aurally presented. During this 
procedure, the subject is informed to learn the 16 words. Next, there are three recall 
trials, each preceded by 20 seconds of counting backward to prevent recall from short-
term memory. Each recall trial consists of two parts. First, each subject is given up to 
120” to recall as many items as possible. Next, aurally presented category cues were 
provided for items not retrieved in free recall. If subjects failed to retrieve the item 
with the category cue, they were reminded by presenting the cue and the item 
together. The sum of free and cued recall gives a measure of total recall (Immediate 
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Recall - IR). The same recall procedure (free and cued) is done after a 30 minute 
interval (Delayed Recall - DR). The selected measures to be analysed within the FCSRT 
were the total of immediately words recalled across the 3 trials (sum of the free and 
cued recalls - FCSRT Total IR), as well as the total of words recalled on delayed trials 
(sum of the free and cued recalls - FCSRT Total DR). 
Statistical analysis 
Based on the methodology described by Berres, Zehnder, Bläsi, and Monsch (2008), all 
raw scores were transformed into demographically adjusted z-scores for comparisons 
of performance between the two groups, on both tests (SRT - Afonso, 2010; FCSRT – 
(Lemos, Simões, Santiago, & Santana, 2015). Statistical analyses were performed using 
the Statistical Package for the Social Sciences (SPSS, version 19.0) (IBM SPSS, Inc., 
Chicago, IL). Statistical significance was set at p<.05. To determine whether the z-
scores of the tests variables were significantly different between the two groups, we 
performed independent two-sample t-tests. Cronbach’s alpha was used as an index of 
internal consistency, independently for each test. Convergent validity was assessed 
with Spearman’s correlation coefficients between the total immediate recall (IR) and 
the total delayed recall (DR) of both SRT and FCSRT.  
To compare recall from LTS between tests, a measure of consistent retrieval among 
the three common learning trials was computed for each patient, as follows: the 
number of words that were recalled on two successive trials without reminding (SRT) 
or cueing (FCSRT) was considered the consistent recall score.  
To account for the fact that the list length and the number of trials differs between the 
SRT and the FCSRT, the number of items recalled during free recall was divided by the 
total number of items, yielding a percentage of items recalled (PIR-IR – immediate 
recall), on the first three trials. The same procedure was used for the delayed recall 
(DR) – percentage of items recalled (PIR-DR). 
A series of binary logistic regressions, using the enter method, were performed to 
assess the effect of the immediate and delayed PIR’s of both the SRT and the FCSRT on 
the differentiation between aMCI and AD patients. A Linear Discriminant Analysis 
(LDA) classificatory model, with an enter method, was performed to determine which 
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measure better distinguished the two groups. Equal a priori classification probabilities 
were used for LDA to avoid biases from the data sets. 
 
Results 
The means, standard deviations, and ranges of the z-scores of the selected SRT and 
FCSRT variables are presented in Table 5.1. P-values of independent two-sample t-test 
(see Table 5.1) revealed that AD patients performed significantly worse (p<.001) on all 
variables.  
Table 5.1 Performance on the SRT and on the FCSRT (z-scores) 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; SRT –Selective Reminding Test; IR – 
Immediate Recall; DR – Delayed Recall; STS – Short-term Storage; LTS – Long-term storage; FCSRT –Free and Cued Selective 
Reminding Test; IR – Immediate Recall; DR – Delayed Recall. 
 
Psychometric properties 
Cronbach’s alpha was 0.929 for immediate recall and 0.802 for delayed recall for the 
SRT; it was 0.926 for immediate recall and 0.881 for delayed recall on the FCSRT, 
indicating overall good reliability of the tests. 
The selected measures (Total IR and Total DR) for the two tests were significantly 
positively correlated (Total IR: r = .638, p <.001; Total DR: r = .665, p <.001), indicative 
of convergent validity. 
Group differences  
Figure 5.1 shows the mean PIR on each learning trial for the SRT and the FCSRT, for the 
two groups. The mean PIR revealed a significantly higher number of items recalled on 
FCSRT than SRT for each trial for the aMCI group (Trial 1: Z=-3.922; p<.001; Trial 2: Z=-
 aMCI (n=20) AD (n=18) 
p-value 
Mean (SD) Range Mean (SD) Range 
SRT Total IR -1.3 (0.97) -3.23 to 0.44 -2.5 (0.83) -4.33 to -0.67 .001 
SRT Total DR -1.34 (0.99) -2.79 to 0.28 -2.566 (0.38) -2.79 to -1.64 .001 
SRT STS 1.41 (1.05) -0.51 to 3.15 2.84 (0.93) 0.86 to 4.06 .001 
SRT LTS -1.41 (1.05) -3.15 to 0.51 -2.97 (0.93) -4.06 to -0.86 .001 
FCSRT Total IR  -1.67 (2.22) -6.33 to 1.10 -5.31 (0.94) -6.87 to -3.43 .001 
FCSRT Total DR -1.88 (2.3) -6.09 to 0.98 -5.76 (0.99) -7.10 to -3.57 .001 
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3.118; p=.002; Trial 3: Z=-3.455; p=.001). In contrast, for the AD group, no comparisons 
between the SRT and FCSRT reached significance; and there was a similar pattern of 
performance in the three learning trials for both tests.  
 
Figure 5.1 Percentage of words recalled (PIR) on the first three trials of the Selective 
Reminding Test (SRT) and the three trials of the Free and Cued Selective Reminding Test 
(FCSRT), between aMCI and AD. Error bars indicate standard errors. 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; SRT –Selective Reminding Test; FCSRT –Free 
and Cued Selective Reminding Test. 
In SRT recall is tested immediately after reminding, allowing one to measure both 
short-term (STS) and long-term storages (LTS). The LTS comprises the words that did 
not demand reminding (assumed to be in LTS after being recalled twice in a row), 
whereas the STS consists of words which required reminding on the previous trial 
(difference between the total number of items and the words of LTS). Unlike SRT, 
recall in FCSRT reflects only LTS, as the 20 second of interference prevents recall from 
STS.  
Figure 5.2 shows the mean percentage of consistent retrieval on the SRT and the 
FCSRT for trials 1 and 2; and 2 and 3, between the two groups. The mean PIR for the 
aMCI group revealed a significantly higher number of items recalled on FCSRT than SRT 
on each trial (Trial 1: Z=-3.922; p<.001; Trial 2: Z=-3.118; p=.002; Trial 3: Z=-3.455; p 
=.001). In contrast, for the AD group, none of the comparisons reached significance. 
That is, again, we found a similar pattern of performance across the three learning 
trials on both tests for the AD group, in contrast to the superior performance of the 
aMCI group on the FCSRT compared to the SRT. 
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Figure 5.2 Percentage of consistent retrieval for trials 1 and 2, and 2 and 3 on the Selective 
Reminding Test (SRT) and the Free and Cued Selective Reminding Test (FCSRT), between aMCI 
and AD. Error bars indicate standard errors. 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; SRT –Selective Reminding Test; FCSRT –Free 
and Cued Selective Reminding Test. 
The delayed mean PIR revealed a significantly higher number of items recalled on 
FCSRT than SRT on both groups (aMCI: Z =-3.400; p =.001; AD: Z =-3.006; p =.003). 
When analyzing the performance on the total immediate (sum of the three learning 
trials), and delayed PIR’s of both the SRT and the FCSRT, a significant difference was 
found between aMCI and AD patients (.05 < p <.001) (Table 5.2). The AD patients had 
worse performance than the aMCI group.  
Table 5.2 Total percentage of words recalled between the two clinical groups on the SRT and 
on the FCSRT 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; SRT –Selective Reminding Test; FCSRT –Free 
and Cued Selective Reminding Test; PIR-Percentage of Items Recalled; IR – Immediate Recall; DR – Delayed Recall.  
 aMCI (n=20) AD (n=18)  
Mean % (SD) Range Mean % (SD) Range p-value 
SRT PIR-IR 33.06 (13.27) 8.33 to 52.78 21.14 (9.86) 8.33 to 47.22 .004 
SRT PIR-DR 30.83 (21.48) 0 to 66.67 5.09 (8.15) 0 to 25 .001 
FCSRT PIR-IR 63.96 (25.56) 10.42 to 95.83 22.11 (10.77) 4.17 to 43.75 .001 
FCSRT PIR-DR 64.69 (28.48) 12.50 to 100 16.67 (12.31) 0 to 43.75 .001 
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Logistic regression revealed a significant effect on both recalls of the FCSRT 
[𝐵𝐹𝐶𝑆𝑅𝑇 𝑃𝐼𝑅−𝐼𝑅 = −.095;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 8.057;  𝑝 = .005; 𝑂𝑅 =  .910; 𝐵𝐹𝐶𝑆𝑅𝑇 𝑃𝐼𝑅−𝐷𝑅 =
−.070;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 6.702;  𝑝 = .010; 𝑂𝑅 =  .933].  
All measures were analyzed independently, as predictor variables, to highlight their 
relative contribution in discriminating the two groups, through a Linear Discriminant 
Analysis (LDA). All Wilks’ lambdas were significant at p<.05. The SRT PIR-IR (λ Wilks 
=.788; χ2(1) = 8.454; p=.004; RCanonical =.460) revealed an accuracy of 65.8% in 
classifying the subjects; while the FCSRT PIR-IR (λ Wilks =.464; χ2(1) = 27.232; p<.001; 
RCanonical =.732) was the predictor with higher accuracy (86.8%) in the subjects 
classification; the SRT PIR-DR (λ Wilks =.612; χ2(1) = 17.441; p<.001; RCanonical =.623) 
had an accuracy of 81.6% in discriminating the groups; and the FCSRT PIR-DR (λ Wilks 
=.452; χ2(1) = 28.221; p<.001; RCanonical =.741) revealed an accuracy of 84.2% in the 
subjects classification (Table 5.3). 
Table 5.3 Classification results of the SRT and the FCSRT 
   Predicted Group 
Membership 
aMCI 
(n=20) 
AD 
(n=18) 
P
IR
 -
 IR
 
SRT  Count (%) 
aMCI 13 (65) 7 (35) 
AD 6 (33.3) 12 (66.7) 
FCSRT  Count (%) 
aMCI 16 (80) 4 (20) 
AD 1 (5.6) 17 (94.4) 
P
IR
 -
 D
R
 
SRT  Count (%) 
aMCI 14 (70) 6 (30) 
AD 1 (5.6) 17 (94.4) 
FCSRT  Count (%) 
aMCI 16 (80) 4 (20) 
AD 2 (11.1) 16 (88.9) 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; PIR-Percentage of Items Recalled; IR – 
Immediate Recall; DR – Delayed Recall; SRT –Selective Reminding Test; FCSRT –Free and Cued Selective Reminding Test.  
 
Discussion 
The aim of this research was to compare the SRT and the FCSRT in distinguishing aMCI 
from AD. We compared the performance of aMCI and AD patients on the two tests, 
analysing their properties and diagnostic accuracy. 
Both tests showed different levels of impairment in the aMCI and AD groups.  
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As expected AD patients performed significantly worse than aMCI subjects on both 
memory tests. Psychometrically, both tests had good internal reliability. Also, the 
variables selected from the two tests (total immediate recall and total delayed recall) 
were significantly positively correlated, indicating convergent validity. To eliminate 
differences stemming from different list length and number of trials on the SRT and 
FCSRT, we converted the raw scores to percentages, for immediate and delayed recall. 
For the aMCI patients, the percentage of items recalled across the three learning trials 
was significantly higher for FCSRT than SRT: More items were retrieved, showing the 
benefit of category cues in the FCSRT for the aMCI group, compared to the mere 
selective reminding in the SRT. In contrast, for the AD group, the pattern of 
performance was similar across the trials on both FCSRT and SRT. The data for 
consistently retrieved words yielded similar results: A significantly higher number of 
items was recalled on FCSRT than SRT for the aMCI group, whereas AD patients’ did 
not differ on FCSRT versus SRT. For the delayed trial, on both groups, significantly more 
items were recalled on FCSRT compared to SRT.  
For the SRT, the delayed recall (81.6%) enabled a higher accuracy of classification than 
the immediate recall (65.8%), whereas, for the FCSRT, the difference between 
classification accuracy was very small (FCSRT PIR-IR: 86.8%; FCSRT PIR-DR: 84.2%). We 
believe that while the FCSRT benefits aMCI patients during learning - their learning 
trials are better than on SRT - that benefit is not seen with AD patients, presumably 
because their semantic processing is impaired. Both sets of patients did better on 
delayed recall on the FCSRT than on SRT, except with regards to accuracy. We did not, 
on delayed recall, find the differential benefit of the FCSRT over the SRT for aMCI 
subjects compared to AD subjects. Thus, it appears that the AD group benefitted from 
the repetition involved in the learning phase of the SRT (total of 12 trials), which 
justifies the superior accuracy found in the delayed recall. While the semantic cueing 
plays an effective role during learning, regardless of the delayed recall, memory tests 
of unrelated list of words, such as the SRT, seems to require extra learning trials to 
reach higher values of accuracy at the level of delayed recall. 
Our results suggest that the reminding paradigms that underlie both the SRT and the 
FCSRT are useful in characterizing the memory impairment found in aMCI and AD 
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patients. However, the results also suggest that the FCSRT, with its category cueing 
procedure, yields better accuracy in distinguishing between aMCI and AD. As noted 
earlier, the FCSRT procedure supports and fosters both attention and semantic 
cognitive processing in the learning process. It is also used in the retrieval phase, 
where the category cue is presented for the missed item. It differs in this regard from 
the SRT, where subjects are merely selectively reminded of the items that were not 
recalled on the previous trial, by re-presenting them. Some authors have pointed out 
that mere repetition facilitates new learning (Hayman, Macdonald, & Tulving, 1993); 
others have stressed that new information is encoded in episodic memory through 
semantic memory - that semantic processing in the encoding phase facilitates learning, 
and, consequently, retrieval of stored information (Tulving & Osler, 1968; Tulving & 
Thomson, 1973). We found this in the present study of individuals with memory 
impairment: The use of semantic cues (FCSRT) improved subsequent recall more than 
just repeating the items not retrieved previously (SRT). The procedure - the method of 
reminding in FCSRT - not only improved recall in comparison to SRT procedures, but 
also yielded better characterization of the process of AD spectrum memory 
impairment. The superiority of the FCSRT has been previously reported in 
differentiating AD patients from individuals in other groups, e.g., healthy controls, and 
patients with other dementias (Buschke et al., 1997; Grober, Hall, Sanders, & Lipton, 
2008; Grober et al., 2010). That led the International Working Group on Alzheimer’s 
disease (Dubois et al., 2007) to suggest the use of the FCSRT to objectively assess the 
memory impairment of these patients. Grober et al. (1997) also found the FCSRT more 
efficient in promoting learning and memory than the SRT in normal aging: twice as 
many words were retrieved from long-term memory in the FCSRT, suggesting that the 
improvement in free recall was due to the procedure - the method of reminding 
involved in the FCSRT.  
Our study is consistent with prior research indicating that different memory test 
paradigms and procedures may yield distinct patterns of performance. Regular word 
list tests demand reproduction of a list of unrelated words. They thus require an active 
effort to organize information both during encoding and retrieval. In contrast, tests 
with semantically organized material (such as the FCSRT) allow for more passive 
learning, and demand less active implementation of retrieval strategies (Perri, Fadda, 
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Caltagirone, & Carlesimo, 2013). We surmise that the structured paradigm that 
underlies the FCSRT, which supports attention and semantic processing, minimizes the 
effects of mild cognitive decline, resulting in a higher percentage of recalled words. We 
further surmise that this may also account for the superiority of the FCSRT in detecting 
demented patients. Demented patients may be sufficiently impaired that they are not 
able to use the supports the FCSRT provides, in contrast to those with mild cognitive 
decline, whose apparent memory difficulties may reflect a lack of use of semantically-
based encoding strategies, rather than a true retention problem. 
Limitations of our current study: We had a relatively small sample size. This gives us 
less confidence that the results will generalize to the broader population of aMCI and 
AD patients. We also did not have a control group and it would be desirable to 
compare controls, aMCI and AD individuals simultaneously, fully to characterize the 
continuum of memory dysfunction.  
We believe our study shows that the paradigm of cued reminding that supports 
elements important to the encoding and retrieval conditions is superior to mere 
selective reminding without cueing. The FCSRT can also result in economy of time and 
effort. That may have the advantage of reducing patient fatigue in achieving learning, 
as it is more efficient than mere SRT: The three learning trials of the FCSRT were found 
to be adequate; they elicited more recalled words than the twelve trials that may be 
needed for the SRT. Of course, these results need to be confirmed in studies using 
larger samples. It will also be important to conduct studies that examine the 
correlation of performance on the tests with AD biomarkers. We suggest studies 
comparing memory tests that use different paradigms. Finally, we suggest the need for 
longitudinal studies, where aMCI subjects are followed over time, to better understand 
the accuracy of these instruments in predicting conversion to dementia.  
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Abstract  
The Logical Memory (LM) and the Verbal Paired Associative Learning (VPAL) are 
subtests from the Wechsler Memory Scale commonly used to characterize the 
memory deficit of amnestic Mild Cognitive Impairment (aMCI) and Alzheimer’s disease 
(AD). The Free and Cued Selective Reminding Test (FCSRT) was suggested to assess the 
memory impairment of AD spectrum patients by the International Working Group on 
AD. In this study, we compared the properties of the tests and their accuracy in 
classifying aMCI and AD. A group of aMCI (n=85) and of AD (n=43) were included. The 
reliability and the validity of the three tests were analyzed.  
AD patients revealed a significant pattern of worst impairment on all tests than aMCI. 
The FCSRT was able to classify more subjects as having memory impairment in the 
aMCI group rather than the WMS subtests. The FCSRT proved to be good in 
discriminating the two groups in both lower and higher educational levels, while the 
LM was more useful in higher educated subjects.  
Although the instruments had good results, the FCSRT was more accurate in 
discriminating MCI from AD and less influenced by the educational level.  
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Introduction 
Memory impairment is essential for the diagnosis of amnestic Mild Cognitive 
Impairment (aMCI; Petersen et al., 1999, 2001) and Alzheimer’s disease (AD; American 
Psychiatric Association, 2000; McKhann et al., 1984, 2011), and a strong predictor of 
dementia’s development (Dubois et al., 2007; Geerlings, Jonker, Bouter, Adèr, & 
Schmand, 1999). A compromise of the episodic long-term memory is the characteristic 
profile of mild AD (Perri, Serra, Carlesimo, Caltagirone, & Early Diagnosis Group of the 
Italian Interdisciplinary Network on Alzheimer’s Disease, 2007), since it reflects the 
early involvement of the hippocampus and its related structures. Moreover, these 
structures are critical in memory consolidation and tasks of delayed recall are 
particularly sensitive to hippocampal dysfunction. However, performance in delayed 
recall and consolidation also reflects the quality of learning, therefore paradigms that 
control and superimpose reinforcement to the encoding process may increase test 
acuity (Belleville, Sylvain-Roy, de Boysson, & Ménard, 2008; Buschke, Sliwinski, 
Kuslansky, & Lipton, 1997; Moulin, James, Freeman, & Jones, 2004; Wang & Zhou, 
2002). 
Standard criteria for the diagnosis of both aMCI and AD require an objective validation 
of the memory dysfunction (American Psychiatric Association, 2000; Dubois et al., 
2007; McKhann et al., 1984, 2011; Petersen et al., 2001). Therefore, the test used to 
identify this memory impairment should be highly accurate (Petersen, Smith, Ivnik, 
Kokmen, & Tangalos, 1994), and individual deviations must be concretely specified 
along with its cut-off values (Petersen, 2004a). 
Valid and accurate neuropsychological tests must have good diagnostic classification 
properties. In terms of memory, a significant impairment in neuropsychological testing 
is essential to the diagnosis of both aMCI and AD (Dubois et al., 2007; Portet et al., 
2006).  
Despite the modifications on the operationalization of the MCI criteria (Jak et al., 2009; 
Petersen et al., 2009; Visser & Verhey, 2008; Winblad et al., 2004) no specific memory 
test was suggested for the diagnosis of aMCI. On the other hand, the International 
Working Group (Dubois et al., 2007, 2010) proposal for the early diagnosis of AD 
suggested the use of the Free and Cued Selective Reminding Test (FCSRT; Buschke, 
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1984; Grober & Buschke, 1987) to objectively assess the memory impairment of AD 
spectrum patients. 
The FCSRT (Buschke, 1984) was designed to coordinate acquisition and retrieval by 
using the same cues to control learning and elicit effective cued recall. Moreover, this 
test provides a measurement of memory under conditions that control attention and 
cognitive processing, in order to obtain an assessment of memory unconfounded by 
normal age-related changes in cognition. The utility of this paradigm has been widely 
reported in AD (Brown & Storandt, 2000; Carlesimo, Perri, & Caltagirone, 2011; Grober 
& Kawas, 1997; Grober et al., 2008; Mahieux et al., 2009; Sarazin et al., 2010; Vogel, 
Mortensen, Gade, & Waldemar, 2007) and MCI (Ivanoiu et al., 2005; Saka, Mihci, 
Topcuoglu, & Balkan, 2006; Wagner et al., 2012). The similar profile of memory 
dysfunction has been described between MCI and AD (Petersen, 2004b; Petersen et 
al., 1999), and in MCI subjects with a higher risk of conversion to AD (Petersen, 2007; 
Sarazin et al., 2010). A poor performance on the FCSRT has also shown a high 
correlation with atrophy in the medial temporal lobe (Sánchez-Benavides et al., 2010; 
Sarazin et al., 2010), and was significantly associated with cerebrospinal fluid AD-
biomarkers (Rami et al., 2011; Wagner et al., 2012).  
The Wechsler Memory Scale (WMS; Wechsler, 1987), particularly the subtests Logical 
Memory (LM) and Verbal Paired Associative Learning (VPAL), have been widely used in 
the characterization of the memory deficit of both AD (Galvin, Fagan, Holtzman, 
Mintun, & Morris, 2010; Gould et al., 2005) and MCI (Guo, Zhao, Chen, Ding, & Hong, 
2009; Rabin et al., 2009; Tremont, Miele, Smith, & Westervelt, 2010). Furthermore, 
performance on the WMS has been associated with a higher rate of conversion to AD 
as compared to other episodic memory tests (Ahmed, Mitchell, Arnold, Nestor, & 
Hodges, 2008; Silva et al., 2012; Tierney et al., 1996). Moreover, the LM subtest is 
suggested for the assessment of memory by the Alzheimer’s Disease Neuroimaging 
Initiative study (Crane et al., 2012; Kennedy, Schneider, Cutter, & Alzheimer’s Disease 
Neuroimaging Initiative, 2012). 
Even though the paradigms that underlie the FCSRT and the subtests of the WMS are 
different, some recent studies have proved the superiority of the FCSRT in predicting 
prodromal AD (Derby et al., 2013; Wagner et al., 2012). 
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In the present study we aimed at comparing the performance of aMCI and AD patients 
on the WMS-R subtests LM and VPAL and on the FCSRT. Our main goal was to 
determine which test is more accurate in classifying aMCI and AD.  
 
Materials and methods 
Participants  
The study included 85 aMCI patients and 43 AD patients, recruited at Neurology 
Department of the Coimbra University Hospital. Diagnostic investigation included: 
standard biochemical laboratory tests, imaging studies (CT or MRI), SPECT and 
Apolipoprotein E allele genotyping. The aMCI group was selected according to 
Petersen’s criteria (Albert et al., 2011; Petersen, 2004b) and included patients 
classified as “amnestic” (single or multi-domain) (Petersen, 2007). The standard 
criteria for the diagnosis of AD were the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR; American Psychiatric Association, 2000); and the National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease 
and Related Disorders (NINCDS-ADRDA; McKhann et al., 1984, 2011). The AD group 
selected for this study only included patients with a global staging of mild dementia 
[Clinical Dementia Rating (CDR; Morris, 1993) = 1 and Mini-Mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975) ≥ 17 points]. Moreover, to be eligible we 
considered that patients had to be in a stable condition and we defined as exclusion 
criteria neurological/psychiatric conditions other than aMCI or AD, and CT/MRI 
demonstration of significant vascular burden (Román et al., 1993). 
All subjects were submitted to the same experimental research protocol and 
performed both the WMS-R subtests and the FCSRT. Informed consent was obtained 
from all participants, and the study was conducted in accordance with the tenets of 
the Declaration of Helsinki, with the approval of our local ethics committee. 
Procedure  
A comprehensive neuropsychological assessment battery that included the following 
tests and scales was carried out:  
The CDR (Garrett et al., 2008; Morris, 1993) as a global staging classificatory and 
independent of the other neuropsychological measures. Because comparisons 
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between the FCSRT and the WMS subtests are part of our main goal analysis, and in 
order to avoid an eventual diagnostic circularity that may bias the results 
interpretation, CDR was used as the major classificatory instrument, independent of 
the neuropsychological measures. Groups were classified as CDR = 0.5 to define MCI 
and CDR = 1.0 to define AD.  
The Geriatric Depression Scale (GDS-30; Barreto, Leuschner, Santos, & Sobral, 2008; 
Yesavage et al., 1982) to exclude severe depression (score ≥ 20). 
Cognitive instruments as the MMSE (Folstein et al., 1975; Guerreiro, Silva, et al., 2008), 
the Alzheimer Disease Assessment Scale-Cognitive (Guerreiro, Fonseca, Barreto, & 
Garcia, 2008; Mohs, Rosen, & Davis, 1983), and a comprehensive neuropsychological 
battery validated for the Portuguese population (Guerreiro, 1998; Silva et al., 2012) 
exploring memory and other cognitive domains. Tests of interest for the present study 
included: the LM (immediate - IR and delayed recalls - DR) and the VPAL (IR), both from 
the WMS. 
The FCSRT [Buschke’s FCSRT. Copyright, 2002. Albert Einstein College of Medicine of 
Yeshiva University, New York. (Buschke, 1984; Lemos, Martins, Simões, & Santana, 
2012)] to assess verbal memory, under a semantic cued selective reminding paradigm. 
Category cues are provided for items not retrieved by free recall. If subjects fail to 
retrieve the item with the category cue, they are reminded by presenting the cue and 
the item together. The sum of free and cued recall gives a measure of total recall (IR). 
The same procedure of recalling (freely and cued) is done after a 30 minute interval 
(DR). 
Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(IBM SPSS Inc., version 19.0, Chicago, IL). When data significantly deviated from 
normal distributions (verified using the Kolmogorov-Smirnov normality check and 
Levene homogeneity tests), we choose to apply non-parametric statistical methods. 
Results with p<.05 were considered statistically significant. Descriptive statistics were 
used for sample’s characterization, and the Mann-Whitney test; the Pearson χ2 test; 
and the independent two-sample t-test allowed the group comparisons. Cronbach’s 
alpha was considered as an index of internal consistency and was measured 
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independently for each test. The convergent validity was assessed through Spearman’s 
correlation coefficients between the WMS-R subtests and the FCSRT on both recalls. 
The neuropsychological assessment was standardized according to the norms for the 
Portuguese population and impairment on the memory tests was defined as scores in 
the impaired range [aMCI: 1.5 SDs and AD: 2 SDs below age and education-adjusted 
mean on LM and VPAL (Guerreiro, 1998; Silva et al., 2012); FCSRT below standardized 
cut-offs (Lemos, Simões, Santiago, & Santana, 2015)], allowing a categorical 
subdivision of “normal” or “abnormal”. The significance of accordance between these 
dichotomous classifications was carried out through the McNemar test. 
The accuracy of the tests for the distinction between the diagnosis of aMCI and AD was 
assessed through the receiver operating characteristics (ROC) curve analysis 
implemented in MedCalc (version 12.7) (MedCalc Software, Acacialaan). The areas 
under the curve (AUC) can vary between 0.5 and 1, with larger AUC indicating better 
diagnostic accuracy. The optimal cut-off points for each measure of both the WMS-R 
subtests and the FCSRT that generated the highest Youden index were selected, thus 
indicating maximization of accuracy. For the analysis of the predictive value we 
calculated, for each cut-off point, the sensitivity, specificity, the positive predictive 
value (PPV), the negative predictive value (NPV), and the classification accuracy. The 
ROC curves were compared according to their AUC (DeLong, DeLong, & Clarke-
Pearson, 1988).  
A series of binary logistic regressions, using the Forward (conditional) method, were 
performed to assess the effect of the different memory tests and of the demographic 
characteristics (age, education and gender) on the differentiation between aMCI and 
AD patients. 
 
Results 
Sample characterization 
Demographic and clinic characteristics of the population are shown in Table 6.1. No 
statistically differences were found on age [t(126) = -1.173, p = .243], educational level 
(U =1533.5, p =.124), or gender [χ2 (1) = .031, p = .859] between the two groups.  
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As expected, a significant effect was found for MMSE (U =507, p <.001) as AD patients 
performed poorly.  
Table 6.1 Demographic and clinic characteristics of the population 
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination.  
Note: Data are expressed as mean (SEM).  
Comparisons between aMCI-AD patients were carried out by independent two-sample sample t-test, Mann-Whitney or Pearson χ2 
test for non-homogenous variables, where: 
*aMCI vs. AD: p <.05.  
 
Psychometric properties 
Within this analysis the Cronbach’s alpha confirmed an overall good reliability of the 
tests, for the total sample: LM (IR: 0.840; DR: 0.851), VPAL (0.867), FCSRT (IR: 0.896; 
DR: 0.873). 
The recalls of the tests were significantly and positively correlated which is indicative 
of convergent validity (IR: LM and VPAL r =.592, p<.001; LM and FCSRT: r =.605, p<.001; 
VPAL and FCSRT: r =.575, p<.001; DR: LM and FCSRT: r =.677, p<.001). 
Group differences and diagnostic classification accuracy of the tests  
AD patients had a worse performance, in all measures (p<.001) (Table 6.2).  
Table 6.2 Performance on the tests  
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; LM – Logical Memory; VPAL – Paired 
Associate Learning; FCSRT –Free and Cued Selective Reminding Test; IR – Immediate Recall; DR – Delayed Recall. 
Note: Data are expressed as mean (SD). 
Comparisons between aMCI-AD patients were carried out by the Mann-Whitney test for non-homogenous variables, where: 
** aMCI vs. AD: p <.001. 
 aMCI 
(n=85) 
AD 
(n=43) 
Gender (m:f) 33:52 16:27 
Age (years) 70.34 (0.84) 72.07 (1.23) 
Education Level (years) 6.81 (0.49) 8.07 (0.75) 
MMSE (score) 26.95 (0.42) 22.77 (0.50)* 
  aMCI 
(n=85) 
AD 
(n=43) 
LM IR 5.95 (.31) 2.95 (.37)** 
 DR 3.72 (.28) .94 (.22)** 
VPAL  IR 11.48 (.44) 8.34 (.56)** 
FCSRT  IR 28.56 (1.20) 15.09 (1.50)** 
 DR 9.12 (.50) 3.80 (.51)** 
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The standardized performance (dichotomous classification) of the two samples on the 
WMS-R subtests and on the FCSRT was compared in order to determine which test was 
better in classifying the memory impairment. Table 6.3 presents the general frequency 
of the classification for each test. 
Table 6.3 Frequency of the dichotomous classification on the tests  
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; LM – Logical Memory; VPAL – Paired 
Associate Learning; FCSRT – Free and Cued Selective Reminding Test; IR – Immediate Recall; DR – Delayed Recall.  
Note: Data are expressed as percentage (%).  
In terms of classification, the FCSRT categorized more subjects, mainly on the aMCI 
group, as having memory impairment than the WMS-R subtests. For AD’s, the DR of 
the LM captured slightly more patients. Among all tests, the VPAL had a higher number 
of misclassifications, as more subjects were categorized as “normal” in terms of 
memory impairment. 
Table 6.4 presents the cross-tabulation of the classification among all the tests (i.e, the 
frequency of one test in respect to another). 
In this analysis, classification of subjects is compared between the tests, by means of 
comparing how many subjects are classified the same way or differently. For aMCI 
subjects the only comparison that had no significant difference was between the two 
recalls of the FCSRT; however there was an effective change in the classification of 
performance between the two recalls of LM, between LM and VPAL, and between the 
WMS-R subtests and FCSRT (both recalls). On the other hand, on AD patients, there 
were no differences in terms of classification among the LM and the FCSRT, nor 
between the two recalls of the FCSRT; still the two recalls of the LM subtest had 
differences among them, as had the VPAL subtest when compared with all the other 
tests. 
  aMCI 
(n=85) 
AD 
(n=43) 
Abnormal Normal Abnormal Normal 
LM IR 25 75 81 19 
DR 54 46 98 2 
VPAL  IR 6 94 44 56 
FCSRT  IR 68 32 91 9 
DR 74 26 93 7 
186 Chapter I 
 
Table 6.4 Cross-tabulation of the dichotomous classification among all the tests  
Abbreviations: aMCI – amnestic Mild Cognitive Impairment; AD – Alzheimer’s disease; LM – Logical Memory; VPAL – Paired 
Associate Learning; FCSRT – Free and Cued Selective Reminding Test; IR – Immediate Recall; DR – Delayed Recall; Ab – Abnormal; 
N - Normal.  
Note: Data are expressed as percentage (%).  
Comparisons between classifications among tests were carried out by the McNemar test for related categorical variables, where: 
*p<.05; 
**p<.001; 
NS – Non significant. 
 
In order to evaluate the diagnostic accuracy of the tests, the ROC curves were 
performed: LM [IR - fair AUC of .786 (95% CI = .705 - .853), DR - good AUC of .812 (95% 
CI = .733 - .876)], VPAL had a fair AUC of.743 (95% CI = .657 - .817), FCSRT [IR: .819 
(95% CI = .741 - .881), DR: .811 (95% CI = .733 - .875)]. No statistically differences were 
found between AUC’s (DeLong et al., 1988) The optimal cut-off scores for maximum 
accuracy of each total recall measure are described in Table 6.5.  
 
 
aM
C
I (
n
=8
5
) 
 LM VPAL FCSRT 
Test DR IR IR DR 
Ab N Ab N Ab N Ab N 
LM 
IR 
Ab 95 5** 14 86** 90 10** 90 10** 
N 40 60 3 97 61 39 69 31 
DR 
Ab   9 91** 87 13* 84 16* 
N   3 97 49 51 64 36 
VPAL IR 
Ab     100 0** 100 0** 
N     66 34 72,5 27,5 
FCSRT  IR 
Ab       97 3 NS 
N       26 74 
A
D
 (
n
=4
3
) 
LM 
IR 
Ab 100 0* 48 52* 94 6NS 97 3 NS 
N 88 12 25 75 75 25 75 25 
DR 
Ab   45 55** 90 10 NS 93 7 NS 
N   0 100 100 0 100 0 
VPAL IR 
Ab     100 0** 100 0** 
N     82 18 86 14 
FCSRT IR 
Ab       97 3 
N       50 50 NS 
Study 6 – The Free and Cued Selective Reminding Test and the Wechsler Memory 
Scale in discriminating mild cognitive impairment from Alzheimer’s disease 
187 
 
 
 
Table 6.5 Diagnostic classification accuracy of the tests 
Abbreviations: LM – Logical Memory (maximum score =21.5); VPAL – Paired Associate Learning (maximum score =21); FCSRT –Free 
and Cued Selective Reminding Test; IR – Immediate Recall (maximum score =48); DR – Delayed Recall (maximum score =16); AUC – 
area under the operating characteristics curve; PPV - positive predictive value; NPV - negative predictive value. 
Note1: Sensitivity, Specificity, PPV, NPV and Classification Accuracy values are expressed in percentage. 
Note2: Cut-off values indicate the minimum score required for absence of signal. 
 
In order to assess the test that better defined the likelihood of having AD, a series of 
binary logistic regression was performed. In this analysis demographic variables were 
included as covariates. Significant effects were found for LM DR, FCSRT IR, and 
education on the logit modelling the probability of being AD 
[(𝐵𝐿𝑀 𝐷𝑅 = −.434;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 8.329;  𝑝 = .004; 𝑂𝑅 =  .648), 
(𝐵𝐹𝐶𝑆𝑅𝑇 𝐼𝑅 = −.079;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 6.988;  𝑝 = .008; 𝑂𝑅 =  .924) and (𝐵𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 =
.128;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 5.557;  𝑝 = .018; 𝑂𝑅 =  1.137)]. The other tests/recalls did not reach 
significance on the distinction between aMCI and AD, neither did age or gender. 
Therefore, we divided the levels of education of the participants into two different 
groups (lower education group: ≤ 6 years of education and higher education group: > 6 
years of education) in order to analyze the impact of the cognitive tests on the 
differentiation between aMCI and AD. A new series of binary logistic regression was 
performed for all the tests, on the differentiation between aMCI and AD. On the lower 
education group, the FCSRT IR was the only measure reaching significance (𝐵𝐹𝐶𝑆𝑅𝑇 𝐼𝑅 =
−.120;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 13.759;  𝑝 < .001; 𝑂𝑅 =  .887), with the models showing an accuracy 
of 82% in the subjects classification; with a specificity of 91%, and a sensitivity of 58%. 
Furthermore, on the higher education group, significant effects were found both on 
the LM DR (𝐵𝐿𝑀 𝐷𝑅 = −.531;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 7.071;  𝑝 = .008; 𝑂𝑅 =  .588) and on the FCSRT 
IR (𝐵𝐹𝐶𝑆𝑅𝑇 𝐼𝑅 = −.104;  𝑋𝑤𝑎𝑙𝑑
2 (1) = 4.745;  𝑝 = .029; 𝑂𝑅 =  .901), with the models 
showing an accuracy of 76% in classification; with a specificity of 79%, and a sensitivity 
of 70%. 
  
Cut-off AUC Sensitivity Specificity PPV NPV 
Classification 
accuracy 
LM 
IR ≤4 .786 77 75 75 77 76 
DR ≤2.5 .812 91 69 75 88 80 
VPAL  IR ≤8.5 .734 69 75 73 71 72 
FCSRT  
IR ≤21 .819 77 74 75 76 76 
DR ≤8 .811 93 57 68 89 75 
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Discussion 
The general purpose of this research was to compare the performance of aMCI and AD 
patients on the WMS-R subtests (LM and VPAL) and on the FCSRT. Our main goal was 
to determine which test was more accurate in classifying aMCI and AD. In order to 
achieve our proposal we analyzed the tests’ properties by comparing the performance 
of aMCI and AD patients.  
Overall, the tests revealed good psychometric properties with a good internal 
consistency, and were significantly and positively correlated indicating convergent 
validity. 
When comparing the performance of both samples, the AD patients revealed a 
significant pattern of worst impairment on both recalls of all tests than aMCI, as 
expected. 
In order to realize which test was better in classifying the memory impairment on the 
two groups, the standardized scoring was used to classify the performance in a 
dichotomous way (“abnormal” versus “normal”). The FCSRT was able to classify more 
subjects as having memory impairment in the aMCI group rather than the LM or the 
VPAL subtests. On the AD sample, the DR of the LM included slightly more patients 
with memory impairment than the other tests. The VPAL subtest had a higher number 
of misclassifications. When the classification of subjects is compared between tests, 
i.e. matching how many subjects are classified the same way or differently among the 
instruments, different results were found on aMCI and on AD patients. On aMCI 
subjects the only comparison that had no significant difference in the classification was 
between the two recalls of the FCSRT. Still, for AD patients, the lack of differences in 
terms of classification is more extended among the instruments and recalls. There 
were no differences of grouping among the LM and the FCSRT, nor between the two 
recalls of the FCSRT. The effective change in the classification performance between 
the different tests in aMCI patients might be the result of the different paradigms that 
underlie the tests, as they have a milder impairment in memory. As for AD patients, 
with a greater impact in memory performance, the impairment is extensive to almost 
all the tests thus resulting in a consistent classification among them. While to classify 
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the impairment of aMCI patients we may need to use different memory instruments, 
to capture the deficit of AD’s a single episodic memory test may be enough. 
When comparing the diagnostic accuracy of the tests in discriminating between aMCI 
and AD patients, the ROC curves confirmed that the VPAL subtest is the less accurate 
in discriminating the two pathological groups. The DR of both the LM and FCSRT was 
more sensitive on discriminating aMCI from AD patients, but were less specific, while 
the IR had similar values of accuracy. 
Moreover, the educational level showed to greatly influence the patients’ 
discrimination, along with the DR of the LM and the IR of the FCSRT. Several studies 
have been showing that education has a great impact on the cerebral organization of 
cognitive skills and on the consequent performance on neuropsychological 
instruments (Ardila, Ostrosky-Solis, Rosselli, & Gómez, 2000; Jefferson et al., 2011). 
Therefore, the levels of education of the participants were divided into lower 
education group and higher education group to analyze the impact of the cognitive 
tests on the differentiation between aMCI and AD. The results showed that while the 
FCSRT (IR) was good to discriminate aMCI from AD patients in both groups, the LM 
(DR) was only useful to differentiate the two samples in the higher educated group. 
This is an important issue for countries with a significant percentage of low educated 
elders, like Portugal. 
The LM test requires more attention, greater learning ability, and better language 
comprehension, as it provides a more specific examination of the episodic memory 
system (closely resembling everyday memory), as well as how language affects the 
memory system (Lezak, Howieson, & Loring, 2004). Therefore, it is reasonable to 
assume that lower education adults have less ability to remember and to describe 
everyday speech than higher education adults (Baek et al., 2011). Nevertheless, in 
FCSRT (Buschke, 1984) the influence of language should be restricted to the semantics 
of words, since it has proved to be independent of education effects (Grober, Lipton, 
Hall, & Crystal, 2000; Lemos et al., 2015).  
Previous studies have showed the high discriminative validity of the FCSRT for 
dementia (Grober et al., 2000; Sánchez-Benavides et al., 2010), its superiority, related 
to LM, to discriminate aMCI from AD (Wagner et al., 2012), and its better predictive 
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value, in comparison to LM, for identifying individuals with memory complaints who 
will develop AD (Derby et al., 2013). 
A weakness of this study is the sample size; ideally these results would be confirmed in 
a larger population. Other limitations of the present study were that it was based in 
standardized scoring and that it focused only on neuropsychological data and other 
biomarkers were not considered.  
In sum, the present study results suggest that the VPAL subtest of the WMS-R does not 
qualify for the distinction of the memory impairment between aMCI and AD patients. 
Although the LM subtest of the WMS-R and the FCSRT proved to be accurate in 
discriminating the two groups, the FCSRT may be preferred as it proved to be 
independent of education effects and can be used in patients of lower and higher 
education thresholds. 
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Abstract 
Memory impairment is often present in frontotemporal dementia (FTD) as a result of 
an inefficient use of learning strategies, sometimes leading to a misdiagnosis of 
Alzheimer’s disease (AD). The Free and Cued Selective Reminding Test (FCSRT) is a 
memory test that controls attention and acquisition, by providing category cues in the 
learning process. The main goal of this study was to show the usefulness of the FCSRT 
in the distinction between behavioral (bv-) FTD and AD. Three matched subgroups of 
participants were considered: bv-FTD (n=32), AD (n=32), and a control group of healthy 
adults (n=32). Results proved that while AD patients exhibited an overall impairment in 
FCSRT, bv-FTD subjects showed to benefit more from the controlled learning through 
category cues. AD patients were 25 times more likely to have an impaired FCSRT. The 
FCSRT has shown its utility in the distinction between bv-FTD and AD, therefore 
increasing the diagnostic accuracy. 
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Introduction 
Memory impairment is one of the most common complaints in the ageing population, 
and one of the most prevalent symptoms in patients with neurological disorders. In 
the field of dementia, a deficit in memory is significant as it may indicate the onset of 
Alzheimer’s disease (AD) or it may pose as a risk factor for the subsequent 
development of AD (Dubois et al., 2007; Geerlings, Jonker, Bouter, Adèr, & Schmand, 
1999). An accurate diagnosis of AD is primarily based on an individual’s performance 
on cognitive tests that are designed to detect memory impairment with high sensitivity 
and specificity (Petersen, Smith, Ivnik, Kokmen, & Tangalos, 1994). Moreover, the 
design of the test is very important as an accurate assessment of memory depends on 
the quality of learning, which is later reflected in an effective retrieval (Buschke, 
Sliwinski, Kuslansky, & Lipton, 1997). However, memory impairment is not necessarily 
evidence of an AD-related memory disorder and can be present in other conditions 
(e.g. Mild Cognitive Impairment, Depression). In patients with AD, the amnestic profile 
is typically characterized by poor learning and rapid memory decay over relatively 
short periods, often concurrent with damage to the mesio-temporal structures, such 
as the hippocampus (Squire, Stark, & Clark, 2004). Though there is some evidence that 
the memory consolidation problems often observed in patients with frontotemporal 
dementia (FTD) may also be linked to hippocampal atrophy (Lindberg et al., 2012; 
Muñoz-Ruiz et al., 2012; van de Pol et al., 2006), memory deficits in FTD are more 
typically reflective of poor organization and lack of efficient learning strategies. Thus, 
this results in a defective encoding of memory leading to an inability to implement 
effective retrieval strategies, due to an involvement of the prefrontal cortex 
(Blumenfeld & Ranganath, 2007). It is of clinical importance that deficits in encoding 
and storage processes that are so characteristic of AD can be distinguished from non-
AD memory deficits that may have a different etiology. The accurate diagnosis of the 
episodic memory deficit, so often observed in AD patients, may be improved upon the 
use of test paradigms that provide information at encoding and retrieval – encoding 
specificity (Buschke et al., 1997). One way of controlling the acquisition and retrieval of 
information is to use the same cues to direct learning and produce effective cued 
recall. The encoding specificity procedure has shown to promote deeper engagement 
198 Chapter I 
 
with attentional and semantic processing in the encoding phase of memory, and it also 
controls the conditions of retrieval (Tulving & Osler, 1968; Tulving & Thomson, 1973). 
Furthermore, memory tests that require the ability to control acquisition and retrieval 
may optimize encoding specificity and thus may be more sensitive to the early signs of 
dementia (Buschke, 1987) than tests that use different paradigms. 
The Free and Cued Selective Reminding Test (FCSRT; Buschke, 1984) is a memory test 
that controls attention and cognitive processing, requiring subjects to search for items 
in response to their category cues, in the learning process. Moreover these same 
category cues are given later to participants in order to elicit the recall of the items not 
retrieved on the free recall trial, thus controlling acquisition and retrieval. Performance 
on the cued recall trial provides an estimate of the items that the subject has stored, 
and it has been shown that this estimate is minimally affected by guessing (Grober, 
Gitlin, Bang, & Buschke, 1992).  
The utility of this cued selective reminding paradigm in the detection of AD-related 
memory dysfunction has been widely reported (Brown & Storandt, 2000; Grober, 
Buschke, Crystal, Bang, & Dresner, 1988; Grober & Buschke, 1987; Grober & Kawas, 
1997; Grober, Hall, Lipton, et al., 2008; Ivanoiu et al., 2005; Vogel, Mortensen, Gade, & 
Waldemar, 2007). A poor performance on the FCSRT has also shown a high correlation 
with atrophy in the medial temporal lobe (Habert et al., 2011; Sánchez-Benavides et 
al., 2010; Sarazin et al., 2010), and was significantly associated with cerebrospinal fluid 
(CSF) biomarkers of AD, thereby supporting the accuracy potential of this paradigm in 
the early detection of AD (Rami et al., 2011; Wagner et al., 2012).  
Furthermore, the potential of the FCSRT being used as a clinical diagnostic tool is 
bolstered by International Working Groups proposal (Dubois et al., 2007, 2010) that it 
could be used to assess memory in patients with suspected AD, given its high 
sensitivity (Grober, Hall, Sanders, & Lipton, 2008; Grober, Sanders, Hall, & Lipton, 
2010). 
FTD is the second most prevalent type of dementia and typically occurs much earlier in 
life than AD, overcoming Lewy Body dementia (Harvey, Skelton-Robinson, & Rossor, 
2003) which is more common later on. The frontal or behavioral variant (bv-FTD) is the 
most common subtype accounting for approximately half of all FTD cases (Johnson et 
al., 2005; H Seelaar et al., 2008). Despite the heterogeneity in its clinical presentation, 
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bv-FTD is characterized by an insidious onset and a progressive decline that is marked 
by personality and/or behavioral changes (McKhann et al., 2001; Neary et al., 1998). 
The cognitive deficits of bv-FTD include impairments on executive function, attention, 
working memory, poor abstraction and difficulty in shifting mental set leading to 
perseverative tendencies (Neary et al., 1998; Weder, Aziz, Wilkins, & Tampi, 2007). It is 
also usually associated with bilateral symmetrical frontal and anterior temporal 
atrophy (Neary et al., 1998; Seelaar, Rohrer, Pijnenburg, Fox, & van Swieten, 2011). 
Research has shown that the specific pattern of impairment of bv-FTD includes a 
relative sparing of memory and visuospatial functions in comparison to executive 
functions which are most commonly affected (Rascovsky et al., 2011). However, since 
impairment in executive functioning can limit effective learning in patients with bv-
FTD, decrements in performance on conventional memory tests may result either from 
primary memory deficits or as a result of executive and attention deficits that hinder 
the use of learning and retrieval strategies (Wang & Miller, 2007). Therefore, the 
memory impaired profiles of patients with bv-FTD and AD may appear similar when 
memory is assessed with tests that place demands on frontal and/or attentional 
processes. In order to distinguish between these cognitive profiles, memory may be 
more accurately assessed with tests that overcome this limitation by controlling for 
attentional and executive processes. Consequently, bv-FTD patients should 
theoretically benefit from controlled learning procedures, like the category cueing 
FCSRT paradigm as this profile of memory impairment seems to be useful in the 
differentiation between bv-FTD and AD patients (Pasquier, Grymonprez, Lebert, & Van 
der Linden, 2001). 
The main goal of this study was to show the utility of the FCSRT in the distinction 
between patients with bv-FTD and patients with AD, which may improve the accuracy 
of the diagnosis. Additionally, we aimed to characterize the memory impairment in 
patients with bv-FTD in comparison with AD patients. Our hypothesis was that the 
proposed cognitive mechanisms underlying these memory deficits would differentiate 
the two pathologies. This would be revealed as bv-FTD patients may benefit more from 
the controlled learning conditions which involves category cueing, than AD patients.  
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Methods 
Participants 
The total sample included 96 subjects divided into 3 subgroups: (i) 32 bv-FTD patients, 
(ii) 32 AD patients, and (iii) 32 cognitively healthy adults. The clinical study sample was 
recruited at the Neurology Department of the Coimbra University Hospital.  
Study eligibility was restricted to patients with a comprehensive clinical, and 
neuropsychological evaluation, with a validated battery for the Portuguese population 
(Guerreiro, 1998), as well as a full investigation using biochemical, structural, and 
functional imaging (magnetic resonance imaging and single photon emission computed 
tomography, and/or positron emission tomography), which are essential to exclude 
other causes of dementia and to establish the clinical diagnosis.  
The bv-FTD group included only patients with a diagnosis of the behavioral variant of 
FTD, established by a multidisciplinary team according to international criteria (Neary 
et al., 1998; Rascovsky et al., 2011). All the individuals who displayed the FTD-related 
Primary Progressive Aphasic syndromes (non-Fluent or semantic dementia) (Gorno-
Tempini et al., 2011) or mixed clinical syndromes were excluded from the study. In 
order to better characterize the study group, all patients with bv-FTD were further 
evaluated using the following instruments: the Montreal Cognitive Assessment 
(Freitas, Simões, Alves, & Santana, 2012), the Frontal Assessment Battery (Dubois, 
Slachevsky, Litvan, & Pillon, 2000), the Maze-Tracing Task (Lezak, Howieson, & Loring, 
2004), the Comprehensive Affect Testing System (Schaffer, Wisniewski, Dahdah, & 
Froming, 2006), the Neuropsychiatric Inventory (Cummings, Mega, Gray, Rosenberg-
Thompson, Carusi, & Gornbein, 1994), and the Frontal Behavior Inventory (Kertesz, 
Nadkami, Davidson, & Thomas, 2000) (data not shown). 
The AD group included patients diagnosed by a multidisciplinary team consensus 
based on international criteria for probable AD [(DSM-IV-TR; American Psychiatric 
Association, 2000); NINCDS-ADRDA; (McKhann et al., 1984, 2011)]. This group was 
recruited to match the patients with bv-FTD by gender, age, education level, and 
severity of cognitive decline (mild forms), as assessed by the Clinical Dementia Rating 
scale (CDR; Garrett et al., 2008; Morris, 1993). Besides the comprehensive 
clinical/neuropsychological standard evaluation, AD patients underwent the following 
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specific investigation: the Montreal Cognitive Assessment (Freitas et al., 2012), and the 
Alzheimer Disease Assessment Scale (Guerreiro, Fonseca, Barreto, & Garcia, 2008; 
Mohs, Rosen, & Davis, 1983). 
The following patient exclusion criteria were established at the outset of the study: an 
unstable clinical condition, with significant comorbidities; high severity dementia (only 
patients with CDR≤1 and Mini-Mental State Examination (MMSE; Folstein, Folstein, & 
McHugh, 1975; Guerreiro, Silva, et al., 2008) ≥15 points were included in the study); 
recent pharmacotherapy changes; recent psychiatric comorbidity (clinically diagnosed 
within 6 months prior to the current neuropsychological evaluation); and significant 
motor, visual or auditory deficits, all of which may influence the cognitive assessment. 
The control group comprised 32 cognitively healthy adults belonging to the local 
community (recruited among the patients’ spouses, hospital or university staff, or their 
relatives), that were age, education, and gender matched to the patients. They had no 
history of neurological or psychiatric relevant condition, including alcohol or drugs 
abuse or head trauma, and no significant motor, visual or auditory deficits which could 
influence the neuropsychological performance. All control subjects were assessed 
using the following instruments: a complete sociodemographic questionnaire; an 
inventory of current clinical health status, past habits and medical history; the MMSE; 
the CDR; and the Geriatric Depression Scale (GDS-30; Barreto, Leuschner, Santos, & 
Sobral, 2008; Yesavage et al., 1982). All control subjects had normal MMSE scores 
(mean 29.06); were fully autonomous, according to the information obtained through 
a general practitioner and/or an informant; and had no Depression (depressive 
complaints were evaluated through a clinical interview and the GDS-30, and subjects 
with a score of 20 or more points were excluded). 
The study was conducted in accordance with the tenets of the Declaration of Helsinki, 
with the approval of our local ethics committee. After obtaining an Informed consent, 
all the participants, were submitted to the same experimental research protocol.  
Demographic and clinical characteristics of the population are shown in Table 7.1. 
Procedure 
Subjects were assessed using the Portuguese version of the FCSRT (Lemos, Martins, 
Simões, & Santana, 2012). Materials and instructions of the FCSRT were provided by 
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the original author (Buschke’s FCSRT. Copyright, 2002. Albert Einstein College of 
Medicine of Yeshiva University, New York). The FCSRT (Buschke, 1984; Grober & 
Buschke, 1987) is a multi-trial memory test that uses a “selective reminding” paradigm 
by presenting only the words not recalled, instead of all the to-be-remembered words, 
thus directing the subject's attention to the words not recalled on the previous trial.  
The test starts by asking subjects to identify words or pictures in response to a unique 
category cue. The 16 items to be learned are presented four at a time on a card, 
distributed by one word per quadrant. The subject is asked to search each card and 
point to and name aloud each item after its semantic cue was aurally presented. 
During this procedure, the subject is informed to learn the 16 words. There are three 
recall trials, each preceded by 20 seconds of counting backward to prevent recall from 
short-term memory. Each recall trial consisted of two parts. First, each subject had up 
to two minutes to freely recall as many items as possible. Next, aurally presented 
category cues were provided for items not retrieved by free immediate recall (Free IR). 
If subjects failed to retrieve the item with the category cue, they were reminded by 
presenting the cue and the item together (Cued IR). The sum of free and cued recall 
gives a measure of total immediate recall (Total IR). The same procedure of recalling 
(freely and cued) is done after a 30 minute interval, during which subjects are required 
to perform non-verbal tasks (Delayed Recall – DR), allowing the measure of the Free 
DR, Cued DR, Total DR). A percentage of retention was also computed, by comparing 
the total number of items recalled freely and on delayed recall to the total of items 
(free and cued) recalled on the third learning trial.  
Besides the FCSRT, other neuropsychological tests were performed in order to attain 
other cognitive functions and evaluate the different performance between the two 
pathological groups: the Digit Span (Forward and Backward recall versions) of the 
WAIS-III (Wechsler, 2008) to assess immediate and working memory; the Trail Making 
Test (A and B) (Partington & Leiter, 1949) to measure speed of attention, working 
memory, sequencing and mental flexibility; the semantic verbal fluency task to 
evaluate the spontaneous production of words (food and animals) (Garcia, 1984); and 
the Brief Visuospatial Memory Test-Revised (BVMT- R; Benedict, 1997) as a measure of 
both visuospatial ability (copy) and visual memory (immediate and delayed recalls, 
learning and retention). 
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Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 19.0) (IBM SPSS, Inc., Chicago, IL). When data significantly deviated from 
normal distributions (verified using the Shapiro-Wilk normality check and Levene 
homogeneity tests) we did therefore choose to apply non-parametric statistical 
methods. Results with p<.05 were considered statistically significant. Descriptive 
statistics were used for sample’s characterization; comparisons between means were 
performed with the use of the general linear model [one-way analysis of variance 
(ANOVA)] with post-hoc Tukey for multiple comparisons or the Kruskal-Wallis one-way 
ANOVA for k samples with pairwise comparisons with adjusted p value. The χ2 test was 
used for comparisons between categorical variables. Cronbach’s alpha reliability 
coefficient was considered as an index of internal consistency, and analyzed separately 
for the immediate and delayed recalls. Non-parametric Wilcoxon test was used to 
compare the performance between the learning trials among each group. 
A logistic regression model was fit to the data with impairment on both total 
immediate and total delayed recalls of the FCSRT as the outcome, and dementia 
subtype was a significant predictor in order to determine the sensitivity and the 
specificity of the FCSRT measures for distinguishing AD from bv-FTD.  
 
Results 
Sample characterization 
Demographical and clinical characteristics of the population are shown in Table 7.1. No 
statistically significant differences were found on age [F(2,93) = .280, p = .756], 
educational level (χ2KW (2) =.115, p =.944), or gender [χ
2 (2) = 2.248, p = .325] between 
the three groups.  
As expected, a significant effect was found for the MMSE performance (χ2KW (2) 
=58.427, p =.000) among the three groups. Therefore, multiple comparisons revealed 
that both bv-FTD (p =.05) and AD (p <.001) performed poorly on the MMSE, when 
compared to control subjects and AD patients had a worst performance, when 
compared to bv-FTD subjects (p <.001).  
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Table 7.1. Demographical and clinical characteristics of the population 
Abbreviations: bv-FTD – behavioral frontotemporal dementia; AD – Alzheimer’s disease; MMSE – Mini-Mental State Examination; 
CDR – Clinical Dementia Rating 
Note: Data are expressed as mean (SEM).  
Comparisons between Controls- bv-FTD, Controls-AD and bv-FTD-AD patients were carried out by a one-way ANOVA with post-hoc 
Tukey tests, Kruskal-Wallis 1-way ANOVA for k samples with pairwise comparisons, or χ2 test, where: 
*Controls vs. bv-FTD: p <.05; Controls vs. AD: p <.001;  
† bv-FTD vs. AD: p <.001. 
 
Preliminary tests 
Concerning the performance on the preliminary neuropsychological tests, main effects 
were found in all of them, except for the Forward Digit Span. The multiple comparison 
analysis showed that AD patients were impaired in all other measures, whereas the bv-
FTD group performed significantly worse than controls on the Trail Making Test (p 
<.05), Verbal Fluencies (p <.05), BVMT recalls and learning (p <.001). Still, bv-FTD 
patients did not differ significantly from controls on the Backward Digit Span, BVMT-R 
copy and retention. The two clinical groups had a similar performance on the 
Backward Digit Span, Verbal Fluency (food) and BVMT-R learning (for details see Table 
7.2). 
Psychometric properties – internal consistency reliability of the FCSRT 
Internal consistency reliability of the FCSRT was estimated using Cronbach’s alpha. 
Within this analysis the Cronbach’s alpha of the FCSRT as an index of internal 
consistency was .914 for the IR and .852 for the DR on the total study sample, 
confirming an overall good reliability of the test scores. This reliability coefficient was 
also computed for each clinical group [α (bv-FTD): IR = .813; DR = .667 and α (AD): IR = 
.799; DR = .862]. 
 
 
 
 Control subjects 
(n=32) 
bv-FTD 
(n=32) 
AD 
(n=32) 
Gender (m:f) 22:10 22:10 17:15 
Age (years) 68.59 (1.27) 68.56 (1.19) 69.72 (1.27) 
Education Level (years) 7.06 (0.86) 6.97 (0.84) 6.91 (0.87) 
MMSE (score) 29.06 (0.20) 26.88 (0.43)* 21.22 (0.70)*/† 
CDR (score) 0 (0) 1 (0) 1 (0) 
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Table 7.2 Performance on the preliminary tests 
 Controls 
(n=32) 
bv-FTD 
(n=32) 
AD 
(n=32) 
χ2KW p value 
Digit Span (Forward) 6.78 (0.32) 6.09 (0.35) 5.91 (0.32) 4.366 NS 
Digit Span (Backward) 4.19 (0.36) 3.16 (0.32) 2.84 (0.24) 7.804 =.02* 
Trail Making Test A 
(time/sec.) 
89.03 (7.48) 143.78 (16.18) 198.75 (14.50) 26.937 <.001** 
Trail Making Test B 
(time/sec.) 
213.81 (20.86) 374.34 (34.22) 544.97 (19.57) 41.723 <.001** 
Verbal Fluency (food) 15.59 (0.82) 11.84 (0.73) 9.47 (0.58) 26.893 <.001# 
Verbal Fluency 
(animals) 
13.81 (0.88) 9.59 (0.75) 7.06 (0.51) 34.712 <.001** 
BVMT-R Copy 11.66 (0.12) 11.13 (0.40) 9.44 (0.65) 12.603 =.002† 
BVMT-R Total IR 16.53 (1.34) 7.06 (1.14) 2.91 (0.48) 51.011 <.001§ 
BVMT-R Learning 4.00 (0.42) 1.63 (0.30) 0.72 (0.21) 33.226 <.001‡ 
BVMT-R Total DR 7.00 (0.57) 3.03 (0.56) 0.38 (0.16) 57.924 <.001¥ 
BVMT-R Retention (%) 90.50 (2.72) 63.44 (7.42) 14.41 (5.13) 42.339 <.001†† 
Abbreviations: bv-FTD – behavioral frontotemporal dementia; AD – Alzheimer’s disease; BVMT-R – Brief Visuospatial Memory 
Test-Revised; IR – Immediate Recall; DR – Delayed Recall 
Note: Data are expressed as mean (SEM).  
Comparisons between Controls- bv-FTD, Controls-AD and bv-FTD-AD patients were carried out by a Kruskal-Wallis 1-way ANOVA 
for k samples with pairwise comparisons, where: 
* Controls vs. AD: p < .05. 
**Controls vs. bv-FTD: p <.05; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.05. 
# Controls vs. bv-FTD: p <.05; Controls vs. AD: p <.001; bv-FTD vs. AD: NS. 
† Controls vs. bv-FTD: NS; Controls vs. AD: p <.05; bv-FTD vs. AD: p <.05. 
§ Controls vs. bv-FTD: p <.001; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.05. 
‡ Controls vs. bv-FTD: p <.001; Controls vs. AD: p <.001; bv-FTD vs. AD: NS. 
¥ Controls vs. bv-FTD: p <.001; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.001. 
†† Controls vs. bv-FTD: NS; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.001. 
NS = not significant (p > .05). 
 
 
Group differences (FCSRT) 
When analyzing the performance on the FCSRT selected measures (free, cued, total 
recalls, and retention), the bv-FTD and the AD groups were impaired relative to 
controls on the free and total recalls (p<.001); nevertheless, only the AD group was 
impaired on the two cued recalls (p<.001) and on the percentage of retention (p<.05). 
There was also a significant difference between the bv-FTD and AD patients in all the 
FCSRT selected measures (Table 7.3).  
 
206 Chapter I 
 
Table 7.3 Performance on the FCSRT 
Abbreviations: bv-FTD – behavioral frontotemporal dementia; AD – Alzheimer’s disease; FCSRT – Free and Cued Selective 
Reminding Test; IR – Immediate Recall; DR – Delayed Recall. 
Note: Data are expressed as mean (SEM).  
Comparisons between Controls- bv-FTD, Controls-AD and bv-FTD-AD patients were carried out by the Kruskal-Wallis 1-way ANOVA 
for k samples with pairwise comparisons, where: 
*Controls vs. bv-FTD: p <.05; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.001. 
† Controls vs. bv-FTD: NS; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.05. 
§ Controls vs. bv-FTD: p <.001; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.001. 
‡ Controls vs. bv-FTD: p <.001; Controls vs. AD: p <.001; bv-FTD vs. AD: p <.05. 
†† Controls vs. bv-FTD: NS; Controls vs. AD: p <.05; bv- FTD vs. AD: p <.05. 
NS = not significant (p >.05). 
 
The learning slopes (along the three trials) among the three groups are shown in Figure 
7.1. Comparing the performance between the learning trials among each group, 
results showed a significant improvement on free recall, on both clinical groups, 
between trials 2 and 3 (bv-FTD: Z=-3.137; p=.002; AD: Z=-2.449; p<.05), but not 
between trials 1 and 2 (p>.05). The control group revealed an improvement between 
the three trials (Trials 2-1: Z=-3.704; p<.001; Trials 3-2: Z=-4.131; p<.001). In order to 
analyze the impact of cueing, the same comparisons were done for the total (free + 
cued) recalls along the three learning trials. Whereas the bv-FTD (Trials 2-1: Z=-3.423; 
p=.001; Trials 3-2: Z=-3.408; p=.001) and the control (Trials 2-1: Z=-4.610; p<.001; Trials 
3-2: Z=-3.779; p<.001) groups showed a significant improvement between the three 
trials, the AD group only benefited from cueing between the third and second trials 
(Trials 2-1: Z=-.558; p>.05; Trials 3-2: Z=-3.567; p<.001).  
 Controls 
(n=32) 
bv-FTD 
(n=32) 
AD 
(n=32) 
χ2KW p value 
FCSRT Free IR 21.84 (0.92) 12.94 (1.16) 3.41 (0.67) 64.157 <.001* 
FCSRT Cued IR 17.41 (0.59) 13.63 (1.18) 7.72 (1.11) 28.902 <.001† 
FCSRT Total IR 39.25 (0.94) 26.56 (2.18) 11.13 (1.61) 55.752 <.001* 
FCSRT Free DR 8.72 (0.35) 4.28 (0.49) 0.72 (0.34) 65.618 <.001§ 
FCSRT Cued DR 5.34 (0.30) 4.09 (0.42) 2.03 (0.34) 29.242 <.001† 
FCSRT Total DR 14.06 (0.30) 8.38 (0.77) 2.75 (0.55) 62.742 <.001‡ 
FCSRT Retention (%)  -36.72 (1.98) -37.11 (2.92) -23.24 (2.95) 14.835 =.001†† 
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Figure 7.1. Free, cued and total recalls (mean) in the FCSRT along the first, second and third 
learning trials. 
Abbreviations: bv-FTD – behavioral frontotemporal dementia; AD – Alzheimer’s disease. 
 
Established cut-off scores (Lemos, Simões, Santiago, & Santana, 2015) for AD were 
used to determine the sensitivity and the specificity of the total immediate and total 
delayed recalls of the FCSRT for patients with AD versus bv-FTD. A logistic regression 
model was fit to the data; impairment on both total immediate and total delayed 
recalls of the FCSRT were used as the outcome; dementia subtype was a significant 
predictor in order to determine the sensitivity and the specificity of the FCSRT 
measures for distinguishing AD from bv-FTD (𝐵𝐷𝑒𝑚𝑒𝑛𝑡𝑖𝑎 𝑆𝑢𝑏𝑡𝑦𝑝𝑒 = 3.219;  𝑋𝑤𝑎𝑙𝑑
2 (1) =
15.542;  𝑝 < .001; 𝑂𝑅 =  25.000). The model showed an accuracy of 78.1% against a 
baseline value of 54.8% (i.e. when the classification is performed randomly) in the 
subjects’ classification, with a specificity of 71.4%, and a sensitivity of 90.9%. Sixty-
three percent (20/32) patients with bv-FTD had an intact FCSRT, whereas only six 
percent (2/32) of AD patients scored normally. Patients with AD were 25 times more 
likely to have impaired FCSRT than patients with bv-FTD. 
 
Discussion 
The main objective of this study was to show the utility of the FCSRT in distinguishing 
bv-FTD from AD patients. Furthermore, we aimed to contribute to the characterization 
of the memory impairment observed in patients with bv-FTD in comparison with AD 
patients.  
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The FCSRT showed an overall good reliability with high indexes of internal consistency 
for the immediate recall and for the delayed recall trials, in this sample of Portuguese 
participants. 
Moreover, the FCSRT showed an accuracy of 78.1%, with 71.4% of specificity and 
90.9% of sensitivity, allowing us to identify ninety-four percent of patients with AD and 
discard sixty-three percent of patients with bv-FTD, indicating that an impaired FCSRT 
performance emphasizes the significance of episodic memory deficits in patients with 
AD. Patients with AD were 25 times more likely to have impaired FCSRT performances 
than patients with bv-FTD.  
Another aim of this study was to compare the pattern of memory impairment on 
FCSRT in patients with bv-FTD and AD. We observed that both groups were relatively 
impaired to the control group on the free and total (immediate and delayed) recalls 
trials. Furthermore, only the AD group showed impairment on the cued recall trial and 
on the percentage of items retained. Our initial hypothesis was that the mechanisms 
underlying the memory deficits observed in these groups would differentiate the two 
pathologies, as bv-FTD patients may benefit more from the controlled learning with 
the use of category cues, than AD patients. Our results confirmed that, although bv-
FTD patients were impaired on the total recall trials, cueing was more efficient for 
patients with bv-FTD than AD. In addition, bv-FTD patients showed an impaired 
delayed recall but their ability to retain information was spared, i.e., when delayed 
recall performance was compared to performance on the third learning trial.  
The slopes of the groups’ performances were compared on free recall of the three 
learning trials. Our results showed that the control group performance improved 
incrementally over the three trials while both the clinical groups’ improvement was 
restricted to just the second and third trials. The impact of cueing resulted, overall in a 
significant improvement over the three trials for both the bv-FTD and control groups. 
However, this effect was only observed between the second and third trials in the AD 
group. These results showed a pattern of impairment for the AD group independently 
of the recall (free or total); whereas the bv-FTD group appeared to benefit from cueing 
which was reflected in a marked improvement in the performance on the total recall 
trial. The concept of cueing, inherent in the design of the FCSRT, requires subjects to 
search for items in response to already given category cues in the learning process, 
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controlling for both attention and cognitive processing. This method of cueing showed 
an improvement of the retrieval ability in bv-FTD patients, which has not been 
observed with tests that employ other methods of cueing (Glosser, Gallo, Clark, & 
Grossman, 2002). It has been reported that learning and memory ability are based on 
the integrity of the temporal and frontal lobe regions of the brain. These are regions 
which may play different roles depending on the task demands and test 
characteristics. Much evidence suggests that basic learning and retrieval aspects of 
memory are supported by the medial temporal lobe. Specifically, it is well documented 
that the hippocampus plays a significant role in the formation and memorization of 
associations between novel non-related items (Squire, 1992). On the other hand, the 
frontal lobes have also been shown to be implicated in learning and memory 
processes, contributing to efficient working memory, conditional learning, and 
encoding strategies (Cummings & Miller, 2007). The FCSRT is a memory test that 
controls for attention and executive processing, by introducing category cues during 
the learning process. Additionally, the same cues are used to elicit recall of the items 
not retrieved on the free recall trial, and thereby control acquisition and retrieval. 
Our study demonstrated memory impairment in patients within the early stages of bv-
FTD. This is common in the early stages of the disease, sometimes leading to a 
misdiagnosis of AD (Wittenberg et al., 2008). In the FCSRT, free and cued recalls were 
poorer in bv-FTD patients than in controls, and free recall was as poorer in bv-FTD 
patients than in AD patients, which is consistent with the findings reported by Pasquier 
et al. (2001). Providing a semantic cue to bv-FTD patients showed a significant increase 
in recall performance, suggesting that there may be impairment in retrieval processes 
when encoding processes are controlled for. The rates of forgetting did not differ 
between bv-FTD patients and control subjects, which was assessed by comparing the 
retention percentages of the two groups, indicating that the bv-FTD group had a 
relatively intact storage processes. In sum, poor free and total recall performance 
rates, both in learning and after a delay, were observed in both dementia groups; low 
scores in cued recalls, and a lower rate of retention were representative of AD, while 
an improvement with category cueing and spared retained items were suggestive of 
bv-FTD. The design characteristics of memory test paradigms may account for the 
distinct pattern of performance of patients with different types of dementia. Regular 
210 Chapter I 
 
word list tests demand a reproduction of a list of unrelated words, thus requiring an 
active effort to organize information at both encoding and retrieval, however, tests 
with semantically organized material (such as story recall tests or the FCSRT) allow for 
more passive learning and implementation of less demanding retrieval strategies 
(Perri, Fadda, Caltagirone, & Carlesimo, 2013). Therefore, while AD patients are 
expected to be impaired on both paradigms, bv-FTD patients are more likely to have 
deficits on regular word list tests than tests which require the participant to organize 
semantic information (Pasquier et al., 2001; Perri et al., 2013), which is consistent with 
the findings from the present study. Concerning the performance on the 
neuropsychological tests that measure other cognitive functions, the bv-FTD group 
showed impairment on attention, working memory, and spontaneous production of 
words, and spared visuospatial ability and retention. These findings are congruent with 
the brain structures reported to be implicated in these abilities and often 
compromised in this disease. Comparison of the two clinical groups revealed that, 
although bv-FTD patients had better results than AD’s on most neuropsychological 
measures, the two samples had similar performances on the Backward Digit Span, 
Verbal Fluency (food) and BVMT-R learning tasks. A general pattern of impairment for 
both bv-FTD and AD patients in the executive domain has already been reported by 
several authors, confirming that there was no difference of performances between 
these two groups (Gregory, Orrell, Sahakian, & Hodges, 1997; Hodges et al., 1999; 
Walker, Meares, Sachdev, & Brodaty, 2005). These findings reinforce the idea that 
executive functions, although expected to be impaired in cases of frontal lobe damage, 
should not be the only focus of attention in the differential diagnosis between AD and 
bv-FTD (Giovagnoli, Erbetta, Reati, & Bugiani, 2008). Nevertheless, executive measures 
that rely on both frontal (compromised in bv-FTD) and parietal (compromised in AD) 
regions comprise a similar pattern of performance in both disease groups. Thus 
frontally specific executive measures are expected to inform the diagnosis of bv-FTD 
and therefore, should be selected (Possin et al., 2013). Moreover, in our study, the 
main pattern of dissociation between bv-FTD and AD was the impairment of parieto-
occipital related functions which seems to be exclusive to AD. Furthermore, 
information regarding aspects of social cognition including personality and/or 
behavioral disorders was taken into consideration during the diagnosis of bv-FTD.  
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An accurate differential diagnosis between AD and bv-FTD is of crucial importance. 
Given that FTD is the second cause of primary degenerative dementia and has 
overlapping symptoms with AD, a misdiagnosis can occur. Deficits in memory are 
common in FTD patients and may be overlooked due to a greater prominence of 
behavioral and/or personality disturbances. For these reasons, it is more informative 
to use memory tests that control for the learning deficit often observed in FTD patients 
so as to elicit the retrieval of stored information. This may aid to isolate the memory 
deficit more typical in AD patients and thereby increase the accuracy of a diagnosis. 
The FCSRT has shown these potentialities in the present study. However, future 
research would benefit by including other types of dementias in order to confirm the 
accuracy values of the FCSRT in informing a diagnosis for AD.  
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The goal of this discussion is to briefly analyse the main results achieved during the 
FCSRT’s work plan that was previously presented in the respective research papers 
(either published, or submitted for publication). We organized and divided this 
discussion chapter into the following topics: Description of Chapter I (Transcultural 
adaptation, Psychometric validity and Clinical validity of the FCSRT); Highlights and 
limitations of these studies; Future outlook; and Conclusions. 
 
Description of Chapter I 
The general purpose of this chapter was to explore, in a clinical perspective, the 
properties and validity of the FCSRT on a memory clinic basis for the AD spectrum early 
diagnosis, in Portugal. Our scientifical purpose was to contribute to the hot topic 
discussion concerning new proposals for the early diagnosis of AD (Dubois et al., 2007, 
Dubois et al.,2014 Albert et al.,2011). Our investigation was initiated soon after the 
publication of the IWG-1 framework criteria for AD (Dubois et al., 2007), which 
specifically suggest the use of cued recall measures, based on encoding specificity to 
assess the memory impairment of AD spectrum disorders, such as the FCSRT (Buschke, 
1984; Grober & Buschke, 1987).  
After the FCSRT transcultural adaptation process, we started a validation set of studies 
that tried to cover both psychometric and clinical validity in a memory clinic basis. 
According to the defined initial objectives we were especially interested in AD 
spectrum disorders (MCI and mild AD). A longitudinal study, i.e., prediction of 
conversion to AD, supported our baseline results regarding the FCSRT utility. We also 
included a group of behavioural variant of frontotemporal dementia (bv-FTD) patients 
with the purpose of isolating the amnestic syndrome of the hippocampal type as 
representative of typical-AD. All these points are in line, and corroborate, the 
arguments of the IWG-1 (Dubois et al., 2007) in favour of the use of the FCSRT in the 
objective assessment of memory in AD spectrum disorders. 
By adapting and validating the FCSRT, we also contributed to the increase of 
Portuguese-adapted neuropsychological instruments’ availability (in general) and to 
present a different paradigm of verbal memory evaluation (in particular). 
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Some of the studies reported here were not defined initially, but were projected 
during the progress of this work plan in order to respond to questions that have arisen 
in the meantime and to enrich and corroborate the achieved results. This argument 
applies to Studies 6 (Lemos, Cunha, et al., 2014), 5 (Lemos, Afonso, et al., 2015) and 3 
(Lemos, Marôco, et al., 2015). In Study 6 (Lemos, Cunha, et al., 2014), we took 
advantage of the data acquired during the regular neuropsychological assessment 
through the use of the Battery of Lisbon for the Assessment of Dementia (BLAD; 
Guerreiro, 1998) that includes the Logical Memory (LM) and Verbal Paired Associative 
Learning (VPAL) subtests from the Wechsler Memory Scale (WMS). This 
comprehensive neuropsychological battery is used to characterize the cognitive profile 
of patients and therefore helps to reach a differential diagnosis. Study 5 (Lemos, 
Afonso, et al., 2015) was developed taking advantage of a masters’ Psychology student 
work plan. As such, the patients included in that project, that have performed the SRT 
(Afonso, 2010), were further assessed with the FCSRT. We designed this study in line 
with the previous work of Grober, Merling, Heimlich, and Lipton, (1997) that compared 
the performance on both the Selective Reminding Test (SRT) and the FCSRT in healthy 
aging, but adjusted it to pathological aging by means of discrimination between aMCI 
and AD patients. Study 3 (Lemos, Marôco, et al., 2015) was designed after Study 2 
(Lemos, Simões, et al., 2014) but both comprise the same samples. The need for 
assessing the construct related validity of the FCSRT in the AD spectrum disorders has 
arisen after the publication of Study 2 (Lemos, Simões, et al., 2014), but it is our 
understanding that the two studies could have been developed together and 
converged in a complete construct and diagnostic validities study of the memory 
assessment of AD spectrum disorders throughout the use of the FCSRT. 
Transcultural Adaptation 
We started by adapting the FCSRT to the Portuguese population, as decribed in Study 1 
(Lemos, Martins, Simões, & Santana, 2012), taking into account linguistic and cultural 
adequacy criteria. The principle required by the FCSRT authors (Buschke, 1984; Grober 
& Buschke, 1987) was followed, i.e., intermediate frequency words were selected 
within a semantic category present in the original version instead of a simple 
translation from English to Portuguese words. The semantic categories were selected 
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from a total of sixteen available in the original version. The other criteria used in the 
selection of words/items derived from linguistic characteristics of Portuguese 
language.  
Moreover, we took into consideration the International Test Commission (ITC) 
guidelines for translating and adapting tests, specifically the test development and 
adaptation recommendation that insures that “the adaptation process takes full 
account of linguistic and cultural differences among the populations for whom adapted 
versions of the test or instrument are intended” (International Test Comission, 2005, p. 
7). Whenever applicable, the Portuguese version sought to respect the equivalence to 
the FCSRT’s original version, according to the model of Herdman, Fox-Rushby, and 
Badia (1998).  
The FCSRT adaption constituted the first step of the present work plan, therefore 
essential to the following validity studies and accurate interpretation of its related 
results. 
Psychometric Validity of the FCSRT 
A complete analysis, in terms of the psychometric properties of an instrument, is a 
valuable advantage that results in an important contribution to outline a more 
systematic and comprehensive neuropsychological evaluation. This project includes 
studies of the psychometric properties: internal consistency, concurrent and construct 
validities.  
In the case of the FCSRT, information on the psychometric properties of its paradigm is 
scarce in the literature and limited to the modified Grober-Buschke (GB) procedure 
(Grober, Ocepek-Welikson, & Teresi, 2009). The GB modified version differs from the 
FCSRT as it includes an immediate cued recall during the learning phase after the 
identification of a group of four items that are very often pictures rather than words. 
Internal consistency: Cronbach’s alpha coefficient was considered as an index of 
FCSRT’s reliability and was analysed on both the immediate (IR) and delayed (DR) 
recalls. Results showed an overall good reliability of the test among all the studied 
samples, with values of 0.915 for the IR and 0.879 for the DR on the AD spectrum 
validation study (Study 2; n=271: 100 aMCI subjects, 70 AD patients and 101 control 
elders; Lemos, Simões, Santiago, & Santana, 2014) and 0.914 for the IR and 0.852 for 
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the DR on the FDT/AD comparison research (Study 7; n=96: 32 FTD subjects, 32 AD 
patients and 32 matched controls; Lemos, Duro, Simões, & Santana, 2014). Moreover, 
in Study 6 (n=128: 85 aMCI subjects, and 43 AD patients; Lemos, Cunha, et al., 2014) 
we found an overall good reliability of the FCSRT (IR: 0.896; DR: 0.873), and the WMS 
subtests [LM (IR: 0.840; DR: 0.851), VPAL (0.867)], for the total sample. In Study 5 
(n=38: 20 aMCI subjects, and 18 AD patients; Lemos et al., 2015) similar good 
reliabilities were found both on the FCSRT (IR: 0.926; DR: 0.881) and the SRT (IR: 0.929; 
DR: 0.802). Our FCSRT results are comparable to the good reliability coefficients 
reported by Grober et al. (2009) for the GB version (Cronbach’s alpha ranging from 
0.85 to 0.88) on all the three available forms among patients from a geriatric centre. 
Concurrent validity: Modest positively significant correlations were verified among the 
FCSRT and other verbal memory tests, such as the SRT (IR: r = .638; DR: r = .665) (Study 
5; n=38: 20 aMCI subjects, and 18 AD patients; Lemos et al., 2015) and both the LM (IR: 
r =.605; DR: r =.677) and VPAL (r =.575) subtests of the WMS (Study 6; n=128: 85 aMCI 
subjects, and 43 AD patients; Lemos, Cunha, et al., 2014). While AD patients revealed a 
significant pattern of worse impairment than aMCI on all tests, the FCSRT showed a 
higher accuracy in discriminating the two groups and was less influenced by the 
educational level. Furthermore, Zimmerman et al. (2015) reported a modest 
association (r=0.36) between the FCSRT free recall and the WMS LM I subtest among 
healthy elders. 
Construct validity is an important concept that relates to the importance of validating a 
psychometric test for use in a particular clinical population (American Educational 
Research Association, American Psychological Association, 1999). The goal is to 
guarantee that the psychological instrument is accurately evaluating the underlying 
dimension(s), rather than something different, in the clinical population in which it is 
being used (Maroof, 2012). In the study of Grober et al. (2009), the factor analysis 
indicated a single construct or dimension, on the three GB test forms, which the 
authors presume to be memory ability. The modified GB version comprises only a free 
recall from the test (learning) phase and does not include a delayed measure. Since we 
used the FCSRT regular version that comprises both IR and DR, we decided to test two 
models using confirmatory factor analysis (CFA) to provide further evidence of FCSRT’s 
construct related validity: a one-factor structure based on the model proposed by 
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Grober et al. (2009) that accounts for the unidimensionality of memory ability; and a 
two-factor model, considering the two factors - learning (total recall) and retention 
(DR) (Study 3; n=271: 100 aMCI subjects, 70 AD patients and 101 control elders; 
Lemos, Marôco, Simões, & Santana, 2015). Our results indicated that both models 
revealed similar adequate fit values; still, the appropriated convergent validity and the 
lack of discriminant validity supported the two-factors as measuring the same 
construct – memory ability). 
As an exception, the inter-rater reliability is not comprised in our studies because the 
FCSRT has a dichotomous scoring, i.e. recalled word=1 and missed word=0; therefore 
this property does not apply for this particular test. Even though we have not analysed 
the test-retest reliability in our longitudinal study (Study 4; Lemos et al., 2015), 
Zimmerman et al. (2015) reported good values of test-retest reliability for the FCSRT 
(free recall – 0.80; total recall – 0.83) on two visits in a randomised counterbalanced 
design study, among healthy elders. 
In sum, the possibility of a complete analysis along with the psychometric properties of 
an instrument is a valuable advantage that results in an important contribution to 
outline a more systematic and comprehensive neuropsychological evaluation. 
Clinical Validity of the FCSRT 
According to the ITC, another essential guideline that should be provided by the test 
developers when adaptating psychological tests, is related to “information on the 
evaluation of validity in all target populations for whom the adapted versions are 
intended” (International Test Comission, 2005, p. 7). Moreover, valid and accurate 
neuropsychological tests must show good diagnostic classification properties which 
means, in terms of memory, that a significant impairment in neuropsychological 
testing is essential to the diagnosis of both aMCI and AD (Dubois et al., 2007, 2014; 
Portet et al., 2006).  
Having this notion in mind, and also the importance that the FCSRT represents to the 
IWG-1 and the IWG-2, we started by validating the FCSRT for aMCI and AD through the 
analysis of the diagnostic accuracy and the suggestion of its cut-off scores (Study 2: 
Lemos, Simões, Santiago, & Santana, 2014; and Study 3: Lemos, Marôco, et al., 2015). 
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Concerning our samples’ general cognitive profile, the brief cognitive evaluation (Mini-
Mental State Examination) revealed a poor performance of patients, when compared 
to control subjects, and also showed a worse pattern of impairment of AD patients in 
comparison to aMCI. More importantly, the performance on the FCSRT was able not 
only to distinguish the clinical groups from the control group, but also to separate the 
degree of impairment between the pathological samples. The AD group was 
significantly worse when compared to the aMCI sample. This gradual pattern of 
impairment among normal ageing, MCI, and AD has already been reported (Boeve et 
al., 2003; Petersen, 2004; Petersen et al., 1999), and supported by Saka, Mihci, 
Topcuoglu, and Balkan (2006) that found enhanced cued recall paradigms to highly and 
moderately discriminate AD and MCI from controls, respectively. 
Study 2 (Lemos, Simões, Santiago, & Santana, 2014) enabled the analysis of the impact 
of the FCSRT measures (free, cued, and total) among the two recalls (IR and DR) on the 
likelihood of having aMCI or AD, where significant effects were found for the two total 
recall trials. Total recall, which is the sum of the free and the cued recalls, reflects the 
amount of information that is stored spontaneously and facilitated by the subject. 
Accordingly, the cut-off scores were set at ≤35 for total IR and ≤12 for total DR, in the 
aMCI group, and at ≤27 for total IR and ≤8 for total DR in the AD group. Moreover, the 
DR measure showed to be more sensitive, although the IR presented a higher value of 
specificity, showing the importance of having a delayed measure to account for the 
milder forms of cognitive decline (Ivanoiu et al., 2005) such as MCI. In Study 3 (Lemos, 
Marôco, et al., 2015), the unidimensional construct of the FCSRT enabled us to add a 
global score for FCSRT (summation of the two recalls). Thus, this total recall (TR) was 
the predictor with higher accuracy (68.3%) in the classification among the three groups 
(controls, aMCI, and AD), followed by the IR (67.9%), and the DR (65.7%). Nonetheless 
the similar results in accuracy among all the recalls, we believe that the outcomes from 
the two-factor model construct validity of the FCSRT allow to additionally support the 
importance of including both total (learning) and delayed (retention) recalls. The 
immediate recall provides qualitative and quantitative information regarding learning, 
while the delayed recall report memory consolidation/retention that is particularly 
sensitive to the hippocampal dysfunction present in AD spectrum disorders. In fact, 
both learning and retention correspond to the process of memory functioning. This 
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shows the significance of a delayed recall to comprise the milder forms of cognitive 
decline (Albert et al., 2011; Grober & Kawas, 1997; Ivanoiu et al., 2005; Sánchez-
Benavides et al., 2014) such as aMCI, and avoid the inclusion of false negatives that can 
happen when learning is the only memory measure tested. According to Salmon 
(2000), clinically, measures of the ability to learn and retain new information are quite 
useful in differentiating between healthy aging elders and AD patients, and delayed 
recall trials revealed to be more effective than measures of learning across trials. As 
such, in Study 3 we suggested a new possibility in terms of using the FCSRT in AD 
spectrum disorders. According to our results, the FCSRT recalls may be used and 
reported: i) independently (for a qualitative approach of the retained material), ii) as a 
composed result/global value (for a more simple way of reporting the result), or iii) as 
a single unit (in order to reduce patients’ fatigue, or on follow-up evaluations).  
As the IWG-1 criteria (Dubois et al., 2007) aimed to capture the earliest stages of the 
disease (AD) and some cases of aMCI may be considered as a preclinical phase of AD or 
prodromal AD (Dubois et al., 2007, 2010), we analysed and compared the performance 
of the two pathological groups on Study 2 (Lemos, Simões, Santiago, & Santana, 2014). 
As such, and in order to better understand an AD-like profile of impairment among 
MCI patients, we subdivided the MCI group into MCI-MCI and MCI-AD sub-groups 
according to the previously established cut-offs. Results showed that almost half of the 
subjects (46%) had an AD-like pattern of impairment. Among the three pathological 
groups, the performance on the FCSRT had an overall profile of MCI-MCI>MCI-AD=AD. 
Furthermore, the MCI-AD group showed a significantly increased distribution of the 
ApoE-ε4 allele when compared to the MCI-MCI group, but with an equivalent 
frequency to that observed in the AD group. A cluster analysis, based on the cognitive 
performance, supported a two cluster solution with MCI-MCI subjects on the first 
group, and a combination of the MCI-AD and AD patients on the second. With this 
novel approach we believe that the heterogeneity of the MCI group may be subdivided 
according to an AD-similar pattern of performance in respect to the FCSRT profile, as 
early as at baseline, thus facilitating the capture of the earliest stages of AD as 
defended by Dubois et al. (2007). Although we assume that our results should be 
correlated with AD biomarkers, a poor performance on the FCSRT has previously 
shown a high correlation with the medial temporal lobe, by means of atrophy 
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(Diamond et al., 2007; Sánchez-Benavides et al., 2010, 2014; Sarazin et al., 2010; 
Wenger, Negash, Petsersen, & Petersen, 2011), hypoperfusion (Habert et al., 2011) 
and hypometabolism (Van Der Gucht et al., 2014), and was also significantly associated 
with CSF profile of AD (Rami et al., 2011; Wagner et al., 2012; Xie et al., 2014). 
Thereafter, a longitudinal study was conducted in order to investigate whether the 
performance on the FCSRT would enhance the ability to predict conversion to AD in an 
aMCI group (Study 4; n=88; Lemos et al., 2015). Both the group of 29 converters and 
the group of 59 stable MCI were matched for demographical variables, though 
significant differences were found concerning the neuropsychological performance 
and also the presence of the ApoE-ε4 allele. There was a high rate of conversion during 
the follow-up time (23.82 months), as 33% of the aMCI population converted to AD. 
This rate of conversion is in line with what is expected for a memory clinic, thus 
attesting the validity of the study. Moreover, it corroborates the concept of prodromal 
AD. An impaired FCSRT IR was the only variable (compared to WMS LM and the 
presence of the ApoE-ε4 allele) significantly associated to the risk of conversion to 
dementia, with a mean time to conversion of 25 months. Thus, the FCSRT 
demonstrates utility for detecting AD at its prodromal stage, supporting its use as a 
valid clinical marker. Other researchers have already described the utility of cued recall 
paradigms for the purpose of predicting AD (Dickerson, Sperling, Hyman, Albert, & 
Blacker, 2007; Ivanoiu et al., 2005; Koric et al., 2013; Mura et al., 2014; Rabin et al., 
2012; Sarazin et al., 2007).  
In sum, our studies showed that the FCSRT was able to differentiate aMCI from AD 
patients at baseline (Study 2; Lemos, Simões, et al., 2014), allowed for the division of 
the aMCI group according to an AD-alike pattern of impairment (MCI-MCI and MCI-AD) 
(Study 2; Lemos, Simões, et al., 2014), and was associated with the risk of conversion 
to AD in follow-up studies (Study 4; Lemos et al., 2015). 
We also aimed at comparing the FCSRT, in terms of accuracy for the memory 
impairment of AD spectrum disorders, with other declarative memory tests with no 
support for encoding or cue for retrieval – free recall procedures. Our results showed 
in Study 6 (Lemos, Cunha, et al., 2014) that the FCSRT was able to classify more 
subjects as having memory impairment in the aMCI group (74%) rather than the WMS 
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subtests (LM – 54% and VPAL – 6%). On the AD sample, the DR of the LM included 
slightly more patients with memory impairment than the other tests. The VPAL subtest 
had a higher number of misclassifications. Previous studies slightly more effectiveness 
of the FCSRT in detecting very mild AD (Brown & Storandt, 2000), in association with 
CSF biomarkers indicative of AD in subjects with MCI (Wagner et al., 2012), and in 
predicting individuals with memory complaints who will develop incident AD (Derby et 
al., 2013), when compared to the WMS LM. Our study also showed that while the 
FCSRT was good in discriminating aMCI from AD both in lower and higher education 
levels, the LM was more useful in higher educated subjects. This is an important issue 
for countries with a significant percentage of low educated elders, like Portugal. 
The IWG-1 also states the imperative need of distinguishing deficits in encoding and 
storage processes (characteristic of AD) from non-AD deficits that can also affect DR 
(Dubois et al., 2007), thus supporting the presence of an amnestic syndrome of the 
hippocampal type as representative of typical-AD spectrum disorders. Others showed 
that the FCSRT was able to differentiate AD patients from other forms of dementia in 
general (Grober, Hall, Mcginn, et al., 2008), and specifically from VaD (Grober, Hall, 
Sanders, & Lipton, 2008; Grober et al., 2010; Traykov et al., 2005) and FTD (Basely, 
Ceccaldi, Boyer, Mundler, & Guedj, 2013; Bertoux et al., 2014; Pasquier, Grymonprez, 
Lebert, & Van der Linden, 2001). Accordingly, in Study 7 (Lemos, Duro, Simões, & 
Santana, 2014) we showed the utility of the FCSRT in the distinction between patients 
with bv-FTD and patients with AD, therefore improving the accuracy of the diagnosis. 
Comparisons between AD and FTD, in Study 7, revealed that FTD subjects benefited 
from the controlled learning through category cues, as their performance was spared 
on both the cued recalls and the percentage of retention. Moreover, the FCSRT had a 
classification accuracy of 78.1%, allowing us to identify ninety-four percent of patients 
with AD and discard sixty-three percent of patients with bv-FTD, indicating that an 
impaired FCSRT performance emphasizes the significance of episodic memory deficits 
in patients with AD. Patients with AD were 25 times more likely to have an impaired 
FCSRT than bv-FTD patients. Moreover, the method of cueing inherent to the FCSRT 
showed an improvement of the retrieval ability in bv-FTD patients, which has not been 
observed with tests that employ other methods of cueing (Glosser, Gallo, Clark, & 
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Grossman, 2002). The pattern of impairment was the following: poor free and total 
recall performance rates, both in learning and after a delay, were observed in both AD 
and bv-FTD groups; low scores in cued recalls, and a lower rate of retention were 
representative of AD; while an improvement with category cueing and spared retained 
items were suggestive of bv-FTD. The achieved results within this study allowed us to 
conclude that it is more informative to use memory tests that control the learning 
deficit often observed in FTD patients so as to elicit the retrieval of stored information. 
This may aid to isolate the memory deficit more typical in AD patients and thereby 
increase the accuracy of a diagnosis.  
 
Highlights and Limitations 
It is our understanding that we were able to reach the main purpose of the present 
work plan – explore, in a clinical perspective, the properties and validity of the FCSRT 
on a memory clinic basis for the AD spectrum early diagnosis, in Portugal. Additionaly, 
we believe to have scientifically contributed to the discussion concerning new 
proposals for the early diagnosis of AD (Dubois et al., 2007, Dubois et al.,2014 Albert et 
al.,2011). 
Noteworthy, the pathological samples included in all the works from this thesis were 
recruited at the Neurology Department of the Coimbra University Hospital, which is a 
reference center, both for clinical and research purposes, where patients and clinical 
staff have access to the most recent and sophisticated supplementary means of clinical 
diagnosis. This setting enables the differential diagnosis to be made accurately. 
As previously reported, some studies were not defined initially, but were developed in 
order to better integrate the results achieved during the progress of this project. 
A common and solid characteristic of all the studies is the fact that the pathological 
groups and the control sample were always equivalent, in terms of demographical 
variables (age, educational level, or gender).  
An important point to be highlighted is the use of the Clinical Dementia Rating as the 
major (staging) classificatory instrument, in Study 6 (Lemos, Cunha, et al., 2014), 
independently of the neuropsychological measures. The rationale for this choice was 
the fact that comparisons between the FCSRT and the WMS subtests were part of our 
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main goal analysis, and it was done in order to avoid diagnostic circularity that may 
bias the results’ interpretation.  
One main limitation across all the reported studies is the relatively small size of the 
samples. In terms of the healthy elders group, we did not intend to work throughout a 
normalization study, as we are aware that it requires a significantly higher number of 
subjects. Instead, we prioritized having a reasonable number of controls to compare 
the clinical samples and therefore allowing us to proceed to all the validation studies. 
In terms of recruitment of the control group, we included cognitively healthy adults 
belonging to the local community that were recruited among the patients’ spouses, 
hospital or university staff, or their relatives. Our main guidelines were taking into 
consideration the demographical aspects of the pathological samples that were being 
included and also making sure that these control subjects had no history of 
neurological or psychiatric relevant condition (including abuse of alcohol or drugs or 
head trauma) neither significant motor, visual or auditory deficits which could 
influence the neuropsychological performance. We excluded all subjects with a score 
of 20 or more points (severe depression) in the Geriatric Depression Scale. Despite all 
the instruments used to assure that these subjects had no cognitive impairment, we 
are aware that a comprehensive neuropsychological evaluation that included validated 
instruments (mainly to assess memory domain), along with other supplementary 
diagnostic means, would have been more accurate. Nonetheless, including more 
instruments to the battery and questionnaires used during our assessment would 
certainly increase significantly the time of evaluation and consequentially discourage 
subjects to participate in our study. 
The FCSRT requires subjects to read the printed words during the test administration. 
This circumstance automatically disregards illiterate subjects to be included. We are 
aware that in Portuguese geriatric populations the number of illiterates is still high and 
that a low education is representative of this age group. Nevertheless, in our studies, 
the absence of an education significant effect enabled us to verify that the FCSRT can 
be used in the classification of subjects without the need of adjustment for different 
educational levels.  
228 Chapter I 
 
We have exclusively included MCI patients of the amnestic type and this is in line with 
our main objective of studying (typical) AD spectrum disorders. These patients have a 
higher risk of conversion to AD, and their memory deficit reflects the early 
involvement of the hippocampus and its related structures, and therefore they were 
intentionally chosen. This circumstance discourages the inclusion of other MCI 
subtypes, and consequently one must be advised against generalizing the obtained 
results to all the MCI subtypes. 
In terms of psychometric properties, we tried to cover all the possible variables in our 
analysis. The temporal stability was not analysed in our longitudinal study, as subjects 
only performed the FCSRT at baseline; therefore, we were not able to compare the 
performance on the FCSRT at different moments.  
Our main objective was mainly to capture the earliest stages of AD by examining the 
pattern of performance in a memory test but it is important to state that 
neuropsychological tests unaided are not enough to characterize patients as 
prodromal AD. In order to reach that purpose, and to support the suggestions of the 
IWG criteria, the results should be corroborated with AD clinical biomarkers – which 
we do not present at the current thesis. 
 
Future Outlook 
It is our understanding that the process of validating an instrument is always an open 
project. Therefore, we could develop a challenging normalization process, throughout 
the inclusion of a significantly higher number of healthy subjects that takes into 
consideration all the country-representative variables.  
The further expansion of the validation studies for other clinical populations is also an 
exciting future plan, as well as the development of concurrent validation investigations 
with the use of other neuropsychological memory tests.  
A mandatory continuity of this project is the development of a correlational study that 
includes data from the FCSRT with AD clinical biomarkers. This study may certainly 
enrich all the results achieved throughout the present thesis and will expectedly 
support the concepts developed by the IWG criteria. 
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Conclusions 
The FCSRT is a verbal memory test that involves the use of a selective reminding 
paradigm with semantic cueing. Because it showed high sensitivity and specificity in 
the differentiation of AD from healthy controls and other dementias, the IWG 
framework criteria for AD suggested its use in the assessment of the memory 
impairment of typical AD spectrum disorders. 
The work presented in this thesis showed the process of transcultural adaptation of 
the FCSRT to the Portuguese population, and explored its psychometric and clinical 
validities. The results allowed us to confirm the FCSRT as a valid and accurate test, as 
well as a useful tool in the objective characterization of the amnestic syndrome 
associated with AD. We highlight our contributions to the development 
neuropsychological instruments to be used in Portugal in the field of ageing and 
dementia, and also to the the operationalization in a research and clinical perspective 
of the international IWG framework criteria for AD.  
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CHAPTER II 
 
 
 
 
 
 
 
 
 
“Do you know where my husband is?” she cried. 
At first I Just laughed, but as she turned more anxious, grabbing my hand and shaking, I saw 
she was serious. That´s when I became speechless. The reason for my reaction is that I am her 
husband.”  
(Bill P., whose wife suffers from Alzheimer’s disease)  
  In What you need to know about Alzheimer’s, JOHN MEDINA 
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 Adapted from: Lemos, R., Patrício, M., & Castelo-Branco, M. (2015). Visual Function in the 
Alzheimer´s disease spectrum: a review. (submitted to publication). 
 
In this chapter we review the progress that has been made in the scientific research on 
visual functions in the AD spectrum. In particular, we will focus on studies that directly 
addressed low and high-level visual functions in both AD and MCI groups suggesting 
the visual perception assessment as an additional diagnostic tool for improving the 
knowledge of AD spectrum disorders. 
 
Background 
As reported earlier, while the first symptoms of AD patients are usually related to 
memory deficits, cognitive dysfunction in at least one other domain – such as 
reasoning and judgment, visuospatial abilities, or language – is often affected 
(McKhann et al., 2011).  
Current cognitive neuroscience models explain memory functions in terms of multiple 
independent systems that process different types of information by using distinct 
encoding, storage and retrieval operations. A similar conceptual framework applies to 
vision concerning sensory, perceptual and attentional processes.  
Apart from the objective memory deficit, visual brain systems may be altered in the AD 
spectrum (Cronin-Golomb, 2004). Although distinct types of memory functions have 
been explicitly and extensively studied in AD and MCI, the same does not hold true for 
visual functions. Nevertheless, the effects of normal ageing on visual perception and 
visual cognition are well established (Greenlee & Sekuler, 2014; Mateus et al., 2013). 
More recent studies revealed that, despite the visual cortical deficits in AD, other parts 
of the visual system may be affected such as the optic nerve and the retina (Tzekov 
and Mullan, 2014), the pupil (Frost et al., 2013), the macular part of the retina (Garcia-
Martin et al., 2014; Mandas et al., 2014; Nolan et al., 2014) and eye movements 
(Molitor, Ko, & Ally, 2015; Peltsch, Hemraj, Garcia, & Munoz, 2014). 
Visuospatial processing is supported by two main cortical pathways (Figure II): i) the 
dorsal pathway, which comprises a network of occipito-parietal regions involved in 
spatial vision and motion perception; and ii) the ventral stream, which consists of a 
network of occipito-temporal regions that underlie recognition of object shape 
properties (Milner & Goodale, 2008).  
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Figure II Dorsal and Ventral parallel visual pathways.  
Visual processing in the brain is handled, in part, by two processing pathways extending from 
primary visual cortex: the dorsal visual stream (where), which projects from the primary visual 
cortex to the parietal lobe and is involved in object spatial location functions; and the ventral 
visual stream (what), that spreads from the primary visual cortex to the temporal lobe and is 
responsible for object identification as well as shape and face processing. (Adapted from 
Milner and Goodale, 2008)  
 
Studies focusing on vision are important because not only the medial temporal lobe 
regions are affected in early AD, but also ventral and dorsal regions that may be 
important for predicting AD and understanding its pathophysiology (Jacobs et al. 2015; 
McKee et al. 2006; Rizzo et al. 2000; Villain, Chételat, et al. 2010; Villain, Fouquet, et al. 
2010). Moreover, recent evidence indicated that sensory and motor changes may 
precede the cognitive symptoms of AD, with strong evidence for neuropathologic 
changes in the olfactory, visual, auditory, and motor systems (Albers et al., 2015). 
MCI reduces attention capacity and slows down attention switching, but a fine 
dissection of visual and attentional deficits and their link to retinocortical and occipito-
parietal damage has not yet been attempted. The need to assess multiple domain loss 
within the visual system is even more obvious in what concerns MCI. Nevertheless, 
there is a relatively low number of studies concerning visual function in MCI, becoming 
even lower if one considers its link with other cognitive domains. 
 
The visual impairment in AD spectrum disorders 
Behavioural and Psychophysical evidence 
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AD is associated with disturbances in basic visual, complex visual and oculomotor 
functions, leading these patients and their caregivers to report frequent visuospatial 
difficulties. The broad range of visual system disorders in AD may result from the 
concentration of neuropathology in visual association cortex and optic nerves in this 
disease (Mendez, Tomsak, & Remler, 1990). Previous reviews on the spectrum of visual 
system disturbances found in AD focused on: visual field deficits, prolonged visual 
evoked potentials, depressed contrast sensitivities, abnormal eye movement 
recordings, and high-order complex visual disturbances (Mendez et al., 1990); nerve 
fiber deficits, and functional losses in the magnocellular pathway (CS and temporal 
processing) (Valenti, 2010); the broad-band pathway, glaucoma, and the ventral and 
dorsal streams of vision (Kirby, Bandelow, & Hogervorst, 2010); visual spatial cognition 
(Possin, 2010).  
There is a relative lack of visual function studies in MCI, especially when compared 
with the amount of research in AD. This fact may be due to its more recent 
categorization. Some studies in the literature report about high-level visual functions, 
showing visual search or attentional impairment to be present in MCI subjects. These 
are indeed impaired in some functions early on, but other functions seem to be 
preserved. Additionally, it is noteworthy to point out that these studies usually do not 
include a large enough number of subjects, which preclude random effects analyses 
that can be generalized to the population. Yet, it is important to investigate how visual 
function is affected in MCI and compare the patients to AD and control subjects. 
Another important goal is assessing the potential conversion predicting value of the 
visual function status. 
In the in the following paragraphs we look into how different dimensions of the visual 
function were addressed, by comparing available evidence in AD and in MCI. 
 Visual acuity, contrast sensitivity (CS) and colour vision  
Given their different neural substrates, it is relevant to analyse low-level visual 
functions (visual acuity, chromatic and achromatic CS) separately from intermediate or 
high level visual functions. 
In the specific case of AD, impairment in primary visual functions is relatively well 
known and it is described in many studies (Rizzo et al. 2000). Visual acuity decreases 
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along the course of the disease although ophthalmological comorbidity (eg. cataract, 
glaucoma and age related macular degeneration) have to be considered in order to 
isolate the specific effects due to cortical pathological ageing (Wolin, 1994). 
Rizzo et al. (2000) have provided one of the most extensive studies analysing visual 
function in AD. The authors aimed to “test the hypothesis that AD produces both 
ventral and dorsal visual pathway deficits while sparing basic sensory functions” and 
correlate such deficits with disease severity. For that purpose, they assessed a large 
number of visual functions by using tasks such as static (Sloan letter shapes) and 
dynamic visual acuity tasks. Subjects were asked to identify five letters which were 
moving in the dynamic task. Additionally, spatial CS was assessed using Pelli charts - 
which measure performance from low to medium spatial frequencies, stereoacuity - by 
using the stereopsis Titmus test, and colour vision - by means of Pseudoisochromatic 
plates. In the latter test, 12 pseudoisochromatic plates made of coloured circles of 
different size, hue and lightness were employed. Participants were asked to identify 
the target figure, or else to trace any perceived pattern with their finger. Although it is 
often claimed that this serves as a ventral visual stream probe, this task does not really 
dissect low and high level visual function. Results suggested that AD pathology affects 
visual functions (colour vision), but several basic visual sensory functions were spared. 
In another article by Rizzo and Nawrot (1998) the ability to identify 2D target shapes 
was measured (Sloan acuity letters) in a dynamic visual acuity task, where “form and 
contour cues were conspicuously available when the shapes were stationary”. The 
specificity of this task was not fully examined, yet AD patients performed in a similar 
way as controls. Wijk et al. (2002) have also reported preserved colour perception 
ability in AD patients. 
Mendola et al. (1995) found significant deficits in AD patients in tests of colour 
discrimination, stereoacuity, CS, and letter-identification with backward masking. In 
this study it was found that low level sensory functions were seemingly not spared. 
Performance in the backward masking task was the most sensitive predictor of the AD 
group status. Results for static binocular acuity were normal in this study. The results 
found for low level vision in this study were similar to those obtained by Rizzo et al. 
(2000). Moreover, these similar results were obtained with different measures of the 
same visual functions, in particular colour vision (“City University Colour Vision test”, 
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“Farnsworth D-15 test”, and “Lanthony New Colour test”) vs. the “Standard 
Pseudoisochromatic Plates” used by Rizzo et al. (2000) and achromatic CS. The only 
visual function diverging in these two studies was stereoacuity, for which in this study 
an impairment in the AD group was found, in contrast to the study of Rizzo et al. 
(2000) which did not report a significant group difference. Other studies describing the 
importance of understanding visual changes in AD population, showing AD deficits in 
colour discrimination, stereoacuity, CS, and backward masking (Cronin-Golomb 1995; 
Cronin-Golomb et al. 1991, 1995; Rizzo et al. 1992). On the other hand, Pache et al. 
(2003) reported an unspecific colour vision deficiency in AD patients that proved to be 
independent of the severity of the disease. Bassi et al. (1993) reported the 
performance of an AD group on visual functions of colour vision, CS and stereoacuity. 
This article did not report differences to have been found for the colour vision task, 
suggesting that this can be due to age-related co-morbidity; stereoacuity was impaired 
in the dementia groups; and low spatial frequency CS was the only function impaired 
in the AD group. The authors concluded that AD patients show deficits in several visual 
functions; nevertheless only deficits in CS seemed to be specific to AD.  
Cronin-Golomb (2004) commented that “spatial frequency CS is the most studied 
visual function in AD”. This function reflects the “minimum amount of contrast that an 
observer needs to resolve a stimulus of a given size”, which is probably relevant 
concerning deficits in daily function in elderly people. The deficits in CS shown by AD 
patients are often described as the visual image being viewed through a filter and it is 
called the “Alzheimer filter”, and the impaired CS at low facial frequencies contributes 
to AD patients poor face discrimination (Cronin-Golomb et al., 2000). Neargarder et al. 
(2003) have reported distinct results in the performance of AD patients among several 
CS measures. It is possible that the variability of CS results in different studies can be 
due to differences in acuity or other characteristics of the subjects studied, or due to 
the visual characteristics of the target and the scene complexity (Neargarder & Cronin-
Golomb, 2005). Accordingly, Cormack et al. (2000); Cronin-Golomb et al. (2007); 
Gilmore and Levy (1991); Gilmore et al. (2005); Nolan et al. (2014); Risacher et al. 
(2013); Valenti (2013) corroborated the CS deficits in AD patients, which were 
independent of AD higher-level cognitive (memory) disturbances impairment (Kéri, 
Antal, Kálmán, Janka, & Benedek, 1999). Trick et al. (1995) showed that the visual field 
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loss in AD is most pronounced in the inferonasal and inferotemporal arcuate regions 
but also involves the central field. Furthermore, AD proved to affect later central visual 
functions than peripheral ones (Schlotterer, Moscovitch, & Crapper-Mclachlan, 1984). 
Moreover, AD subjects also proved to benefit from increasing contrast, presumably by 
compensating for their CS deficit (Hutton, Morris, Elias, & Poston, 1993; Laudate et al., 
2012). 
Research of visual function on MCI comprises mainly high-level visual functions, like 
attention or visual search tasks. The literature available on low level visual functions is 
scarce. However, Risacher et al. (2013) proved an early deficit in CS to be present in 
amnestic MCI patients. 
 Motion Perception  
The involvement of occipito-parietal regions in AD may lead to visuospatial 
disorientation and consequently patients may get lost even in familiar surroundings. 
The occipito-parietal cortex involves processing the radial patterns of visual motion 
that create optic flow and guide movements through the environment by showing 
one's direction of self-movement. Tetewsky and Duffy (1999) studied whether AD 
patients are impaired in perceiving visual patterns of optic flow, suggesting a 
perceptual mechanism of visuospatial disorientation. These authors showed that AD 
greatly impairs the ability to see radial patterns of optic flow, and concluded that this 
may interfere with the use of visual information to guide self-movement and maintain 
spatial orientation. 
Rizzo and Nawrot (1998) published a study about the performance of a group of AD 
patients in tasks requiring the perception of movement and shape. In one of the 
experiments they tested the perception of motion direction using “Random-Dot- 
Cinematograms” (RDC) stimuli. These stimuli “present a motion signal amid spatially 
random background noise and allow for variation of spatial displacement and temporal 
intervals at programmable exposure durations”. AD had significant effects on the 
perception of SFM but had relative sparing of dynamic visual acuity and motion 
direction discrimination. Rizzo et al. (2000) studied movement perception, by using 
either a motion direction discrimination task that required subjects to indicate the 
perceived direction of the motion in the stimulus after a 195 ms presentation, and a 
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two-alternative forced-choice SFM task where the observer had to report the shape of 
the presented object. AD patients revealed to be impaired in the latter task. 
More conspicuous evidence for impairment in AD has been found with high level 
motion tests. Using measures of horizontal motion and radial optic flow, Duffy et al. 
(2000) found an impairment in AD patients’ performance, when compared with two 
control groups (young - YN and elderly normal - EN). Nevertheless, the AD group could 
be divided in two sub-groups considering the performance: about half of the AD 
subjects had similar thresholds as compared to those seen in the EN group, while the 
other half showed much higher radial optic flow thresholds than horizontal motion 
thresholds. These results not only confirm the recognition of visual motion processing 
deficits in AD patients, but also demonstrate a selective impairment in radial optic flow 
perception that can be linked to navigational deficits. These deficits found in AD do not 
seem to reflect impairments in basic visual function, but somewhat reflect high level 
dysfunction of the visual extrastriate cortex, and are consistent with the notion that 
higher level deficits tend to dominate.  
Kavcic et al. (2011) showed that AD was associated with poorer heading direction and 
speed perception at lower temporal periodicity, with smaller effects of spatial texture, 
using the radial patterns of visual motion in optic flow. AD patients were particularly 
impaired by motion incoherence created by adding randomly moving dots to the optic 
flow, when compared to young, middle-aged and older normal subjects. 
Tippett and Sergio (2006) examined the accuracy of movements requiring a 
visuomotor transformation in neurologically healthy elderly subjects and patients 
diagnosed with AD, using a task where they had to make sliding finger movements 
over a clear touch-sensitive screen. The latter was positioned in three spatial planes 
and patients were asked to displace a cursor from a central target to one of four 
peripheral targets viewed on a monitor. Significant main effects were observed on 
reaction time and movement time measures, as well as significant increases in task 
completion errors, in the patient population. Furthermore, the performance was 
affected more by the visual feedback changes relative to the plane location changes. 
The authors suggest that the integration of eye and hand information may be impaired 
in AD. In a later article involving some of the same authors, the ability to successfully 
complete procedures involving short-term spatial visuomotor memory tasks and tasks 
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involving increasingly complex visuomotor transformations was examined in the same 
groups (Tippett et al. 2007). Overall, these new results revealed that AD patients show 
substantial declines in their ability to process and integrate visual information to 
produce motor responses, therefore providing evidence that AD can affect anatomical 
regions supporting vision for action. 
Hawkins and Sergio (2014) used kinematic measures, under conditions that place 
demands on visual-spatial and cognitive-motor processing, to suggest that the 
impairments observed in individuals at increased AD risk may reflect inherent brain 
alteration and/or early neuropathology disrupting the reciprocal communication 
between hippocampal, parietal, and frontal brain regions required to successfully 
prepare and update complex reaching movements. Such impairment may affect 
activities of daily living, and could serve as a sensitive measure of functional ability in 
at-risk AD adults. 
Nevertheless, in MCI most of the evidence comes from neuroimaging studies that do 
not directly measure performance. However, a study by Mapstone et al. (2003) did 
evaluate the performance of an MCI group and an AD group, in comparison with young 
and older control groups, on motion detection (horizontal and radial optic flow) and 
spatial orientation (Money Road Map Test) tasks. The results showed an impairment of 
MCI patients in radial motion detection. The AD group performed worse than the MCI 
group both in spatial orientation and in the radial motion detection. The performance 
in the horizontal motion detection was similar for all groups. This study reveals a 
correlation between radial optic flow results and spatial orientation scores across all 
groups that proved to be independent of memory deficits, thus supporting the 
existence of a link between impaired optic flow perception and visuospatial 
disorientation. This result may explain why AD patients may readily become spatially 
lost, because of their visual perceptual impairments rather than forgetting their path 
or location, in line with the idea that visuospatial impairment is independent of 
memory processing. MCI patients showed selective impairments in the radial motion 
tasks, and all patients who were impaired in one radial optic flow task were impaired 
in the other, but not in the processing of horizontal motion stimuli. This may imply that 
some MCI patients have significant visual perceptual deficits along with memory 
impairment, whereas others have memory impairment without significant visual 
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perceptual deficits. This finding led the authors to suggest a visuospatial variant of 
MCI.  
 Visual Attention 
Concerning visual attention, Rizzo et al. (2000) have studied it using two tasks: the 
useful field of view (UFOV) and the starry night task. The former used the Visual 
Attention Analyser, Model 2000, which includes three subtests to provide a measure 
of speed of visual processing discrimination, divided attention and selective attention. 
The latter tests the subject’s ability to detect “on” and “off” signals presented to both 
hemifields, since the performance depends on an observer’s visual sensory function 
and ability over time to sustain visual attention across a spatial array. The AD group 
was significantly worse on both tasks of visual attention. 
Foster et al. (1999) investigated selective attention in AD patients, using a visual search 
procedure. Patients showed deficits, as expressed by increased reaction time, both on 
simple and conjoined feature search tasks; and had also more difficulty in detecting 
targets on the right side of hemispace and in more peripheral locations. 
Parasuraman et al. (2000) studied spatial attention and visual search in an AD group, 
comparing it with two healthy control groups. They showed that the AD group was 
impaired both in accuracy and reaction time in a cued visual search task where the 
subjects had to identify a target in different conditions. Participants had to search for 
feature or conjunction targets in a search display preceded by a cue that varied in 
validity (valid, invalid or neutral), size and precision of spatial localization. The cue size 
effect was evident both in feature and conjunction search, but it was reduced both in 
AD and older control group, when compared with the younger control group. 
Nonetheless, the AD group seemed to benefit from precise cues in spatial attention.  
Tales et al. (2002) studied the performance of AD patients on a visual attention task. 
They showed that the performance when detecting a target (visual search) may 
depend on the type of target used. Two types of cues were used: endogenous cues – 
that have a meaning, are learnt and require conscious recruitment of attentional 
processes; and exogenous cues – which automatically attract attention and are 
suggested (ex: the automatic orienting triggered by a flash of light). Cueing effects 
were found, for both type of cues, for either the two control groups (younger and 
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older age-matched) and the AD group. Nevertheless, the AD patients showed a normal 
performance for the endogenous cueing condition and impairment when exogenous 
cues were used, implying that automatic attention processes are affected in AD, while 
controlled attention is spared. The exact neural mechanism underlying these deficits 
remains to be explored.  
In another study, Tales, Butler, et al. (2002), asked whether AD was particularly 
affected by the features (orientation and lightness) of the target and if performance 
depends on some shifting of attention, during a visual search task. Two non-
conjunction control conditions were employed: the first was a pre-attentive, single-
feature, "pop-out" task, detecting a vertical target among horizontal distractors; 
whereas the second was a single-feature, partly attentive task in which the target 
element was slightly larger than the distractors - a "size" task. The results suggested 
that AD patients had a particular impairment in the conjunction task but not in the 
single-feature size or pre-attentive tasks. This may imply that AD particularly affects 
those mechanisms which compare across more than one feature type, and spares the 
other systems and is not therefore simply an 'attention-related' impairment. 
Distinctions across putative mechanisms were explored in a study by Tales et al. 
(2004). These authors concluded that AD patients are impaired on visual search tasks 
as a combination of both inefficacy on attention shifting and target processing factors. 
The ease of attention shifting was manipulated in this visual search task, by controlling 
both target salience and task difficulty, where AD patients showed greater effects of 
manipulations. 
Butter et al. (1996) studied two AD groups, one with and another without visual 
symptoms, along with a healthy control group. The article explored the assumption 
that the high level visual-spatial dysfunction in AD patients can explain their visual 
symptoms. The battery administered included the assessment of visual-spatial skills, 
form identification, colour vision, and visual memory. The results showed that the two 
AD groups differed significantly, in which concerns visual-spatial test scores. It was 
concluded that visual symptoms in AD are related primarily to high level visual-spatial 
deficits.  
One may conclude at this point that visual attention is impaired in AD at different 
levels. These deficits have been linked to dysfunction of the posterior parietal cortex 
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and associated networks, and are qualitatively and quantitatively different from the 
visual attentional changes in normal ageing. 
Studies on the time course of visual attention, that examine how quickly attention can 
be directed to and for how long attention remains directed at a stimulus, have 
suggested a temporary functional blindness in MCI patients – incapacity to attend a 
second stimulus presented within 500 ms of the first one. This phenomenon is known 
as the attentional blink or attentional dwell time (Perry & Hodges, 2003). These 
authors have examined the neural correlates of this phenomenon and its relationship 
to mechanisms that control attention in a MCI group. Their paradigm was divided in 
two situations: in the first one, subjects had to identify both a number and a letter that 
were rapidly and sequentially presented on a visual display – the effect that the need 
to identify the first stimulus had on the ability to identify the second was used as a 
measure of the attentional blink. In the second situation, subjects were asked to 
identify only one of the two stimuli – the ability to ignore the first stimulus was a 
function of their top-down attentional control. Results showed that MCI patients had a 
normal performance on the attentional dwell time task, but top-down inhibitory 
attentional control was impaired. This dissociation suggests that these two aspects of 
visual attention have a distinct neural basis. 
Levinoff et al. (2005) used three reaction time attentional tasks to assess the nature of 
focused attention impairments in AD and in MCI, in comparison with a normal elderly 
control group. The experiment was divided in three tasks: 1) a simple reaction time 
task – where subjects had to respond as rapidly as possible to a single stimulus – as a 
measure of psychomotor speed; 2) a choice reaction time task (CRT) – where 
participants had to carry out one of two response options based on the nature of the 
stimulus that was presented – obtaining a focused attention measure; 3) a cued choice 
reaction time task (CCRT) – where cues are provided before the stimulus presentation 
– assessing a cueing effect. The results showed that AD patients were slower on the 
three situations, while MCI patients were only impaired on CRT and CCRT, which 
provides evidence for impaired focused attention and the inability to benefit from a 
cue in both the MCI and AD groups. 
Visual attention mechanisms have an important relationship (bottom-up or top-down) 
with other brain functions, such as mnemonic, high-level cognitive, perceptual and 
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sensory (feedback effects in the latter). Within this context, Tales et al. (2005) studied 
the ability for visual search in both MCI and AD patients. In the visual search task, 
participants had to find a target element that was one of the symbols “<” or “>” (i.e., a 
black left or right-pointing arrow). These were presented alone or amongst distracter 
elements with the same shape as the target but rotated, pointing up or down (“^” or 
“v”). Results indicated a similar performance between MCI and control groups when 
the target appeared alone but when it appeared surrounded by distractors, the 
reaction time of MCI responses increased significantly. AD patients were impaired on 
both conditions. The pattern of results displayed by the MCI group indicated that 
patients who appear clinically to suffer only from a deficit in memory also exhibit a 
deficit in visual attention-related processing, even though not as severe as those with 
AD. 
 Object Perception  
Object perception in AD has rarely been separated from amnestic deficits. In this 
manner, it remains difficult to prove a specific domain-specific deficit of object or more 
specifically face perception in AD. Testing memory for faces and names has been 
widely applied in clinical contexts, and it has been claimed that this provides highly 
sensitive indices of episodic and semantic memory performance (Werheid & Clare, 
2007). The elucidation of specific object perception deficits and their contribution to 
such performance measures remains to be established. 
In the experiment of Rizzo et al. (2000) the observer reported the shape of the object 
presented in each trial, in a two-alternative forced-choice task. Results of this study 
showed that the amount of signal needed for threshold discrimination of SFM is higher 
in the AD group. 
Cronin-Golomb (2004) stated that “deficits in spatial contrast sensitivity result in 
increased difficulty in face discrimination” not only in healthy elderly individuals but 
especially in patients with AD. They have found that a reduced face size influences 
contrast sensitivity at different spatial frequencies, resulting in normal face 
discrimination for only that face size. This suggests that it is important to control for 
low level mechanisms when assessing object perception in AD. 
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In the previously reported study of Rizzo and Nawrot (1998) AD patients were impaired 
in perceiving shapes defined by motion cues (SFM task). These findings suggest that 
even if retinal pathology cannot be excluded, it alone cannot explain the pattern of the 
defects observed. The deficits in the processing of complex motion patterns are likely 
to have a cortical basis and are probably related with lesions in visual extrastriate 
cortex. 
Surprisingly, few studies are available to study object perception in MCI. Most of the 
evidence comes from neuroimaging studies (see Neuroimaging section). To make 
issues even more complicated most of these do not directly measure performance. 
The problem is that MCI is not explicitly defined in most of the studies dealing with 
object perception. A good example is a study of visual object and face processing in 
mild-to-moderate AD (Tippett et al. 2003). The authors suggested that small, but in 
most cases reliable, impairments in visual perception, which are independent of 
degree of cognitive decline, could be found. Deficits in basic shape processing 
influenced performance on some higher level visual tasks. Poor performance on face 
processing, or the deficit on object naming, seemed however to be related to high 
level semantic-lexical impairment. 
Neurophysiological evidence 
Visual task and performance-related oscillatory activity and its synchronization may 
prove to provide important biomarkers in AD and MCI research (Uhlhaas & Singer, 
2006). This is the case because, as pointed by these authors, synchronization of 
oscillatory responses in the beta and gamma-band is involved in a variety of cognitive 
functions, such as perceptual grouping, attention-dependent stimulus selection, 
routing of signals across distributed cortical networks, sensory-motor integration, 
working memory, and perceptual awareness. However, evidence in this respect is 
quite tentative Jackson and Snyder (2008). It is nevertheless to be expected that new 
fingerprints will be identified and that extended application of Electroencephalography 
(EEG) and event related potential (ERP) studies will provide novel biomarkers of MCI 
and early AD. 
 Retina and subcortical structures 
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Yin et al. (2008) have revived the idea that retinal (glaucoma) and cortical age related 
degenerations (AD) may share similar mechanisms, in a theory-driven hypothetical 
paper. This idea was also explored in animal models (Ding et al., 2008; Ning, Cui, To, 
Ashe, & Matsubara, 2008).  
Paquet et al. (2007) had suggested that that the retinal nerve fibre layer (RNFL) 
seemed to be involved early during the course of amnestic MCI. Berisha et al. (2007) 
had similar results and further showed that retinal abnormalities in early AD include 
not only a specific pattern of RNFL loss, but also narrow veins, and decreased retinal 
blood flow. Bambo et al. (2014) and; Kesler et al. (2011) found significant correlations 
between visual function tests and RNFL thickness with the severity of AD. Interestingly, 
melatonin receptor profiles in the retina are also altered in AD (Savaskan et al., 2007), 
suggesting that changes in circadian biology can have a retinal basis in this disease. 
 Visual cortical pathways 
Most of the efforts to elucidate the neurophysiology of visual processing in AD concern 
brain imaging, although EEG/ERP studies are also available. Unfortunately, no 
systematic attempts have yet been made in human research to assess retinotopic 
maps in AD and MCI.  
An EEG source image study that suggested the existence of three different neural 
patterns in aged individuals, while viewing a visual stimulus: i) left hippocampus and 
midbrain in mild AD, ii) left lateral orbitofrontal gyrus, left nucleus accumbens, caudate 
nucleus, thalamus, posterior cinguli, right precuneus, right superior parietal lobe in 
MCI, and iii) right lateral-medial orbitofrontal gyrus, caudate nucleus, thalamus, right 
lateral occipito-temporal gyrus in elderly controls (Haupt, González-Hernández, & 
Scherbaum, 2008). However this study must be taken with caution, because it is 
arguable that EEG source mapping can reliably reach deep structures. 
Stothart et al. (2015) used visual evoked potentials (VEPs) to assess the functional 
integrity of visual association area processing in AD and amnestic MCI. Results were 
interpreted as suggesting that changes in VEPs in AD may be a consequence of the 
microscopic AD pathology found in the extrastriate cortex, and that therefore neural 
measures of visual processing may help to better characterize subgroups of aMCI 
patients likely to develop AD. Fix et al. (2015) examined the diagnostic accuracy of 
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flash VEPs in MCI subjects, and speculated that MCI have compromised cholinergic 
functioning that result in impaired visual processing.  
Yener et al. (2014) compared visual sensory-evoked oscillations and event-related 
oscillations in MCI to explore brain dynamics. The topography of oscillatory responses 
showed to differ depending on stimuli and tasks: visual sensory responses are highest 
over occipital and cognitive responses over frontal regions. A group effect was 
observed in MCI indicating that visual sensory and cognitive circuits behave differently 
indicating preserved visual sensory responses, but decreased cognitive responses. 
Neuroimaging 
The diagnosis of dementia is still essentially grounded on clinical criteria, but 
neuroimaging can often aid in providing further assessment. The identification of AD 
histological alterations is still mandatory for a definitive diagnosis, according to the 
most recent diagnostic criteria for AD (Dubois et al., 2007, 2014; McKhann et al., 
2011). Nevertheless, the higher specificity correlation between amyloid deposition in 
the Pittsburgh compound B-Positron emission tomography (PiB-PET) and AD pathology 
in post-mortem studies enabled this functional neuroimaging technique to be 
considered as a valid pathophysiological marker of brain fibrillar amyloid pathology 
(Dubois et al., 2014). Accordingly, it is included in the more recent framework criteria 
both as a pathophysiological biomarker (Dubois et al., 2014) and as a biomarker of Aβ 
accumulation (Jack et al., 2011).  
One cannot overemphasize the importance of post-mortem studies which in fact 
represent the diagnostic golden standard (Huddleston & Small, 2005). These studies 
have shown that initial amyloid deposits are formed in temporal, parietal and frontal 
lobes (Huddleston & Small, 2005). Visual cortex and primary sensorimotor cortex are 
apparently only affected in the latest stage of the disease (Braak & Braak, 1997). These 
notions are however at odds with recent neuroimaging results (in particular the 
functional imaging techniques) and represent a major challenge for future studies. One 
should, however, take into consideration the fact that visual functions actually span 
from the occipital, parietal, temporal and even frontal networks. 
Although initially amyloid is deposited in temporal, parietal and frontal lobes, the first 
symptoms of AD are associated to neocortical-hippocampal deficits. It is becoming 
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clear that brain imaging is changing the way we view this and other causes of 
dementia, and that this trend will increase, which will probably force upcoming 
adjustments of the accepted diagnostic criteria (American Psychiatric Association, 
2000; Dubois et al., 2007, 2010, 2014; McKhann et al., 1984, 2011).  
Through neuroimaging techniques, either structural [Magnetic Resonance Imaging 
(MRI)], or functional [functional MRI (fMRI), nuclear imaging: Single-photon emission 
computed tomography (SPECT), and fluorodeoxyglucose-Positron emission 
tomography (FDG-PET), and PiB-PET], clinical investigations aim to achieve a better 
way to diagnose and monitor AD (Huddleston & Small, 2005).  
 Structural Imaging 
MRI and Computed Tomography (CT) are useful tools to identify non-degenerative and 
potentially treatable causes of dementia (Huddleston & Small, 2005; Klöppel et al., 
2008). High-resolution volumetric MRI has increased the capacity to identify the 
various forms of the frontotemporal lobar degeneration spectrum and some forms of 
parkinsonism or cerebellar neurodegenerative disorders (Vitali, Migliaccio, Agosta, 
Rosen, & Geschwind, 2008). Patterns of cortical and subcortical abnormalities on MRI 
can be very informative in this regard. 
To be useful in diagnosis, the structural MRI should help distinguish early stage AD 
from normal ageing (Klöppel et al., 2008).  
Regardless of visual function-related regions, a study by Frisoni et al. (2007) using MRI 
allowed distinguishing between individuals affected by AD with early and late forms. 
Those affected early on show greater atrophy of the parietal and occipital lobes. On 
the other hand, the individuals affected later on had increased atrophy of the 
hippocampus (Frisoni et al., 2007). 
Finally, among the new MRI methods, diffusion-weighted MRI is also slowly entering 
the clinical arena. Tensor-based morphometry (TBM) may indeed help detect regional 
structural brain differences between patients with AD or MCI and controls (Hua et al., 
2008). This technique may become quite important because in addition to the 
deterioration of the cortical grey matter, also the brain white matter (WM) is affected. 
Indeed, Bozzali et al. (2002) have demonstrated that the deterioration of WM is due to 
wallerian degeneration of fiber tracts due to neuronal loss in cortical associative areas. 
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This study showed that WM pathology is not homogeneously distributed, preferably 
involving the fibres connecting association cortices, the corpus callosum and as well as 
pathways linking temporal, frontal, and parietal lobes in the detriment of little 
involvement of motor (internal capsule) or early visual pathways (optic radiations). 
Moreover, Cooley et al. (2014) had examined WM abnormalities of brain regions, 
including those associated with visual processing. Using diffusion tensor imaging (DTI) 
the authors studied a group of "probable MCI" compared to a group of cognitively 
healthy subjects, by comparison with a brief cognitive screening tool. Results indicate 
that there were posterior WM microstructural changes in individuals with probable 
MCI. These differences demonstrated that WM abnormalities are evident among 
individuals with cognitive impairment in regions beyond those commonly associated 
with AD and anterior brain ageing patterns. In another study, Nishioka et al. (2014) 
used DTI to analyse the visual pathway in healthy controls, MCI and AD patients. Their 
findings indicate that WM damage extends to the visual system, namely to the optic 
nerves and the splenium of the corpus callosum, and may help explain the visual 
deficits experienced by AD patients 
 Functional Imaging 
Functional MRI (fMRI) 
fMRI is a promising technique to evaluate the dynamic changes in the degenerating 
brain. If successful in the detection of early functional damage it might allow for 
studies of early intervention to slow or prevent disease progression (Petrella, Coleman, 
& Doraiswamy, 2003). Smith et al. (1999) showed that cognitively normal individuals at 
high risk for AD, with family history of AD and corresponding apolipoprotein E allele 
status, demonstrated decreased brain activation in the mid- and posterior 
inferotemporal regions bilaterally during visual naming and letter fluency tasks. The 
authors claim to have provided evidence of a window of opportunity for disease-
modifying treatment before the onset of symptomatic AD. 
Concerning high level regions, a study has attempted to characterize activity in 
putative human V4, the right fusiform face area (FFA) (face task) and superior 
temporal sulcus (STS) (for a motion task) (Sauer, Ffytche, Ballard, Brown, & Howard, 
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2006). As reported by the authors, these differences could be explained by behavioural 
performance, failing to reach significance in the covariance analysis.  
Thiyagesh et al. (2009) claim to be the first ones to explore the neuroanatomy of depth 
and motion perception in AD, during an fMRI study. AD patients showed a 
hypoactivation of V5 area, superior parietal lobe, occipito-parietal cortex and 
premotor cortices, but a greater activation in inferior parietal lobule and activated 
additional areas. This abnormal visual profile of AD supports a pathophysiological basis 
for the visuospatial disorientation. 
More recently, Li et al. (2015) conducted a meta-analysis study examining brain 
network dysfunction in MCI and AD along task-based fMRI studies, supporting studies 
that investigated the brain network dysfunction from the system level (including visual 
functional areas). The meta-analytic results revealed that: i) MCI patients showed 
hypoactivation in default, frontoparietal, and visual networks relative to healthy 
controls; ii) AD-related hypoactivation mainly located in visual, default, and ventral 
attention networks relative to healthy controls; and both MCI-related and AD-related 
hyperactivation fell in frontoparietal, ventral attention, default, and somatomotor 
networks relative to healthy controls. 
Vannini et al. (2008) investigated task demand-dependent signal changes in mild AD 
patients, using an approach that modelled the dependency of the blood oxygenation 
level-dependent (BOLD) signal on the subject's reaction time. Along with controls, AD 
patients showed overlapping neural networks engaged in angle discrimination, 
including the occipito-parietal and frontal regions. Moreover, they also demonstrated, 
in several network regions, a significantly weaker and sometimes no BOLD signal due 
to increased task demand; and a general task demand-independent increase of 
activation in right middle temporal gyrus. The authors suggest that this finding may 
indicate an attempt to compensate for dysfunctional areas in the dorsal visual 
pathway, in AD pathology. Accordingly, a three-year prospective study of the same 
authors (Vannini, Almkvist, Dierks, Lehmann, & Wahlund, 2007) aimed to investigate 
the functioning of brain regions in the visuospatial networks responsible for preclinical 
symptoms in AD using event-related fMRI. Again, an angle discrimination task with 
varying task demands was used, not yielding any performance differences. However, a 
network of bilateral activations in the dorsal pathway showed increased linearly 
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activity, with increasing task demand, in all subjects. Increased parietal activation in 
progressing MCI was suggested to reflect a reduced “neuronal efficacy” due to 
accumulating AD pathology and to be predictive of future clinical decline in MCI 
patients.  
Another study focused not so much on performance but more on activation patterns 
and their correlations with morphometric measures (Teipel et al., 2007). This showed 
that during face matching tasks, fusiform activation is positively correlated with 
cortical grey matter density of brain areas belonging to the ventral visual stream and 
negatively correlated with grey matter density of brain areas belonging to the dorsal 
visual stream. It further reported that these effects were more pronounced in MCI 
patients than in controls (Teipel et al., 2007). In this type of task there were no 
statistical differences found, in performance or activation, between groups (Bokde et 
al., 2006). MCI showed to affect functional connectivity from the right middle fusiform 
gyrus to the visual areas and medial frontal areas. A higher linear correlation in the 
MCI group, in the parietal lobe, might indicate the initial appearance of compensatory 
processes (Bokde et al., 2006). 
Additionally, the study of Rombouts et al. (2005) focused on altered resting state 
networks in MCI in AD during a visual task. Deactivation was found in the default mode 
network involving the anterior frontal, precuneus, and posterior cingulate cortex. MCI 
patients showed less deactivation than controls, but more than AD subjects. The 
default mode network response in the anterior frontal cortex significantly 
distinguished MCI from both controls (in the medial frontal) and AD subjects (in the 
anterior cingulate cortex). The response in the precuneus could only distinguish 
between patients and controls, not between MCI and AD. The study showed early 
changes in MCI in the posterior cingulate cortex and precuneus. 
As posited by Werheid and Clare (2007), neuroimaging has revealed face perception 
requires a complex interplay of highly specialized visual areas located in the occipito-
temporal cortex which interact with a widely distributed system of cortical areas 
subserving other cognitive operations. This helps explain why progress is slow and 
strongly dependent on unravelling cognitive operations. 
Teipel et al. (2007) showed that, during face matching tasks, fusiform activation is 
positively correlated with cortical grey matter density of brain areas belonging to the 
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ventral visual stream and negatively correlated with grey matter density of brain areas 
belonging to the dorsal visual stream and that these effects are more pronounced in 
MCI patients than in controls.  
Activation changes were compared by means of BOLD signal functional magnetic 
resonance imaging in the visual system between MCI and healthy control subjects 
(Bokde et al., 2008). The findings of this study showed that there were no areas of 
increased activation in the control group compared with the MCI group. Patterns of 
activation also reflected some differences since the control group selectively activated 
the ventral and dorsal pathways during face and location matching tasks, respectively. 
Graewe et al. (2013) showed that an increased representation of low-level stimulus 
aspects may impair face perception in MCI, as elevated depth sensitivity was present in 
left FFA/OFA (occipital face area). Discriminant function analysis using face and depth 
sensitivity indices in FFA/OFA classified MCI and healthy elderly with 88.2% accuracy. 
Potentially related findings include altered activation patterns in dorsal–ventral stream 
integration regions and attention related networks of MCI patients. Their results 
highlight aberrant visual and additional potentially compensatory processes that 
identify dispositions of preclinical AD. 
Yamasaki et al. (2012), in a ERPs and fMRI review study, concluded that visual 
impairments in patients with AD and MCI are mainly caused by dysfunction in higher-
level parallel visual pathways. In particular, a deficit in ventro-dorsal stream function 
related to optic flow perception is responsible for the earliest and most prominent 
visual symptoms in MCI.  
More recently, Krajcovicova et al. (2014) studied the changes in connectivity of the 
posterior node of the default mode network (DMN) using fMRI, in AD patients. Results 
showed that while in controls the task-induced connectivity decreases between the 
posterior cingulate and middle temporal and occipital visual cortices – implying a 
successful involvement of the ventral visual pathway during the visual processing; in 
AD, the involvement of the areas engaged in the ventral visual pathway was observed 
only in a small volume of the right middle temporal gyrus. Additional connectivity 
decreases in AD were present between the posterior cingulate and superior temporal 
gyrus when switching from baseline to task condition, thus reflecting deficits and 
compensatory mechanisms within the large scale brain networks in this population. 
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Brewer and Barton (2014) used fMRI to compare the visual field map (VFM) 
organization and population receptive fields (pRFs) between young adults and healthy 
ageing subjects. Healthy ageing subjects did not show major VFM organizational 
deficits, but had reduced surface area and increased pRF sizes. Later, the authors 
demonstrated the feasibility and first characterization of these measurements in two 
patients with mild AD, which reveal potential changes in the visual cortex as part of the 
pathophysiology of AD by showing more irregularities in the organization of the 
posterior VFMs. 
The aforementioned studies focused on demonstrating that functional connectivity 
can be an effective marker for the detection of changes in brain function in MCI 
subjects, regardless of performance differences. 
Nuclear imaging [Single-photon emission computed tomography (SPECT), 
fluorodeoxyglucose-Positron emission tomography (FDG-PET), and Pittsburgh compound B-
Positron emission tomography (PiB-PET)] 
Although imaging approaches are now trying to address visual performance, a link with 
clear cut impairment is still lacking.  
SPECT was clinically used to characterize the ageing process. Regarding its use for 
visual research purposes, it has scarcely been used to probe structure-function 
attentional mechanisms in AD. Buck et al. (1997) showed the ability of AD patients to 
shift attention between spatial locations and between objects, and the brain regions 
involved in these cognitive tasks using SPECT imaging. In AD patients, hypoperfusion in 
the right superior parietal lobe was correlated with shifts of attention between 
different spatial locations, while hypoperfusion in the left inferior parietal lobe was 
correlated with shifts of attention between different objects. These results support the 
specialized role of the right and left parietal regions in the spatial and object 
mechanisms of attention shifting respectively, and suggest that the cognitive profile 
associated with AD includes attentional impairments in both spatial and object-based 
levels. 
van Rhijn et al. (2004) investigated the relationships between intermediate visual 
processes involving object and space perception and regional brain activity using FDG-
PET and SPECT, in a group of AD patients. Their results showed significant region 
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specific correlations between unfamiliar face matching and cerebral activity in the left 
occipito-temporal region and middle/inferior temporal regions bilaterally. Letter-word 
identification was significantly correlated with brain activity in the angular gyri and 
occipital association cortices bilaterally, as well as a broad region of activation in the 
left hemisphere temporal, parietal and occipital lobes. Moreover, a significant 
correlation was found between ratings of performance of instrumental activities of 
daily living and brain activity in occipito-temporal and middle/inferior temporal 
regions, proving that the neuropathological distribution typical of AD corresponds to 
impairments in specific aspects of intermediate visual perceptual processing, and is 
related to the impairment on daily living skills of these patients. 
Pietrini et al. (1996) also used FDG-PET to study two groups of AD patients: one with 
visual disturbances at onset and the other without them, comprising measures of 
regional cerebral glucose metabolic rates. Their aim was to investigate whether 
specific cortical networks associated with visual processes were preferentially affected 
in the subgroup with visual disturbances, and determine the clinical implications of 
such abnormalities. The results revealed that the two groups of patients showed 
reduced glucose metabolism in parietal and in middle and superior temporal regions, 
when compared to controls. The AD subgroup without visual disturbances also showed 
reductions in inferior temporal, frontal, and limbic structures, as is typical of this 
disease. In contrast, the subgroup with visual symptoms had larger metabolic deficits 
in the parietal and occipital cortices (including the primary visual cortex), with a 
relative sparing of inferior temporal, frontal and limbic regions. These results showed 
that AD patients with visual symptoms had significantly greater visuospatial deficits, 
and less severe memory impairments, than patients with no visual disturbances. The 
authors concluded that AD patients with visuospatial deficits have a distinctive 
regional distribution of cerebral metabolic impairment which is related to a specific 
cognitive impairment, thus distinguishable from patients with typical AD disturbance. 
Fujimori et al. (2000) showed that visuospatial disturbance was related to bilateral 
parietal metabolism, and that visuoperceptual disturbance was related to right 
temporo-parietal metabolism in patients with mild-to-moderate AD, in a FDG-PET 
experience within tasks of visuospatial recognition. Mielke et al. (1995) also found an 
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involvement of the secondary visual cortex in the pathological changes in AD, in a FDG-
PET study. 
These findings imply that regional disparities in brain dysfunction can occur in AD, with 
differential involvement of cortical structures resulting in distinctive clinical subgroups. 
The neuropathological findings characteristic of AD, including neurofibrillary tangles 
(NFT) and neuritic plaques (NP), are also present in the visual cortical areas, especially 
in the visual association areas (Hof & Bouras, 1991). Armstrong (1996) suggested that 
pathological differences between cuneal and lingual gyri could contribute to the 
reported visual field defects in some AD patients, due to differences in density of NP 
and NFT in these areas. Butter et al. (1996) findings also proved that patients with AD, 
who have prominent visual symptoms, have accentuated histologic and metabolic 
abnormalities in the occipito-parietal regions known to process visual-spatial 
information. 
The Pittsburgh Compound-B (PIB) ligand for PET (PiB-PET) imaging is one of the 
molecules that are improving the ability to differentiate AD from other 
neurodegenerative dementias. This compound and others have allowed for the 
delineation of maps of deposition of amyloid which will allow us to answer several 
questions but also raised several conundrums. If this distribution map of amyloid 
plaques should be used to differential diagnosis between AD and normal ageing, how 
can we reconcile them with the differences obtained with the other methods 
(Huddleston & Small, 2005)? Future in vivo studies should improve this scenario, 
because so far the number of case studies is relatively small. Moreover, not all 
conclusions agree with information from post-mortem studies (Klunk et al., 2004; 
Shoghi-Jadid et al., 2002). PET studies during activation indicate the brain's reserve 
capacity to respond to functional tasks. Since metabolism in AD patients during 
activation is more severely impaired than at rest, PET studies during (visual) functional 
tests could help in the selection of patients with a potential to benefit from 
therapeutic intervention (Kessler, Herholz, Grond, & Heiss, 1991). 
In recent years, many studies have been proposed with the goal of developing 
substances which bind to amyloid plaques. These are meant to allow visualizing and 
locating plaques in vivo by PiB-PET (Jack et al., 2008). According to a study by 
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Ikonomovic et al. (2012), the above mentioned radiotracer PIB is considered one of the 
most valuable markers. In fact this marker that binds with high affinity to Aβ and 
seems to be one of the most relevant PET methods for in vivo evaluation of AD 
(Ikonomovic et al., 2012). Ishibashi et al. (2014) quantified the Aβ deposition in the 
striatum and several cortical regions, in patients with AD, through a PiB-PET study. 
These authors confirmed that there were ventral > dorsal, and anterior > posterior 
gradients of Aβ deposition in patients with AD, and provided the first evidence of a 
robust correlation between Aβ deposition levels in the ventral striatum and the medial 
part of the orbitofrontal area. 
Other biomarkers of great utility, such as FDG-PET were used in addition to the PIB-PET 
in several studies, aiming to unveil the link between amyloid deposition and abnormal 
metabolism. Though some of the apparent discrepancies that were identified between 
studies may be explained by distinct binding affinities, the mismatches remain 
nevertheless puzzling: (i) Shoghi-Jadid et al. (2002), in their studies, used the 
radioligand [18F]FDDNP that binds to both amyloid plaques and neurofibrillary tangles. 
Main deposits were found in the medial-temporal lobe; nevertheless this was not in 
accordance with metabolic defects that were observed in lateral-temporal lobe using 
FDG-PET; (ii) Klunk et al. (2004) used the PiB-PET which selectively binds to only 
amyloid plaques and observed a large binding pattern in frontal lobe but the major 
metabolic defects were observed in parietal lobe.  
One of the main interim conclusions has been that amyloid plaques deposits do not 
necessarily predict brain dysfunctions observed in AD (Huddleston & Small, 2005). One 
of the possible explanations to this divergence between cognitive and metabolic 
deficits and radioligand binding on patients may be that soluble amyloid oligomers are 
toxic but deposits may actually be innocuous per se or even protective by constituting 
an inert compartment (Engler et al., 2006; Mintun et al., 2006).  
It is important to note that there is no definite consensus on the best neuroimaging 
technique to calculate the gradual conversion of MCI in AD. Yuan et al. (2009) 
concluded that FDG-PET showed better predictive capacity than SPECT or structural 
MRI techniques. 
Posterior cortical Atrophy (ACP) – a visual variant of AD 
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Up to now we have focused on studies related to the typical AD (Dubois et al., 2010, 
2014) or amnestic presentation (McKhann et al., 2011). Nevertheless, since we are 
focusing on the visual deficits of AD, it is imperative to refer that the recent criteria for 
AD comprise atypical forms of AD that include the posterior cortical atrophy (PCA; 
Dubois et al. 2010, 2014), or in the words of McKhann et al. (2011) - the visuospatial 
presentation of AD. Latter clinical criteria include: deficits are in spatial cognition, 
including object agnosia, impaired face recognition, simultanagnosia, and alexia, and 
deficits in other cognitive domains. In this section, we only wanted to take a brief 
overview on PCA’s concept and not review research studies on this pathology. For a 
recent literature review see Beh et al. (2015); Borruat (2013). 
PCA is an insidiously progressive dementia characterized by prominent disorders of 
higher visual processing as a result of an atrophy of the occipital and occipito-parietal 
regions of the brain. Benson et al. (1988) introduced the term PCA in 1988 to describe 
five patients with a progressive dementia, whose first symptoms were apraxia, alexia 
and visual agnosia. These patients usually have visual complaints, due to deficits in 
complex visual processing. This condition most commonly begins in the 50s or 60s with 
equal gender involvement, and a course of about 6-12 years (Cronin-Golomb, 2004). 
PCA patients have normal visual acuity but mild-to-moderate constriction of the 
peripheral visual fields; contrast sensitivity for low spatial frequencies can be severely 
impaired (as can be found for AD patients). These patients probably have deficits in 
depth perception similar to those seen in typical AD, and show an impairment in global 
as opposed to local processing (Cronin-Golomb, 2004) – simultanagnosia. 
Visuospatial deficits such as Bálint’s Syndrome (BS) are among the most common 
manifestations of PCA. This syndrome described by Rezso Bálint “is caused by bilateral 
lesions of the occipito-parietal junction that rendered its victims functionally blind” 
(Rafal, 2001). PCA patients can show: inability to copy or trace drawings 
(“constructional apraxia”); difficulty in visual integration of whole scenes (“ventral 
simultanagnosia”) and detection of two or more stimuli simultaneously (“dorsal 
simultanagnosia”) (Benson et al., 1988). This last condition leads patients to have their 
attention fixed on a single object or detail in the scene and neglect all the other objects 
– they perceive each object at a time (Rafal, 2001). Dorsal simultanagnosia is part of 
the triad of BS along with inability to look towards a stimulus by visual guidance 
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(oculomotor apraxia); and inability to reach for a stimulus by visual guidance (optic 
ataxia) (Cronin-Golomb, 2004).  
Subjects with PCA may present dorsal simultanagnosia as an initial manifestation, but 
can manifest other isolated symptoms of BS during the course of the disease (Cronin-
Golomb, 2004). These patients can also have deficits in visuospatial attention resulting 
in right or left visual field extinction, hemi-inattention, or hemispatial neglect. PCA is 
related with other visuospatial disturbances such as: general difficulty with spatial 
localization, environmental disorientation, dressing apraxia, and disturbed spatial 
cognition (determining the orientation or axes of non-upright objects) (Cronin-Golomb, 
2004). 
PCA patients can also show perceptual visual symptoms, as progressive visual agnosia, 
with impaired visual recognition, in the presence of intact tactile recognition. This 
condition is usually of the apperceptive type, given the presence of difficulty with 
figure-ground discrimination, vulnerability to ambient illumination, visual synthesis, 
fragmented or degraded stimuli, and matching and copying shapes. Colour perception 
can also be altered in PCA in the forms of hemiachromatopsia, colour anomia, or 
colour agnosia. Problems as prosopagnosia, or recognition of familiar faces, are less 
common in PCA probably due to sparing of the more anterior, inferior temporal lobes 
(Cronin-Golomb, 2004). 
PCA subjects often complain of difficulties in reading or writing. Alexia that is 
disproportionate in comparison to other language problems is the most common 
disturbance in PCA. In addition to “pure alexia” (alexia without agraphia), visual 
disturbances such as simultanagnosia can play a role in producing alexia and in 
particular, letter-by-letter reading (Cronin-Golomb, 2004). 
PCA have two major types of asymmetric variants: i) BS - if it comprises the dorsal 
“where” (occipito-parietal) visual pathway, thus resulting in spatial perception 
impairment; and ii) visual agnosia and impairment in object perception – if the ventral 
“what” (occipito-temporal) visual pathway is involved. This segregation of deficits into 
dorsal and ventral streams is not precise, and some patients have a mixture of 
disturbances from both. It is worth to note that PCA may affect one hemisphere more 
than the other. A great involvement of the left hemisphere can result in a progressive 
visual agnosia, Gerstmann’s syndrome (linguistic agraphia, acalculia, right-left 
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disorientation, and finger agnosia), right hemiachromatopsia, and pure alexia without 
agraphia. A predominant involvement of the right hemisphere can result in left visual 
hemi-neglect, oculomotor apraxia, dressing apraxia, alexia for music, and spatial 
agraphia (Cronin-Golomb, 2004). 
PCA differs in several ways from typical clinical AD. PCA patients usually have a 
younger age of onset than those with typical AD. In PCA, memory and language are 
quite preserved until later in the course of the disease (Goethals & Santens, 2001), due 
to a relative sparing of the mesio-temporal region on this condition. In contrast, 
patients with typical AD have complex visual deficits later in the course of the disease, 
in contrast with PCA where a massive deposition of neurofibrillary tangles and neuritic 
plaques may occur in primary visual and visual association areas. PCA patients have 
also more insight for their illness and more depression, consistent with sparing of the 
frontal lobe (Cronin-Golomb, 2004). These patients showed hypometabolism in 
primary and extrastriate visual areas and in parietal and superior temporal cortical 
areas, relative to healthy aged controls; and hypometabolism in visual association 
areas, relative to amnestic AD subjects (Bokde et al., 2001), proving the selective 
involvement of the visual areas on this specific condition. 
PCA is most commonly, but not exclusively, an atypical/non-amnestic form of AD. It 
corresponds to the “visual variant” of AD due to the neuropathology in primary visual 
and visual association areas (Cronin-Golomb, 2004). 
 
General outline and aims of Chapter II 
The main purpose of Chapter II of the current thesis was to investigate the visuospatial 
processing of AD and MCI pathologies and to further explore it as a potential new 
biomarker. 
As previously reported, there is a lack of visual function studies in MCI when compared 
with the amount of research in AD. Some studies report an involvement of high-level 
visual functions, showing visual search/attentional impairment in MCI (Mapstone et al. 
2003; Tales et al. 2005). Nevertheless, other functions may still be preserved in this 
condition (Rizzo et al. 2000). Despite the lack of cure or prevention for AD at the 
present moment, medication for modifying or slowing down the progression of the 
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disease is currently being developed, making biomarkers for early detection of true 
preclinical AD a major concern and priority. Given MCI’s potential conversion 
predicting value, it is important to study visual function at its stage. 
Moreover, Cronin-Golomb et al. (1995) suggested that visual dysfunction is a 
“significant predictor of cognitive dysfunction in AD” and “may have a strong 
functional impact on cognitive domains”. This idea is corroborated by recent evidence 
indicating that sensory and motor changes may precede the cognitive symptoms of AD 
(visual system included) (Albers et al., 2015). 
Behavioural studies through the use of psychophysical techniques are among the 
majority of references reported. But it is noteworthy that, in the recent years, the role 
of neuroimaging in the understanding of disease mechanisms in AD is becoming 
increasingly recognized. Neuroimaging has the potential to provide novel biomarkers, 
in addition to psychophysical and neurophysiological measures and to confirm the 
involvement of specific brain regions while performing visual paradigms. 
Study 8, Specific dorsal and ventral visual stream deficits in Mild Cognitive Impairment 
and Alzheimer’s disease, explored both the dorsal and ventral processings in AD and 
MCI. The inclusion of tasks requiring low-level visual engagement, as well as more 
high-level motion coherence detection paradigms, aimed at highlighting the visual 
dorsal stream dysfunction of AD and exploring the performance of MCI patients. An 
additional goal was to correlate the performance across the visual tasks with the 
cognitive results. 
In Study 9 our main goal was to identify the structural correlates of the results 
observed in Study 8 and in Graewe et al. (2013) where deficits in complex face and 
object recognition in MCI patients were found. We wanted to explore the contribution 
of both ventral and dorsal visual areas as a putative biomarker of AD symptomatology. 
Our approach included a behavioral experimental paradigm with 3D SFM defined faces 
and objects and morphometric analysis including the computation of cortical thickness 
maps and hippocampal volumetry using MRI, in MCI. 
At the end of this chapter, we present a discussion emphasising the main results of this 
studies, and thus reflecting on their main limitations, as well as the implications of 
including new protocols that quantify visual dysfunction in monitoring the disease 
progression in MCI and AD. 
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Abstract  
The nature of visual impairments in Alzheimer’s disease (AD) and their relation with 
other cognitive deficits remains highly debated. We asked whether independent visual 
deficits are present in AD and amnestic forms of Mild Cognitive Impairment (MCI) in 
the absence of other comorbidities by performing a hierarchical analysis of low-level 
and high-level visual function in MCI and AD. Since parietal structures are a frequent 
pathophysiological target in AD and sub-serve 3D vision driven by motion cues, we 
hypothesized that the parietal visual dorsal stream function is predominantly affected 
in these conditions. We used a novel 3D task combining three critical variables to 
challenge parietal function: 3D motion coherence of objects of unknown orientation, 
with constrained temporal integration of these cues. Groups of amnestic MCI (N=20), 
AD (N=19) and matched controls (N=20) were studied. Low-level visual function was 
assessed using psychophysical contrast sensitivity tests probing the magnocellular, 
parvocellular and koniocellular pathways. We probed visual ventral stream function 
using the Benton Face recognition task.  
We have found hierarchical visual impairment in AD, independently of 
neuropsychological deficits, in particular in the novel parietal 3D task, which was 
selectively affected in MCI. Integration of local motion cues into 3D objects was 
specifically and most strongly impaired in AD and MCI, especially when 3D motion was 
unpredictable, with variable orientation and short-lived in space and time. 
In sum, specific early dorsal stream visual impairment occurs independently of ventral 
stream, low-level visual and neuropsychological deficits, in amnestic types of MCI and 
AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common type of dementia and its 
pathophysiology may start years before the clinical onset, leading to the concept of 
preclinical AD (Albert et al., 2011; Dubois et al., 2007, 2010). This entity is separable 
from the clinical definition of Mild Cognitive Impairment (MCI; Petersen et al., 1999) 
and is operationally defined based on biomarkers such as CSF amyloid or elevated 
tracer retention on PET amyloid imaging. MCI is characterized by a greater cognitive 
impairment than that expected for age and education level but not into an extent to 
qualify patients as demented (Petersen et al., 1999). In AD it is however hard to find a 
solid link between the appearance of any specific biomarker and the subsequent 
emergence of clinical symptoms, and a substantial amount of work is still needed to 
validate and standardize the criteria that use biomarkers (Albert et al., 2011). In this 
study we have therefore focused on established AD and MCI. 
AD is known to involve visual pathways, but the nature of its effects on vision in 
relation to functional pathways and disease stage still remains elusive (for a review see 
Duffy (2009). This point is of outstanding importance give that multimodal imaging 
studies have shown that dorsal stream parietal regions involved in 3D object 
processing (Mendes et al., 2005; Orban, 2011; Verhoef, Vogels, & Janssen, 2010) seem 
to be an early target of disease pathology in terms of cortical thinning (Ewers et al., 
2011); amyloid binding (Apostolova et al., 2010; Chételat et al., 2010; Tosun, Schuff, 
Mathis, Jagust, & Weiner, 2011) and impaired  metabolism (FDG-PET; Herholz, 2011; 
Morbelli et al., 2010). 
Most previous functional studies do not separate visual processing across specific 
features and pathways from other cognitive processes. A notable exception is a study 
(Rizzo, Anderson, & Nawrot, 2000) in participants with AD which suggested static 
visual acuity, stereoacuity, dynamic visual acuity or motion direction discrimination are 
preserved or less affected in AD, in comparison with static spatial contrast sensitivity 
(CS), visual attention, shape-from-motion, color, visuospatial construction and visual 
memory. In any case, these studies on visual cognition have focused on established AD 
and not MCI. In addition to the described dorsal stream deficits (Rizzo et al., 2000) and 
attentional impairments (Tales, Muir, Bayer, & Snowden, 2002; Tales, Haworth, 
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Nelson, Snowden, & Wilcock, 2005), ventral stream (object recognition) deficits have 
also been reported, using the Benton Facial Recognition Test and the Overlapping 
figures task (Mosimann et al., 2004). A recent fMRI study examined visual processing in 
MCI (Bokde et al., 2008) but did not find any differences in task performance, in spite 
of the observed differences in activation patterns. 
An event-related fMRI three-year prospective study (Vannini, Almkvist, Dierks, 
Lehmann, & Wahlund, 2007) investigated the function of brain regions in the 
visuospatial networks underlying preclinical symptoms in AD but no performance 
differences were found using an angle discrimination task.  Nevertheless, increased 
parietal activation in progressing MCI has been suggested to reflect a reduced 
“neuronal efficacy” (a still controversial concept) due to accumulating AD pathology 
and to be predictive of future clinical decline.  In line with this reasoning, another 
study (Teipel et al., 2007) showed that during face matching tasks, fusiform gyrus 
activation is positively correlated with cortical grey matter density of brain areas 
belonging to the ventral visual stream and negatively correlated with grey matter 
density of brain areas belonging to the dorsal visual stream, and that these effects are 
more pronounced in MCI patients than in controls. In this type of task there were no 
statistical differences found in task performance or activation between groups (Bokde 
et al., 2006). These studies are important because they pinpoint the occurrence of 
functional and structural changes in regions of the cerebral cortex (fusiform and in 
particular parietal) involved in the perception of 3D objects (Whitwell et al., 2007), but 
do not directly address differences in performance levels across clinical populations. 
Similar findings have been uncovered by electro-encephalography (EEG) measures, 
such as defined by a source image study that found three different neural patterns in 
aged individuals (Haupt, González-Hernández, & Scherbaum, 2008). Still other studies 
(Rombouts, Barkhof, Goekoop, Stam, & Scheltens, 2005) have focused on altered 
resting state networks in MCI in AD. However, in spite of the value of pattern 
recognition based neuroimaging strategies, direct approaches that focus on 
psychophysical performance are needed. Here we chose to analyze low and high level 
visual performance in MCI and AD, with an emphasis on dorsal stream (parietal) 
performance in 3D vision tasks. 
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This hierarchical approach is justified by the notion that the retinocortical 
magnocellular pathway (sensitive to local motion and with high CS) represents the 
main projection to the visual dorsal stream, where motion integration takes place 
(Castelo-Branco et al., 2002, 2006, 2007). The parvocellular pathway is, on the 
contrary, contrast and motion insensitive, and responds to spatial detail (Silva et al., 
2005) (its neurons behaving as high resolution channels, sensitive to high spatial 
frequencies). Importantly, it is essential to compare performance across multiple low 
and high-level tasks and understand their interdependence. Magnocellular impairment 
occurs in other neurodegenerative disorders such as Parkinson disease, and does not 
necessarily predict high-level motion integration deficits (Castelo-Branco et al., 2009; 
Silva et al., 2005). It is important to understand how these deficits in MCI and AD relate 
to intermediate (motion detection, speed and direction discrimination) and high-level 
motion processing (requiring global integration of coherent motion cues). We used a 
simple 3D visual task that required integration of motion cues (3D motion coherence 
task). Direction of motion was unpredictable and time constraints were either present 
or absent (Mendes et al., 2005). 
In our study, we have therefore explored tasks requiring low-level visual engagement, 
as well as more high-level motion coherence detection paradigms (Mendes et al., 
2005). Based on previous studies in other models of dorsal stream function (Castelo-
Branco et al., 2007, 2009; Mendes et al., 2005), we designed a novel 3D task made to 
target dorsal stream (parietal) brain functions involved in AD pathology. Subjects just 
had to detect the presence of a “sphere” and task comprehension could be objectively 
controlled for in every subject by verifying that the shape of curve of the 
psychophysical response staircase moved monotonically to a threshold value. The 
“sphere” could be integrated from “signal” dots moving with its surfaces. “Noise” dots 
(not belonging to the surface) were also present. The percentage of signal dots 
(coherence level) varied between 0 and 100%. 
In sum, the main goal was to highlight visual dorsal stream dysfunction in established 
AD and MCI by forcing participants to extract 3D motion coherence of objects of 
unknown orientation, with constrained temporal integration of these cues. An 
additional goal was to establish a correlation between performance across tasks 
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recruiting different levels and streams of visual analysis, and 
clinical/neuropsychological stage. 
 
Methods 
Participants 
Both MCI (n=20) and AD (n=19) patients were recruited from the Neurology 
Department of Coimbra University Hospital. The clinical evaluation was performed by 
one of the authors (I.S.) and the diagnosis was established following Petersen’s 
classification criteria for MCI (Petersen, 2004) and NINCDS-ADRDA (McKhann et al., 
1984) criteria for AD. MCI patients included in this study were of the amnestic type and 
the diagnosis was made in accordance with published criteria (Albert et al., 2011; 
Petersen, 2004; Petersen et al., 1999) and taking into account the use of imaging 
biomarkers to exclude other comorbidities (Albert et al., 2011). We have focused on 
patients with amnestic single domain MCI (at high risk for AD) and excluded patients 
with amnestic multidomain MCI. Controls underwent the same evaluation to exclude 
MCI, as well as ophthalmological assessment concerning exclusion criteria for visual 
conditions (Castelo-Branco, Faria, Forjaz, Kozak, & Azevedo, 2004). 
Diagnostic investigation included a standard clinical evaluation, an extensive cognitive 
and staging assessment, laboratory tests and imaging studies. Standard laboratory 
tests (including apolipoprotein E (ApoE) allele genotyping, imaging studies (CT or MRI) 
and SPECT were always performed in both patient groups. For genotyping, DNA was 
isolated from whole blood using a commercial kit (Roche Diagnostics GmbH, Manheim, 
Germany), as described by the manufacturer. ApoE genotype was determined by 
polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) 
assay. A comprehensive diagnostic battery was administered, including: 1) Cognitive 
instruments as the Mini-Mental State Examination (MMSE; Folstein, Folstein, & 
McHugh, 1975) Portuguese version (cut off scores were adjusted for education level 
according to (Guerreiro et al., 2008: 3 cut offs for 3 education levels), the Alzheimer 
Disease Assessment Scale-Cognitive [ADAS-Cog; Mohs, Rosen, & Davis, 1983) 
Portuguese version (Guerreiro, Fonseca, Barreto, & Garcia, 2008)] and a 
comprehensive neuropsychological battery with normative data for the Portuguese 
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population (BLAD; Guerreiro, 1998) exploring memory (Wechsler Memory Scale 
subtests) and other cognitive domains; 2) The Clinical Dementia Rating (CDR; Garrett 
et al., 2008; Morris, 1993) was used for global staging.  
MCI patients were identified as follows: 1) A subjective complaint of memory decline 
(reported by the subject or an informant); 2) An objective memory impairment 
(considered when scores on standard Wechsler memory tests were 1.5 standard 
deviation below age/education adjusted norms); 3) Normal general cognition suggested 
by normal scores in the MMSE and ADAS-Cog using the Portuguese cut off scores 
(Guerreiro, Fonseca, et al., 2008; Guerreiro, Silva, et al., 2008); 4) Largely normal daily 
life activities; 5) Absence of dementia, indicated by a CDR rating of 0.5; and 6) 
Exclusion of co-morbidities using imaging methods. The patients of the MCI group 
were previously characterized in two previous studies from our group (Baldeiras et al., 
2008, 2010) the first concerning oxidative damage, and the second being a follow-up 
study of progression to AD. In this last study, within the group showing conversion to 
dementia (within two years), 6 subjects were part of the present study and 4 were 
ApoE-ε4 allele carriers. 
Control subjects (n=20) were recruited among the patients’ spouses, age-matched 
hospital or university staff, or their relatives, all participants belonging to the local 
community, without any neurological or psychiatric relevant condition. All control 
subjects had normal MMSE scores (mean 28.9), absence of memory impairment and 
normal daily life activities. All subjects from the 3 groups were submitted to the same 
experimental research protocol. 
Informed consent was obtained from all participants, and the study was conducted in 
accordance with the tenets of the Declaration of Helsinki, with the approval of the 
ethics committee of the Faculty of Medicine of Coimbra. All subjects underwent full 
ophthalmologic examination that consisted of best-corrected visual acuity (VA; Snellen 
chart), slit lamp examination of anterior chamber, IOP measurement (Goldman 
applanation tonometer), angle and fundus examination (Goldman lens), cataract 
grading by the Lens Opacities Classification System II (LOCS) and the assessment of 
subjective visual complaints. 
As exclusion criteria we considered neurological/psychiatric conditions other than MCI 
and AD; CT or MRI demonstration of significant vascular burden (Román et al., 1993) 
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(large cortico-subcortical infarct; subcortical white matter lesions superior to 25%; uni 
or bilateral thalamic lacune; lacune in head of caudate nucleus; more than 2 lacunes); 
diabetes, glaucoma, visual acuity < 0.6 , high ammetropy (sphere dpt > 4 and cylinder 
dpt > 2), untreated cataract requiring surgery, ocular motor paralysis, congenital 
amblyopia or hereditary colour blindness of retinal origin and other ophthalmological 
diseases. 
The three groups were matched for age [F(2,56)=1.800, p=0.143] and education levels 
[F(2,56)=0.225, p=0.79]. The education level was not significantly correlated with 
sensory performance.  
Demographic and clinical characteristics of the population are shown in Table 8.1. 
Procedure 
 Neuropsychological assessment 
To study overall cognitive functioning of the three groups, we used an extensive 
neuropsychological test battery. The general cognitive function/verbal intelligence was 
measured with the Vocabulary subtest of the Wechsler Adult Intelligence Scale (WAIS-
III; Wechsler, 2008). Verbal memory was assessed with the Portuguese version of the 
Rey Auditory Verbal Learning Test (RAVLT; Cavaco et al., 2008), and visual memory was 
measured by the Benton Visual Retention Test (BVRT; Benton, Hamsher, & Spreen, 
1994). The Digit Span (Forward and Backward recall versions) and the Digit Symbol of 
the WAIS-III (Wechsler, 2008) were also tested. Face perception was assessed by the 
Benton Facial Recognition Test (Benton et al., 1994). Handedness was defined by using 
a translated version of the Edinburgh Handedness Inventory (Oldfield, 1971).  
 Psychophysical assessment of visual function 
All participants performed chromatic and achromatic CS testing under monocular 
conditions (using the dominant eye as a pseudorandom choice criterion), in centre (5 
degrees) and peripheral (5 to 10 and 10 to 20 degrees) visual locations. Stimuli were 
displayed on a 21 inch monitor (GDM-F520; Sony, Tokyo, Japan) that was gamma-
corrected. 
Hierarchical approach to study the magnocellular and dorsal stream processing’s.  
1) Assessment of low-level (magnocellular) performance:  
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Here we used a very simple contrast detection task, using stimulus characteristics that 
are suited to activate the magnocellular pathway. This pathway is motion and CS and 
feeds to the visual dorsal pathway. 
CS measurements were therefore applied using stimuli with high temporal and low 
spatial frequency. We have applied CS multiple interleaved staircase test strategies, 
where stimuli were patches of 0.25 cpd (cycle per degree) of vertically oriented 
sinusoidal gratings, undergoing 25 Hz counterphase flicker, that are best suited to 
assess the magnocellular system (Castelo-Branco et al., 2006; Silva et al., 2005; 2008). 
Standard voltage–luminance curves were measured for each phosphor with software 
and hardware (including a Minolta colorimeter) provided by CRS (Cambridge Research 
Systems, Rochester, UK), which ensured gamma correction. Mean background 
luminance was 61.7 cd/m2.  
2) Parvocellular/Koniocellular pathways: 
The parvocellular pathway is sensitive to specific modulations of red-green color 
contrast whereas the koniocellular pathway is modulated by chromatic modulations in 
the blue-yellow axis. Our psychophysical strategy did therefore rely on these types of 
manipulation. 
We have probed the parvo and koniocellular pathways using a computer controlled 
psychophysical method taken from the Cambridge Color Test [Cambridge Research 
Systems (CRS), Rochester, UK] (Castelo-Branco et al., 2004). This technique uses a 
luminance noise strategy that forces the subject to rely exclusively on color cues to 
identify the position of a gap in a Landolt-like C-shaped ring. Implementation and 
calibration procedures were performed with software and hardware provided by CRS 
(Minolta colorimeter; calibration software and CRS/VSG 2/5 graphics card, with 15-bit 
contrast resolution per pixel). All participants viewed with refraction corrected for 
viewing distance a screen with a pattern of circles of various sizes and luminance with 
superimposed chromatic contrast defining the C-ring. The monocular viewing 
conditions were such that of all areas it was the macular area of the retina that the 
patients had to use to perform chromatic comparisons. Given the subjects’ average 
age, and to exclude confounding factors such as motor errors, the experimenter 
recorded subjects’ oral responses using a 4-button response box. To further emphasize 
accuracy versus speed in the measurement of psychophysical responses, subjects were 
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instructed that they had up to 20 seconds to report their decision. The subject had to 
indicate one out of four possible gap positions (bottom, top, left and right) of the 
Landolt C stimulus. Luminance and size variation of stimulus patches forced the subject 
to use specific color cues, since he/she could not use spatial or luminance cues to infer 
the embedded shape. These patches were randomly assigned six different luminance 
noise levels (8 to 18 cd/m2 in steps of two units). A minimum excursion of 0.002 units 
in CIE 1976 u’ v’ color space was then superimposed on such noise levels, to define the 
chromatic shape. 
The chromaticity of the Landolt C shape was adjusted according to a staircase 
procedure (see below). Quantitative adjustment in terms of modulation of chromatic 
contrast allowed for isolation of cone or color-opponent specific responses in CIE 1976 
(u’ v’ color space). Chromatic performance along the classical cone axes (protan, 
deutan and tritan) were explored with algorithms implementing three independent 
random staircases, from the Trivector version of the test, which ensured unbiased 
measurement of thresholds across the three main chromatic axes. 
Hierarchical approach to the study of integrative dorsal stream’s processing.  
1) Assessment of high-level 3D structure-from-motion (SFM) performance: 
The choice of the task was made to target functions from dorsal stream brain regions 
(posterior parietal) involved in AD pathology and sub-serving 3D vision. Given the 
nature of the clinical populations we designed a very simple task where subjects just 
need to report the presence of a “ball or sphere”. This task is very easy to perform 
because the “sphere” becomes very noticeable, with a strong 3D percept, once stimuli 
are above threshold. Comprehension and performance can objectively be controlled 
by analysing the shape of the curve of the psychophysical staircase (if the subjects 
understand the task, the staircase converges in a monotonic way to asymptotic 
threshold levels). This represents a great methodological advance because one can 
reliably control for correct task performance using objective criteria. We also had a 
familiarization session prior to the formal test and made sure that all subjects 
understood the task. This was then verified by analysis of the psychophysical staircase.   
Motion stimuli were generated using Vision-WorksTM for Windows (Vision Research 
Graphics, Wisconsin, USA) in a Trinitron GDM-F520 monitor. Viewing distance was 56 
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cm. Pixel size was 0.056 degree2 and dot size was 3*2 pixels. Dot density was 3 
dots/degree2. Background luminance was ~0 cd/m2 and one pixel had approximately 
18 cd/m2. In all experiments, a two-alternative forced-choice staircase method 
(temporal) was used (with 12 reversals, 6 practice and 6 experimental). Steps were 
0.01 log units in size. Durations of fixed stimulus presentations were of 200 ms in the 
main test, after which a grey background appeared, and was present until the subject 
responded and the next trial commenced. In an additional control task stimuli were 
present until the behavioural response. 
Visual thresholds were measured in terms of motion coherence of spherical surfaces. 
The stimulus consisted of dots placed on the surface of a rotating sphere 3-in diameter 
revolving around an imaginary axis, whose angle varied in a pseudo-random way. 
Speed of revolution was purposefully slow (20 rpm). The sphere alternated within one 
aperture with a stimulus consisting of 100% noise dots that moved at 2 degrees/s. 
Subjects had to report the presence or absence of a rotating sphere.  
Statistical analysis 
Statistical analysis was performed with the STATVIEW and SPSS software packages 
(SAS, Cary, NC and SPSS, Inc., Chicago, IL, respectively). We have used ANOVA after 
verifying statistical assumptions using the Kolmogorov-Smirnov normality check and 
Levene homogeneity tests. Pearson correlation analysis between visual low 
(magno/parvo), high level (dorsal/ventral) parameters of visual function and 
neuropsychological measures was also performed. 
 
Results 
Neuropsychological evaluation 
Concerning demographic variables (Table 8.1), ANOVA showed neither group effects 
concerning age nor education.  
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Table 8.1. Demographic and Clinical characteristics of the population 
 Controls 
(n=20) 
MCI 
(n=20) 
AD 
(n=19) 
Gender (m:f) 10:10 10:10 7:12 
Age (years) 67.6 (8.7) 69.9 (8.1) 73.1 (8.9) 
Education Level (years) 9.7 (6) 8.8 (5.3) 8.5 (5.7) 
MMSE (score) 28.9 (1.1) 27.8 (2.1) 22.4 (3.3) 
CDR (score) -- 0.5 (0.0) 1.0 (0.0) 
ApoE 4 carrier, n(%) -- 9 (45) 9 (47) 
Abbreviations: MCI = Mild Cognitive Impairment 
AD = Alzheimer’s disease 
MMSE = Mini-Mental State Examination 
CDR = Clinical Dementia Rating 
Note: Data are expressed as mean (SEM) except for the ApoE carrier state. 
 
For neuropsychological performance, we found main effects for Digit Symbol 
[F(2,56)=10.8, p<.001]; Backward Digit Span [F(2,56)=5, p=.01]; Vocabulary subtest of 
the WAIS-III [F(2,56)=7.6, p=.001]; BVRT [F(2,56)=20, p<.001] and RAVLT. Except for the 
expected deterioration observed in MCI for RAVLT measures, post hoc (Dunnett) 
analysis showed that these differences were mainly due to the deterioration observed 
in AD patients (post hoc t comparisons with the control group: Digit Symbol, p<.001; 
Backward Digit Span, p=.01; Vocabulary, p<.001; BVRT, p<.001). MCI participants 
showed a performance pattern in these tasks that did not significantly differ from 
controls except in RAVLT, as expected. Concerning memory performance, we did 
indeed observe the expected pattern of amnestic deterioration as indexed by 
performance differences in the RAVLT (total trials 1-5, recall and recognition measures) 
depicted in Table 8.1 (F(2,56)=11.4, p<.001, total trials 1-5 RAVLT;  F(2,56)=40.6, 
p<.001, recall RAVLT; F(2,56)=39.2, p<.001, recognition RAVLT). In all these memory 
measures, the two pathological groups were impaired (post hoc Dunnett: Total trials 1-
5, Controls versus AD: p<.001; Recall Controls versus MCI: p<.05; and Recognition, 
Controls vs. MCI: p<.01). 
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Table 8.2. Neuropsychological data  
 
Controls 
(n=20) 
MCI 
(n=20) 
AD 
(n=19) 
F 
Between-
group 
comparisons 
Handedness (R:L) 19:1 20:0 19:0 NA NA 
Vocabulary – WAIS-III (raw score) 44.2 (3.2) 36.5 (2.9) 27.6 (2.7) 7.6 p =.001* 
RAVLT (total trials 1-5) 43.4 (1.8) 36.5 (2.3) 20.9 (1.8) 11.4 p <.001† 
RAVLT (Recall) 10.0 (0.6) 6.6 (0.8) 1.3 (0.6) 40.6 p <.001‡ 
RAVLT (Recognition) 29.3 (0.3) 26.5 (0.7) 21.2 (0.9) 39.2 p <.001‡ 
BVRT (total correct) 4.6 (0.3) 4.4 (0.3) 1.9 (0.3) 20.0 p <.001* 
BVRT (errors) 8.9 (0.6) 10.5 (1.0) 17.6 (0.9) 30.6 p <.001* 
Digit Span – WAIS-III (forward) 7.2 (0.4) 7.3 (0.4)  
 
6.6 (0.4) 0.6 NS 
Digit Span – WAIS-III (backward) 4.8 (0.4) 4.7 (0.4) 3.3 (0.3) 5.0 p =.01§ 
Digit Span – WAIS-III (total) 12.0 (0.7) 11.9 (0.6) 9.9 (0.7) 2.9 NS 
Digit Symbol – WAIS-III (raw score) 30.4 (3.5) 22.8 (2.1) 13.0 (1.9) 10.8 p <.001* 
Abbreviations: WAIS-III  = Wechsler Adult Intelligence Scale-Third edition. 
RAVLT = Rey Auditory Verbal Learning Test. 
BVRT = Benton Visual Retention Test 
Note: Data are expressed as mean (SEM). 
Post hoc Dunnett tests compared Controls vs. MCI, Controls vs. AD, MCI vs. AD, and significant group differences are reported: 
* Controls vs. AD: p <.001. 
† Controls vs. MCI: p <.05; Controls vs. AD: p <.001; MCI vs. AD: p <.001. 
‡ Controls vs. MCI: p <.01; Controls vs. AD: p <.001; MCI vs. AD: p <.001. 
§ Controls vs. AD: p <.05. 
NA = not applicable. 
NS = not significant (p >.05). 
 
Low-level visual magno and parvocellular function in central and peripheral visual field 
 Functional evaluation of the magnocellular pathway (sensitive to local motion 
and with high CS): 
Central visual performance was preserved in all groups, in contrast to peripheral visual 
field performance (main effects: F(2,56) >7 for all peripheral regions: p<.001 for nasal, 
temporal and inferior regions, p<.002 for superior regions. Post hoc comparisons were 
all significant for the AD group (p<.001, for all tests). Interestingly, the MCI group 
showed a specific pattern of impairment in the temporal region (Figure 8.1, p=.04, post 
hoc Dunnett t test). 
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Figure 8.1 Performance of the magnocellular system (sensitive to local motion and contrast) 
across the visual field is preserved in central vision for both clinical groups, impaired in all 
peripheral regions in AD (black), and notably, already significantly impaired in the peripheral 
temporal region in MCI (grey) when compared to controls (white). This region is known to 
vulnerable to early damage in some neurophthalmological diseases.  
Error bars depict standard error of the mean (SEM). The dependent measure is CS measured in decibel units. 
 *p <.05; ***p <.001. 
 
 Functional evaluation of the parvocellular and koniocellular pathways (sensitive 
to chromatic contrast along the red-green and blue yellow axes, respectively): 
We isolated the function of parvocellular and koniocellular pathways by means of 
imposed colour modulation across specific contrast axes. We found a main group 
effect of CS loss across tritan (blue cone), protan (red cone) and deutan (green cone) 
pathways (F(2,56) = 7.6; 4.9; and 7.68, respectively with p=.001; .01 and .001, 
respectively). Post hoc analyses confirmed that these effects stemmed from the 
differences observed between the AD and the control group (p=.001; .01 and .001, 
respectively, in post hoc t tests). In sum, both parvocellular (red-green) and 
koniocellular (blue-yellow) pathways show significant impairment in AD, no significant 
changes being observed in MCI (Figure 8.2). 
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Figure 8.2 Both parvocellular (red-green) and koniocellular (blue-yellow) pathways show 
significant impairment in AD (black), no significant changes being observed in MCI (grey) when 
compared to controls (white).  
Error bars depict standard error of the mean (SEM). The dependent measure is color excursion units measured in CIE u’ v’color 
space units (enabling measures of chromatic contrast). 
***p <.001. 
 
High-level visual function in the dorsal parietal (3D object perception from motion 
cues) and ventral streams (static 2D object perception) 
We assessed object recognition, as an index of ventral stream function by means of 
the Benton Face Recognition Test. We observed again a main group effect 
(F(2,56)=13.5; p<.001) which was again solely explained by the difference between the 
AD group and the control group (Dunnett test, p<.001). This finding is further 
illustrated in Figure 8.3, which suggests that face discrimination recognition 
performance is significantly impaired only in the AD group. 
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Figure 8.3 Visual ventral stream performance in AD and MCI. Face discrimination recognition 
performance (as measured with the Benton Face Recognition Test) is significantly impaired 
only in AD.  
Error bars depict standard error of the mean (SEM). The dependent measure is number of correct responses. 
***p <.001. 
 
Concerning dorsal stream function, we have used the novel 3D visual task (Figure 8.4). 
To increase the dorsal stream demands of the task, the 3D spheres had a random axis 
of rotation, which forced discrimination of signal versus noise across multiple possible 
orientations. This rendered the task quite difficult especially for the 200 ms temporal 
presentation time condition. In an additional control condition, the participant was 
exposed to no limited stimulus presentation, rendering the task free of temporal 
integration constraints. Under both conditions (short and unlimited temporal 
presentation) a main effect of group was observed (F(2,56) =26.3 and 10, respectively, 
p<.001 for both conditions). Post hoc analysis showed that this effect was significant 
for the MCI group only in the temporally constrained integration condition (p=.035 for 
the comparison between MCI and control participants, p<.001 for the comparison 
between AD and control participants, post hoc t tests). Time is therefore a critical 
variable in the performance of this 3D task. In sum, the ability to detect simple 3D 
spheres with unpredictable axis of rotation and immersed in noise (variable 3D 
structure-from-motion task) is significantly impaired in AD and even MCI subjects 
(Figure 8.4). Interestingly, ROC analysis of this novel measure showed a significant 
discriminatory power of the AUC (area under the curve measure) in AD (AUC=0.96, 
#
 C
o
rr
e
c
t 
re
s
p
o
n
s
e
s
 
Benton Face Recognition Test 
Study 8 – Specific dorsal and ventral visual stream deficits in Mild Cognitive 
Impairment and Alzheimer’s disease 
287 
 
 
p<.001, with sensitivity reaching 90% for a specificity above 95%). In MCI 
discriminatory power was also significant (AUC=0.7, p<.05, with sensitivity reaching 
70% for a specificity above 65%). The novel 3D task was the most discriminative in 
terms of identifying visual dysfunction (as measured by the ROC based AUC) in AD 
(AUC = 96%, as compared to 78% in magnocellular measures, and 87% in parvocellular 
measures). 
 
Figure 8.4 Visual dorsal stream performance in AD and MCI, using a novel 3D task. The ability 
to detect moving 3D spheres with unpredictable axis of rotation, during a fixed temporal 
exposure (200 ms) and immersed in motion noise (variable 3D structure from motion task) is 
significantly impaired in MCI and AD.  
Error bars depict standard error of the mean (SEM). The dependent measure is % coherence (percentage of signal dots that are 
necessary for the subject to report the presence of a sphere). 
*p <.05; ***p <.001. 
 
Correlation analysis between visual low (magno/parvo), high-level (dorsal/ventral) 
parameters of visual function, and neuropsychological measures. 
 Control Group 
Visual function measures were found to be uncorrelated between performance 
measures testing low and high-levels of processing, as expected from the stimulus 
construction approach, which attempted isolation of distinct functional mechanisms 
(magno, konio, parvocellular, high level 3D vision and high level cognitive functions). 
Accordingly, correlations between high level (3D perception), low level magnocellular, 
parvocellular and neuropsychological measures (Vocabulary, MMSE, Digit Span and 
Digit Symbol, RAVLT) were absent. 
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 AD 
Concerning the AD group, no significant correlations were observed between 
magnocellular and dorsal stream 3D motion integration measures. Surprisingly, 
parvocellular function was significantly correlated with 3D motion coherence 
performance when temporal integration was constrained (p (corrected) <.05 for the 
green cone pathway, r=0.53) suggesting concomitant pathophysiology.  
Interestingly, both SFM (structure from motion 3D tasks, with or without in time 
constraints) share a relatively low amount of variance (25% percent in this group), 
which is consistent with the observation that visual temporal integration is strongly 
impaired in AD. 
Correlations between high level (3D perception) and neuropsychological measures 
(RAVLT, Vocabulary, MMSE, Digit Span and Digit Symbol) were not significant except 
for the MMSE measure (r=- 0.74, p<.05). Low level magnocellular and parvocellular 
visual measures were not significantly correlated with neuropsychological measures. 
 MCI 
The MCI group showed a correlation pattern that was more similar to the AD group 
than to controls, with parvocellular measures showing correlations with SFM (3D 
structure from motion) performance at both temporal presentation schemes (in 
particular for the red pathway, p (corrected) <.05 , r=0.60). Interestingly, temporal field 
magnocellular measures also showed significant correlations with SFM performance in 
particular for the short presentation condition (p (corrected) <.05, r = -0.56). The 
negative correlation is due to the fact that higher SFM scores correspond to worse 
performance and high achromatic CS scores in magnocellular tasks correspond to 
better performance. Correlations between high level (3D perception), low level 
magnocellular, parvocellular visual measures and neuropsychological measures were 
not significant, showing that other cognitive factors were not influencing task 
performance. 
 
Discussion 
Our results provide evidence for early dysfunction of dorsal stream (parietal) pathways 
processing 3D motion information relevant to object perception in MCI and AD, by 
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using objective psychophysical tests of achromatic CS, colour perception, 3D structure 
from motion and face perception. The specific pattern of impairment found in our 
patient samples suggests that occipital and parietal networks involved in 3D 
perception are dominantly affected in the course of disease, in relation to early visual 
magno, parvo and koniocelullar pathways. 
The 3D task was made to target functions from dorsal stream brain regions (posterior 
parietal) involved in AD pathology and sub-serving 3D vision. The task was very easy to 
perform because the subjects just had to detect the presence of a “sphere” and 
comprehension and performance could be objectively analysed by the shape of curve 
of the psychophysical response staircase (moving asymptotically to a threshold value). 
This type of impairment in 3D visual perception was found to be selectively present in 
MCI as opposed to magno/parvocellular impairment (related to local motion and 
spatial resolution processing, respectively) and high level visual processing deficits 
based on the ventral stream (related to static 2D object processing). The visual deficit 
in 3D processing was also dominant in AD. We were able in this way to show that high-
level integration of local motion cues into 3D objects was impaired in MCI and AD, 
especially when 3D motion was unpredictable and short lived. This independent 
impairment was not explained by other neuropsychological deficits, as revealed by 
correlation analysis, and was significantly discriminatory of AD and MCI groups, as 
revealed by ROC analysis.  
Although it is already known that high level object perception is impaired in AD (Duffy, 
2009), studies focusing on sensitive and specific paradigms that can unravel pathway 
specific impairment in this condition and MCI are still lacking. The combination of 
three critical variables that are relevant for dorsal stream function: 3D motion 
coherence (% signal versus noise motion cues), requiring motion cue integration, 
discrimination of 3D orientation of objects, and temporal integration of these cues, 
was relevant in this respect. This is because we have probed the ability to integrate 
motion signals from noise signals (which percentage varied) to perceive 3D rotating 
spheres with unpredictable orientation. Performance under noisy conditions may be 
important in real life conditions as well as in biomarker search. To increase the dorsal 
stream demands of the task, these spheres had indeed a random axis of rotation, 
which forced discrimination of signal versus noise across multiple possible integration 
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axes. Interestingly, we also found evidence that available time is critical in perceptual 
integration in this condition. 
Previous studies have shown impaired space-motion perception in late stages of 
Parkinson’s disease (accompanied with dementia) (Mosimann et al., 2004), and our 
study extends its logic and design by exploring motion perception in a hierarchical 
manner (separating local from global motion perception), in MCI and AD. Furthermore, 
we have explicitly correlated motion integration skills with magnocellular function. 
Impairment of more basic detection of local displacement had been reported 
previously in Parkinson’s disease, but the low versus high-level correlation with 
magno/dorsal stream dysfunction was not explicitly attempted (Silva et al., 2008). Our 
correlation analysis shows the expected absence of association across measures of low 
and high level visual function in normal subjects. Remarkably significant correlations 
between visual function measures were observed in both patient groups, suggesting 
an ongoing pathophysiological process that commonly affected multiple pathways. 
Notably, these correlations were not observed with neuropsychological measures, 
showing that psychophysical measures were genuinely independent. 
Interestingly, we found a magnocellular pattern of loss in the supero-temporal visual 
field in MCI. This pattern of early damage in some is in agreement with the known 
physiological lower functional reserve of this region (Silva et al., 2008, 2010) and 
features a vulnerability that is also observed in other visual disorders (Castelo-Branco 
et al., 2002; Maia-Lopes et al., 2008; Mendes et al., 2005).  
Concerning MCI patients it appears that parietal (dorsal visual) function, as measured 
by the novel 3D task, is probably affected earlier than occipital (early visual) cortex and 
infero-temporal (ventral visual) functions. In AD patients, this task was the most 
discriminative in terms of identifying visual dysfunction (as measured by the ROC 
based AUC measure). However, we also find that CS impairments are more salient in 
visual peripheral representations (in AD and to a smaller extent in MCI) suggesting a 
novel dissociation pattern between central (foveal) and peripheral loss patterns in 
these conditions. This dissociative profile is consistent with our previous findings 
concerning physiological integration of signals in central and peripheral processing 
(Kozak & Castelo-Branco, 2009; Ribeiro & Castelo-Branco, 2010). In any case, the 
demonstration that low signal to noise strength in space and time have a strong impact 
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on performance, generalizes to high level domains the notion that enhanced stimulus 
strength may improve visual cognition in aging and AD (Cronin-Golomb, Gilmore, 
Neargarder, Morrison, & Laudate, 2007).  
One limitation of our study is however that we could not address 
preclinical/prodromal AD, as operationally defined using biomarker criteria (Albert et 
al., 2011). Future studies should address this issue. 
We conclude that impaired dorsal stream (parietal) integration of 3D moving objects in 
short time windows occurs independently of ventral visual stream and 
neuropsychological deficits in amnestic types of MCI and AD. These deficits can be 
detected with high sensitivity both in MCI, and particularly in AD, using the reported 
novel 3D task, which allows separation between low and high level visual and other 
cognitive deficits. 
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Dorsal-ventral integration in the recognition of 3D SFM 
objects in mild cognitive impairment: a structure-function 
correlational study 
 
 
 
 
 
 
 
 
 
Adapted from: Lemos, R., Santana, I., Caetano, G., Bernardino, I., Morais, R., Farivar, R., & 
Castelo-Branco, M. (2015). 3D face recognition in Mild Cognitive Impairment: a psychophysical 
and structural MR study. (submitted to publication)  
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Abstract  
Mild Cognitive Impairment (MCI) has been associated with a high risk of conversion to 
Alzheimer’s disease (AD). In addition to memory complaints, impairments in the visuo-
spatial domain have been reported in this condition. We have previously shown that 
deficits in perceiving structure-from-motion (SFM) objects are reflected in functional 
reorganization of brain activity within the visual ventral stream. Here we aimed to 
identify structural correlates of psychophysical face recognition performance in 
amnestic MCI patients (n=30 versus n=25 controls). This study was therefore motivated 
by evidence from recent studies showing that a combination of visual information 
across dorsal and ventral visual streams may be needed for the perception of 3D SFM 
objects.  
In our experimental paradigm participants had to discriminate 3D SFM objects (faces) 
from 3D SFM meaningless (scrambled) shapes. Morphometric analysis established 
biological evidence for impairment in MCI as demonstrated by reduction of left 
hippocampal volume. We found association between cortical thickness and face 
recognition performance, comprising occipital lobe and visual ventral stream fusiform 
regions (overlapping the known location of face fusiform area) in the right hemisphere, 
in MCI.  
We conclude that impairment of 3D visual integration already exists at an early stage 
of MCI which also involves the visual ventral stream and contributes to face 
recognition deficits in biologically identified prodromal AD. The specificity of such 
observed structure-function correlation for faces suggests a special role of this 
processing pathway in health and disease. 
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Introduction  
The clinical interest in predicting progression of cognitive impairment to dementia 
(particularly Alzheimer’s disease – AD) has led to the definition of a transition period 
between normal cognitive function and dementia. This period has been defined using 
various clinical syndromal terms such as mild cognitive impairment (MCI; Petersen et 
al., 1999), prodromal AD (Dubois et al., 2007, 2010) and “MCI due to AD”(Albert et al., 
2011). 
In addition to the expected objective memory deficit, other brain systems may be 
altered in the preclinical (pre-dementia) phases of AD, including visual function. 
Distinct forms of visual impairment have been extensively reported in AD, ranging 
from contrast sensitivity and color perception deficits to impairments in higher-order 
visual functions, including object and face perception and visual attention, as well as 
visual memory and learning (Butter, Trobe, Foster, & Berent, 1996; Duffy, Tetewsky, & 
O’Brien, 2000; Rizzo, Anderson, & Nawrot, 2000). 
In a previous study, we found a selective deficit regarding integration of local motion 
cues into 3D objects  (structure-from-motion – SFM – stimulus) in a MCI group (Lemos, 
Figueiredo, Santana, Simões, & Castelo-Branco, 2012). The perception of SFM stimulus 
requires the integration of the local motion cues to extract the 3 D global 
configuration. Accordingly, the neural correlates of SFM perception involve the 
integration of two main visual cortical pathways: the ventral stream underlying the 
recognition of object shape properties and the dorsal pathway involved in spatial 
vision and motion perception (Farivar, Blanke, & Chaudhuri, 2009; Konen & Kastner, 
2008). 
Early evidence from primate studies reported strong tuning in MT for motion gradient 
selective neurons (Xiao, Marcar, Raiguel, & Orban, 1997), suggesting that the center-
surround structure may support 3-D slant and curvature perception. Mysore, Vogels, 
Raiguel, Todd, & Orban (2010) showed the selectivity of FST neurons for stimuli 
depicting specific shapes, coding motion-defined 3D shape fragments and 
underscoring the central role of FST in processing 3D SFM. 
Interestingly, the neural substrates of SFM perception in MCI patients were found to 
predominantly relate to aberrant patterns of activation in FFA/OFA in the presence of 
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normal recruitment of motion selective areas (MT), suggesting the activation pattern 
within the ventral visual stream as a putative biomarker for MCI (Graewe et al., 2013). 
The study of visuospatial perception in the MCI group using an experimental paradigm 
requiring dorsal and ventral processing may be important to clarify the role of these 
two visual pathways in the prediction of AD and better understand its 
pathophysiology, besides medial temporal lobe areas already known to be affected in 
this disorder (Jacobs et al., 2015; McKee et al., 2006; Villain, Chételat, Desgranges, & 
Eustache, 2010; Villain, Fouquet, et al., 2010). 
Psychophysical evidence corroborates this need, by indicating that the ventral visual 
pathway is more affected in full blown AD (Cronin-Golomb, 2004; Rizzo et al., 2000). 
Dorsal visual deficits have nevertheless also been documented in AD (A. L. W. Bokde et 
al., 2010; Kavcic, Vaughn, & Duffy, 2011; Lemos et al., 2012). Previous functional 
Magnetic Resonance Imaging (fMRI) studies suggested that reorganization may occur 
in both streams (Bokde et al., 2006; Prvulovic et al., 2002; Teipel et al., 2007; Vannini, 
Almkvist, Dierks, Lehmann, & Wahlund, 2007; Yamasaki, Muranaka, Kaseda, Mimori, & 
Tobimatsu, 2012). 
The main goal of this study was to identify the structural correlates of the previously 
observed (Graewe et al., 2013; Lemos et al., 2012) deficits in complex face and object 
recognition, in MCI patients, and explore the contribution of both ventral and dorsal 
visual areas as putative biomarker of AD symptomatology. 
Our approach included a behavioral experimental paradigm with 3D SFM defined faces 
and objects and morphometric analysis including the computation of cortical thickness 
(CT) maps and hippocampal volumetry using Magnetic Resonance Imaging (MRI). 
 
Methods 
Participants 
MCI patients (n=30) were recruited from the Neurology Department of the Coimbra 
University Hospital. Diagnosis was reached through gold standard neurological and 
neuropsychological assessment following published classification criteria for MCI 
(Albert et al., 2011; Petersen, 2004). All patients were of the amnestic MCI type (at 
high risk for AD). Diagnostic investigation included a standard clinical evaluation, a 
Study 9 – Dorsal-ventral integration in the recognition of 3D SFM objects in mild 
cognitive impairment: a structure-function correlational study 
299 
 
 
staging assessment as well as laboratory tests including apolipoprotein E (ApoE) allele 
genotyping and imaging studies (MRI, and SPECT/CT). 
The neuropsychological evaluation included a comprehensive diagnostic battery: 1) 
Cognitive instruments as the Mini-Mental State Examination (MMSE; Folstein, Folstein, 
& McHugh, 1975) Portuguese version (Guerreiro, Silva, et al., 2008), the Alzheimer 
Disease Assessment Scale-Cognitive (ADAS-Cog; Mohs, Rosen, & Davis, 1983) 
Portuguese version (Guerreiro, Fonseca, Barreto, & Garcia, 2008), and a 
comprehensive neuropsychological battery with normative data for the Portuguese 
population (BLAD; Guerreiro, 1998) exploring memory (Wechsler Memory Scale sub-
tests) and other cognitive domains; 2) The Clinical Dementia Rating (CDR; Morris, 
1993) Portuguese version (Garrett et al., 2008) was used for global staging.  
The inclusion criteria for MCI were those proposed by Petersen for MCI (Petersen, 
2004; Petersen et al., 2001) and were operationalized as follows: 1) A subjective 
complaint of memory decline (reported by the subject or an informant); 2) An 
objective memory impairment (considered when scores on standard Wechsler 
memory tests were 1.5 standard deviation below age/education adjusted norms) with 
or without deficits in other cognitive domains; 3) Normal general cognition suggested 
by normal scores in the MMSE and ADAS-Cog using the Portuguese cut off scores 
(Guerreiro, Fonseca, et al., 2008; Guerreiro, Silva, et al., 2008); 4) Largely normal daily 
life activities; 5) Absence of dementia, indicated by  a CDR rating of 0.5 (Morris, 1993). 
Patients were excluded if they had other psychiatric or neurological conditions than 
MCI; CT or MRI demonstration of significant vascular burden (Román et al., 1993) 
(large cortico-subcortical infarction; extensive subcortical white matter lesions 
superior to 25%; uni or bilateral thalamic lacunae; lacunae in head of caudate nucleus; 
more than 2 lacunae).  
Control subjects (n=25) were recruited among the patients’ spouses, age-matched 
hospital or university staff, or their relatives; with no relevant history of neurological or 
psychiatric conditions. All control subjects had normal MMSE scores (mean 29.3), 
absence of cognitive complaints and were independently functioning members of the 
community. 
All participants had no history of abnormal ophthalmological conditions and had 
normal or corrected-to-normal vision. 
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Informed consent was obtained from all participants, and the study was conducted in 
accordance with the tenets of the Declaration of Helsinki, with the approval of our 
local ethics committee. 
The two groups were matched for age [t (53) =-1.149, p=.256], education levels [t (53) 
=.841, p<.404], and gender [χ2 (2) =.039, p=.843]. As expected MCI patients performed 
poorly on the MMSE [t (53) =2.479, p<.016]. Demographical and clinical characteristics 
of the population are shown in Table 9.1.  
Table 9.1 Demographical and clinical characteristics of the population. 
 Control subjects 
 (n=25) 
MCI 
(n=30) 
Gender (m:f) 11:14 14:16 
Age (years) 63.4 (1.7) 66.1 (1.5) 
Education Level (years) 8.5 (0.7) 7.5 (0.8) 
MMSE (score) 29.3 (0.2) 28.5 (0.3)* 
CDR (score) -- 0.5 (0.0) 
ApoE 4 carrier, n(%)1 -- 11 (36.7) 
Note: 
MCI – Mild Cognitive Impairment 
MMSE – Mini-Mental State Examination 
CDR = Clinical Dementia Rating 
Data are expressed as mean (SEM) 
*p<.05 
1DNA was isolated from whole blood using a commercial kit (Roche Diagnostics GmbH, Manheim, Germany), as described by the 
manufacturer. ApoE genotype was determined by polymerase chain reaction-restriction fragment length polymorphisms (PCR-
RFLP) assay. 
 
Stimuli 
The paradigm used in this study is based on the study of Graewe et al. (2013), 
nevertheless, only the intermediate duration condition (160 ms) was used as it was the 
only one capable of discriminating MCI patients from healthy elderly controls. Videos 
of 3D SFM defined faces (for details see Farivar et al., 2009), scrambled faces, chairs 
and scrambled chairs were used as stimuli. The face stimulus consisted of one laser-
scanned facial surface taken from the Max-Planck Face Database (Troje & Bülthoff, 
1996). The surfaces were rendered a volumetric texture map to ensure uniform 
texture density – a process analogous to carving a surface out of a stone block. 
Shadows and shading were removed from the rendering. The faces were rendered 
against a similarly textured random-dot background. During the animation, the face 
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rotated from -22.5 degrees to 22.5 degrees, centered at the frontal plan, in one cycle 
(Figure 9.1a). The chair stimulus was obtained from a chair model database and was 
rendered in exactly the same manner as the face stimulus. Scrambled versions of the 
two stimuli were constructed by cutting the rendered whole object (face or chair) 
videos on the horizontal plane into ten blocks and scrambling their local 
curvatures/positions. The resulting scrambled stimuli share many of the low-level 
features of the original videos and are recognized as unfamiliar objects. It is important 
to note that these motion-defined objects are only visible when the animation is 
playing; otherwise participants are not able to interpret the SFM cues in order to 
extract a vivid three-dimensional percept, as desired.  
Procedure  
Participants were individually tested in a quiet and darkened room. They were seated 
in a comfortable chair at a distance of 50 cm from the computer screen. The stimuli, 
subtending ~13º horizontally and ~10º vertically, were presented in the center of a   
33,8 cm x 27,1 cm dark computer screen (1280 x 1024 pixels) using the software 
package Presentation (Neurobehavioral systems). 
Participants had to discriminate 3D SFM objects (faces and chairs) from 3D SFM 
meaningless objects (scrambled faces and scrambled chairs) on videos of 160ms 
duration. The investigator recorded subjects’ verbal responses using a 2-button 
response box to exclude confounding factors such as motor errors. On both Face and 
Chair tasks, depth was manipulated with the purpose of increasing the task complexity 
and unpredictability at variable 3D levels (full, intermediate and flat) (Figure 9.1b). 10 
trials per parameter value were included, in a total of 120 trials (Figure 9.1c). Before 
performing the experimental tasks, all participants underwent a demonstration and a 
practice phase. In the demonstration phase, the stimuli included in both Face and 
Chair tasks were shown in order to allow the participants to become familiar with the 
objects that they would be asked to recognize afterwards. The practice phase was 
applied before each experimental task and included 18 trials in which the different 
conditions were randomly presented. The practice phase was repeated whenever the 
participant did not understand the instructions.  
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Figure 9.1 – Stimuli and paradigm (adapted from Graewe et al., 2013): a) SFM faces and chairs 
rotated from left to right in one cycle and were shown during 160 ms. Object perception is 
rendered possible by integration of the moving dot pattern, the object being physically absent 
when the rotation/motion is absent; b) The depth modulation resulted in SFM stimulus 
conditions with variable depth levels parameterized in terms of anterior-posterior range; c) 
Stimuli were presented randomly at one of the three depth levels, separated by a fixation 
period during which the participants had unlimited time for response.  
Note: The images of the heads just illustrate the structure in the SFM stimuli (because they are physically absent and not visible in 
static images) and do not represent the exact percept constructed during the movies’ presentation. 
 
Image (MRI) acquisition 
Participants underwent Magnetic Resonance Imaging (MRI) scanning on a 3T Siemens 
Magnetom Trio scanner (Erlangen, Germany), using a 12-channel birdcage head coil. 
All participants belong to a local MRI cohort database, comprising a total of 108 MCI 
and 76 controls, from which 30 MCI and 18 controls participated in the psychophysics 
experiment described in the above section. 
1 (and often 2) high-resolution 3D T1-weighted magnetization-prepared rapid gradient 
echo (MP-RAGE) scans were collected per participant, with parameters defined on the 
basis of guidelines from the Alzheimer’s Disease Network Initiative (Jack et al., 2008): 
FOV=256, 160 slices, voxel resolution 1 x 1 x 1 mm3, TR = 2300 ms, TE = 2.98 ms, TI = 
900 ms, 9° flip angle, bandwidth 240Hz/px,  acceleration factor of 2 with 24 reference 
lines in the phase encoding direction. Acquisition parameters were optimized for 
increased great-white matter image contrast, while minimizing acquisition time.  
 Image Analysis Procedures 
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Measurement of cortical thickness and volumes in individual participants 
The structural MRI scans were processed using the FreeSurfer 5.0.0 software package 
(http://surfer.nmr.mgh.harvard.edu), using methods that are fully automated and 
extensively described (Dale, Fischl, & Sereno, 1999; Desikan et al., 2006; Fischl & Dale, 
2000; Fischl, Sereno, & Dale, 1999; Fischl et al., 2004; Fischl et al., 2002; Han et al., 
2006). Each MPRAGE MRI acquisition image was visually inspected for abnormalities 
unrelated to the underlying pathology, such as movement artifacts or concomitant 
pathologies. When available, two MRI acquisitions for each participant were motion 
corrected, averaged and normalized for intensity inhomogeneities, resulting on a 
single image with increased contrast-to-noise ratio. The resulting volume was used to 
locate the grey/white matter boundary, then used as a starting the point to define the 
grey/CSF boundary across the entire cortical mantle. For each participant, cortical 
thickness was estimated at each point of the cortical mantle by finding the shortest 
distance from the white matter surface to the grey matter surface (and vice-versa) and 
averaging those two values (Fischl & Dale, 2000). The neocortex was parcellated onto 
32 gyral-based regions-of-interest (ROI) (Fischl et al., 2004; Fischl et al., 2002) in each 
hemisphere, and in addition non-neocortical ROIs, such as hippocampus, were defined 
on the basis of automated procedures (Desikan et al., 2006). 
For each participant, the accuracy of the grey and white matter surfaces and of each 
individual ROI was carefully inspected by a trained neuroradiologist. When necessary, 
manual editing and corrections were applied, precluding skull stripping, white matter, 
control points, and removing inclusion of dura matter in grey matter surface 
(http://surfer.nmr.mgh.harvard.edu/fswiki/FsTutorial/). 
Registration and group cortical thickness maps 
For each participant, the white matter surface was morphed to an average spherical 
surface folding pattern representation – this is performed one hemisphere at a time – 
from which surface maps of cortical thickness were generated, at each vertex of the 
cortical mantle (Fischl et al., 1999). Smoothing of the data on the cortical tessellation 
was performed with a 2D surface-based Gaussian kernel of ≈20 mm full width half 
maximum. 
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Statistical analysis 
Statistical analysis was performed with the SPSS statistical software package, version 
19.0 (SPSS, Inc., Chicago, IL) with parametric and non-parametric tests corrected for 
multiple comparisons, when applicable. Results with p<.05 were considered 
statistically significant.  
 Psychophysics 
For the statistical analysis of the behavioral data a d’ (dprime) performance measure 
was computed for face and chair detection for each participant [d' = Z(hit rate) - Z(false 
alarm rate)]. A hit was considered when the subject recognized correctly the stimulus, 
whereas a false alarm was considered for conditions when the subject reported 
face/chair detection in the presence of a scrambled stimulus.  Independent t-tests 
were performed for comparison between the two groups.  
 Imaging 
Hippocampal volumes 
Two non-neocortical ROIs (left and right hemisphere hippocampus) were used in this 
study, with the purpose of assessing differences between MCI and control groups, in 
regions known to be pivotal in AD pathology. Volume measures were normalized for 
differences in estimated total intracranial volume (eTIV) through a ratio procedure. 
Group differences were assessed two-fold (Wilcoxon-Mann-Whitney, Bonferroni 
corrected): within the local MRI cohort database, and within the study sub-sample 
with structural MR images.  
Cortical thickness and vertex-based correlational analysis 
Analysis was performed using the cortical thickness maps obtained through spherical 
mapping and smoothing. A vertex-by-vertex analysis was carried out using a general 
linear model, with cortical thickness as the dependent variable and group as the 
independent variable. Age interaction effects were scrutinized for, and the number of 
structural MR images was introduced as a nuisance factor. Corrections for multiple 
comparisons were applied using false discovery rate (FDR) at a .05 significance level. 
Correlational analysis was performed, on a vertex-by-vertex basis, regressing cortical 
thickness against behavioral performance measures (dprime), and Nuisance factors 
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were taken into account, with the inclusion of participants’ age and the number of 
structural images per participant.  
 
Results 
Psychophysics 
We found significant group differences for face recognition performance (t (53) = 
2.503, p=.015). Interestingly, performance differences were also found for the chairs 
category (t (53) = 2.491, p=.016), albeit at a higher performance level.   
 
Figure 9.2 – Performance (as assessed by dprime measures) for the global Face and Chair 
Conditions. Stimulus duration: 160 ms. 
 
Hippocampal volumetry and cortical thickness and vertex-based correlational analysis  
 Hippocampal volumes were decreased bilaterally in the MCI study group, in 
particular in the left hemisphere (p<.01):  
Significant differences in the hippocampal volume were found in both the local cohort 
and the study sub-sample. In the former, hippocampal volumes were decreased 
bilaterally in the MCI group (Wilcoxon Mann-Whitney, p<.001, Bonferroni corrected), 
whereas in the latter, decreased volume was significant in the left hemisphere 
(Wilcoxon Mann-Whitney, p<.01, Bonferroni Corrected). 
At the level of cortical thickness analysis, we found that these measures were matched 
across the study group structural MR scans. Significant correlations between cortical 
thickness and behavioral measures were detected and can be found depicted in Figure 
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9.3 (with correction for multiple comparisons). Positive associations of cortical 
thickness and the face recognition performance (as assessed by dprime values), for the 
right hemisphere (in line with the known right hemispheric lateralization for face 
recognition), were identified in the MCI group, comprising occipital lobe (BA18) and 
fusiform (BA37) regions [(Table 9.2, showing a region overlapping FFA as identified by 
Graewe et al. (2013)] involved in visual face processing. No significant correlations 
applied for the chairs condition. 
Table 9.2 – Cortical areas showing positive correlations between thickness and psychophysical 
dprime scores in the MCI group in the face integration condition that differentiates between 
groups. 
Note: BA – Broadmann area; Area – Cluster surface area in mm2.  
p values are reported at the vertex maxima for each cluster, and respective Talairach coordinates were estimated on basis of non-
linear MNI to Talairach transformation (white matter surface). The fusiform cluster overlaps the previously described Face 
Fusiform Area region (Graewe et al., 2013). 
 
 
Figure 9.3 – Statistical results rendered on an inflated grey matter surface.  
Note: The cortical areas in which thickness correlates positively with dprime scores (see Table 9.2) are depicted. The color scale 
represents the p values as depicted for significant correlations (corrected for multiple comparisons: FDR significance level at .05).  
 
Discussion 
Here we investigated the role of visual integration of three-dimensional SFM face 
objects, in MCI. Our paradigm requires visual integration across features with an 
important role for the visual ventral stream (Farivar et al., 2009; Graewe et al., 2013).  
 BA Hemisphere Area p value Talairach Coordinates 
Occipital Lobe BA18 R 1676 .000012 26, -96, -2 
Fusiform BA37 R 309 .000069 41, -53, -7 
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Behavioral results confirmed that high level integration in visual face recognition  is 
impaired in MCI, thereby extending previous results on coherence thresholds of simple 
spherical objects (Lemos et al., 2012). Temporal requirements for visual integration 
were chosen (160 ms) to impose a performance challenge. This work supports the idea 
that either dorsal or ventral stream impairment will cause poor performance on this 
task. In other words, we found an association of task performance with the ventral 
stream integrity, which may support different aspects of the task than does the dorsal 
stream. 
It is known that integration of information from dorsal and ventral visual streams is 
crucial to recognize 3D SFM stimuli. The present results suggest that the ventral 
pathway represents an important role, specifically for face stimuli, as suggested by 
structure-function correlation analysis. Indeed, the patients with larger fusiform 
cortical thickness had more preserved recognition performance, but only for faces and 
not chairs. These results do not dispute the notion that the dorsal stream is also 
affected as suggested by the work of Rizzo et al. (2000) on motion perception and our 
own previous psychophysical and studies (Graewe et al., 2013; Lemos et al., 2012). 
Nevertheless, the results from the present study do not exclude the involvement of an 
impaired dorsal stream in the recognition of 3D SFM faces in MCI patients. 
The main finding of this study is the observed specificity of structural functional 
correlations for faces. This suggests that different circuits and biomarkers may track 
face rather than chair recognition, even though chair recognition is also impaired. 
Another novelty of our study is the report of visual structure-function correlations at 
the early stage of MCI, as the majority of imaging studies on AD-related pathology 
have documented structural/functional changes of regions related with the memory 
impairment, such as the hippocampus and related structures in the medial temporal 
lobe (Albert et al., 2011; Dubois et al., 2007, 2014; Sperling, 2011; Teipel et al., 2013). 
Nonetheless, previous studies have suggested that visual responses are modified in 
MCI and AD (Bokde et al., 2006; Mentis et al., 1996; Prvulovic et al., 2002; Teipel et al., 
2007; Vannini et al., 2007; Yamasaki et al., 2012). However it has remained difficult to 
establish a direct correlation with performance. 
In our study we found that behavioral performance is significantly correlated with 
cortical thickness. Accordingly, after controlling for different nuisance factors, we 
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found significantly positive correlations with face recognition condition and thickness 
in both the occipital lobe (BA18), and the ventral fusiform (BA37) areas on the right 
hemisphere, in the MCI group. These correlations were found in the condition that was 
previously reported (Graewe et al., 2013) to better discriminate MCI patients from 
healthy elderly and corroborated in the present study. Some psychophysical studies 
had indicated that the ventral visual pathway is more affected in AD spectrum (Cronin-
Golomb, 2004; Rizzo et al., 2000) although, as stated above, this does not exclude 
afferent dorsal stream deficits (Bokde et al., 2010; Kavcic et al., 2011; Lemos et al., 
2012). The lack of cortical differences in the control group, as function of face 
recognition performance, suggest a disease specific mechanism. 
Our results confirm the tenet that the fusiform gyrus (BA37), comprising the fusiform 
face area, may be critically affected in distinct stages of the natural history of AD 
(Bokde et al., 2006; Graewe et al., 2013; Teipel et al., 2007). Furthermore, our findings 
do suggest that the right BA37 is more closely associated with performance changes 
which is also consistent with the notion of lateralization of face-selective responses in 
right hemisphere (for a review, see Cabeza & Nyberg, 2000). Moreover, the findings 
from the present work corroborate the previous findings of Graewe et al. (2013) on 
the decreased sensitivity for faces in the right FFA, in MCI patients. The fusiform region 
identified in this study overlaps the FFA region described in that study. The 
involvement of extrastriate visual cortex may help explain the early visual deficits in 
AD-related pathology found by other groups (Risacher et al., 2013; Rizzo et al., 2000; 
Rose et al., 2006).  
We propose that both dorsal, and ventral, processing are required in the visual 
integration task used in this study. This is consistent with previous studies (James, 
Humphrey, Gati, Menon, & Goodale, 2002; Klaver et al., 2008; Konen & Kastner, 2008; 
Orban, Sunaert, Todd, Van Hecke, & Marchal, 1999). The decreased thickness present 
in MCI patients is not explained by atrophy as no differences in the same regions were 
found between patients and controls. This may suggest that our observations may be 
related to compensatory mechanisms.  
Our study also suggests new ways of studying complex object recognition (in particular 
face processing) and its neural correlates in pathological ageing. Dynamic aspects of a 
visual scene provide important cues for object segregation and identification, and 3D 
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SFM paradigms are particularly relevant in this context. Dynamic cues are highly 
informative of an object’s shape and may be capable of driving complex recognition 
processes in the absence of other shape cues. The visual integration ability needed to 
achieve holistic perception of the whole 3D shape from local information seems to be 
impaired in MCI patients, and to also require the ventral pathway. Our results suggest 
the existence of a ventral pathway that provides the substrate for information re-
routing and reorganization in the presence of dorsal stream vulnerability.  
In sum, we found evidence for a strong correlation between recognition of complex 3D 
moving faces and integrity in extrastriate and a fusiform region overlapping FFA in 
MCI. 
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This discussion briefly analyses the main results achieved during Studies 8 and 9. It is 
divided into the following topics: Description of Chapter II (Dorsal pathway, Ventral 
pathway, and Dorsal-ventral integration in the AD spectrum disorders); Highlights and 
limitations of the two studies; Future outlook; and Conclusions. 
 
Description of Chapter II 
In the current chapter we explored the visuospatial processing in MCI and AD patients. 
AD pathology is known to involve the visual pathways, leading to impairments in 
several visual functions. In particular, the dorsal and ventral pathways were considered 
throughout the performance of these pathological groups in psychophysical tasks 
(research papers either published or submitted for publication). Accordingly, visual 
function studies associated with these two pathways allow inferring about the 
functioning of the temporal and parietal lobes areas, known to be involved in AD 
spectrum disorders. In the visual cortex, the lateral geniculate nucleus (LGN) has 
shown to be affected in AD patients: neuropathological findings have been reported in 
both the magno and the parvocellular layers of the LGN with the latter showing a 
higher number of senile plaques (Gilmore, Morrison, & Groth, 2004). As we reported 
earlier, there is already a great amount of research considering the visual function in 
AD pathology; nevertheless, the same does not apply for studies in MCI and is almost 
circumscribed to research about high-level visual functions (visual search or attention). 
We presume that this may be due to its more recent categorization as a diagnostic 
entity. We tried to lift the veil on this scarcity by deepening our research into MCI, 
mainly due to its diagnostic conversion predicting value and also to the imperative 
need of finding new AD biomarkers. 
This discussion chapter was organized under the following topics: Dorsal pathway in 
the AD spectrum disorders, Ventral pathway in the AD spectrum disorders, Dorsal-
ventral integration in the AD spectrum disorders, Highlights and limitations, Future 
outlook, and Conclusions. 
Dorsal pathway in the AD spectrum disorders 
The dorsal (or magnocellular, or where) pathway is involved in object spatial location 
functions (Ungerleider & Mishkin, 1982) such as: spatial vision, motion perception, 
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direction integration, and speed discrimination. Nonetheless, Goodale & Milner (1992) 
argued that the key function of the dorsal stream is to mediate visually guided motor 
movements; this notion has been supported by studies of patients with parietal lesions 
whose difficulty is to form objects appropriate grasp size and orientation, in the 
presence of a preserved ability to describe the spatial location of these objects.  
Undoubtedly is the network of brain regions involved in this pathway spanning from 
the occipital lobe to parietal regions (Ungerleider & Mishkin, 1982). In fact, a 
hierarchical approach is justified by the notion that this retinocortical magnocellular 
pathway flows forward from the primary visual cortex to the visual dorsal stream 
(where motion integration takes place) (Castelo-Branco et al., 2002).  
Contrast sensitivity (CS), as a low-level function of the dorsal stream, is the most 
studied task in the AD spectrum (Cronin-Golomb, 2004) and, while the majority of 
researchers found it to be impaired (Lemos, Patrício, & Castelo-Branco, 2015), few 
researchers proved it as a spared visual function in this condition (Rizzo & Nawrot, 
1998; Schlotterer, Moscovitch, & Crapper-Mclachlan, 1984). CS reflects the “minimum 
amount of contrast that an observer needs to resolve a stimulus of a given 
size”(Cronin-Golomb et al., 2000), which is probably relevant concerning deficits in 
daily function activities in elderly people. The deficits in CS shown by AD patients are 
often described as the visual image being viewed through a filter and it is called the 
“Alzheimer filter”; moreover, this impaired CS at low facial frequencies contributes to 
the poor face discrimination observed in AD patients (Cronin-Golomb et al., 2000). 
Another commonly reported visuospatial deficit in AD patients is the spatial 
disorientation that consequently led patients to get lost even in familiar surroundings. 
The involvement of occipito-parietal regions includes the radial patterns of visual 
motion that create optic flow and guide movements through the environment by 
showing one's direction of self-movement. Tetewsky and Duffy (1999) proved that the 
ability to see radial patterns of optic flow is impaired in AD, interfering with their use 
of visual information to guide self-movement and maintain spatial orientation and 
leading to visuospatial disorientation. In general, deficits in global motion perception 
have been commonly reported in AD patients, with more noticeable evidence for 
impairment in higher level motion tests (Lemos, Patrício, et al., 2015). Concerning MCI, 
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Mapstone, Steffenella, and Duffy (2003) reported a subdivided pattern of performance 
among this group: while some have significant visual perceptual deficits along with 
memory impairment, others have isolated memory impairment with no visual 
perceptual deficits. This finding led the authors to suggest a visuospatial variant of 
MCI.  
In Study 8 (Lemos, Figueiredo, Santana, Simões, & Castelo-Branco, 2012) we explored 
the magnocellular processing both at low and high-level performances in MCI and AD 
patients. For the former we comprised a very simple CS detection task, using stimuli 
with high temporal and low spatial frequencies in order to activate the magnocellular 
pathway; in the latter a task of 3D motion coherence objects of unknown orientation 
with constrained temporal integration of cues was included. Our results enabled us to 
corroborate the AD CS impairment in the peripheral visual fields, in spite of a 
preserved central visual performance, and to show a specific pattern of impairment 
only in the peripheral-temporal region in the MCI group. Concerning the high-level 3D 
SFM performance, an impaired cue combination of 3D orientation and motion of 
simple objects in short time windows proved specific early dorsal stream impairment 
both in AD and MCI groups. 
The deterioration of magnocellular processing is quite important in understanding the 
behavior of AD spectrum disorder patients. Firstly, a reduced sensitivity may adversely 
affect routine perceptual activities that depend on low spatial frequencies, such as 
face and object recognition; secondly a deficit in perceiving moving objects leads to 
problems in visuospatial disorientation. 
Ventral pathway in the AD spectrum disorders 
The ventral visual-processing stream (or parvocellular, or what) identifies objects from 
their visual features (Ungerleider & Mishkin, 1982). This pathway, through a network 
of projections from the striate cortex to the inferotemporal cortex, plays the major 
role in the perceptual identification of objects (Goodale & Milner, 1992). 
The parvocellular pathway is, contrariwise to the magnocellular stream, contrast and 
motion insensitive, and responds to spatial detail (Silva et al., 2005) with its neurons 
behaving as high resolution channels, sensitive to high spatial frequencies. 
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At an initial level of an object’s registration one must attend to its local features, such 
as colour. Ventral visual perceptual processing in AD patients have mostly focused on 
early levels of visual perception, such as colour vision, although not necessarily 
implying that higher levels of perception are impaired in AD (Tippett, 2004). Isolating 
the stages of ventral visual processing at an intermediate and/or high-level in (typical) 
AD is a demanding task due to semantic and lexical (naming), or memory deficits that 
may bias the object recognition (that is also expected to be compromised), leading to 
an ambiguous underlying cause of impairment: language, memory or visual processing 
(Tippett, Blackwood, & Farah, 2003; Tippett, 2004)? 
In Study 8 (Lemos, Figueiredo, Santana, Simões, & Castelo-Branco, 2012) we 
investigated the parvocellular pathway through a computer controlled psychophysical 
colour perception task. Our results proved a significant impairment in AD’s 
parvocellular pathways in the presence of a spared colour perception in MCI subjects. 
Colour discrimination deficits among AD patients have been extensively reported 
(Lemos, Patrício, et al., 2015) either on clinical tests or psychophysical assessments, 
principally along the tritan (blue-yellow) colour axis (Rocco, 2004). Nevertheless, Wijk 
et al. (2002) argued in favour of a preserved colour perception ability in AD pathology. 
In respect to MCI performance relative to colour discrimination, we believe that our 
Study 8 was the first reporting a lack of deficits in colour vision in this pathological 
group. 
At a higher-level of ventral visual processing is the object recognition, including face 
perception, both reported as being impaired in AD (Kurylo, 2004; Lemos, Patrício, et 
al., 2015). In Study 8 (Lemos, Figueiredo, Santana, Simões, & Castelo-Branco, 2012) we 
explored face recognition, as an index of ventral stream function, both in AD and MCI 
groups, by means of the Benton Face Recognition Test (BFRT). We observed a pattern 
of face discrimination recognition impairment specifically on the AD group. Cronin-
Golomb et al. (2000) found AD subjects to be impaired at discriminating medium or 
large faces in the BFRT, but with a normal discrimination of small faces. The authors 
conclude that impaired CS at low facial frequencies contributes to the poor face 
discrimination of AD. Thus, by reducing the size of face stimuli, the perception of the 
low facial frequency content improves, thereby improving face discrimination in AD. 
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The development of recent research techniques such as the functional MRI (fMRI) 
endorsed the study of face perception independently of other cognitive deficits, by 
allowing the achievement of patterns of cerebral areas activation during face matching 
tasks (Lemos, Patrício, et al., 2015). These studies enabled a deepened understanding 
of face-specific cerebral regions both in AD patients, but also in MCI subjects. 
Dorsal-ventral integration in the AD spectrum disorders 
Despite the concomitant involvement of the dorsal and ventral stream in order to 
completely perceive a detailed moving scene, it is known that the parvocellular must 
contribute substantially to the magnocellular pathway in motion processing 
capabilities (Gilmore et al., 2004). This notion is supported by the importance of the 
local cues to extract the global configuration. Accordingly, the neural correlates of 
motion perception involve the integration of the ventral stream underlying the 
recognition of object shape properties and the dorsal pathway involved in spatial 
vision and motion perception (Farivar, 2009; Konen & Kastner, 2008; Milner & 
Goodale, 2008). 
In AD, the majority of studies reporting deficits in coherent motion perception use 
stimuli that drive the magno channel more actively than the parvocellular (Gilmore et 
al., 2004). Yet, if this coherent motion threshold impairment in AD is attributable to an 
interaction deficit or even a sole parvo deficit, opposite results should be found 
(Gilmore et al., 2004). Furthermore, the neural substrates of 3D motion perception in 
MCI patients were found to predominantly relate to aberrant patterns of activation in 
face and object perception (FFA/OFA) areas in the presence of normal recruitment of 
motion selective areas, suggesting the activation pattern within the ventral visual 
stream as a putative biomarker for this pre-dementia stage (Graewe et al., 2013). 
Previous functional imaging reports also suggest that reorganization may occur in both 
streams in AD spectrum disorders (Lemos, Patrício, et al., 2015). 
Among all the reported visual deficits present in AD are object recognition, including 
disrupted facial recognition, and impaired recognition of familiar objects (Lemos, 
Patrício, et al., 2015). This impaired object recognition is attributable to an abnormal 
organization of the visual scene where an improper use of discrete visual elements is 
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present, either in segregating and identifying coherent objects, or in simultaneously 
processing multiple elements to interpret the image (Kurylo, 2004). 
With these notions, we moved forward to Study 9 (Lemos, Santana, et al., 2015) in 
order to study the visuospatial perception in MCI using an experimental paradigm that 
required both dorsal and ventral processing. Our rationale was the clarification of 
these two visual pathways’ role and understanding its pathophysiology as a putative 
biomarker of AD symptomatology. For this, we included a behavioral experimental 
paradigm with 3D SFM defined faces and objects and morphometric analysis including 
the computation of cortical thickness (CT) maps and hippocampal volumetry using 
MRI. Our results confirmed that high level integration in visual face recognition is 
impaired in MCI, thereby extending the results on coherence thresholds of simple 
spherical objects from Study 8 (Lemos et al., 2012). Moreover, the ventral pathway 
represented an important role, specifically for face stimuli, as suggested by structure-
function correlation analysis: patients with larger fusiform CT had more preserved 
recognition performance for faces; positive correlations between face recognition 
condition and thickness either in the right occipital lobe and the right ventral fusiform 
areas were found. These findings corroborated our previous functional outcomes 
(Graewe et al. 2013) on the decreased sensitivity for faces in the right fusiform face 
area (FFA) in MCI patients, as the fusiform region identified in Study 9 overlaps the FFA 
region described before. The visual integration ability needed to achieve holistic 
perception of the whole 3D shape from local information was found to require the 
involvement of the ventral pathway, and was impaired in MCI patients. These results 
suggest that the ventral pathway provides the substrate for information re-routing and 
reorganization in the presence of dorsal stream vulnerability in MCI. 
 
Highlights and Limitations 
We understand that we were able to explore the visual function deficits in AD 
spectrum disorders. The structure and function of the visual cortex was studied as an 
innovative field for the early diagnosis, by exploring the interaction between dorsal 
and ventral streams in MCI patients; additionaly, we suggest these as alternative tools 
in MCI/AD assessment.  
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As reported in part I of the current thesis, the pathological groups were recruited at 
the Neurology Department of the Coimbra University Hospital, where the most recent 
and sophisticated supplementary means of clinical diagnosis are available, therefore 
enabling an accurate differential diagnosis. Additionally, the experiments reported in 
this section were developed and run in the Visual Neuroscience Laboratory of the 
Institute of Biomedical Research in Light and Image from the Faculty of Medicine of the 
University of Coimbra, which is a research reference center not only in visual studies 
but also in clinical neuroscience. 
Our main guidelines for the control groups’ selection were taking into consideration 
the demographical aspects of the pathological groups and also making sure that these 
subjects had no history of neurological, psychiatric, or ophthalmological relevant 
conditions, neither significant motor or auditory deficits which could influence their 
performance.  
All subjects performed a comprehensive neuropsychological assessment at baseline in 
order to define the cognitive profile of impairment and the diagnosis of the 
pathological groups, and to assure the lack of cognitive impairment among the control 
subjects; in Study 8 the cognitive results were found not to be correlated with visual 
performance among all the groups. 
Study 9 was developed in order to test whether three-dimensional SFM cues were 
sufficient to drive complex object recognition in MCI patients, therefore 
complementing the achievements of Study 8 where 3D motion integration was 
specifically impaired, thus indicating that parietal function may become affected early 
in the course of the disease. While Study 8 comprised a behavioral psychophysical task 
used both MCI and AD patients, in Study 9 we moved forward and included data from 
structural imaging that was correlated with results from a different visual experimental 
paradigm. 
One main limitation of the two studies is the relatively small groups’ size, even though 
it is in line with the majority of studies in this area (Lemos, Patrício, et al., 2015). 
Accounting for this limitation is the strict criteria of exclusively including subjects with 
no ophthalmological diseases so that our results would only been explained in terms of 
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cortical vision performance; moreover, in Study 8 all subjects underwent full 
ophthalmologic examination.  
The MCI groups included in both studies were of the amnestic type, due to their higher 
risk of conversion to AD. This circumstance discourages the inclusion of other subtypes 
of MCI, and consequently the results obtained in our studies should not be generalized 
to all MCI subtypes. 
The main objectives of both studies were addressed through the use of psychophysical 
research experiments to assess the cortical vision function. Despite the 
neuropsychological examination, data of ApoE genotype (presence of ε4 allele) among 
the pathological groups was included in both studies, and in Study 9 morphometric 
analysis established biological evidence for impairment in MCI as demonstrated by 
reduction of left hippocampal volume. Nonetheless, we are aware that these results 
should be corroborated with AD clinical biomarkers in order to address 
preclinical/prodromal AD as defined by specific diagnosis criteria. 
 
Future Outlook 
We think that results from visual function studies should be further explored in MCI 
patients that have AD clinical biomarkers and may be considered as 
preclinical/prodromal AD. As such, cortical vision tasks may possibly be seen as 
alternative tools in the AD spectrum assessment.  
Among the AD spectrum disorders in general, and relative to the visual dysfunction in 
particular, it is mandatory to refer the extreme point of impairment as is the posterior 
cortical atrophy (PCA; Dubois et al., 2010, 2014), or the visuospatial presentation of AD 
(McKhann et al., 2011), that is an insidiously progressive dementia characterized by 
prominent disorders of higher visual processing as a result of an atrophy of the 
occipital and occipito-parietal regions of the brain. We think that analyzing the 
performance of this atypical form of AD in the same, or similar, psychophysical visual 
tasks would enhance a complete understanding of the visual function in AD spectrum 
disorders. 
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Conclusions 
AD patients, caregivers, and health professionals are liable to misinterpret the visual 
disabilities as cognitive problems, leading to undiagnosed visual deficits. With the work 
presented in the current thesis, we believe to have contributed to this topic and to 
have further explored and confirmed the existence of AD visual deficits as early as in 
the MCI stage not only through behavioral psychophysical results, but also in terms of 
neural correlates. By suggesting visual assessment as an additional diagnostic tool, we 
consider that future interventions can be designed to compensate for visual problems 
in AD spectrum disorders, such as increasing signal strength through the use of higher 
contrast or larger stimuli.  
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Concluding Remarks 
The work presented in this thesis allowed us to confirm the usefulness of the FCSRT as a valid 
and accurate memory test in the objective characterization of the amnestic syndrome 
associated with AD, thus corroborating the suggestion of the IWG-1 and 2 criteria. By adapting 
and validating the FCSRT, we also contributed to the increase of Portuguese-adapted 
neuropsychological instruments’ availability and to introduce a different paradigm of verbal 
memory evaluation in this context in our country. 
Furthermore, we corroborated the existence of deficits among the two visual pathways on AD 
patients and showed specific impairments on motion perception and integration in the MCI. 
We went further in the understanding of the important and specific role of the ventral 
pathway for face stimuli on structure-function correlation analysis, suggesting that the ventral 
pathway provides the substrate for information re-routing and reorganization in the presence 
of dorsal stream vulnerability in MCI. These findings improve our knowledge of the visual 
deficits in AD spectrum disorders, as early as in the MCI stage, and allow us both to suggest the 
assessment of visual functions as an additional diagnostic tool for AD spectrum disorders and 
to consider that future interventions can be designed to compensate for visual problems in 
these pathologies, such as using higher contrast or larger stimuli. 
  
 327 
 
 
List of Publications  
Baldeiras, I., Santana, I., Garrucho, M. H., Pascoal, R., Lemos, R., Santiago, B., & Oliveira, C. (2012). CSF 
biomarkers for the early diagnosis of Alzheimer’s disease in a routine clinical setting – the first 
Portuguese study. Sinapse, 12(2), 14–22. 
Baldeiras, I., Santana, I., Leitão, M. J., Ribeiro, M. H., Pascoal, R., Duro, D., Lemos, R., … Oliveira, C. R. 
(2015). Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar 
Degeneration and Alzheimer’s Disease. Journal of the Neurological Sciences. 
doi:10.1016/j.jns.2015.09.022 
Graewe, B., Lemos, R., Ferreira, C., Santana, I., Farivar, R., De Weerd, P., & Castelo-Branco, M. (2013). 
Impaired processing of 3D motion-defined faces in mild cognitive impairment and healthy aging: 
an fMRI study. Cerebral Cortex, 23(10), 2489–2499. doi:10.1093/cercor/bhs246 
Lemos, R., Afonso, A., Martins, C., Waters, J. H., Blanco, F. S., Simões, M. R., & Santana, I. (2015). 
Selective reminding and free and cued selective reminding in mild cognitive impairment and 
alzheimer disease. Applied Neuropsychology. Adult, 1–9. doi:10.1080/23279095.2015.1012761 
Lemos, R., Cunha, C., Marôco, J., Afonso, A., Simões, M. R., & Santana, I. (2014). Free and Cued Selective 
Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive 
impairment from Alzheimer’s disease. Geriatrics & Gerontology International. 
doi:10.1111/ggi.12374 
Lemos, R., Duro, D., Simões, M. R., & Santana, I. (2014). The free and cued selective reminding test 
distinguishes frontotemporal dementia from Alzheimer’s disease. Archives of Clinical 
Neuropsychology, 29(7), 670–679. doi:10.1093/arclin/acu031 
Lemos, R., Figueiredo, P., Santana, I., Simões, M. R., & Castelo-Branco, M. (2012). Temporal integration 
of 3D coherent motion cues defining visual objects of unknown orientation is impaired in amnestic 
mild cognitive impairment and Alzheimer’s disease. Journal of Alzheimer’s Disease, 28(4), 885–96. 
doi:10.3233/JAD-2011-110719 
Lemos, R., Marôco, J., Simões, M. R., Santiago, B., Tomás, J., & Santana, I. (2015). The free and cued 
selective reminding test for predicting progression to Alzheimer’s disease in patients with mild 
cognitive impairment: A prospective longitudinal study. Journal of Neuropsychology. 
doi:10.1111/jnp.12075 
Lemos, R., Martins, C., Simões, M., & Santana, I. (2012). Estudo de adaptação do Teste de Recordação 
Selectiva Livre e Guiada para a população portuguesa. [Adaptation study of the Free and Cued 
Selective Reminding Test to the Portuguese population]. Avaliação Psicológica, 11(1), 49–61.  
Lemos, R., Simões, M. R., Santiago, B., & Santana, I. (2015). The free and cued selective reminding test: 
Validation for mild cognitive impairment and Alzheimer’s disease. Journal of Neuropsychology, 
9(2), 242–257. doi:10.1111/jnp.12048 
Marques, S. C. F., Lemos, R., Ferreiro, E., Martins, M., de Mendonça, A., Santana, I., … Pereira, C. M. F. 
(2012). Epigenetic regulation of BACE1 in Alzheimer’s disease patients and in transgenic mice. 
Neuroscience, 220, 256–266. doi:10.1016/j.neuroscience.2012.06.029 
Mateus, C., Lemos, R., Silva, M. F., Reis, A., Fonseca, P., Oliveiros, B., & Castelo-Branco, M. (2013). Aging 
of low and high level vision: from chromatic and achromatic contrast sensitivity to local and 3D 
object motion perception. PloS One, 8(1), e55348. doi:10.1371/journal.pone.0055348 
Sá, F., Pinto, P., Cunha, C., Lemos, R., Letra, L., Simões, M., & Santana, I. (2012). Differences between 
Early and Late-Onset Alzheimer’s Disease in Neuropsychological Tests. Frontiers in Neurology, 3, 
81. doi:10.3389/fneur.2012.00081 
Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., … Santana, I; Lemos, R… Visser, 
P. J. (2015). Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment 
stage. Brain, 1–12. doi:10.1093/brain/awv029 
328  
 
 
Curriculum Vitae 
  
Raquel Lemos Oliveira was born on October 13, 1980 in Braga, Portugal. In 1997, she 
concluded her secondary school education at Escola Secundária Carlos Amarante in Braga, 
after which she studied Psychology at the Faculty of Psychology and Educational Sciences of 
the University of Coimbra, graduating in 2003. Her internship was completed  at the Neurology 
Department of the Hospitais da Universidade de Coimbra, under the supervision of Professors 
Isabel Santana and Mário Rodrigues Simões. She worked as a clinical psychologist at Hospital 
de São João de Deus – Barcelos, from 2005 to 2006. After working as a research assistant in 
neuropsychology for five years, first  in the Instituto de Imagem Biomédica e Ciências da Vida, 
(Faculty of Medicine, University of Coimbra), and then in the Neurology Department of the 
Hospitais da Universidade de Coimbra. In 2008, she started her PhD in Neuropsychology under 
the supervision of Professor Isabel Santana and the co-supervision of Professors Mário 
Rodrigues Simões and Miguel Castelo-Branco, for which in 2011 she received a scholarship 
from the Fundação para a Ciência e Tecnologia – Portugal. 
